"doi";"PMID";"section";"ITC num";"Ind studies num";"questions";"answer"
"10.1001/jamaophthalmol.2021.6284";"35175308";"general_information";"";"";"Medical Condition of Interest Name";"thyroid eye disease"
"10.1001/jamaophthalmol.2021.6284";"35175308";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1001/jamaophthalmol.2021.6284";"35175308";"general_information";"";"";"Countries of last author affiliations";"canada"
"10.1001/jamaophthalmol.2021.6284";"35175308";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Private Data Analysis Company"
"10.1001/jamaophthalmol.2021.6284";"35175308";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1001/jamaophthalmol.2021.6284";"35175308";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1001/jamaophthalmol.2021.6284";"35175308";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1001/jamaophthalmol.2021.6284";"35175308";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01868997"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03298867"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"3";"Patient-level data used";"No"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"3";"Data source name (only if observational study or clinical trial without NCT)";"bartalena at al., 2012"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1001/jamaophthalmol.2021.6284";"35175308";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1001/jamaophthalmol.2021.6284";"35175308";"methodology";"1";"";"Treatment name 1";"teprotumumab"
"10.1001/jamaophthalmol.2021.6284";"35175308";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1001/jamaophthalmol.2021.6284";"35175308";"methodology";"1";"";"Treatment name 2";"intravenous methylprednisolone"
"10.1001/jamaophthalmol.2021.6284";"35175308";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3"
"10.1001/jamaophthalmol.2021.6284";"35175308";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1001/jamaophthalmol.2021.6284";"35175308";"methodology";"1";"";"Anchored comparison?";"No"
"10.1001/jamaophthalmol.2021.6284";"35175308";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1001/jamaophthalmol.2021.6284";"35175308";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1001/jamaophthalmol.2021.6284";"35175308";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"change from baseline in proptosis in mm"
"10.1001/jamaophthalmol.2021.6284";"35175308";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1001/jamaophthalmol.2021.6284";"35175308";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1001/jamaophthalmol.2021.6284";"35175308";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1001/jamaophthalmol.2021.6284";"35175308";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1001/jamaophthalmol.2021.6284";"35175308";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1001/jamaophthalmol.2021.6284";"35175308";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1001/jamaophthalmol.2021.6284";"35175308";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"419"
"10.1001/jamaophthalmol.2021.6284";"35175308";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"79"
"10.1001/jamaophthalmol.2021.6284";"35175308";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"56"
"10.1001/jamaophthalmol.2021.6284";"35175308";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1001/jamaophthalmol.2021.6284";"35175308";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1001/jamaophthalmol.2021.6284";"35175308";"results";"1";"";"Number of covariates adjusted for/matched on";"3"
"10.1001/jamaophthalmol.2021.6284";"35175308";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Other(s)"
"10.1001/jamaophthalmol.2021.6284";"35175308";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1001/jamaophthalmol.2021.6284";"35175308";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1001/jamaophthalmol.2021.6284";"35175308";"results";"1";"";"Primary outcome: unadjusted treatment effect";"-2.38"
"10.1001/jamaophthalmol.2021.6284";"35175308";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-3.49;-1.27]"
"10.1001/jamaophthalmol.2021.6284";"35175308";"results";"1";"";"Primary outcome: adjusted treatment effect";"-2.31"
"10.1001/jamaophthalmol.2021.6284";"35175308";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-3.45;-1.17]"
"10.1002/edm2.259";"34277983";"general_information";"";"";"Medical Condition of Interest Name";"type 2 diabetes"
"10.1002/edm2.259";"34277983";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.1002/edm2.259";"34277983";"general_information";"";"";"Countries of last author affiliations";"uk"
"10.1002/edm2.259";"34277983";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1002/edm2.259";"34277983";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1002/edm2.259";"34277983";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1002/edm2.259";"34277983";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1002/edm2.259";"34277983";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1002/edm2.259";"34277983";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1002/edm2.259";"34277983";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1002/edm2.259";"34277983";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01720446"
"10.1002/edm2.259";"34277983";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1002/edm2.259";"34277983";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1002/edm2.259";"34277983";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1002/edm2.259";"34277983";"study_information";"";"2";"Patient-level data used";"No"
"10.1002/edm2.259";"34277983";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1002/edm2.259";"34277983";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01394952"
"10.1002/edm2.259";"34277983";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1002/edm2.259";"34277983";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1002/edm2.259";"34277983";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1002/edm2.259";"34277983";"methodology";"1";"";"Treatment name 1";"semaglutide"
"10.1002/edm2.259";"34277983";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1002/edm2.259";"34277983";"methodology";"1";"";"Treatment name 2";"dulaglutide"
"10.1002/edm2.259";"34277983";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1002/edm2.259";"34277983";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1002/edm2.259";"34277983";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1002/edm2.259";"34277983";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1002/edm2.259";"34277983";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1002/edm2.259";"34277983";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"3 point mace (cardiovascular death, non-fatal myocardial infraction, non-fatal stroke)"
"10.1002/edm2.259";"34277983";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1002/edm2.259";"34277983";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1002/edm2.259";"34277983";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1002/edm2.259";"34277983";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1002/edm2.259";"34277983";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1002/edm2.259";"34277983";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1002/edm2.259";"34277983";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1002/edm2.259";"34277983";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1002/edm2.259";"34277983";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.1002/edm2.259";"34277983";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1002/edm2.259";"34277983";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1002/edm2.259";"34277983";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1002/edm2.259";"34277983";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.74"
"10.1002/edm2.259";"34277983";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.06"
"10.1002/edm2.259";"34277983";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"4949"
"10.1002/edm2.259";"34277983";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"4952"
"10.1002/edm2.259";"34277983";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"1648"
"10.1002/edm2.259";"34277983";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"1649"
"10.1007/bf03261873";"23113551";"general_information";"";"";"Medical Condition of Interest Name";"attention-deficit/hyperactivity disorder"
"10.1007/bf03261873";"23113551";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1007/bf03261873";"23113551";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1007/bf03261873";"23113551";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/bf03261873";"23113551";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/bf03261873";"23113551";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/bf03261873";"23113551";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/bf03261873";"23113551";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/bf03261873";"23113551";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/bf03261873";"23113551";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/bf03261873";"23113551";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00152009"
"10.1007/bf03261873";"23113551";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/bf03261873";"23113551";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/bf03261873";"23113551";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.1007/bf03261873";"23113551";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1007/bf03261873";"23113551";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/bf03261873";"23113551";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00150618"
"10.1007/bf03261873";"23113551";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/bf03261873";"23113551";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/bf03261873";"23113551";"study_information";"";"2";"Data source name (only if observational study or clinical trial without NCT)";"sallee et al. (2009)"
"10.1007/bf03261873";"23113551";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1007/bf03261873";"23113551";"study_information";"";"3";"Patient-level data used";"No"
"10.1007/bf03261873";"23113551";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1007/bf03261873";"23113551";"study_information";"";"3";"Data source name (only if observational study or clinical trial without NCT)";"michelson et al. (2001)"
"10.1007/bf03261873";"23113551";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1007/bf03261873";"23113551";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/bf03261873";"23113551";"methodology";"1";"";"Treatment name 1";"guanfacine extended-release low dose"
"10.1007/bf03261873";"23113551";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1007/bf03261873";"23113551";"methodology";"1";"";"Treatment name 2";"atomoxetine"
"10.1007/bf03261873";"23113551";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3"
"10.1007/bf03261873";"23113551";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/bf03261873";"23113551";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/bf03261873";"23113551";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/bf03261873";"23113551";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1007/bf03261873";"23113551";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"adhd-rs-iv total score"
"10.1007/bf03261873";"23113551";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/bf03261873";"23113551";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/bf03261873";"23113551";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/bf03261873";"23113551";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/bf03261873";"23113551";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1007/bf03261873";"23113551";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/bf03261873";"23113551";"methodology";"2";"";"Treatment name 1";"guanfacine extended-release mid dose"
"10.1007/bf03261873";"23113551";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1007/bf03261873";"23113551";"methodology";"2";"";"Treatment name 2";"atomoxetine"
"10.1007/bf03261873";"23113551";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.1007/bf03261873";"23113551";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/bf03261873";"23113551";"methodology";"2";"";"Anchored comparison?";"No"
"10.1007/bf03261873";"23113551";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/bf03261873";"23113551";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1007/bf03261873";"23113551";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"adhd-rs-iv total score"
"10.1007/bf03261873";"23113551";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/bf03261873";"23113551";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/bf03261873";"23113551";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/bf03261873";"23113551";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/bf03261873";"23113551";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1007/bf03261873";"23113551";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/bf03261873";"23113551";"methodology";"3";"";"Treatment name 1";"guanfacine extended-release high dose"
"10.1007/bf03261873";"23113551";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1007/bf03261873";"23113551";"methodology";"3";"";"Treatment name 2";"atomoxetine"
"10.1007/bf03261873";"23113551";"methodology";"3";"";"Study 'number(s)' for treatment 2";"3"
"10.1007/bf03261873";"23113551";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/bf03261873";"23113551";"methodology";"3";"";"Anchored comparison?";"No"
"10.1007/bf03261873";"23113551";"methodology";"3";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/bf03261873";"23113551";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1007/bf03261873";"23113551";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"adhd-rs-iv total score"
"10.1007/bf03261873";"23113551";"methodology";"3";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/bf03261873";"23113551";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/bf03261873";"23113551";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/bf03261873";"23113551";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/bf03261873";"23113551";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1007/bf03261873";"23113551";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/bf03261873";"23113551";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"84"
"10.1007/bf03261873";"23113551";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"147"
"10.1007/bf03261873";"23113551";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"49"
"10.1007/bf03261873";"23113551";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/bf03261873";"23113551";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/bf03261873";"23113551";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.1007/bf03261873";"23113551";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1007/bf03261873";"23113551";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1007/bf03261873";"23113551";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1007/bf03261873";"23113551";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/bf03261873";"23113551";"results";"1";"";"Primary outcome: adjusted treatment effect";"-6"
"10.1007/bf03261873";"23113551";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"84"
"10.1007/bf03261873";"23113551";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"46"
"10.1007/bf03261873";"23113551";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"16"
"10.1007/bf03261873";"23113551";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/bf03261873";"23113551";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/bf03261873";"23113551";"results";"2";"";"Number of covariates adjusted for/matched on";"6"
"10.1007/bf03261873";"23113551";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1007/bf03261873";"23113551";"results";"2";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1007/bf03261873";"23113551";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.02"
"10.1007/bf03261873";"23113551";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/bf03261873";"23113551";"results";"2";"";"Primary outcome: adjusted treatment effect";"-6"
"10.1007/bf03261873";"23113551";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"84"
"10.1007/bf03261873";"23113551";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"82"
"10.1007/bf03261873";"23113551";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"38"
"10.1007/bf03261873";"23113551";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/bf03261873";"23113551";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/bf03261873";"23113551";"results";"3";"";"Number of covariates adjusted for/matched on";"6"
"10.1007/bf03261873";"23113551";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1007/bf03261873";"23113551";"results";"3";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1007/bf03261873";"23113551";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.07"
"10.1007/bf03261873";"23113551";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/bf03261873";"23113551";"results";"3";"";"Primary outcome: adjusted treatment effect";"-3.7"
"10.1007/s00432-021-03602-w";"33745079";"general_information";"";"";"Medical Condition of Interest Name";"unresectable hepatocellular carcinoma"
"10.1007/s00432-021-03602-w";"33745079";"general_information";"";"";"Countries of first author affiliations";"italy"
"10.1007/s00432-021-03602-w";"33745079";"general_information";"";"";"Countries of last author affiliations";"italy"
"10.1007/s00432-021-03602-w";"33745079";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic"
"10.1007/s00432-021-03602-w";"33745079";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s00432-021-03602-w";"33745079";"general_information";"";"";"Mentioned sources of funding";"No fundings"
"10.1007/s00432-021-03602-w";"33745079";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"None"
"10.1007/s00432-021-03602-w";"33745079";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1007/s00432-021-03602-w";"33745079";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s00432-021-03602-w";"33745079";"study_information";"";"1";"Clinical Trial";"No"
"10.1007/s00432-021-03602-w";"33745079";"study_information";"";"1";"Data source name (only if observational study or clinical trial without NCT)";"nothing mentioned for the ipd population origin"
"10.1007/s00432-021-03602-w";"33745079";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s00432-021-03602-w";"33745079";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s00432-021-03602-w";"33745079";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01908426"
"10.1007/s00432-021-03602-w";"33745079";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s00432-021-03602-w";"33745079";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s00432-021-03602-w";"33745079";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s00432-021-03602-w";"33745079";"methodology";"1";"";"Treatment name 1";"regorafenib"
"10.1007/s00432-021-03602-w";"33745079";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s00432-021-03602-w";"33745079";"methodology";"1";"";"Treatment name 2";"cabozantinib"
"10.1007/s00432-021-03602-w";"33745079";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s00432-021-03602-w";"33745079";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s00432-021-03602-w";"33745079";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s00432-021-03602-w";"33745079";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s00432-021-03602-w";"33745079";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1007/s00432-021-03602-w";"33745079";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1007/s00432-021-03602-w";"33745079";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1007/s00432-021-03602-w";"33745079";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s00432-021-03602-w";"33745079";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s00432-021-03602-w";"33745079";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s00432-021-03602-w";"33745079";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s00432-021-03602-w";"33745079";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s00432-021-03602-w";"33745079";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"331"
"10.1007/s00432-021-03602-w";"33745079";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"278"
"10.1007/s00432-021-03602-w";"33745079";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s00432-021-03602-w";"33745079";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.1007/s00432-021-03602-w";"33745079";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1007/s00432-021-03602-w";"33745079";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s00432-021-03602-w";"33745079";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.8"
"10.1007/s00432-021-03602-w";"33745079";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.66;0.97]"
"10.1007/s00432-021-03602-w";"33745079";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.83"
"10.1007/s00432-021-03602-w";"33745079";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.62;1.09]"
"10.1007/s11523-021-00803-8";"33638735";"general_information";"";"";"Medical Condition of Interest Name";"unresectable hepatocellular carcinoma"
"10.1007/s11523-021-00803-8";"33638735";"general_information";"";"";"Countries of first author affiliations";"italy"
"10.1007/s11523-021-00803-8";"33638735";"general_information";"";"";"Countries of last author affiliations";"italy"
"10.1007/s11523-021-00803-8";"33638735";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic"
"10.1007/s11523-021-00803-8";"33638735";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Not mentioned"
"10.1007/s11523-021-00803-8";"33638735";"general_information";"";"";"Mentioned sources of funding";"No fundings"
"10.1007/s11523-021-00803-8";"33638735";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s11523-021-00803-8";"33638735";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1007/s11523-021-00803-8";"33638735";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s11523-021-00803-8";"33638735";"study_information";"";"1";"Clinical Trial";"No"
"10.1007/s11523-021-00803-8";"33638735";"study_information";"";"1";"Data source name (only if observational study or clinical trial without NCT)";"455 patients from 12 japanese centers from march 2018 to may 2020"
"10.1007/s11523-021-00803-8";"33638735";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"japan"
"10.1007/s11523-021-00803-8";"33638735";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s11523-021-00803-8";"33638735";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s11523-021-00803-8";"33638735";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03434379"
"10.1007/s11523-021-00803-8";"33638735";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s11523-021-00803-8";"33638735";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s11523-021-00803-8";"33638735";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s11523-021-00803-8";"33638735";"methodology";"1";"";"Treatment name 1";"lenvatinib"
"10.1007/s11523-021-00803-8";"33638735";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s11523-021-00803-8";"33638735";"methodology";"1";"";"Treatment name 2";"atezolizumab + bevacizumab"
"10.1007/s11523-021-00803-8";"33638735";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s11523-021-00803-8";"33638735";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s11523-021-00803-8";"33638735";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s11523-021-00803-8";"33638735";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s11523-021-00803-8";"33638735";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1007/s11523-021-00803-8";"33638735";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1007/s11523-021-00803-8";"33638735";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1007/s11523-021-00803-8";"33638735";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s11523-021-00803-8";"33638735";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1007/s11523-021-00803-8";"33638735";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s11523-021-00803-8";"33638735";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s11523-021-00803-8";"33638735";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s11523-021-00803-8";"33638735";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"478"
"10.1007/s11523-021-00803-8";"33638735";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"455"
"10.1007/s11523-021-00803-8";"33638735";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s11523-021-00803-8";"33638735";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s11523-021-00803-8";"33638735";"results";"1";"";"Number of covariates adjusted for/matched on";"12"
"10.1007/s11523-021-00803-8";"33638735";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1007/s11523-021-00803-8";"33638735";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1007/s11523-021-00803-8";"33638735";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s11523-021-00803-8";"33638735";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.59"
"10.1007/s11523-021-00803-8";"33638735";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.46;0.75]"
"10.1007/s12325-014-0167-z";"25414048";"general_information";"";"";"Medical Condition of Interest Name";"relapsing-remitting multiple sclerosis"
"10.1007/s12325-014-0167-z";"25414048";"general_information";"";"";"Countries of first author affiliations";"switzerland"
"10.1007/s12325-014-0167-z";"25414048";"general_information";"";"";"Countries of last author affiliations";"uk"
"10.1007/s12325-014-0167-z";"25414048";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.1007/s12325-014-0167-z";"25414048";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-014-0167-z";"25414048";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00289978"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00355134"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"3";"Patient-level data used";"No"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00420212"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"4";"Patient-level data used";"No"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00451451"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"5";"Patient-level data used";"No"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00134563"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-014-0167-z";"25414048";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"1";"";"Treatment name 1";"fingolimod 0.5mg"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"1";"";"Treatment name 2";"dimethyl fumarate 240 mg twice daily"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3;4"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall no evidence of disease activity status"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"2";"";"Treatment name 1";"fingolimod 0.5mg"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"2";"";"Treatment name 2";"teriflunomide 7mg"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"2";"";"Study 'number(s)' for treatment 2";"5"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall no evidence of disease activity status"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"3";"";"Treatment name 1";"fingolimod 0.5mg"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"3";"";"Treatment name 2";"teriflunomide 14mg"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"3";"";"Study 'number(s)' for treatment 2";"5"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"3";"";"Anchored comparison?";"No"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"3";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall no evidence of disease activity status"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"3";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-014-0167-z";"25414048";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"769"
"10.1007/s12325-014-0167-z";"25414048";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"771"
"10.1007/s12325-014-0167-z";"25414048";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"783"
"10.1007/s12325-014-0167-z";"25414048";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"783"
"10.1007/s12325-014-0167-z";"25414048";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"773"
"10.1007/s12325-014-0167-z";"25414048";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"773"
"10.1007/s12325-014-0167-z";"25414048";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"results";"1";"";"Number of covariates adjusted for/matched on";"2"
"10.1007/s12325-014-0167-z";"25414048";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Past treatments for the disease of interest"
"10.1007/s12325-014-0167-z";"25414048";"results";"1";"";"Primary outcome: treatment effect contrast";"RR"
"10.1007/s12325-014-0167-z";"25414048";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-014-0167-z";"25414048";"results";"1";"";"Primary outcome: unadjusted treatment effect";"1.58"
"10.1007/s12325-014-0167-z";"25414048";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[1.00;2.50]"
"10.1007/s12325-014-0167-z";"25414048";"results";"1";"";"Primary outcome: adjusted treatment effect";"1.67"
"10.1007/s12325-014-0167-z";"25414048";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[1.08;2.57]"
"10.1007/s12325-014-0167-z";"25414048";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"365"
"10.1007/s12325-014-0167-z";"25414048";"results";"2";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"363"
"10.1007/s12325-014-0167-z";"25414048";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"783"
"10.1007/s12325-014-0167-z";"25414048";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"783"
"10.1007/s12325-014-0167-z";"25414048";"results";"2";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"773"
"10.1007/s12325-014-0167-z";"25414048";"results";"2";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"773"
"10.1007/s12325-014-0167-z";"25414048";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"results";"2";"";"Number of covariates adjusted for/matched on";"1"
"10.1007/s12325-014-0167-z";"25414048";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age"
"10.1007/s12325-014-0167-z";"25414048";"results";"2";"";"Primary outcome: treatment effect contrast";"RR"
"10.1007/s12325-014-0167-z";"25414048";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-014-0167-z";"25414048";"results";"2";"";"Primary outcome: unadjusted treatment effect";"2.18"
"10.1007/s12325-014-0167-z";"25414048";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[1.46;3.25]"
"10.1007/s12325-014-0167-z";"25414048";"results";"2";"";"Primary outcome: adjusted treatment effect";"2.01"
"10.1007/s12325-014-0167-z";"25414048";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[1.38;2.93]"
"10.1007/s12325-014-0167-z";"25414048";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"358"
"10.1007/s12325-014-0167-z";"25414048";"results";"3";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"363"
"10.1007/s12325-014-0167-z";"25414048";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"783"
"10.1007/s12325-014-0167-z";"25414048";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"783"
"10.1007/s12325-014-0167-z";"25414048";"results";"3";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"773"
"10.1007/s12325-014-0167-z";"25414048";"results";"3";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"773"
"10.1007/s12325-014-0167-z";"25414048";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-014-0167-z";"25414048";"results";"3";"";"Number of covariates adjusted for/matched on";"1"
"10.1007/s12325-014-0167-z";"25414048";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age"
"10.1007/s12325-014-0167-z";"25414048";"results";"3";"";"Primary outcome: treatment effect contrast";"RR"
"10.1007/s12325-014-0167-z";"25414048";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-014-0167-z";"25414048";"results";"3";"";"Primary outcome: unadjusted treatment effect";"1.75"
"10.1007/s12325-014-0167-z";"25414048";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[1.18;2.57]"
"10.1007/s12325-014-0167-z";"25414048";"results";"3";"";"Primary outcome: adjusted treatment effect";"1.61"
"10.1007/s12325-014-0167-z";"25414048";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[1.12;2.31]"
"10.1007/s12325-017-0564-1";"28573505";"general_information";"";"";"Medical Condition of Interest Name";"chronic lymphocytic leukemia"
"10.1007/s12325-017-0564-1";"28573505";"general_information";"";"";"Countries of first author affiliations";"belgium"
"10.1007/s12325-017-0564-1";"28573505";"general_information";"";"";"Countries of last author affiliations";"uk"
"10.1007/s12325-017-0564-1";"28573505";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry"
"10.1007/s12325-017-0564-1";"28573505";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Not mentioned"
"10.1007/s12325-017-0564-1";"28573505";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-017-0564-1";"28573505";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-017-0564-1";"28573505";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1007/s12325-017-0564-1";"28573505";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-017-0564-1";"28573505";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-017-0564-1";"28573505";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01722487"
"10.1007/s12325-017-0564-1";"28573505";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-017-0564-1";"28573505";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-017-0564-1";"28573505";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-017-0564-1";"28573505";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-017-0564-1";"28573505";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s12325-017-0564-1";"28573505";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01010061"
"10.1007/s12325-017-0564-1";"28573505";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-017-0564-1";"28573505";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-017-0564-1";"28573505";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-017-0564-1";"28573505";"methodology";"1";"";"Treatment name 1";"ibrutinib1"
"10.1007/s12325-017-0564-1";"28573505";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-017-0564-1";"28573505";"methodology";"1";"";"Treatment name 2";"obinutuzumab + chlorambucil"
"10.1007/s12325-017-0564-1";"28573505";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-017-0564-1";"28573505";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-017-0564-1";"28573505";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1007/s12325-017-0564-1";"28573505";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-017-0564-1";"28573505";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-017-0564-1";"28573505";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1007/s12325-017-0564-1";"28573505";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1007/s12325-017-0564-1";"28573505";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s12325-017-0564-1";"28573505";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1007/s12325-017-0564-1";"28573505";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-017-0564-1";"28573505";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-017-0564-1";"28573505";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-017-0564-1";"28573505";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-017-0564-1";"28573505";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-017-0564-1";"28573505";"results";"1";"";"Number of covariates adjusted for/matched on";"9"
"10.1007/s12325-017-0564-1";"28573505";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1007/s12325-017-0564-1";"28573505";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1007/s12325-017-0564-1";"28573505";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-017-0564-1";"28573505";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.5"
"10.1007/s12325-017-0564-1";"28573505";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.22;1.15]"
"10.1007/s12325-017-0564-1";"28573505";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.24"
"10.1007/s12325-017-0564-1";"28573505";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.04;1.35]"
"10.1007/s12325-017-0564-1";"28573505";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"589"
"10.1007/s12325-017-0564-1";"28573505";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"191"
"10.1007/s12325-017-0564-1";"28573505";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"35"
"10.1007/s12325-018-0734-9";"29949047";"general_information";"";"";"Medical Condition of Interest Name";"braf v600e-mutant advanced or metastatic non-small-cell lung cancer"
"10.1007/s12325-018-0734-9";"29949047";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1007/s12325-018-0734-9";"29949047";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1007/s12325-018-0734-9";"29949047";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s12325-018-0734-9";"29949047";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s12325-018-0734-9";"29949047";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-018-0734-9";"29949047";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-018-0734-9";"29949047";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s12325-018-0734-9";"29949047";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-018-0734-9";"29949047";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-018-0734-9";"29949047";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01336634"
"10.1007/s12325-018-0734-9";"29949047";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-018-0734-9";"29949047";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.1007/s12325-018-0734-9";"29949047";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s12325-018-0734-9";"29949047";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-018-0734-9";"29949047";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s12325-018-0734-9";"29949047";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01673867"
"10.1007/s12325-018-0734-9";"29949047";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-018-0734-9";"29949047";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-018-0734-9";"29949047";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-018-0734-9";"29949047";"methodology";"1";"";"Treatment name 1";"dabrafenib + trametinib"
"10.1007/s12325-018-0734-9";"29949047";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-018-0734-9";"29949047";"methodology";"1";"";"Treatment name 2";"nivolumab"
"10.1007/s12325-018-0734-9";"29949047";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-018-0734-9";"29949047";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-018-0734-9";"29949047";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1007/s12325-018-0734-9";"29949047";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-018-0734-9";"29949047";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-018-0734-9";"29949047";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1007/s12325-018-0734-9";"29949047";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s12325-018-0734-9";"29949047";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s12325-018-0734-9";"29949047";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s12325-018-0734-9";"29949047";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s12325-018-0734-9";"29949047";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-018-0734-9";"29949047";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-018-0734-9";"29949047";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"290"
"10.1007/s12325-018-0734-9";"29949047";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"57"
"10.1007/s12325-018-0734-9";"29949047";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-018-0734-9";"29949047";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-018-0734-9";"29949047";"results";"1";"";"Number of covariates adjusted for/matched on";"10"
"10.1007/s12325-018-0734-9";"29949047";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)"
"10.1007/s12325-018-0734-9";"29949047";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"34"
"10.1007/s12325-018-0734-9";"29949047";"results";"1";"";"Primary outcome: treatment effect contrast";"Risk difference"
"10.1007/s12325-018-0734-9";"29949047";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-018-0734-9";"29949047";"results";"1";"";"Primary outcome: adjusted treatment effect";"46.4"
"10.1007/s12325-018-0734-9";"29949047";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.001"
"10.1007/s12325-019-00991-w";"31140123";"general_information";"";"";"Medical Condition of Interest Name";"relapsed or refractory acute lymphoblastic leukemia"
"10.1007/s12325-019-00991-w";"31140123";"general_information";"";"";"Countries of first author affiliations";"canada"
"10.1007/s12325-019-00991-w";"31140123";"general_information";"";"";"Countries of last author affiliations";"germany"
"10.1007/s12325-019-00991-w";"31140123";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s12325-019-00991-w";"31140123";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s12325-019-00991-w";"31140123";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-019-00991-w";"31140123";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-019-00991-w";"31140123";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1007/s12325-019-00991-w";"31140123";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-019-00991-w";"31140123";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-019-00991-w";"31140123";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01564784"
"10.1007/s12325-019-00991-w";"31140123";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-019-00991-w";"31140123";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-019-00991-w";"31140123";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-019-00991-w";"31140123";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-019-00991-w";"31140123";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s12325-019-00991-w";"31140123";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02013167"
"10.1007/s12325-019-00991-w";"31140123";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-019-00991-w";"31140123";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-019-00991-w";"31140123";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"1";"";"Treatment name 1";"inotuzumab ozogamicin"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"1";"";"Treatment name 2";"blinatumomab"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"remission rate"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"2";"";"Treatment name 1";"inotuzumab ozogamicin"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"2";"";"Treatment name 2";"blinatumomab"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"remission rate"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-019-00991-w";"31140123";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-019-00991-w";"31140123";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"271"
"10.1007/s12325-019-00991-w";"31140123";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"134"
"10.1007/s12325-019-00991-w";"31140123";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"164"
"10.1007/s12325-019-00991-w";"31140123";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"53"
"10.1007/s12325-019-00991-w";"31140123";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"162"
"10.1007/s12325-019-00991-w";"31140123";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"53"
"10.1007/s12325-019-00991-w";"31140123";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-019-00991-w";"31140123";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-019-00991-w";"31140123";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.1007/s12325-019-00991-w";"31140123";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1007/s12325-019-00991-w";"31140123";"results";"1";"";"Primary outcome: treatment effect contrast";"OR"
"10.1007/s12325-019-00991-w";"31140123";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-019-00991-w";"31140123";"results";"1";"";"Primary outcome: unadjusted treatment effect";"2.63"
"10.1007/s12325-019-00991-w";"31140123";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[1.35;5.12]"
"10.1007/s12325-019-00991-w";"31140123";"results";"1";"";"Primary outcome: adjusted treatment effect";"2.81"
"10.1007/s12325-019-00991-w";"31140123";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[1.12;7.05]"
"10.1007/s12325-019-00991-w";"31140123";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"271"
"10.1007/s12325-019-00991-w";"31140123";"results";"2";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"134"
"10.1007/s12325-019-00991-w";"31140123";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"164"
"10.1007/s12325-019-00991-w";"31140123";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"138"
"10.1007/s12325-019-00991-w";"31140123";"results";"2";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"162"
"10.1007/s12325-019-00991-w";"31140123";"results";"2";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"53"
"10.1007/s12325-019-00991-w";"31140123";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-019-00991-w";"31140123";"results";"2";"";"Number of covariates adjusted for/matched on";"6"
"10.1007/s12325-019-00991-w";"31140123";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1007/s12325-019-00991-w";"31140123";"results";"2";"";"Primary outcome: treatment effect contrast";"OR"
"10.1007/s12325-019-00991-w";"31140123";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-019-00991-w";"31140123";"results";"2";"";"Primary outcome: unadjusted treatment effect";"2.63"
"10.1007/s12325-019-00991-w";"31140123";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[1.35;5.12]"
"10.1007/s12325-019-00991-w";"31140123";"results";"2";"";"Primary outcome: adjusted treatment effect";"3.91"
"10.1007/s12325-019-00991-w";"31140123";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[1.53;9.99]"
"10.1007/s12325-019-01156-5";"31813086";"general_information";"";"";"Medical Condition of Interest Name";"non-metastatic castration-resistant prostate cancer"
"10.1007/s12325-019-01156-5";"31813086";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.1007/s12325-019-01156-5";"31813086";"general_information";"";"";"Countries of last author affiliations";"germany"
"10.1007/s12325-019-01156-5";"31813086";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s12325-019-01156-5";"31813086";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s12325-019-01156-5";"31813086";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-019-01156-5";"31813086";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-019-01156-5";"31813086";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1007/s12325-019-01156-5";"31813086";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-019-01156-5";"31813086";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-019-01156-5";"31813086";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01946204"
"10.1007/s12325-019-01156-5";"31813086";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-019-01156-5";"31813086";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-019-01156-5";"31813086";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-019-01156-5";"31813086";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-019-01156-5";"31813086";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s12325-019-01156-5";"31813086";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02003924"
"10.1007/s12325-019-01156-5";"31813086";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-019-01156-5";"31813086";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-019-01156-5";"31813086";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-019-01156-5";"31813086";"methodology";"1";"";"Treatment name 1";"apalutamide"
"10.1007/s12325-019-01156-5";"31813086";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-019-01156-5";"31813086";"methodology";"1";"";"Treatment name 2";"enzalutamide"
"10.1007/s12325-019-01156-5";"31813086";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-019-01156-5";"31813086";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-019-01156-5";"31813086";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1007/s12325-019-01156-5";"31813086";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-019-01156-5";"31813086";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-019-01156-5";"31813086";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"metastasis free survival"
"10.1007/s12325-019-01156-5";"31813086";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1007/s12325-019-01156-5";"31813086";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s12325-019-01156-5";"31813086";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1007/s12325-019-01156-5";"31813086";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-019-01156-5";"31813086";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-019-01156-5";"31813086";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-019-01156-5";"31813086";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"933"
"10.1007/s12325-019-01156-5";"31813086";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"468"
"10.1007/s12325-019-01156-5";"31813086";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"806"
"10.1007/s12325-019-01156-5";"31813086";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"401"
"10.1007/s12325-019-01156-5";"31813086";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-019-01156-5";"31813086";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-019-01156-5";"31813086";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.1007/s12325-019-01156-5";"31813086";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1007/s12325-019-01156-5";"31813086";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1007/s12325-019-01156-5";"31813086";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-019-01156-5";"31813086";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.91"
"10.1007/s12325-019-01156-5";"31813086";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"p(hr < 1)] = 0.736"
"10.1007/s12325-019-01157-4";"31813087";"general_information";"";"";"Medical Condition of Interest Name";"non-metastatic castration-resistant prostate cancer"
"10.1007/s12325-019-01157-4";"31813087";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.1007/s12325-019-01157-4";"31813087";"general_information";"";"";"Countries of last author affiliations";"germany"
"10.1007/s12325-019-01157-4";"31813087";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s12325-019-01157-4";"31813087";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s12325-019-01157-4";"31813087";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-019-01157-4";"31813087";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-019-01157-4";"31813087";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1007/s12325-019-01157-4";"31813087";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-019-01157-4";"31813087";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-019-01157-4";"31813087";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01946204"
"10.1007/s12325-019-01157-4";"31813087";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-019-01157-4";"31813087";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-019-01157-4";"31813087";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-019-01157-4";"31813087";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-019-01157-4";"31813087";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s12325-019-01157-4";"31813087";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02003924"
"10.1007/s12325-019-01157-4";"31813087";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-019-01157-4";"31813087";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-019-01157-4";"31813087";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-019-01157-4";"31813087";"methodology";"1";"";"Treatment name 1";"apalutamide"
"10.1007/s12325-019-01157-4";"31813087";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-019-01157-4";"31813087";"methodology";"1";"";"Treatment name 2";"enzalutamide"
"10.1007/s12325-019-01157-4";"31813087";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-019-01157-4";"31813087";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-019-01157-4";"31813087";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1007/s12325-019-01157-4";"31813087";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-019-01157-4";"31813087";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-019-01157-4";"31813087";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"fatigue occurrence"
"10.1007/s12325-019-01157-4";"31813087";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s12325-019-01157-4";"31813087";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s12325-019-01157-4";"31813087";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1007/s12325-019-01157-4";"31813087";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-019-01157-4";"31813087";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-019-01157-4";"31813087";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-019-01157-4";"31813087";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"933"
"10.1007/s12325-019-01157-4";"31813087";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"468"
"10.1007/s12325-019-01157-4";"31813087";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"806"
"10.1007/s12325-019-01157-4";"31813087";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"401"
"10.1007/s12325-019-01157-4";"31813087";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-019-01157-4";"31813087";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-019-01157-4";"31813087";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.1007/s12325-019-01157-4";"31813087";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1007/s12325-019-01157-4";"31813087";"results";"1";"";"Primary outcome: treatment effect contrast";"OR"
"10.1007/s12325-019-01157-4";"31813087";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-019-01157-4";"31813087";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.57"
"10.1007/s12325-019-01157-4";"31813087";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"p(or < 1) = 0.995"
"10.1007/s12325-019-01173-4";"31865547";"general_information";"";"";"Medical Condition of Interest Name";"atrial fibrillation"
"10.1007/s12325-019-01173-4";"31865547";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1007/s12325-019-01173-4";"31865547";"general_information";"";"";"Countries of last author affiliations";"italy"
"10.1007/s12325-019-01173-4";"31865547";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s12325-019-01173-4";"31865547";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s12325-019-01173-4";"31865547";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-019-01173-4";"31865547";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-019-01173-4";"31865547";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s12325-019-01173-4";"31865547";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-019-01173-4";"31865547";"study_information";"";"1";"Clinical Trial";"No"
"10.1007/s12325-019-01173-4";"31865547";"study_information";"";"1";"Data source name (only if observational study or clinical trial without NCT)";"solimene et al. doi: 10.1007/s10840-018-0420-5"
"10.1007/s12325-019-01173-4";"31865547";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"italy"
"10.1007/s12325-019-01173-4";"31865547";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-019-01173-4";"31865547";"study_information";"";"2";"Clinical Trial";"No"
"10.1007/s12325-019-01173-4";"31865547";"study_information";"";"2";"Data source name (only if observational study or clinical trial without NCT)";"jourda et al."
"10.1007/s12325-019-01173-4";"31865547";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"france"
"10.1007/s12325-019-01173-4";"31865547";"study_information";"";"3";"Patient-level data used";"No"
"10.1007/s12325-019-01173-4";"31865547";"study_information";"";"3";"Clinical Trial";"No"
"10.1007/s12325-019-01173-4";"31865547";"study_information";"";"3";"Data source name (only if observational study or clinical trial without NCT)";"giovanni et al. 10.1111/jce.12409"
"10.1007/s12325-019-01173-4";"31865547";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"belgium"
"10.1007/s12325-019-01173-4";"31865547";"study_information";"";"4";"Patient-level data used";"No"
"10.1007/s12325-019-01173-4";"31865547";"study_information";"";"4";"Clinical Trial";"No"
"10.1007/s12325-019-01173-4";"31865547";"study_information";"";"4";"Data source name (only if observational study or clinical trial without NCT)";"zhao et al. doi: 10.1016/j.acvd.2017.01.015"
"10.1007/s12325-019-01173-4";"31865547";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"france"
"10.1007/s12325-019-01173-4";"31865547";"methodology";"1";"";"Treatment name 1";"ratiofrequency catheter ablation with ablation index"
"10.1007/s12325-019-01173-4";"31865547";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-019-01173-4";"31865547";"methodology";"1";"";"Treatment name 2";"ratiofrequency catheter ablation with cryoballoon"
"10.1007/s12325-019-01173-4";"31865547";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2;3;4"
"10.1007/s12325-019-01173-4";"31865547";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-019-01173-4";"31865547";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s12325-019-01173-4";"31865547";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/s12325-019-01173-4";"31865547";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-019-01173-4";"31865547";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"rate of arrythmia recurrence"
"10.1007/s12325-019-01173-4";"31865547";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1007/s12325-019-01173-4";"31865547";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1007/s12325-019-01173-4";"31865547";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s12325-019-01173-4";"31865547";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-019-01173-4";"31865547";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-019-01173-4";"31865547";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-019-01173-4";"31865547";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"155"
"10.1007/s12325-019-01173-4";"31865547";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"132"
"10.1007/s12325-019-01173-4";"31865547";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"125"
"10.1007/s12325-019-01173-4";"31865547";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-019-01173-4";"31865547";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-019-01173-4";"31865547";"results";"1";"";"Number of covariates adjusted for/matched on";"1"
"10.1007/s12325-019-01173-4";"31865547";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age"
"10.1007/s12325-019-01173-4";"31865547";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1007/s12325-019-01173-4";"31865547";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-019-01173-4";"31865547";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.42"
"10.1007/s12325-019-01173-4";"31865547";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.21;0.86]"
"10.1007/s12325-019-01173-4";"31865547";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.41"
"10.1007/s12325-019-01173-4";"31865547";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.20;0.85]"
"10.1007/s12325-019-0873-7";"30758745";"general_information";"";"";"Medical Condition of Interest Name";"relapsed or refractory acute lymphoblastic leukemia"
"10.1007/s12325-019-0873-7";"30758745";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1007/s12325-019-0873-7";"30758745";"general_information";"";"";"Countries of last author affiliations";"uk"
"10.1007/s12325-019-0873-7";"30758745";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s12325-019-0873-7";"30758745";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s12325-019-0873-7";"30758745";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-019-0873-7";"30758745";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-019-0873-7";"30758745";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1007/s12325-019-0873-7";"30758745";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-019-0873-7";"30758745";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-019-0873-7";"30758745";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02013167"
"10.1007/s12325-019-0873-7";"30758745";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-019-0873-7";"30758745";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-019-0873-7";"30758745";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-019-0873-7";"30758745";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-019-0873-7";"30758745";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s12325-019-0873-7";"30758745";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01564784"
"10.1007/s12325-019-0873-7";"30758745";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-019-0873-7";"30758745";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-019-0873-7";"30758745";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"1";"";"Treatment name 1";"blinatumomab"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"1";"";"Treatment name 2";"inotuzumab ozogamicin"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"restricted mean survival time at 12 months"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"Yes"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"2";"";"Treatment name 1";"blinatumomab"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"2";"";"Treatment name 2";"inotuzumab ozogamicin"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"2";"";"Anchored comparison?";"No"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"restricted mean survival time at 12 months"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-019-0873-7";"30758745";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"Yes"
"10.1007/s12325-019-0873-7";"30758745";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"164"
"10.1007/s12325-019-0873-7";"30758745";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"162"
"10.1007/s12325-019-0873-7";"30758745";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"203"
"10.1007/s12325-019-0873-7";"30758745";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"107"
"10.1007/s12325-019-0873-7";"30758745";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-019-0873-7";"30758745";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-019-0873-7";"30758745";"results";"1";"";"Number of covariates adjusted for/matched on";"9"
"10.1007/s12325-019-0873-7";"30758745";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1007/s12325-019-0873-7";"30758745";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1007/s12325-019-0873-7";"30758745";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-019-0873-7";"30758745";"results";"1";"";"Primary outcome: unadjusted treatment effect";"1.02"
"10.1007/s12325-019-0873-7";"30758745";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.16"
"10.1007/s12325-019-0873-7";"30758745";"results";"1";"";"Primary outcome: adjusted treatment effect";"1.62"
"10.1007/s12325-019-0873-7";"30758745";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.04"
"10.1007/s12325-019-0873-7";"30758745";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"107"
"10.1007/s12325-019-0873-7";"30758745";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"164"
"10.1007/s12325-019-0873-7";"30758745";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"203"
"10.1007/s12325-019-0873-7";"30758745";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-019-0873-7";"30758745";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-019-0873-7";"30758745";"results";"2";"";"Number of covariates adjusted for/matched on";"9"
"10.1007/s12325-019-0873-7";"30758745";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1007/s12325-019-0873-7";"30758745";"results";"2";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1007/s12325-019-0873-7";"30758745";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-019-0873-7";"30758745";"results";"2";"";"Primary outcome: unadjusted treatment effect";"-0.18"
"10.1007/s12325-019-0873-7";"30758745";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.69"
"10.1007/s12325-019-0873-7";"30758745";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.15"
"10.1007/s12325-019-0873-7";"30758745";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.76"
"10.1007/s12325-020-01298-x";"32222903";"general_information";"";"";"Medical Condition of Interest Name";"age-related macular degeneration"
"10.1007/s12325-020-01298-x";"32222903";"general_information";"";"";"Countries of first author affiliations";"japan"
"10.1007/s12325-020-01298-x";"32222903";"general_information";"";"";"Countries of last author affiliations";"germany"
"10.1007/s12325-020-01298-x";"32222903";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s12325-020-01298-x";"32222903";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s12325-020-01298-x";"32222903";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-020-01298-x";"32222903";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-020-01298-x";"32222903";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02305238"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"japan"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"4"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00509795"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"3";"Patient-level data used";"No"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00637377"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-020-01298-x";"32222903";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-020-01298-x";"32222903";"methodology";"1";"";"Treatment name 1";"intravitreally administered aflibercept treat- + -extent 2 weeks"
"10.1007/s12325-020-01298-x";"32222903";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-020-01298-x";"32222903";"methodology";"1";"";"Treatment name 2";"intravitreally administered aflibercept 8 weeks"
"10.1007/s12325-020-01298-x";"32222903";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2;3"
"10.1007/s12325-020-01298-x";"32222903";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-020-01298-x";"32222903";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s12325-020-01298-x";"32222903";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/s12325-020-01298-x";"32222903";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-020-01298-x";"32222903";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"difference in visual acuity gain"
"10.1007/s12325-020-01298-x";"32222903";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/s12325-020-01298-x";"32222903";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s12325-020-01298-x";"32222903";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s12325-020-01298-x";"32222903";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s12325-020-01298-x";"32222903";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-020-01298-x";"32222903";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-020-01298-x";"32222903";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"607"
"10.1007/s12325-020-01298-x";"32222903";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"124"
"10.1007/s12325-020-01298-x";"32222903";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-020-01298-x";"32222903";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-020-01298-x";"32222903";"results";"1";"";"Number of covariates adjusted for/matched on";"3"
"10.1007/s12325-020-01298-x";"32222903";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1007/s12325-020-01298-x";"32222903";"results";"1";"";"Primary outcome: treatment effect contrast";"Median difference"
"10.1007/s12325-020-01298-x";"32222903";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-020-01298-x";"32222903";"results";"1";"";"Primary outcome: adjusted treatment effect";"-0.99"
"10.1007/s12325-020-01298-x";"32222903";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-3.90;1.93]"
"10.1007/s12325-020-01378-y";"32424805";"general_information";"";"";"Medical Condition of Interest Name";"advanced hepatocellular carcinoma"
"10.1007/s12325-020-01378-y";"32424805";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1007/s12325-020-01378-y";"32424805";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1007/s12325-020-01378-y";"32424805";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s12325-020-01378-y";"32424805";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s12325-020-01378-y";"32424805";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-020-01378-y";"32424805";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-020-01378-y";"32424805";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s12325-020-01378-y";"32424805";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-020-01378-y";"32424805";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-020-01378-y";"32424805";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01908426"
"10.1007/s12325-020-01378-y";"32424805";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-020-01378-y";"32424805";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-020-01378-y";"32424805";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-020-01378-y";"32424805";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-020-01378-y";"32424805";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s12325-020-01378-y";"32424805";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01774344"
"10.1007/s12325-020-01378-y";"32424805";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-020-01378-y";"32424805";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-020-01378-y";"32424805";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"1";"";"Treatment name 1";"cabozantinib"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"1";"";"Treatment name 2";"regorafenib"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"2";"";"Treatment name 1";"cabozantinib"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"2";"";"Treatment name 2";"regorafenib"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"frequency of grade 3 or 4 teaes (treatment-emergent adverse events) : fatigue"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-020-01378-y";"32424805";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-020-01378-y";"32424805";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"379"
"10.1007/s12325-020-01378-y";"32424805";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"326"
"10.1007/s12325-020-01378-y";"32424805";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"187"
"10.1007/s12325-020-01378-y";"32424805";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-020-01378-y";"32424805";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-020-01378-y";"32424805";"results";"1";"";"Number of covariates adjusted for/matched on";"11"
"10.1007/s12325-020-01378-y";"32424805";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)"
"10.1007/s12325-020-01378-y";"32424805";"results";"1";"";"Primary outcome: treatment effect contrast";"Median difference"
"10.1007/s12325-020-01378-y";"32424805";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-020-01378-y";"32424805";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.8"
"10.1007/s12325-020-01378-y";"32424805";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.3474"
"10.1007/s12325-020-01378-y";"32424805";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"379"
"10.1007/s12325-020-01378-y";"32424805";"results";"2";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"194"
"10.1007/s12325-020-01378-y";"32424805";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"470"
"10.1007/s12325-020-01378-y";"32424805";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"187"
"10.1007/s12325-020-01378-y";"32424805";"results";"2";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"237"
"10.1007/s12325-020-01378-y";"32424805";"results";"2";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"81"
"10.1007/s12325-020-01378-y";"32424805";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-020-01378-y";"32424805";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-020-01378-y";"32424805";"results";"2";"";"Number of covariates adjusted for/matched on";"10"
"10.1007/s12325-020-01378-y";"32424805";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)"
"10.1007/s12325-020-01378-y";"32424805";"results";"2";"";"Primary outcome: treatment effect contrast";"Log-OR"
"10.1007/s12325-020-01378-y";"32424805";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-020-01378-y";"32424805";"results";"2";"";"Primary outcome: unadjusted treatment effect";"0.07"
"10.1007/s12325-020-01378-y";"32424805";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.9404"
"10.1007/s12325-020-01378-y";"32424805";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.09"
"10.1007/s12325-020-01378-y";"32424805";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.9313"
"10.1007/s12325-020-01599-1";"33377987";"general_information";"";"";"Medical Condition of Interest Name";"haemophilia a"
"10.1007/s12325-020-01599-1";"33377987";"general_information";"";"";"Countries of first author affiliations";"sweden"
"10.1007/s12325-020-01599-1";"33377987";"general_information";"";"";"Countries of last author affiliations";"sweden"
"10.1007/s12325-020-01599-1";"33377987";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.1007/s12325-020-01599-1";"33377987";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Not mentioned"
"10.1007/s12325-020-01599-1";"33377987";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-020-01599-1";"33377987";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-020-01599-1";"33377987";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1007/s12325-020-01599-1";"33377987";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-020-01599-1";"33377987";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-020-01599-1";"33377987";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01181128"
"10.1007/s12325-020-01599-1";"33377987";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-020-01599-1";"33377987";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-020-01599-1";"33377987";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s12325-020-01599-1";"33377987";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-020-01599-1";"33377987";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s12325-020-01599-1";"33377987";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01580293"
"10.1007/s12325-020-01599-1";"33377987";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-020-01599-1";"33377987";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2, 3"
"10.1007/s12325-020-01599-1";"33377987";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"1";"";"Treatment name 1";"recombinant fviiifc"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"1";"";"Treatment name 2";"damoctocog alfa pegol (pooled prophylaxis)"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"mean annualized bleeding rates"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"2";"";"Treatment name 1";"recombinant fviiifc"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"2";"";"Treatment name 2";"damoctocog alfa pegol twice weekly"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"2";"";"Anchored comparison?";"No"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"mean annualised bleeding rate"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"3";"";"Treatment name 1";"recombinant fviiifc"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"3";"";"Treatment name 2";"damoctocog alfa pegol q5d"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"3";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"3";"";"Anchored comparison?";"No"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"mean annualised bleeding rate"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"3";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"4";"";"Treatment name 1";"recombinant fviiifc"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"4";"";"Treatment name 2";"damoctocog alfa pegol q7d"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"4";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"4";"";"Anchored comparison?";"No"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"4";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"mean annualised bleeding rate"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"4";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1007/s12325-020-01599-1";"33377987";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-020-01599-1";"33377987";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"110"
"10.1007/s12325-020-01599-1";"33377987";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"117"
"10.1007/s12325-020-01599-1";"33377987";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"81"
"10.1007/s12325-020-01599-1";"33377987";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-020-01599-1";"33377987";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-020-01599-1";"33377987";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.1007/s12325-020-01599-1";"33377987";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)"
"10.1007/s12325-020-01599-1";"33377987";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1007/s12325-020-01599-1";"33377987";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-020-01599-1";"33377987";"results";"1";"";"Primary outcome: unadjusted treatment effect";"-2"
"10.1007/s12325-020-01599-1";"33377987";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-3.5;-0.4]"
"10.1007/s12325-020-01599-1";"33377987";"results";"1";"";"Primary outcome: adjusted treatment effect";"-1.9"
"10.1007/s12325-020-01599-1";"33377987";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-3.5;-0.4]"
"10.1007/s12325-020-01599-1";"33377987";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"24"
"10.1007/s12325-020-01599-1";"33377987";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"117"
"10.1007/s12325-020-01599-1";"33377987";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"62"
"10.1007/s12325-020-01599-1";"33377987";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-020-01599-1";"33377987";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-020-01599-1";"33377987";"results";"2";"";"Number of covariates adjusted for/matched on";"6"
"10.1007/s12325-020-01599-1";"33377987";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)"
"10.1007/s12325-020-01599-1";"33377987";"results";"2";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1007/s12325-020-01599-1";"33377987";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-020-01599-1";"33377987";"results";"2";"";"Primary outcome: unadjusted treatment effect";"-2"
"10.1007/s12325-020-01599-1";"33377987";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-4.6;-0.4]"
"10.1007/s12325-020-01599-1";"33377987";"results";"2";"";"Primary outcome: adjusted treatment effect";"-1.6"
"10.1007/s12325-020-01599-1";"33377987";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-4.2;1.1]"
"10.1007/s12325-020-01599-1";"33377987";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"43"
"10.1007/s12325-020-01599-1";"33377987";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"117"
"10.1007/s12325-020-01599-1";"33377987";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"43"
"10.1007/s12325-020-01599-1";"33377987";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-020-01599-1";"33377987";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-020-01599-1";"33377987";"results";"3";"";"Number of covariates adjusted for/matched on";"6"
"10.1007/s12325-020-01599-1";"33377987";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)"
"10.1007/s12325-020-01599-1";"33377987";"results";"3";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1007/s12325-020-01599-1";"33377987";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-020-01599-1";"33377987";"results";"3";"";"Primary outcome: unadjusted treatment effect";"-0.4"
"10.1007/s12325-020-01599-1";"33377987";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-1.9;1.1]"
"10.1007/s12325-020-01599-1";"33377987";"results";"3";"";"Primary outcome: adjusted treatment effect";"-0.6"
"10.1007/s12325-020-01599-1";"33377987";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-2.0;0.8]"
"10.1007/s12325-020-01599-1";"33377987";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"43"
"10.1007/s12325-020-01599-1";"33377987";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"117"
"10.1007/s12325-020-01599-1";"33377987";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"45"
"10.1007/s12325-020-01599-1";"33377987";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-020-01599-1";"33377987";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-020-01599-1";"33377987";"results";"4";"";"Number of covariates adjusted for/matched on";"6"
"10.1007/s12325-020-01599-1";"33377987";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)"
"10.1007/s12325-020-01599-1";"33377987";"results";"4";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1007/s12325-020-01599-1";"33377987";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-020-01599-1";"33377987";"results";"4";"";"Primary outcome: unadjusted treatment effect";"-3.5"
"10.1007/s12325-020-01599-1";"33377987";"results";"4";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-6.6;-0.4]"
"10.1007/s12325-020-01599-1";"33377987";"results";"4";"";"Primary outcome: adjusted treatment effect";"-3.3"
"10.1007/s12325-020-01599-1";"33377987";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-6.4;-0.2]"
"10.1007/s12325-021-01700-2";"33822328";"general_information";"";"";"Medical Condition of Interest Name";"hepatocellular carcinoma"
"10.1007/s12325-021-01700-2";"33822328";"general_information";"";"";"Countries of first author affiliations";"germany"
"10.1007/s12325-021-01700-2";"33822328";"general_information";"";"";"Countries of last author affiliations";"germany"
"10.1007/s12325-021-01700-2";"33822328";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s12325-021-01700-2";"33822328";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s12325-021-01700-2";"33822328";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-021-01700-2";"33822328";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-021-01700-2";"33822328";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1007/s12325-021-01700-2";"33822328";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-021-01700-2";"33822328";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-021-01700-2";"33822328";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01908426"
"10.1007/s12325-021-01700-2";"33822328";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-021-01700-2";"33822328";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-021-01700-2";"33822328";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-021-01700-2";"33822328";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-021-01700-2";"33822328";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s12325-021-01700-2";"33822328";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02435433"
"10.1007/s12325-021-01700-2";"33822328";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-021-01700-2";"33822328";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-021-01700-2";"33822328";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-021-01700-2";"33822328";"methodology";"1";"";"Treatment name 1";"cabozantinib"
"10.1007/s12325-021-01700-2";"33822328";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-021-01700-2";"33822328";"methodology";"1";"";"Treatment name 2";"ramucirumab"
"10.1007/s12325-021-01700-2";"33822328";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-021-01700-2";"33822328";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-021-01700-2";"33822328";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s12325-021-01700-2";"33822328";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-021-01700-2";"33822328";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-021-01700-2";"33822328";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"median overall survival"
"10.1007/s12325-021-01700-2";"33822328";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/s12325-021-01700-2";"33822328";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1007/s12325-021-01700-2";"33822328";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1007/s12325-021-01700-2";"33822328";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-021-01700-2";"33822328";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-021-01700-2";"33822328";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"Yes"
"10.1007/s12325-021-01700-2";"33822328";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"197"
"10.1007/s12325-021-01700-2";"33822328";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"114"
"10.1007/s12325-021-01700-2";"33822328";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"63"
"10.1007/s12325-021-01700-2";"33822328";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1007/s12325-021-01700-2";"33822328";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-021-01700-2";"33822328";"results";"1";"";"Number of covariates adjusted for/matched on";"9"
"10.1007/s12325-021-01700-2";"33822328";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1007/s12325-021-01700-2";"33822328";"results";"1";"";"Primary outcome: treatment effect contrast";"Median difference"
"10.1007/s12325-021-01700-2";"33822328";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-021-01700-2";"33822328";"results";"1";"";"Primary outcome: adjusted treatment effect";"1.9"
"10.1007/s12325-021-01700-2";"33822328";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.104"
"10.1007/s12325-021-01756-0";"33970454";"general_information";"";"";"Medical Condition of Interest Name";"relapsed/refractory diffuse large b-cell lymphoma"
"10.1007/s12325-021-01756-0";"33970454";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1007/s12325-021-01756-0";"33970454";"general_information";"";"";"Countries of last author affiliations";"switzerland"
"10.1007/s12325-021-01756-0";"33970454";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s12325-021-01756-0";"33970454";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s12325-021-01756-0";"33970454";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-021-01756-0";"33970454";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-021-01756-0";"33970454";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s12325-021-01756-0";"33970454";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-021-01756-0";"33970454";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-021-01756-0";"33970454";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02631044"
"10.1007/s12325-021-01756-0";"33970454";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1007/s12325-021-01756-0";"33970454";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1"
"10.1007/s12325-021-01756-0";"33970454";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s12325-021-01756-0";"33970454";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-021-01756-0";"33970454";"study_information";"";"2";"Clinical Trial";"No"
"10.1007/s12325-021-01756-0";"33970454";"study_information";"";"2";"Data source name (only if observational study or clinical trial without NCT)";"scholar-1"
"10.1007/s12325-021-01756-0";"33970454";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-021-01756-0";"33970454";"methodology";"1";"";"Treatment name 1";"lisocabtagene maraleucel"
"10.1007/s12325-021-01756-0";"33970454";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-021-01756-0";"33970454";"methodology";"1";"";"Treatment name 2";"salvage chemotherapy"
"10.1007/s12325-021-01756-0";"33970454";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-021-01756-0";"33970454";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-021-01756-0";"33970454";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s12325-021-01756-0";"33970454";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-021-01756-0";"33970454";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-021-01756-0";"33970454";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1007/s12325-021-01756-0";"33970454";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s12325-021-01756-0";"33970454";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s12325-021-01756-0";"33970454";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s12325-021-01756-0";"33970454";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s12325-021-01756-0";"33970454";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-021-01756-0";"33970454";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-021-01756-0";"33970454";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"523"
"10.1007/s12325-021-01756-0";"33970454";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"248"
"10.1007/s12325-021-01756-0";"33970454";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"143"
"10.1007/s12325-021-01756-0";"33970454";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-021-01756-0";"33970454";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-021-01756-0";"33970454";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.1007/s12325-021-01756-0";"33970454";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1007/s12325-021-01756-0";"33970454";"results";"1";"";"Primary outcome: treatment effect contrast";"OR"
"10.1007/s12325-021-01756-0";"33970454";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-021-01756-0";"33970454";"results";"1";"";"Primary outcome: unadjusted treatment effect";"7.7"
"10.1007/s12325-021-01756-0";"33970454";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.1007/s12325-021-01756-0";"33970454";"results";"1";"";"Primary outcome: adjusted treatment effect";"7"
"10.1007/s12325-021-01756-0";"33970454";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1007/s12325-021-01846-z";"34250584";"general_information";"";"";"Medical Condition of Interest Name";"persistent atrial fibrillation"
"10.1007/s12325-021-01846-z";"34250584";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1007/s12325-021-01846-z";"34250584";"general_information";"";"";"Countries of last author affiliations";"uk"
"10.1007/s12325-021-01846-z";"34250584";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s12325-021-01846-z";"34250584";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s12325-021-01846-z";"34250584";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-021-01846-z";"34250584";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-021-01846-z";"34250584";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"1";"Clinical Trial";"No"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"1";"Data source name (only if observational study or clinical trial without NCT)";"hussein et al. (2017)"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"2";"Clinical Trial";"No"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02628730"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"3";"Patient-level data used";"Yes"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"3";"Clinical Trial";"No"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"3";"Data source name (only if observational study or clinical trial without NCT)";"solimene et al. (2019)"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"4";"Patient-level data used";"Yes"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"4";"Clinical Trial";"No"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03277976"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"italy"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"4";"Data source name (only if observational study or clinical trial without NCT)";"stabile et al. (2020)"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"5";"Patient-level data used";"No"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"5";"Clinical Trial";"No"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"5";"Data source name (only if observational study or clinical trial without NCT)";"gramlich et al. (2019)"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"6";"Patient-level data used";"No"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"6";"Clinical Trial";"No"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"6";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02213731"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"6";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"6";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"7";"Patient-level data used";"No"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"7";"Clinical Trial";"No"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"7";"Data source name (only if observational study or clinical trial without NCT)";"circonte et al. (2015)"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"8";"Patient-level data used";"No"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"8";"Clinical Trial";"No"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"8";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03012841"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"8";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-021-01846-z";"34250584";"study_information";"";"8";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s12325-021-01846-z";"34250584";"methodology";"1";"";"Treatment name 1";"thermocool smarttouchtm catheter or the thermocool smarttouchtm sf catheter with ai/visitag surpointtm module"
"10.1007/s12325-021-01846-z";"34250584";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2;3;4"
"10.1007/s12325-021-01846-z";"34250584";"methodology";"1";"";"Treatment name 2";"cb catheter (arctic front advancetm)"
"10.1007/s12325-021-01846-z";"34250584";"methodology";"1";"";"Study 'number(s)' for treatment 2";"5;6;7;8"
"10.1007/s12325-021-01846-z";"34250584";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-021-01846-z";"34250584";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s12325-021-01846-z";"34250584";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/s12325-021-01846-z";"34250584";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1007/s12325-021-01846-z";"34250584";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"rate of arrhythmia recurrence"
"10.1007/s12325-021-01846-z";"34250584";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1007/s12325-021-01846-z";"34250584";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1007/s12325-021-01846-z";"34250584";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s12325-021-01846-z";"34250584";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-021-01846-z";"34250584";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-021-01846-z";"34250584";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-021-01846-z";"34250584";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"389"
"10.1007/s12325-021-01846-z";"34250584";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"191"
"10.1007/s12325-021-01846-z";"34250584";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"156"
"10.1007/s12325-021-01846-z";"34250584";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1007/s12325-021-01846-z";"34250584";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-021-01846-z";"34250584";"results";"1";"";"Number of covariates adjusted for/matched on";"4"
"10.1007/s12325-021-01846-z";"34250584";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1007/s12325-021-01846-z";"34250584";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1007/s12325-021-01846-z";"34250584";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-021-01846-z";"34250584";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.39"
"10.1007/s12325-021-01846-z";"34250584";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.27;0.56]"
"10.1007/s12325-021-01846-z";"34250584";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.35"
"10.1007/s12325-021-01846-z";"34250584";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.23;0.52]"
"10.1007/s12325-021-01853-0";"34368918";"general_information";"";"";"Medical Condition of Interest Name";"severe haemophilia a"
"10.1007/s12325-021-01853-0";"34368918";"general_information";"";"";"Countries of first author affiliations";"spain"
"10.1007/s12325-021-01853-0";"34368918";"general_information";"";"";"Countries of last author affiliations";"portugal"
"10.1007/s12325-021-01853-0";"34368918";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s12325-021-01853-0";"34368918";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s12325-021-01853-0";"34368918";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-021-01853-0";"34368918";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-021-01853-0";"34368918";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01486927"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2, 3"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"2";"Data source name (only if observational study or clinical trial without NCT)";"rahf-pfm-2004 - part 2 10.1111/j.1365-2516.2004.00932.x"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"3";"Patient-level data used";"No"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00243386"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"4"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"4";"Patient-level data used";"No"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02172950"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-021-01853-0";"34368918";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"1";"";"Treatment name 1";"rviii-singlechain lonoctocog alfa"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"1";"";"Treatment name 2";"rahf-pfm octocog alfa"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"mean annualized bleeding rates"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"2";"";"Treatment name 1";"rviii-singlechain lonoctocog alfa"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"2";"";"Treatment name 2";"rahf-pfm octocog alf"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"2";"";"Anchored comparison?";"No"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"mean annualized bleeding rates"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"3";"";"Treatment name 1";"rviii-singlechain lonoctocog alfa"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"3";"";"Treatment name 2";"rfviiifc (efmoroctocog alfa)"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"3";"";"Study 'number(s)' for treatment 2";"4"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"3";"";"Anchored comparison?";"No"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"mean annualized bleeding rates"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"3";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-021-01853-0";"34368918";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-021-01853-0";"34368918";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"111"
"10.1007/s12325-021-01853-0";"34368918";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"146"
"10.1007/s12325-021-01853-0";"34368918";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"25.01"
"10.1007/s12325-021-01853-0";"34368918";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-021-01853-0";"34368918";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-021-01853-0";"34368918";"results";"1";"";"Number of covariates adjusted for/matched on";"4"
"10.1007/s12325-021-01853-0";"34368918";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Race/ethnicity, Other(s)"
"10.1007/s12325-021-01853-0";"34368918";"results";"1";"";"Primary outcome: treatment effect contrast";"RR"
"10.1007/s12325-021-01853-0";"34368918";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-021-01853-0";"34368918";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.55"
"10.1007/s12325-021-01853-0";"34368918";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.17;3.12]"
"10.1007/s12325-021-01853-0";"34368918";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.74"
"10.1007/s12325-021-01853-0";"34368918";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.16;3.48]"
"10.1007/s12325-021-01853-0";"34368918";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"32"
"10.1007/s12325-021-01853-0";"34368918";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"146"
"10.1007/s12325-021-01853-0";"34368918";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"79"
"10.1007/s12325-021-01853-0";"34368918";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-021-01853-0";"34368918";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-021-01853-0";"34368918";"results";"2";"";"Number of covariates adjusted for/matched on";"2"
"10.1007/s12325-021-01853-0";"34368918";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Race/ethnicity"
"10.1007/s12325-021-01853-0";"34368918";"results";"2";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1007/s12325-021-01853-0";"34368918";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-021-01853-0";"34368918";"results";"2";"";"Primary outcome: unadjusted treatment effect";"0.07"
"10.1007/s12325-021-01853-0";"34368918";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-3.09;3.23]"
"10.1007/s12325-021-01853-0";"34368918";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.01"
"10.1007/s12325-021-01853-0";"34368918";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-2.36;2.37]"
"10.1007/s12325-021-01853-0";"34368918";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"118"
"10.1007/s12325-021-01853-0";"34368918";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"146"
"10.1007/s12325-021-01853-0";"34368918";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"123.6"
"10.1007/s12325-021-01853-0";"34368918";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-021-01853-0";"34368918";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-021-01853-0";"34368918";"results";"3";"";"Number of covariates adjusted for/matched on";"4"
"10.1007/s12325-021-01853-0";"34368918";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Race/ethnicity, Other(s)"
"10.1007/s12325-021-01853-0";"34368918";"results";"3";"";"Primary outcome: treatment effect contrast";"RR"
"10.1007/s12325-021-01853-0";"34368918";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-021-01853-0";"34368918";"results";"3";"";"Primary outcome: unadjusted treatment effect";"1.14"
"10.1007/s12325-021-01853-0";"34368918";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.82;1.57]"
"10.1007/s12325-021-01853-0";"34368918";"results";"3";"";"Primary outcome: adjusted treatment effect";"1.18"
"10.1007/s12325-021-01853-0";"34368918";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.85;1.65]"
"10.1007/s12325-021-01884-7";"34561812";"general_information";"";"";"Medical Condition of Interest Name";"relapsed/refractory multiple myeloma"
"10.1007/s12325-021-01884-7";"34561812";"general_information";"";"";"Countries of first author affiliations";"france"
"10.1007/s12325-021-01884-7";"34561812";"general_information";"";"";"Countries of last author affiliations";"uk"
"10.1007/s12325-021-01884-7";"34561812";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s12325-021-01884-7";"34561812";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s12325-021-01884-7";"34561812";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-021-01884-7";"34561812";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-021-01884-7";"34561812";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s12325-021-01884-7";"34561812";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-021-01884-7";"34561812";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-021-01884-7";"34561812";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03525678"
"10.1007/s12325-021-01884-7";"34561812";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-021-01884-7";"34561812";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.1007/s12325-021-01884-7";"34561812";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s12325-021-01884-7";"34561812";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-021-01884-7";"34561812";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s12325-021-01884-7";"34561812";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02336815"
"10.1007/s12325-021-01884-7";"34561812";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-021-01884-7";"34561812";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2"
"10.1007/s12325-021-01884-7";"34561812";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s12325-021-01884-7";"34561812";"methodology";"1";"";"Treatment name 1";"belantamab mafodotin"
"10.1007/s12325-021-01884-7";"34561812";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-021-01884-7";"34561812";"methodology";"1";"";"Treatment name 2";"selinexor + low-dose dexamethasone"
"10.1007/s12325-021-01884-7";"34561812";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-021-01884-7";"34561812";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-021-01884-7";"34561812";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s12325-021-01884-7";"34561812";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-021-01884-7";"34561812";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-021-01884-7";"34561812";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1007/s12325-021-01884-7";"34561812";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1007/s12325-021-01884-7";"34561812";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s12325-021-01884-7";"34561812";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s12325-021-01884-7";"34561812";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s12325-021-01884-7";"34561812";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-021-01884-7";"34561812";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-021-01884-7";"34561812";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"123"
"10.1007/s12325-021-01884-7";"34561812";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"95"
"10.1007/s12325-021-01884-7";"34561812";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"63.46"
"10.1007/s12325-021-01884-7";"34561812";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1007/s12325-021-01884-7";"34561812";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-021-01884-7";"34561812";"results";"1";"";"Number of covariates adjusted for/matched on";"8"
"10.1007/s12325-021-01884-7";"34561812";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1007/s12325-021-01884-7";"34561812";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1007/s12325-021-01884-7";"34561812";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-021-01884-7";"34561812";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.6"
"10.1007/s12325-021-01884-7";"34561812";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.01"
"10.1007/s12325-021-01884-7";"34561812";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.53"
"10.1007/s12325-021-01884-7";"34561812";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.005"
"10.1007/s12325-021-01885-6";"34797506";"general_information";"";"";"Medical Condition of Interest Name";"non-metastatic castration-resistant prostate cancer receiving androgen deprivation therapy"
"10.1007/s12325-021-01885-6";"34797506";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.1007/s12325-021-01885-6";"34797506";"general_information";"";"";"Countries of last author affiliations";"germany"
"10.1007/s12325-021-01885-6";"34797506";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.1007/s12325-021-01885-6";"34797506";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Not mentioned"
"10.1007/s12325-021-01885-6";"34797506";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-021-01885-6";"34797506";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-021-01885-6";"34797506";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1007/s12325-021-01885-6";"34797506";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-021-01885-6";"34797506";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-021-01885-6";"34797506";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01946204"
"10.1007/s12325-021-01885-6";"34797506";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-021-01885-6";"34797506";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-021-01885-6";"34797506";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-021-01885-6";"34797506";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-021-01885-6";"34797506";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s12325-021-01885-6";"34797506";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02200614"
"10.1007/s12325-021-01885-6";"34797506";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-021-01885-6";"34797506";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-021-01885-6";"34797506";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-021-01885-6";"34797506";"methodology";"1";"";"Treatment name 1";"apalutamide"
"10.1007/s12325-021-01885-6";"34797506";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-021-01885-6";"34797506";"methodology";"1";"";"Treatment name 2";"darolutamide"
"10.1007/s12325-021-01885-6";"34797506";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-021-01885-6";"34797506";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-021-01885-6";"34797506";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1007/s12325-021-01885-6";"34797506";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-021-01885-6";"34797506";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1007/s12325-021-01885-6";"34797506";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"metastasis-free survival"
"10.1007/s12325-021-01885-6";"34797506";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1007/s12325-021-01885-6";"34797506";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s12325-021-01885-6";"34797506";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s12325-021-01885-6";"34797506";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-021-01885-6";"34797506";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-021-01885-6";"34797506";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-021-01885-6";"34797506";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-021-01885-6";"34797506";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-021-01885-6";"34797506";"results";"1";"";"Number of covariates adjusted for/matched on";"9"
"10.1007/s12325-021-01885-6";"34797506";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)"
"10.1007/s12325-021-01885-6";"34797506";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1007/s12325-021-01885-6";"34797506";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-021-01885-6";"34797506";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.7"
"10.1007/s12325-021-01885-6";"34797506";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.51.0.98]"
"10.1007/s12325-021-01885-6";"34797506";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"955"
"10.1007/s12325-021-01885-6";"34797506";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"554"
"10.1007/s12325-022-02054-z";"35157216";"general_information";"";"";"Medical Condition of Interest Name";"relapsed or refractory follicular lymphoma"
"10.1007/s12325-022-02054-z";"35157216";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1007/s12325-022-02054-z";"35157216";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1007/s12325-022-02054-z";"35157216";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s12325-022-02054-z";"35157216";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-022-02054-z";"35157216";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01897571"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01282424"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"3";"Patient-level data used";"No"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"2"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01882803"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"4";"Patient-level data used";"No"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01660451"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"2"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"5";"Patient-level data used";"No"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02793583"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"2"
"10.1007/s12325-022-02054-z";"35157216";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"1";"";"Treatment name 1";"tazemetostat"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"1";"";"Treatment name 2";"idelalisib"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"grade >= 3 treatment emergent adverse event"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"2";"";"Treatment name 1";"tazemetostat"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"2";"";"Treatment name 2";"duvelisib"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"2";"";"Anchored comparison?";"No"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"grade >= 3 treatment emergent adverse event"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"3";"";"Treatment name 1";"tazemetostat"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"3";"";"Treatment name 2";"copanlisib"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"3";"";"Study 'number(s)' for treatment 2";"4"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"3";"";"Anchored comparison?";"No"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"grade >= 3 treatment emergent adverse event"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"3";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"4";"";"Treatment name 1";"tazemetostat"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"4";"";"Treatment name 2";"umbralisib"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"4";"";"Study 'number(s)' for treatment 2";"5"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"4";"";"Anchored comparison?";"No"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"4";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"grade >= 3 treatment emergent adverse event"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"4";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-022-02054-z";"35157216";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s12325-022-02054-z";"35157216";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"72"
"10.1007/s12325-022-02054-z";"35157216";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"99"
"10.1007/s12325-022-02054-z";"35157216";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"36"
"10.1007/s12325-022-02054-z";"35157216";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-022-02054-z";"35157216";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1007/s12325-022-02054-z";"35157216";"results";"1";"";"Primary outcome: treatment effect contrast";"RR"
"10.1007/s12325-022-02054-z";"35157216";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-022-02054-z";"35157216";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.59"
"10.1007/s12325-022-02054-z";"35157216";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.1007/s12325-022-02054-z";"35157216";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.45"
"10.1007/s12325-022-02054-z";"35157216";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1007/s12325-022-02054-z";"35157216";"results";"1";"";"Number of covariates adjusted for/matched on";"8"
"10.1007/s12325-022-02054-z";"35157216";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"129"
"10.1007/s12325-022-02054-z";"35157216";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"99"
"10.1007/s12325-022-02054-z";"35157216";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"24"
"10.1007/s12325-022-02054-z";"35157216";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-022-02054-z";"35157216";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"results";"2";"";"Number of covariates adjusted for/matched on";"7"
"10.1007/s12325-022-02054-z";"35157216";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1007/s12325-022-02054-z";"35157216";"results";"2";"";"Primary outcome: treatment effect contrast";"RR"
"10.1007/s12325-022-02054-z";"35157216";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-022-02054-z";"35157216";"results";"2";"";"Primary outcome: unadjusted treatment effect";"0.45"
"10.1007/s12325-022-02054-z";"35157216";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.1007/s12325-022-02054-z";"35157216";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.35"
"10.1007/s12325-022-02054-z";"35157216";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1007/s12325-022-02054-z";"35157216";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"142"
"10.1007/s12325-022-02054-z";"35157216";"results";"3";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"na"
"10.1007/s12325-022-02054-z";"35157216";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"99"
"10.1007/s12325-022-02054-z";"35157216";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"66"
"10.1007/s12325-022-02054-z";"35157216";"results";"3";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"na"
"10.1007/s12325-022-02054-z";"35157216";"results";"3";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"na"
"10.1007/s12325-022-02054-z";"35157216";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-022-02054-z";"35157216";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"results";"3";"";"Number of covariates adjusted for/matched on";"7"
"10.1007/s12325-022-02054-z";"35157216";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1007/s12325-022-02054-z";"35157216";"results";"3";"";"Primary outcome: treatment effect contrast";"RR"
"10.1007/s12325-022-02054-z";"35157216";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-022-02054-z";"35157216";"results";"3";"";"Primary outcome: unadjusted treatment effect";"0.47"
"10.1007/s12325-022-02054-z";"35157216";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.1007/s12325-022-02054-z";"35157216";"results";"3";"";"Primary outcome: adjusted treatment effect";"0.37"
"10.1007/s12325-022-02054-z";"35157216";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1007/s12325-022-02054-z";"35157216";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"208"
"10.1007/s12325-022-02054-z";"35157216";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"99"
"10.1007/s12325-022-02054-z";"35157216";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"60"
"10.1007/s12325-022-02054-z";"35157216";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-022-02054-z";"35157216";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-022-02054-z";"35157216";"results";"4";"";"Number of covariates adjusted for/matched on";"7"
"10.1007/s12325-022-02054-z";"35157216";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1007/s12325-022-02054-z";"35157216";"results";"4";"";"Primary outcome: treatment effect contrast";"RR"
"10.1007/s12325-022-02054-z";"35157216";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-022-02054-z";"35157216";"results";"4";"";"Primary outcome: unadjusted treatment effect";"0.74"
"10.1007/s12325-022-02054-z";"35157216";"results";"4";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.05"
"10.1007/s12325-022-02054-z";"35157216";"results";"4";"";"Primary outcome: adjusted treatment effect";"0.65"
"10.1007/s12325-022-02054-z";"35157216";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.01"
"10.1007/s12325-022-02099-0";"35279814";"general_information";"";"";"Medical Condition of Interest Name";"hepatocellular carcinom"
"10.1007/s12325-022-02099-0";"35279814";"general_information";"";"";"Countries of first author affiliations";"germany"
"10.1007/s12325-022-02099-0";"35279814";"general_information";"";"";"Countries of last author affiliations";"france"
"10.1007/s12325-022-02099-0";"35279814";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.1007/s12325-022-02099-0";"35279814";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s12325-022-02099-0";"35279814";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s12325-022-02099-0";"35279814";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s12325-022-02099-0";"35279814";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1007/s12325-022-02099-0";"35279814";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s12325-022-02099-0";"35279814";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s12325-022-02099-0";"35279814";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01482442"
"10.1007/s12325-022-02099-0";"35279814";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"france"
"10.1007/s12325-022-02099-0";"35279814";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-022-02099-0";"35279814";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-022-02099-0";"35279814";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s12325-022-02099-0";"35279814";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s12325-022-02099-0";"35279814";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03434379"
"10.1007/s12325-022-02099-0";"35279814";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s12325-022-02099-0";"35279814";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s12325-022-02099-0";"35279814";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s12325-022-02099-0";"35279814";"methodology";"1";"";"Treatment name 1";"tare using sir-spheres (radioembolization)"
"10.1007/s12325-022-02099-0";"35279814";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s12325-022-02099-0";"35279814";"methodology";"1";"";"Treatment name 2";"atezolizumab + bevacizumab"
"10.1007/s12325-022-02099-0";"35279814";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s12325-022-02099-0";"35279814";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s12325-022-02099-0";"35279814";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1007/s12325-022-02099-0";"35279814";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s12325-022-02099-0";"35279814";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1007/s12325-022-02099-0";"35279814";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"time to deterioration in quality of life"
"10.1007/s12325-022-02099-0";"35279814";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1007/s12325-022-02099-0";"35279814";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s12325-022-02099-0";"35279814";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1007/s12325-022-02099-0";"35279814";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s12325-022-02099-0";"35279814";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s12325-022-02099-0";"35279814";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"Yes"
"10.1007/s12325-022-02099-0";"35279814";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"336"
"10.1007/s12325-022-02099-0";"35279814";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"165"
"10.1007/s12325-022-02099-0";"35279814";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"135"
"10.1007/s12325-022-02099-0";"35279814";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"53"
"10.1007/s12325-022-02099-0";"35279814";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"123"
"10.1007/s12325-022-02099-0";"35279814";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"78"
"10.1007/s12325-022-02099-0";"35279814";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s12325-022-02099-0";"35279814";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s12325-022-02099-0";"35279814";"results";"1";"";"Number of covariates adjusted for/matched on";"4"
"10.1007/s12325-022-02099-0";"35279814";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score"
"10.1007/s12325-022-02099-0";"35279814";"results";"1";"";"Primary outcome: treatment effect contrast";"log HR"
"10.1007/s12325-022-02099-0";"35279814";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s12325-022-02099-0";"35279814";"results";"1";"";"Primary outcome: adjusted treatment effect";"1.06"
"10.1007/s12325-022-02099-0";"35279814";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.725"
"10.1007/s13555-021-00646-1";"34877623";"general_information";"";"";"Medical Condition of Interest Name";"mild-to-moderate atopic dermatitis"
"10.1007/s13555-021-00646-1";"34877623";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.1007/s13555-021-00646-1";"34877623";"general_information";"";"";"Countries of last author affiliations";"denmark"
"10.1007/s13555-021-00646-1";"34877623";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.1007/s13555-021-00646-1";"34877623";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s13555-021-00646-1";"34877623";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02118766"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02118792"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"3";"Patient-level data used";"No"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"3";"Data source name (only if observational study or clinical trial without NCT)";"schachner et al. (2005)"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"4";"Patient-level data used";"No"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"4";"Data source name (only if observational study or clinical trial without NCT)";"kempers et al. (2004)"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"5";"Patient-level data used";"No"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00667160"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"4"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"5";"Data source name (only if observational study or clinical trial without NCT)";"paller et al. (2005)"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"6";"Patient-level data used";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"6";"Clinical Trial";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"6";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00666302"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"6";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"6";"Phase of the clinical trial (clinical trial only)";"4"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"6";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"6";"Data source name (only if observational study or clinical trial without NCT)";"abramovits et al. (2008)"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"7";"Patient-level data used";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"7";"Clinical Trial";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"7";"Data source name (only if observational study or clinical trial without NCT)";"eichenfield et al. (2002)"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"7";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"7";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"8";"Patient-level data used";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"8";"Clinical Trial";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"8";"Data source name (only if observational study or clinical trial without NCT)";"chapman et al. (2005)"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"8";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"8";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"9";"Patient-level data used";"No"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"9";"Clinical Trial";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"9";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00480896"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"9";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"9";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"9";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s13555-021-00646-1";"34877623";"study_information";"";"9";"Data source name (only if observational study or clinical trial without NCT)";"levy et al. (2005)"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"1";"";"Treatment name 1";"crisaborole"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"1";"";"Treatment name 2";"pimecrolimus 1%"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"1";"";"Study 'number(s)' for treatment 2";"4;5;6;7"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"investigator’s static global assessment improvement score of 0–1"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"2";"";"Treatment name 1";"crisaborole"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"2";"";"Treatment name 2";"tacrolimus 0.03%"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3;4;5;8;9"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"2";"";"Anchored comparison?";"No"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"investigator’s static global assessment improvement score of 0–1"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"3";"";"Treatment name 1";"crisaborole"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"3";"";"Treatment name 2";"tacrolimus 0.1%"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"3";"";"Study 'number(s)' for treatment 2";"6"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"3";"";"Anchored comparison?";"No"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"3";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"investigator’s static global assessment improvement score of 0–1"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"3";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s13555-021-00646-1";"34877623";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"1021"
"10.1007/s13555-021-00646-1";"34877623";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"627"
"10.1007/s13555-021-00646-1";"34877623";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1007/s13555-021-00646-1";"34877623";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.1007/s13555-021-00646-1";"34877623";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest"
"10.1007/s13555-021-00646-1";"34877623";"results";"1";"";"Primary outcome: treatment effect contrast";"OR"
"10.1007/s13555-021-00646-1";"34877623";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s13555-021-00646-1";"34877623";"results";"1";"";"Primary outcome: unadjusted treatment effect";"2.04"
"10.1007/s13555-021-00646-1";"34877623";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[1.47;2.82]"
"10.1007/s13555-021-00646-1";"34877623";"results";"1";"";"Primary outcome: adjusted treatment effect";"2.03"
"10.1007/s13555-021-00646-1";"34877623";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[1.45;2.85]"
"10.1007/s13555-021-00646-1";"34877623";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"1021"
"10.1007/s13555-021-00646-1";"34877623";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"311"
"10.1007/s13555-021-00646-1";"34877623";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1007/s13555-021-00646-1";"34877623";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"results";"2";"";"Number of covariates adjusted for/matched on";"7"
"10.1007/s13555-021-00646-1";"34877623";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest"
"10.1007/s13555-021-00646-1";"34877623";"results";"2";"";"Primary outcome: treatment effect contrast";"OR"
"10.1007/s13555-021-00646-1";"34877623";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s13555-021-00646-1";"34877623";"results";"2";"";"Primary outcome: unadjusted treatment effect";"1.31"
"10.1007/s13555-021-00646-1";"34877623";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.80;1.83]"
"10.1007/s13555-021-00646-1";"34877623";"results";"2";"";"Primary outcome: adjusted treatment effect";"1.03"
"10.1007/s13555-021-00646-1";"34877623";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.58;1.82]"
"10.1007/s13555-021-00646-1";"34877623";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"1021"
"10.1007/s13555-021-00646-1";"34877623";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"94"
"10.1007/s13555-021-00646-1";"34877623";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1007/s13555-021-00646-1";"34877623";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s13555-021-00646-1";"34877623";"results";"3";"";"Number of covariates adjusted for/matched on";"7"
"10.1007/s13555-021-00646-1";"34877623";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest"
"10.1007/s13555-021-00646-1";"34877623";"results";"3";"";"Primary outcome: treatment effect contrast";"OR"
"10.1007/s13555-021-00646-1";"34877623";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s13555-021-00646-1";"34877623";"results";"3";"";"Primary outcome: unadjusted treatment effect";"1.21"
"10.1007/s13555-021-00646-1";"34877623";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.80;1.83]"
"10.1007/s13555-021-00646-1";"34877623";"results";"3";"";"Primary outcome: adjusted treatment effect";"1.03"
"10.1007/s13555-021-00646-1";"34877623";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.58;1.82]"
"10.1007/s40258-016-0271-0";"27550239";"general_information";"";"";"Medical Condition of Interest Name";"relapsed and/or refractory multiple myeloma"
"10.1007/s40258-016-0271-0";"27550239";"general_information";"";"";"Countries of first author affiliations";"the netherlands"
"10.1007/s40258-016-0271-0";"27550239";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1007/s40258-016-0271-0";"27550239";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s40258-016-0271-0";"27550239";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s40258-016-0271-0";"27550239";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s40258-016-0271-0";"27550239";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s40258-016-0271-0";"27550239";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01023308"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00056160"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"3";"Patient-level data used";"No"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00424047"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40258-016-0271-0";"27550239";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40258-016-0271-0";"27550239";"methodology";"1";"";"Treatment name 1";"panobinostat + bortezomib + dexamethasone"
"10.1007/s40258-016-0271-0";"27550239";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s40258-016-0271-0";"27550239";"methodology";"1";"";"Treatment name 2";"lenalidomide + dexamethasone"
"10.1007/s40258-016-0271-0";"27550239";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2;3"
"10.1007/s40258-016-0271-0";"27550239";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s40258-016-0271-0";"27550239";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s40258-016-0271-0";"27550239";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/s40258-016-0271-0";"27550239";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s40258-016-0271-0";"27550239";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1007/s40258-016-0271-0";"27550239";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1007/s40258-016-0271-0";"27550239";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s40258-016-0271-0";"27550239";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s40258-016-0271-0";"27550239";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s40258-016-0271-0";"27550239";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s40258-016-0271-0";"27550239";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s40258-016-0271-0";"27550239";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"220"
"10.1007/s40258-016-0271-0";"27550239";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"142"
"10.1007/s40258-016-0271-0";"27550239";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"138"
"10.1007/s40258-016-0271-0";"27550239";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s40258-016-0271-0";"27550239";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s40258-016-0271-0";"27550239";"results";"1";"";"Number of covariates adjusted for/matched on";"3"
"10.1007/s40258-016-0271-0";"27550239";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1007/s40258-016-0271-0";"27550239";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1007/s40258-016-0271-0";"27550239";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s40258-016-0271-0";"27550239";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.96"
"10.1007/s40258-016-0271-0";"27550239";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.72;1.28]"
"10.1007/s40263-013-0102-x";"23975660";"general_information";"";"";"Medical Condition of Interest Name";"attention-deficit/hyperactivity disorder in children and adolescents"
"10.1007/s40263-013-0102-x";"23975660";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1007/s40263-013-0102-x";"23975660";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1007/s40263-013-0102-x";"23975660";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s40263-013-0102-x";"23975660";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s40263-013-0102-x";"23975660";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s40263-013-0102-x";"23975660";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s40263-013-0102-x";"23975660";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00152009"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00150618"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"2";"Data source name (only if observational study or clinical trial without NCT)";"sallee et al. (2009)"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"3";"Patient-level data used";"No"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"3";"Data source name (only if observational study or clinical trial without NCT)";"spencer et al. (2002)"
"10.1007/s40263-013-0102-x";"23975660";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40263-013-0102-x";"23975660";"methodology";"1";"";"Treatment name 1";"guanfacine extended release"
"10.1007/s40263-013-0102-x";"23975660";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1007/s40263-013-0102-x";"23975660";"methodology";"1";"";"Treatment name 2";"atomoxetine"
"10.1007/s40263-013-0102-x";"23975660";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3"
"10.1007/s40263-013-0102-x";"23975660";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s40263-013-0102-x";"23975660";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1007/s40263-013-0102-x";"23975660";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s40263-013-0102-x";"23975660";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s40263-013-0102-x";"23975660";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"change in adhd rating scale iv total score"
"10.1007/s40263-013-0102-x";"23975660";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/s40263-013-0102-x";"23975660";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s40263-013-0102-x";"23975660";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s40263-013-0102-x";"23975660";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s40263-013-0102-x";"23975660";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1007/s40263-013-0102-x";"23975660";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s40263-013-0102-x";"23975660";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"84"
"10.1007/s40263-013-0102-x";"23975660";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"82"
"10.1007/s40263-013-0102-x";"23975660";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s40263-013-0102-x";"23975660";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s40263-013-0102-x";"23975660";"results";"1";"";"Number of covariates adjusted for/matched on";"8"
"10.1007/s40263-013-0102-x";"23975660";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)"
"10.1007/s40263-013-0102-x";"23975660";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1007/s40263-013-0102-x";"23975660";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s40263-013-0102-x";"23975660";"results";"1";"";"Primary outcome: unadjusted treatment effect";"-9.2"
"10.1007/s40263-013-0102-x";"23975660";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.01"
"10.1007/s40263-013-0102-x";"23975660";"results";"1";"";"Primary outcome: adjusted treatment effect";"-7"
"10.1007/s40263-013-0102-x";"23975660";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.01"
"10.1007/s40263-013-0102-x";"23975660";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"83"
"10.1007/s40263-013-0102-x";"23975660";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"136"
"10.1007/s40263-019-00672-w";"31642037";"general_information";"";"";"Medical Condition of Interest Name";"postpartum depression"
"10.1007/s40263-019-00672-w";"31642037";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.1007/s40263-019-00672-w";"31642037";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1007/s40263-019-00672-w";"31642037";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s40263-019-00672-w";"31642037";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s40263-019-00672-w";"31642037";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s40263-019-00672-w";"31642037";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s40263-019-00672-w";"31642037";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02614547"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02942004"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"3";"Patient-level data used";"Yes"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02942017"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"4";"Patient-level data used";"No"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"4";"Data source name (only if observational study or clinical trial without NCT)";"yonkers et al. (2008)"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"5";"Patient-level data used";"No"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"5";"Data source name (only if observational study or clinical trial without NCT)";"sharp et al. (2010)"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"uk"
"10.1007/s40263-019-00672-w";"31642037";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40263-019-00672-w";"31642037";"methodology";"1";"";"Treatment name 1";"brexanolone"
"10.1007/s40263-019-00672-w";"31642037";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.1007/s40263-019-00672-w";"31642037";"methodology";"1";"";"Treatment name 2";"placebo"
"10.1007/s40263-019-00672-w";"31642037";"methodology";"1";"";"Study 'number(s)' for treatment 2";"4"
"10.1007/s40263-019-00672-w";"31642037";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s40263-019-00672-w";"31642037";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s40263-019-00672-w";"31642037";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/s40263-019-00672-w";"31642037";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s40263-019-00672-w";"31642037";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"change from baseline hamilton-depression scale"
"10.1007/s40263-019-00672-w";"31642037";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/s40263-019-00672-w";"31642037";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s40263-019-00672-w";"31642037";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s40263-019-00672-w";"31642037";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s40263-019-00672-w";"31642037";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1007/s40263-019-00672-w";"31642037";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s40263-019-00672-w";"31642037";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"30"
"10.1007/s40263-019-00672-w";"31642037";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"63.2"
"10.1007/s40263-019-00672-w";"31642037";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s40263-019-00672-w";"31642037";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s40263-019-00672-w";"31642037";"results";"1";"";"Number of covariates adjusted for/matched on";"3"
"10.1007/s40263-019-00672-w";"31642037";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Race/ethnicity, Past treatments for the disease of interest"
"10.1007/s40263-019-00672-w";"31642037";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1007/s40263-019-00672-w";"31642037";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s40263-019-00672-w";"31642037";"results";"1";"";"Primary outcome: unadjusted treatment effect";"3.8"
"10.1007/s40263-019-00672-w";"31642037";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[1.86;5.74]"
"10.1007/s40263-019-00672-w";"31642037";"results";"1";"";"Primary outcome: adjusted treatment effect";"13.9"
"10.1007/s40263-019-00672-w";"31642037";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[9.84;17.10]"
"10.1007/s40263-021-00805-0";"33847901";"general_information";"";"";"Medical Condition of Interest Name";"multiple sclerosis"
"10.1007/s40263-021-00805-0";"33847901";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1007/s40263-021-00805-0";"33847901";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1007/s40263-021-00805-0";"33847901";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s40263-021-00805-0";"33847901";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s40263-021-00805-0";"33847901";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s40263-021-00805-0";"33847901";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s40263-021-00805-0";"33847901";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02294058"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02047734"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"3";"Patient-level data used";"No"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00451451"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"4";"Patient-level data used";"No"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00420212"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40263-021-00805-0";"33847901";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40263-021-00805-0";"33847901";"methodology";"1";"";"Treatment name 1";"ozanimod"
"10.1007/s40263-021-00805-0";"33847901";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1007/s40263-021-00805-0";"33847901";"methodology";"1";"";"Treatment name 2";"dimethyl fumarate"
"10.1007/s40263-021-00805-0";"33847901";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3;4"
"10.1007/s40263-021-00805-0";"33847901";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s40263-021-00805-0";"33847901";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s40263-021-00805-0";"33847901";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/s40263-021-00805-0";"33847901";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s40263-021-00805-0";"33847901";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"annualized relapse rate"
"10.1007/s40263-021-00805-0";"33847901";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s40263-021-00805-0";"33847901";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s40263-021-00805-0";"33847901";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s40263-021-00805-0";"33847901";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s40263-021-00805-0";"33847901";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1007/s40263-021-00805-0";"33847901";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s40263-021-00805-0";"33847901";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"769"
"10.1007/s40263-021-00805-0";"33847901";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"850"
"10.1007/s40263-021-00805-0";"33847901";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"744"
"10.1007/s40263-021-00805-0";"33847901";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1007/s40263-021-00805-0";"33847901";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s40263-021-00805-0";"33847901";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.1007/s40263-021-00805-0";"33847901";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1007/s40263-021-00805-0";"33847901";"results";"1";"";"Primary outcome: treatment effect contrast";"RR"
"10.1007/s40263-021-00805-0";"33847901";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s40263-021-00805-0";"33847901";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.8"
"10.1007/s40263-021-00805-0";"33847901";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.67;0.97]"
"10.1007/s40273-021-01015-8";"34080140";"general_information";"";"";"Medical Condition of Interest Name";"alk-rearranged non-small-cell lung cancer"
"10.1007/s40273-021-01015-8";"34080140";"general_information";"";"";"Countries of first author affiliations";"sweden"
"10.1007/s40273-021-01015-8";"34080140";"general_information";"";"";"Countries of last author affiliations";"uk"
"10.1007/s40273-021-01015-8";"34080140";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s40273-021-01015-8";"34080140";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s40273-021-01015-8";"34080140";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s40273-021-01015-8";"34080140";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s40273-021-01015-8";"34080140";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01970865"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02604342"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"3";"Patient-level data used";"No"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01828112"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"4";"Patient-level data used";"No"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"4";"Data source name (only if observational study or clinical trial without NCT)";"ou et al. (2014)"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00585195"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"1"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"5";"Patient-level data used";"No"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00932451"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"2"
"10.1007/s40273-021-01015-8";"34080140";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"1"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"1";"";"Treatment name 1";"lorlatinib"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"1";"";"Treatment name 2";"pemetrexed or docetaxel"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2;3"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"1";"";"Anchored comparison?";"No"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"2";"";"Treatment name 1";"lorlatinib"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"2";"";"Treatment name 2";"crizotinib"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"2";"";"Study 'number(s)' for treatment 2";"4;5"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"2";"";"Anchored comparison?";"No"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s40273-021-01015-8";"34080140";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s40273-021-01015-8";"34080140";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"151"
"10.1007/s40273-021-01015-8";"34080140";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"59"
"10.1007/s40273-021-01015-8";"34080140";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"53.4"
"10.1007/s40273-021-01015-8";"34080140";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s40273-021-01015-8";"34080140";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s40273-021-01015-8";"34080140";"results";"1";"";"Number of covariates adjusted for/matched on";"4"
"10.1007/s40273-021-01015-8";"34080140";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1007/s40273-021-01015-8";"34080140";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1007/s40273-021-01015-8";"34080140";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s40273-021-01015-8";"34080140";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.224"
"10.1007/s40273-021-01015-8";"34080140";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.154;0.312]"
"10.1007/s40273-021-01015-8";"34080140";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"37"
"10.1007/s40273-021-01015-8";"34080140";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"59"
"10.1007/s40273-021-01015-8";"34080140";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"24.5"
"10.1007/s40273-021-01015-8";"34080140";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s40273-021-01015-8";"34080140";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.1007/s40273-021-01015-8";"34080140";"results";"2";"";"Number of covariates adjusted for/matched on";"4"
"10.1007/s40273-021-01015-8";"34080140";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1007/s40273-021-01015-8";"34080140";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.1007/s40273-021-01015-8";"34080140";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s40273-021-01015-8";"34080140";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.159"
"10.1007/s40273-021-01015-8";"34080140";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.052;0.356]"
"10.1007/s40744-017-0070-6";"28762213";"general_information";"";"";"Medical Condition of Interest Name";"active psoriatic arthritis"
"10.1007/s40744-017-0070-6";"28762213";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1007/s40744-017-0070-6";"28762213";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1007/s40744-017-0070-6";"28762213";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s40744-017-0070-6";"28762213";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s40744-017-0070-6";"28762213";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s40744-017-0070-6";"28762213";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s40744-017-0070-6";"28762213";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00195689"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01392326"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"3";"Patient-level data used";"No"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01752634"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40744-017-0070-6";"28762213";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"1";"";"Treatment name 1";"adalimumab"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"1";"";"Treatment name 2";"secukinumab 150 mg"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2;3"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"response rate in relative acr 20"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"2";"";"Treatment name 1";"adalimumab"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"2";"";"Treatment name 2";"secukinumab 300 mg"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2;3"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"response rate in relative acr 20"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s40744-017-0070-6";"28762213";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s40744-017-0070-6";"28762213";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"302"
"10.1007/s40744-017-0070-6";"28762213";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"300"
"10.1007/s40744-017-0070-6";"28762213";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"134"
"10.1007/s40744-017-0070-6";"28762213";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"49"
"10.1007/s40744-017-0070-6";"28762213";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"147"
"10.1007/s40744-017-0070-6";"28762213";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"79"
"10.1007/s40744-017-0070-6";"28762213";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s40744-017-0070-6";"28762213";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s40744-017-0070-6";"28762213";"results";"1";"";"Number of covariates adjusted for/matched on";"10"
"10.1007/s40744-017-0070-6";"28762213";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.1007/s40744-017-0070-6";"28762213";"results";"1";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1007/s40744-017-0070-6";"28762213";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s40744-017-0070-6";"28762213";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.095"
"10.1007/s40744-017-0070-6";"28762213";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.176"
"10.1007/s40744-017-0070-6";"28762213";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"100"
"10.1007/s40744-017-0070-6";"28762213";"results";"2";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"300"
"10.1007/s40744-017-0070-6";"28762213";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"134"
"10.1007/s40744-017-0070-6";"28762213";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"76"
"10.1007/s40744-017-0070-6";"28762213";"results";"2";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"147"
"10.1007/s40744-017-0070-6";"28762213";"results";"2";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"79"
"10.1007/s40744-017-0070-6";"28762213";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s40744-017-0070-6";"28762213";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s40744-017-0070-6";"28762213";"results";"2";"";"Number of covariates adjusted for/matched on";"10"
"10.1007/s40744-017-0070-6";"28762213";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.1007/s40744-017-0070-6";"28762213";"results";"2";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1007/s40744-017-0070-6";"28762213";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s40744-017-0070-6";"28762213";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.053"
"10.1007/s40744-017-0070-6";"28762213";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.507"
"10.1007/s40744-018-0106-6";"29605841";"general_information";"";"";"Medical Condition of Interest Name";"active psoriatic arthritis"
"10.1007/s40744-018-0106-6";"29605841";"general_information";"";"";"Countries of first author affiliations";"australia"
"10.1007/s40744-018-0106-6";"29605841";"general_information";"";"";"Countries of last author affiliations";"switzerland"
"10.1007/s40744-018-0106-6";"29605841";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s40744-018-0106-6";"29605841";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s40744-018-0106-6";"29605841";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01752634"
"10.1007/s40744-018-0106-6";"29605841";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40744-018-0106-6";"29605841";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40744-018-0106-6";"29605841";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40744-018-0106-6";"29605841";"study_information";"";"2";"Patient-level data used";"No"
"10.1007/s40744-018-0106-6";"29605841";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00195689"
"10.1007/s40744-018-0106-6";"29605841";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40744-018-0106-6";"29605841";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40744-018-0106-6";"29605841";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"1";"";"Treatment name 1";"secukinumab 150 mg"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"1";"";"Treatment name 2";"adalimumab"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"acr response rate at week 12"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"2";"";"Treatment name 1";"secukinumab 300 mg"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"2";"";"Treatment name 2";"adalimumab"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"acr response rate at week 16"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"3";"";"Treatment name 1";"secukinumab 150 mg"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"3";"";"Treatment name 2";"adalimumab"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"3";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"3";"";"Anchored comparison?";"No"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"acr response rate at week 16"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"3";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"4";"";"Treatment name 1";"secukinumab 300 mg"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"4";"";"Treatment name 2";"adalimumab"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"4";"";"Study 'number(s)' for treatment 2";"2"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"4";"";"Anchored comparison?";"No"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"4";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"acr response rate at week 16"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"4";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s40744-018-0106-6";"29605841";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s40744-018-0106-6";"29605841";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"151"
"10.1007/s40744-018-0106-6";"29605841";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"162"
"10.1007/s40744-018-0106-6";"29605841";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"100"
"10.1007/s40744-018-0106-6";"29605841";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"36"
"10.1007/s40744-018-0106-6";"29605841";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"98"
"10.1007/s40744-018-0106-6";"29605841";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"27"
"10.1007/s40744-018-0106-6";"29605841";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s40744-018-0106-6";"29605841";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"results";"1";"";"Number of covariates adjusted for/matched on";"10"
"10.1007/s40744-018-0106-6";"29605841";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.1007/s40744-018-0106-6";"29605841";"results";"1";"";"Primary outcome: treatment effect contrast";"RR"
"10.1007/s40744-018-0106-6";"29605841";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s40744-018-0106-6";"29605841";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.69"
"10.1007/s40744-018-0106-6";"29605841";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.34;1.43]"
"10.1007/s40744-018-0106-6";"29605841";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"151"
"10.1007/s40744-018-0106-6";"29605841";"results";"2";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"162"
"10.1007/s40744-018-0106-6";"29605841";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"100"
"10.1007/s40744-018-0106-6";"29605841";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"38"
"10.1007/s40744-018-0106-6";"29605841";"results";"2";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"98"
"10.1007/s40744-018-0106-6";"29605841";"results";"2";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"27"
"10.1007/s40744-018-0106-6";"29605841";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s40744-018-0106-6";"29605841";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"results";"2";"";"Number of covariates adjusted for/matched on";"10"
"10.1007/s40744-018-0106-6";"29605841";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.1007/s40744-018-0106-6";"29605841";"results";"2";"";"Primary outcome: treatment effect contrast";"RR"
"10.1007/s40744-018-0106-6";"29605841";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s40744-018-0106-6";"29605841";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.61"
"10.1007/s40744-018-0106-6";"29605841";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.29;127]"
"10.1007/s40744-018-0106-6";"29605841";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"151"
"10.1007/s40744-018-0106-6";"29605841";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"100"
"10.1007/s40744-018-0106-6";"29605841";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"36"
"10.1007/s40744-018-0106-6";"29605841";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s40744-018-0106-6";"29605841";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"results";"3";"";"Number of covariates adjusted for/matched on";"10"
"10.1007/s40744-018-0106-6";"29605841";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.1007/s40744-018-0106-6";"29605841";"results";"3";"";"Primary outcome: treatment effect contrast";"RR"
"10.1007/s40744-018-0106-6";"29605841";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s40744-018-0106-6";"29605841";"results";"3";"";"Primary outcome: adjusted treatment effect";"1.34"
"10.1007/s40744-018-0106-6";"29605841";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.29;1.54]"
"10.1007/s40744-018-0106-6";"29605841";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"151"
"10.1007/s40744-018-0106-6";"29605841";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"100"
"10.1007/s40744-018-0106-6";"29605841";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"38"
"10.1007/s40744-018-0106-6";"29605841";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s40744-018-0106-6";"29605841";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s40744-018-0106-6";"29605841";"results";"4";"";"Number of covariates adjusted for/matched on";"10"
"10.1007/s40744-018-0106-6";"29605841";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1007/s40744-018-0106-6";"29605841";"results";"4";"";"Primary outcome: treatment effect contrast";"RR"
"10.1007/s40744-018-0106-6";"29605841";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s40744-018-0106-6";"29605841";"results";"4";"";"Primary outcome: adjusted treatment effect";"1.18"
"10.1007/s40744-018-0106-6";"29605841";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.90;1.54]"
"10.1007/s40744-020-00257-w";"33244703";"general_information";"";"";"Medical Condition of Interest Name";"moderate-to-severe rheumatoid arthritis"
"10.1007/s40744-020-00257-w";"33244703";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.1007/s40744-020-00257-w";"33244703";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1007/s40744-020-00257-w";"33244703";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1007/s40744-020-00257-w";"33244703";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1007/s40744-020-00257-w";"33244703";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1007/s40744-020-00257-w";"33244703";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1007/s40744-020-00257-w";"33244703";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02706951"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02629159"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"3";"Patient-level data used";"No"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00853385"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"4";"Patient-level data used";"No"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02187055"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3, 4"
"10.1007/s40744-020-00257-w";"33244703";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"1";"";"Treatment name 1";"upadacitinib"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"1";"";"Treatment name 2";"tofacitinib + methotrexate"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"american college of rheumatology 70% criteria"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"2";"";"Treatment name 1";"upadacitinib + methotrexate"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"2";"";"Study 'number(s)' for treatment 1";"2"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"2";"";"Treatment name 2";"tofacitinib + methotrexate"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"2";"";"Study 'number(s)' for treatment 2";"4"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"american college of rheumatology 50% criteria"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1007/s40744-020-00257-w";"33244703";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1007/s40744-020-00257-w";"33244703";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"204"
"10.1007/s40744-020-00257-w";"33244703";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"108"
"10.1007/s40744-020-00257-w";"33244703";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"217"
"10.1007/s40744-020-00257-w";"33244703";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"173"
"10.1007/s40744-020-00257-w";"33244703";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"216"
"10.1007/s40744-020-00257-w";"33244703";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"158"
"10.1007/s40744-020-00257-w";"33244703";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s40744-020-00257-w";"33244703";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s40744-020-00257-w";"33244703";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.1007/s40744-020-00257-w";"33244703";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity"
"10.1007/s40744-020-00257-w";"33244703";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1007/s40744-020-00257-w";"33244703";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s40744-020-00257-w";"33244703";"results";"1";"";"Primary outcome: unadjusted treatment effect";"9.6"
"10.1007/s40744-020-00257-w";"33244703";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.018"
"10.1007/s40744-020-00257-w";"33244703";"results";"1";"";"Primary outcome: adjusted treatment effect";"9.9"
"10.1007/s40744-020-00257-w";"33244703";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.019"
"10.1007/s40744-020-00257-w";"33244703";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"376"
"10.1007/s40744-020-00257-w";"33244703";"results";"2";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"386"
"10.1007/s40744-020-00257-w";"33244703";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"647"
"10.1007/s40744-020-00257-w";"33244703";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"480"
"10.1007/s40744-020-00257-w";"33244703";"results";"2";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"324"
"10.1007/s40744-020-00257-w";"33244703";"results";"2";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"228"
"10.1007/s40744-020-00257-w";"33244703";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1007/s40744-020-00257-w";"33244703";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1007/s40744-020-00257-w";"33244703";"results";"2";"";"Number of covariates adjusted for/matched on";"7"
"10.1007/s40744-020-00257-w";"33244703";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity"
"10.1007/s40744-020-00257-w";"33244703";"results";"2";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1007/s40744-020-00257-w";"33244703";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1007/s40744-020-00257-w";"33244703";"results";"2";"";"Primary outcome: unadjusted treatment effect";"12.7"
"10.1007/s40744-020-00257-w";"33244703";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.008"
"10.1007/s40744-020-00257-w";"33244703";"results";"2";"";"Primary outcome: adjusted treatment effect";"12.9"
"10.1007/s40744-020-00257-w";"33244703";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.011"
"10.1016/j.bbmt.2020.06.008";"32561336";"general_information";"";"";"Medical Condition of Interest Name";"relapsed/refractory large b cell lymphoma"
"10.1016/j.bbmt.2020.06.008";"32561336";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1016/j.bbmt.2020.06.008";"32561336";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1016/j.bbmt.2020.06.008";"32561336";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1016/j.bbmt.2020.06.008";"32561336";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1016/j.bbmt.2020.06.008";"32561336";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1016/j.bbmt.2020.06.008";"32561336";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1016/j.bbmt.2020.06.008";"32561336";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1016/j.bbmt.2020.06.008";"32561336";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1016/j.bbmt.2020.06.008";"32561336";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1016/j.bbmt.2020.06.008";"32561336";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02348216"
"10.1016/j.bbmt.2020.06.008";"32561336";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.bbmt.2020.06.008";"32561336";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.1016/j.bbmt.2020.06.008";"32561336";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.bbmt.2020.06.008";"32561336";"study_information";"";"2";"Patient-level data used";"No"
"10.1016/j.bbmt.2020.06.008";"32561336";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1016/j.bbmt.2020.06.008";"32561336";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02445248"
"10.1016/j.bbmt.2020.06.008";"32561336";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.bbmt.2020.06.008";"32561336";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.bbmt.2020.06.008";"32561336";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"1";"";"Treatment name 1";"axicabtagene ciloleucel"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"1";"";"Treatment name 2";"tisagenlecleucel"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"1";"";"Anchored comparison?";"No"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"2";"";"Treatment name 1";"axicabtagene ciloleucel"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"2";"";"Treatment name 2";"tisagenlecleucel"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"2";"";"Anchored comparison?";"No"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"rate of grades 1-2 crs (cytokine release syndrome)"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.bbmt.2020.06.008";"32561336";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"115"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"101"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"39.59"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"1";"";"Primary outcome: treatment effect contrast";"RR"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"1";"";"Primary outcome: unadjusted treatment effect";"1.42"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[1.15;1.75]"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"1";"";"Primary outcome: adjusted treatment effect";"1.61"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[1.29;2.01]"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"111"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"108"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"47.65"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"2";"";"Number of covariates adjusted for/matched on";"7"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"2";"";"Primary outcome: treatment effect contrast";"RR"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"2";"";"Primary outcome: unadjusted treatment effect";"2.06"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[1.61;2.63]"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"2";"";"Primary outcome: adjusted treatment effect";"2.03"
"10.1016/j.bbmt.2020.06.008";"32561336";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[1.55;2.65]"
"10.1016/j.clgc.2020.07.006";"32826180";"general_information";"";"";"Medical Condition of Interest Name";"locally advanced or metastatic urothelial cancer"
"10.1016/j.clgc.2020.07.006";"32826180";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.1016/j.clgc.2020.07.006";"32826180";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1016/j.clgc.2020.07.006";"32826180";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1016/j.clgc.2020.07.006";"32826180";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1016/j.clgc.2020.07.006";"32826180";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1016/j.clgc.2020.07.006";"32826180";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1016/j.clgc.2020.07.006";"32826180";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02335424"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"2";"Patient-level data used";"No"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"2";"Data source name (only if observational study or clinical trial without NCT)";"bamias et al. (2007)"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"greece"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"3";"Patient-level data used";"No"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"3";"Clinical Trial";"No"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"3";"Data source name (only if observational study or clinical trial without NCT)";"carles et al. (2000)"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"spain"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"4";"Patient-level data used";"No"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00111787"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"5";"Patient-level data used";"No"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"5";"Data source name (only if observational study or clinical trial without NCT)";"linardou et al. (2004)"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"greece"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.clgc.2020.07.006";"32826180";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clgc.2020.07.006";"32826180";"methodology";"1";"";"Treatment name 1";"pembrolizumab"
"10.1016/j.clgc.2020.07.006";"32826180";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.clgc.2020.07.006";"32826180";"methodology";"1";"";"Treatment name 2";"carboplatin + gemcitabine"
"10.1016/j.clgc.2020.07.006";"32826180";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2;3;4;5²"
"10.1016/j.clgc.2020.07.006";"32826180";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.1016/j.clgc.2020.07.006";"32826180";"methodology";"1";"";"Anchored comparison?";"No"
"10.1016/j.clgc.2020.07.006";"32826180";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1016/j.clgc.2020.07.006";"32826180";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.clgc.2020.07.006";"32826180";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1016/j.clgc.2020.07.006";"32826180";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.clgc.2020.07.006";"32826180";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1016/j.clgc.2020.07.006";"32826180";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1016/j.clgc.2020.07.006";"32826180";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.clgc.2020.07.006";"32826180";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.clgc.2020.07.006";"32826180";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.clgc.2020.07.006";"32826180";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.clgc.2020.07.006";"32826180";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.1016/j.clgc.2020.07.006";"32826180";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.clgc.2020.07.006";"32826180";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Denominator if ratio, or rightside if difference"
"10.1016/j.clgc.2020.07.006";"32826180";"results";"1";"";"Primary outcome: adjusted treatment effect";"2.34"
"10.1016/j.clgc.2020.07.006";"32826180";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[1.92;2.85]"
"10.1016/j.clinthera.2015.09.013";"26602976";"general_information";"";"";"Medical Condition of Interest Name";"metastatic advanced renal cell carcinoma"
"10.1016/j.clinthera.2015.09.013";"26602976";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1016/j.clinthera.2015.09.013";"26602976";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1016/j.clinthera.2015.09.013";"26602976";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1016/j.clinthera.2015.09.013";"26602976";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1016/j.clinthera.2015.09.013";"26602976";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1016/j.clinthera.2015.09.013";"26602976";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1016/j.clinthera.2015.09.013";"26602976";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1016/j.clinthera.2015.09.013";"26602976";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1016/j.clinthera.2015.09.013";"26602976";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2015.09.013";"26602976";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00410124"
"10.1016/j.clinthera.2015.09.013";"26602976";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2015.09.013";"26602976";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.clinthera.2015.09.013";"26602976";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.clinthera.2015.09.013";"26602976";"study_information";"";"2";"Patient-level data used";"No"
"10.1016/j.clinthera.2015.09.013";"26602976";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2015.09.013";"26602976";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00678392"
"10.1016/j.clinthera.2015.09.013";"26602976";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2015.09.013";"26602976";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.clinthera.2015.09.013";"26602976";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.clinthera.2015.09.013";"26602976";"methodology";"1";"";"Treatment name 1";"everolimus"
"10.1016/j.clinthera.2015.09.013";"26602976";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.clinthera.2015.09.013";"26602976";"methodology";"1";"";"Treatment name 2";"axitinib"
"10.1016/j.clinthera.2015.09.013";"26602976";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1016/j.clinthera.2015.09.013";"26602976";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.clinthera.2015.09.013";"26602976";"methodology";"1";"";"Anchored comparison?";"No"
"10.1016/j.clinthera.2015.09.013";"26602976";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.clinthera.2015.09.013";"26602976";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1016/j.clinthera.2015.09.013";"26602976";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1016/j.clinthera.2015.09.013";"26602976";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.clinthera.2015.09.013";"26602976";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1016/j.clinthera.2015.09.013";"26602976";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1016/j.clinthera.2015.09.013";"26602976";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.clinthera.2015.09.013";"26602976";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.clinthera.2015.09.013";"26602976";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.clinthera.2015.09.013";"26602976";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"194"
"10.1016/j.clinthera.2015.09.013";"26602976";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"43"
"10.1016/j.clinthera.2015.09.013";"26602976";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"43"
"10.1016/j.clinthera.2015.09.013";"26602976";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.clinthera.2015.09.013";"26602976";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.clinthera.2015.09.013";"26602976";"results";"1";"";"Number of covariates adjusted for/matched on";"3"
"10.1016/j.clinthera.2015.09.013";"26602976";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1016/j.clinthera.2015.09.013";"26602976";"results";"1";"";"Primary outcome: treatment effect contrast";"No relative effect statistic has been calculated"
"10.1016/j.clinthera.2015.12.017";"26839044";"general_information";"";"";"Medical Condition of Interest Name";"chronic hepatitis c coinfected with hiv"
"10.1016/j.clinthera.2015.12.017";"26839044";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1016/j.clinthera.2015.12.017";"26839044";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1016/j.clinthera.2015.12.017";"26839044";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1016/j.clinthera.2015.12.017";"26839044";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1016/j.clinthera.2015.12.017";"26839044";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1016/j.clinthera.2015.12.017";"26839044";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1016/j.clinthera.2015.12.017";"26839044";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02032901"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"2";"Patient-level data used";"No"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01667731"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"3";"Patient-level data used";"No"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01783678"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.clinthera.2015.12.017";"26839044";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clinthera.2015.12.017";"26839044";"methodology";"1";"";"Treatment name 1";"daclatasvir + sofosbuvir"
"10.1016/j.clinthera.2015.12.017";"26839044";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.clinthera.2015.12.017";"26839044";"methodology";"1";"";"Treatment name 2";"sofosbuvir + ribavirin"
"10.1016/j.clinthera.2015.12.017";"26839044";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2;3"
"10.1016/j.clinthera.2015.12.017";"26839044";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.clinthera.2015.12.017";"26839044";"methodology";"1";"";"Anchored comparison?";"No"
"10.1016/j.clinthera.2015.12.017";"26839044";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1016/j.clinthera.2015.12.017";"26839044";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1016/j.clinthera.2015.12.017";"26839044";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained virologic response at week 12 post-treatment"
"10.1016/j.clinthera.2015.12.017";"26839044";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1016/j.clinthera.2015.12.017";"26839044";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1016/j.clinthera.2015.12.017";"26839044";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1016/j.clinthera.2015.12.017";"26839044";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.clinthera.2015.12.017";"26839044";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.clinthera.2015.12.017";"26839044";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.clinthera.2015.12.017";"26839044";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"455"
"10.1016/j.clinthera.2015.12.017";"26839044";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"91"
"10.1016/j.clinthera.2015.12.017";"26839044";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.clinthera.2015.12.017";"26839044";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.clinthera.2015.12.017";"26839044";"results";"1";"";"Number of covariates adjusted for/matched on";"12"
"10.1016/j.clinthera.2015.12.017";"26839044";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.1016/j.clinthera.2015.12.017";"26839044";"results";"1";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1016/j.clinthera.2015.12.017";"26839044";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.clinthera.2015.12.017";"26839044";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.12"
"10.1016/j.clinthera.2015.12.017";"26839044";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.002"
"10.1016/j.clinthera.2015.12.017";"26839044";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.15"
"10.1016/j.clinthera.2015.12.017";"26839044";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1016/j.clinthera.2017.08.010";"28967482";"general_information";"";"";"Medical Condition of Interest Name";"relapsed-refractory multiple myeloma"
"10.1016/j.clinthera.2017.08.010";"28967482";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1016/j.clinthera.2017.08.010";"28967482";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1016/j.clinthera.2017.08.010";"28967482";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1016/j.clinthera.2017.08.010";"28967482";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1016/j.clinthera.2017.08.010";"28967482";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1016/j.clinthera.2017.08.010";"28967482";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1016/j.clinthera.2017.08.010";"28967482";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00833833"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"2";"Patient-level data used";"No"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01985126"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"3";"Patient-level data used";"No"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00511238"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.clinthera.2017.08.010";"28967482";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"1";"";"Treatment name 1";"pomalidomide + dexamethasone"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"1";"";"Treatment name 2";"daratumumab"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"1";"";"Anchored comparison?";"No"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression free survival"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"2";"";"Treatment name 1";"pomalidomide + dexamethasone"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"2";"";"Treatment name 2";"carfilzomib"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"2";"";"Anchored comparison?";"No"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.clinthera.2017.08.010";"28967482";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.clinthera.2017.08.010";"28967482";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.clinthera.2017.08.010";"28967482";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.clinthera.2017.08.010";"28967482";"results";"1";"";"Number of covariates adjusted for/matched on";"8"
"10.1016/j.clinthera.2017.08.010";"28967482";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1016/j.clinthera.2017.08.010";"28967482";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.clinthera.2017.08.010";"28967482";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.clinthera.2017.08.010";"28967482";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.945"
"10.1016/j.clinthera.2017.08.010";"28967482";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.749"
"10.1016/j.clinthera.2017.08.010";"28967482";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.clinthera.2017.08.010";"28967482";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.clinthera.2017.08.010";"28967482";"results";"2";"";"Number of covariates adjusted for/matched on";"8"
"10.1016/j.clinthera.2017.08.010";"28967482";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1016/j.clinthera.2017.08.010";"28967482";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.clinthera.2017.08.010";"28967482";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.clinthera.2017.08.010";"28967482";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.833"
"10.1016/j.clinthera.2017.08.010";"28967482";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.238"
"10.1016/j.clinthera.2019.09.012";"31699438";"general_information";"";"";"Medical Condition of Interest Name";"relapsed/refractory mantle cell lymphoma"
"10.1016/j.clinthera.2019.09.012";"31699438";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1016/j.clinthera.2019.09.012";"31699438";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1016/j.clinthera.2019.09.012";"31699438";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1016/j.clinthera.2019.09.012";"31699438";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1016/j.clinthera.2019.09.012";"31699438";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02213926"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"10";"Patient-level data used";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"10";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"10";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01880567"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"10";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"10";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"10";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"11";"Patient-level data used";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"11";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"11";"Data source name (only if observational study or clinical trial without NCT)";"czuczman 2015"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"11";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"11";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"11";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"12";"Patient-level data used";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"12";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"12";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00294632"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"12";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"12";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"12";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"2";"Patient-level data used";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01646021"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"3";"Patient-level data used";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01236391"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"4";"Patient-level data used";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01599949"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"5";"Patient-level data used";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"5";"Data source name (only if observational study or clinical trial without NCT)";"pinnacle"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"6";"Patient-level data used";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"6";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"6";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00875667"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"6";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"6";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"6";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"7";"Patient-level data used";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"7";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"7";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00737529"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"7";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"7";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"7";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"8";"Patient-level data used";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"8";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"8";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00117598"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"8";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"8";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"8";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"9";"Patient-level data used";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"9";"Clinical Trial";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"9";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01180049"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"9";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"9";"Phase of the clinical trial (clinical trial only)";"4"
"10.1016/j.clinthera.2019.09.012";"31699438";"study_information";"";"9";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"1";"";"Treatment name 1";"acalabrutinib"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"1";"";"Treatment name 2";"ibrutinib"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2;3;4"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"1";"";"Anchored comparison?";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"2";"";"Treatment name 1";"acalabrutinib"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"2";"";"Treatment name 2";"bortezomib"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"2";"";"Study 'number(s)' for treatment 2";"5"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"2";"";"Anchored comparison?";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"3";"";"Treatment name 1";"acalabrutinib"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"3";"";"Treatment name 2";"lenalidomide"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"3";"";"Study 'number(s)' for treatment 2";"6;7"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"3";"";"Anchored comparison?";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"3";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"3";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"4";"";"Treatment name 1";"acalabrutinib"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"4";"";"Treatment name 2";"temsirolimus"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"4";"";"Study 'number(s)' for treatment 2";"2;8;9"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"4";"";"Anchored comparison?";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"4";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"4";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"5";"";"Treatment name 1";"acalabrutinib"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"5";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"5";"";"Treatment name 2";"ibrutinib + rituximab"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"5";"";"Study 'number(s)' for treatment 2";"10"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"5";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"5";"";"Anchored comparison?";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"5";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"5";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"5";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"5";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"5";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"5";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"5";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"5";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"5";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"6";"";"Treatment name 1";"acalabrutinib"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"6";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"6";"";"Treatment name 2";"ibrutinib + rituximab"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"6";"";"Study 'number(s)' for treatment 2";"11"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"6";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"6";"";"Anchored comparison?";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"6";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"6";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"6";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"6";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"6";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"6";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"6";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"6";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"6";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"7";"";"Treatment name 1";"acalabrutinib"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"7";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"7";"";"Treatment name 2";"lenalidomide + rituximab"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"7";"";"Study 'number(s)' for treatment 2";"12"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"7";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"7";"";"Anchored comparison?";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"7";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"7";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"7";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"7";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"7";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"7";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"7";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"7";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"methodology";"7";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"370"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"123"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"45"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"1";"";"Number of covariates adjusted for/matched on";"10"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex,Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"1";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"1";"";"Primary outcome: unadjusted treatment effect";"10.2"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.05"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"1";"";"Primary outcome: adjusted treatment effect";"9.3"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"155"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"124"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"61"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"2";"";"Number of covariates adjusted for/matched on";"9"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"2";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"2";"";"Primary outcome: unadjusted treatment effect";"46"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"2";"";"Primary outcome: adjusted treatment effect";"50.6"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"304"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"122"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"28"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"3";"";"Number of covariates adjusted for/matched on";"12"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"3";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"3";"";"Primary outcome: unadjusted treatment effect";"39.7"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"3";"";"Primary outcome: adjusted treatment effect";"38.1"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"242"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"123"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"120"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"4";"";"Number of covariates adjusted for/matched on";"3"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"4";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"4";"";"Primary outcome: unadjusted treatment effect";"40.9"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"4";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"4";"";"Primary outcome: adjusted treatment effect";"40.7"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"5";"";"Sample size of the population of interest in the non IPD treatment arm";"50"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"5";"";"Initial sample size of the population of interest in the IPD treatment arm";"84"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"5";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"16"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"5";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"5";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"5";"";"Number of covariates adjusted for/matched on";"8"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"5";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"5";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"5";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"5";"";"Primary outcome: unadjusted treatment effect";"-14.2"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"5";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.05"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"5";"";"Primary outcome: adjusted treatment effect";"-10.6"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"5";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.09"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"6";"";"Sample size of the population of interest in the non IPD treatment arm";"145"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"6";"";"Initial sample size of the population of interest in the IPD treatment arm";"121"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"6";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"56"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"6";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"6";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"6";"";"Number of covariates adjusted for/matched on";"5"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"6";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"6";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"6";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"6";"";"Primary outcome: unadjusted treatment effect";"-7"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"6";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.31"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"6";"";"Primary outcome: adjusted treatment effect";"-9.8"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"6";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.22"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"7";"";"Sample size of the population of interest in the non IPD treatment arm";"44"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"7";"";"Initial sample size of the population of interest in the IPD treatment arm";"124"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"7";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"64"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"7";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"7";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"7";"";"Number of covariates adjusted for/matched on";"7"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"7";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"7";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"7";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"7";"";"Primary outcome: unadjusted treatment effect";"16.3"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"7";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.06"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"7";"";"Primary outcome: adjusted treatment effect";"14.1"
"10.1016/j.clinthera.2019.09.012";"31699438";"results";"7";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.13"
"10.1016/j.ejcsup.2021.06.002";"34912478";"general_information";"";"";"Medical Condition of Interest Name";"advanced unresctable gastroenteropancreatic neuroendocrine tumor"
"10.1016/j.ejcsup.2021.06.002";"34912478";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.1016/j.ejcsup.2021.06.002";"34912478";"general_information";"";"";"Countries of last author affiliations";"germany"
"10.1016/j.ejcsup.2021.06.002";"34912478";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Private Data Analysis Company"
"10.1016/j.ejcsup.2021.06.002";"34912478";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1016/j.ejcsup.2021.06.002";"34912478";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"1";"Data source name (only if observational study or clinical trial without NCT)";"erasmus study"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"netherlands"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"2";"Patient-level data used";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01524783"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"3";"Patient-level data used";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00510068"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"4";"Patient-level data used";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00428597"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.ejcsup.2021.06.002";"34912478";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"1";"";"Treatment name 1";"[177lu]lu-dota-tate"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"1";"";"Treatment name 2";"everolimus"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"1";"";"Anchored comparison?";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"2";"";"Treatment name 1";"[177lu]lu-dota-tate"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"2";"";"Treatment name 2";"everolimus"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"2";"";"Anchored comparison?";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"3";"";"Treatment name 1";"[177lu]lu-dota-tate"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"3";"";"Treatment name 2";"sunitinib"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"3";"";"Study 'number(s)' for treatment 2";"4"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"3";"";"Anchored comparison?";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"3";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"4";"";"Treatment name 1";"[177lu]lu-dota-tate"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"4";"";"Treatment name 2";"best supportive care"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"4";"";"Study 'number(s)' for treatment 2";"4"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"4";"";"Anchored comparison?";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"4";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"4";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"5";"";"Treatment name 1";"[177lu]lu-dota-tate"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"5";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"5";"";"Treatment name 2";"everolimus"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"5";"";"Study 'number(s)' for treatment 2";"3"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"5";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"5";"";"Anchored comparison?";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"5";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"5";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"5";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"5";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"5";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"5";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"5";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"5";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"5";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"6";"";"Treatment name 1";"[177lu]lu-dota-tate"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"6";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"6";"";"Treatment name 2";"best supportive care"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"6";"";"Study 'number(s)' for treatment 2";"3"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"6";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"6";"";"Anchored comparison?";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"6";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"6";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"6";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"6";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"6";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"6";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"6";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"6";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"methodology";"6";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"118"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"111"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"105"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"1";"";"Number of covariates adjusted for/matched on";"1"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.38"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.25;0.58]"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"57"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"111"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"95"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"2";"";"Number of covariates adjusted for/matched on";"1"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.35"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.24;0.59]"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"86"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"62"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"48"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"3";"";"Number of covariates adjusted for/matched on";"4"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"3";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"3";"";"Primary outcome: adjusted treatment effect";"0.36"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.18;0.70]"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"85"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"62"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"35"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"4";"";"Number of covariates adjusted for/matched on";"4"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"4";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"4";"";"Primary outcome: adjusted treatment effect";"0.13"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.08;0.22]"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"5";"";"Sample size of the population of interest in the non IPD treatment arm";"207"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"5";"";"Initial sample size of the population of interest in the IPD treatment arm";"62"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"5";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"22"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"5";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"5";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"5";"";"Number of covariates adjusted for/matched on";"4"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"5";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, , Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"5";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"5";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"5";"";"Primary outcome: adjusted treatment effect";"0.46"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"5";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.30;0.71]"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"6";"";"Sample size of the population of interest in the non IPD treatment arm";"203"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"6";"";"Initial sample size of the population of interest in the IPD treatment arm";"62"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"6";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"18"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"6";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"6";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"6";"";"Number of covariates adjusted for/matched on";"4"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"6";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"6";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"6";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"6";"";"Primary outcome: adjusted treatment effect";"0.21"
"10.1016/j.ejcsup.2021.06.002";"34912478";"results";"6";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.13;0.32]"
"10.1016/j.esmoop.2021.100050";"33556898";"general_information";"";"";"Medical Condition of Interest Name";"braf v600-mutant advanced melanoma"
"10.1016/j.esmoop.2021.100050";"33556898";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1016/j.esmoop.2021.100050";"33556898";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1016/j.esmoop.2021.100050";"33556898";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1016/j.esmoop.2021.100050";"33556898";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1016/j.esmoop.2021.100050";"33556898";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1016/j.esmoop.2021.100050";"33556898";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1016/j.esmoop.2021.100050";"33556898";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01844505"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"2";"Patient-level data used";"No"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01584648"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"3";"Patient-level data used";"No"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01597908"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"4";"Patient-level data used";"No"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01909453"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"5";"Patient-level data used";"No"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01689519"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.esmoop.2021.100050";"33556898";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"1";"";"Treatment name 1";"nivolumab + ipilimumab"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"1";"";"Treatment name 2";"dbragenib + trametinib"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2;3"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"1";"";"Anchored comparison?";"No"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"2";"";"Treatment name 1";"nivolumab + ipilimumab"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"2";"";"Treatment name 2";"encorafenib + binimetinib"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"2";"";"Study 'number(s)' for treatment 2";"4"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"2";"";"Anchored comparison?";"No"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"3";"";"Treatment name 1";"nivolumab + ipilimumab"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"3";"";"Treatment name 2";"vemurafenib + cobimetinib"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"3";"";"Study 'number(s)' for treatment 2";"5"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"3";"";"Anchored comparison?";"No"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"3";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.esmoop.2021.100050";"33556898";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"56"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"103"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"91.68"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"1";"";"Number of covariates adjusted for/matched on";"5"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.53"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.39;0.73]"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"192"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"103"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"93.81"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"2";"";"Number of covariates adjusted for/matched on";"5"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.6"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.42;0.85]"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"247"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"103"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"91.69"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"3";"";"Number of covariates adjusted for/matched on";"5"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"3";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"3";"";"Primary outcome: adjusted treatment effect";"0.5"
"10.1016/j.esmoop.2021.100050";"33556898";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.36;0.70]"
"10.1016/j.euo.2018.09.009";"31412011";"general_information";"";"";"Medical Condition of Interest Name";"advanced, unresectable, or metastatic urothelial cancer"
"10.1016/j.euo.2018.09.009";"31412011";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.1016/j.euo.2018.09.009";"31412011";"general_information";"";"";"Countries of last author affiliations";"netherlands"
"10.1016/j.euo.2018.09.009";"31412011";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1016/j.euo.2018.09.009";"31412011";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1016/j.euo.2018.09.009";"31412011";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1016/j.euo.2018.09.009";"31412011";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1016/j.euo.2018.09.009";"31412011";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01704287"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"2";"Patient-level data used";"No"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"2";"Data source name (only if observational study or clinical trial without NCT)";"unknown"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00014274"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2, 3"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"3";"Patient-level data used";"No"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"3";"Data source name (only if observational study or clinical trial without NCT)";"getug v01"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"france"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"4";"Patient-level data used";"No"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"4";"Data source name (only if observational study or clinical trial without NCT)";"bamias et al. (2007)"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"greece"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"5";"Patient-level data used";"No"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"5";"Data source name (only if observational study or clinical trial without NCT)";"carles et al. (2000)"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"spain"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"6";"Patient-level data used";"No"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"6";"Clinical Trial";"Yes"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"6";"Data source name (only if observational study or clinical trial without NCT)";"linardou et al. (2003)"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"6";"Country where the clinical trial/observational study was conducted (international if more than one)";"greece"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"6";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.euo.2018.09.009";"31412011";"study_information";"";"6";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"1";"";"Treatment name 1";"pembrolizumab"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"1";"";"Treatment name 2";"carboplatin + gemcitabine"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"1";"";"Anchored comparison?";"No"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"2";"";"Treatment name 1";"pembrolizumab"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"2";"";"Treatment name 2";"gemcitabine"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"2";"";"Anchored comparison?";"No"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.euo.2018.09.009";"31412011";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.euo.2018.09.009";"31412011";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.1016/j.euo.2018.09.009";"31412011";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.euo.2018.09.009";"31412011";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.euo.2018.09.009";"31412011";"results";"1";"";"Primary outcome: adjusted treatment effect";"2.78"
"10.1016/j.euo.2018.09.009";"31412011";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[2.29;3.38]"
"10.1016/j.euo.2018.09.009";"31412011";"results";"1";"";"Number of covariates adjusted for/matched on";"3"
"10.1016/j.euo.2018.09.009";"31412011";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1016/j.euo.2018.09.009";"31412011";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.1016/j.euo.2018.09.009";"31412011";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.euo.2018.09.009";"31412011";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.euo.2018.09.009";"31412011";"results";"2";"";"Primary outcome: adjusted treatment effect";"2.94"
"10.1016/j.euo.2018.09.009";"31412011";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[2.42;3.57]"
"10.1016/j.euo.2018.09.009";"31412011";"results";"2";"";"Number of covariates adjusted for/matched on";"3"
"10.1016/j.euo.2018.09.009";"31412011";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1016/j.jtho.2016.05.029";"27288979";"general_information";"";"";"Medical Condition of Interest Name";"advanced or metastatic non-small cell lung cancer"
"10.1016/j.jtho.2016.05.029";"27288979";"general_information";"";"";"Countries of first author affiliations";"singapore"
"10.1016/j.jtho.2016.05.029";"27288979";"general_information";"";"";"Countries of last author affiliations";"canada"
"10.1016/j.jtho.2016.05.029";"27288979";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1016/j.jtho.2016.05.029";"27288979";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1016/j.jtho.2016.05.029";"27288979";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1016/j.jtho.2016.05.029";"27288979";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1016/j.jtho.2016.05.029";"27288979";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01283516"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01685138"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"3";"Patient-level data used";"No"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00585195"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"1"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"4";"Patient-level data used";"No"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00932451"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"5";"Patient-level data used";"No"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00932893"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.jtho.2016.05.029";"27288979";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.jtho.2016.05.029";"27288979";"methodology";"1";"";"Treatment name 1";"ceritinib"
"10.1016/j.jtho.2016.05.029";"27288979";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1016/j.jtho.2016.05.029";"27288979";"methodology";"1";"";"Treatment name 2";"crizotinib"
"10.1016/j.jtho.2016.05.029";"27288979";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3;4;5"
"10.1016/j.jtho.2016.05.029";"27288979";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.jtho.2016.05.029";"27288979";"methodology";"1";"";"Anchored comparison?";"No"
"10.1016/j.jtho.2016.05.029";"27288979";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1016/j.jtho.2016.05.029";"27288979";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.jtho.2016.05.029";"27288979";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1016/j.jtho.2016.05.029";"27288979";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.jtho.2016.05.029";"27288979";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1016/j.jtho.2016.05.029";"27288979";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1016/j.jtho.2016.05.029";"27288979";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1016/j.jtho.2016.05.029";"27288979";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.jtho.2016.05.029";"27288979";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.jtho.2016.05.029";"27288979";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"557"
"10.1016/j.jtho.2016.05.029";"27288979";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"189"
"10.1016/j.jtho.2016.05.029";"27288979";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"143"
"10.1016/j.jtho.2016.05.029";"27288979";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.jtho.2016.05.029";"27288979";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.jtho.2016.05.029";"27288979";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.1016/j.jtho.2016.05.029";"27288979";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1016/j.jtho.2016.05.029";"27288979";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.jtho.2016.05.029";"27288979";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.jtho.2016.05.029";"27288979";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.49"
"10.1016/j.jtho.2016.05.029";"27288979";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.1016/j.jtho.2016.05.029";"27288979";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.59"
"10.1016/j.jtho.2016.05.029";"27288979";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.46;0.75]"
"10.1016/j.jtho.2016.05.029";"27288979";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"na"
"10.1016/j.jtho.2016.05.029";"27288979";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"na"
"10.1016/j.jval.2018.03.015";"30314617";"general_information";"";"";"Medical Condition of Interest Name";"tremor"
"10.1016/j.jval.2018.03.015";"30314617";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.1016/j.jval.2018.03.015";"30314617";"general_information";"";"";"Countries of last author affiliations";"israel"
"10.1016/j.jval.2018.03.015";"30314617";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1016/j.jval.2018.03.015";"30314617";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1016/j.jval.2018.03.015";"30314617";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1016/j.jval.2018.03.015";"30314617";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1016/j.jval.2018.03.015";"30314617";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1016/j.jval.2018.03.015";"30314617";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1016/j.jval.2018.03.015";"30314617";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1016/j.jval.2018.03.015";"30314617";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01827904"
"10.1016/j.jval.2018.03.015";"30314617";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.jval.2018.03.015";"30314617";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.jval.2018.03.015";"30314617";"study_information";"";"2";"Patient-level data used";"No"
"10.1016/j.jval.2018.03.015";"30314617";"study_information";"";"2";"Clinical Trial";"No"
"10.1016/j.jval.2018.03.015";"30314617";"study_information";"";"2";"Data source name (only if observational study or clinical trial without NCT)";"putzke et al. (2005)"
"10.1016/j.jval.2018.03.015";"30314617";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1016/j.jval.2018.03.015";"30314617";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"1";"";"Treatment name 1";"magnetic resonance-guided focused ultrasound"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"1";"";"Treatment name 2";"unilateral deep brain stimulation"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"1";"";"Anchored comparison?";"No"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"clinical rating scale for tremor part c at 1 month"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"2";"";"Treatment name 1";"magnetic resonance-guided focused ultrasound"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"2";"";"Treatment name 2";"unilateral deep brain stimulation (dbs)"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"2";"";"Anchored comparison?";"No"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"clinical rating scale for tremor part c at 1 month"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.jval.2018.03.015";"30314617";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.jval.2018.03.015";"30314617";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"22"
"10.1016/j.jval.2018.03.015";"30314617";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"56"
"10.1016/j.jval.2018.03.015";"30314617";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"35.8"
"10.1016/j.jval.2018.03.015";"30314617";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.jval.2018.03.015";"30314617";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.jval.2018.03.015";"30314617";"results";"1";"";"Number of covariates adjusted for/matched on";"3"
"10.1016/j.jval.2018.03.015";"30314617";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1016/j.jval.2018.03.015";"30314617";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1016/j.jval.2018.03.015";"30314617";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.jval.2018.03.015";"30314617";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.35"
"10.1016/j.jval.2018.03.015";"30314617";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-2.17;2.87]"
"10.1016/j.jval.2018.03.015";"30314617";"results";"1";"";"Primary outcome: adjusted treatment effect";"1.92"
"10.1016/j.jval.2018.03.015";"30314617";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-0.94;4.79]"
"10.1016/j.jval.2018.03.015";"30314617";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"22"
"10.1016/j.jval.2018.03.015";"30314617";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"56"
"10.1016/j.jval.2018.03.015";"30314617";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"56"
"10.1016/j.jval.2018.03.015";"30314617";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.jval.2018.03.015";"30314617";"results";"2";"";"Number of covariates adjusted for/matched on";"3"
"10.1016/j.jval.2018.03.015";"30314617";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1016/j.jval.2018.03.015";"30314617";"results";"2";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1016/j.jval.2018.03.015";"30314617";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.jval.2018.03.015";"30314617";"results";"2";"";"Primary outcome: unadjusted treatment effect";"0.35"
"10.1016/j.jval.2018.03.015";"30314617";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-2.17;2.87]"
"10.1016/j.jval.2018.03.015";"30314617";"results";"2";"";"Primary outcome: adjusted treatment effect";"1.67"
"10.1016/j.jval.2018.03.015";"30314617";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-0.74;4.08]"
"10.1016/j.lungcan.2021.03.020";"33839603";"general_information";"";"";"Medical Condition of Interest Name";"non-squamous non-small cell lung cancer"
"10.1016/j.lungcan.2021.03.020";"33839603";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1016/j.lungcan.2021.03.020";"33839603";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1016/j.lungcan.2021.03.020";"33839603";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1016/j.lungcan.2021.03.020";"33839603";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1016/j.lungcan.2021.03.020";"33839603";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1016/j.lungcan.2021.03.020";"33839603";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1016/j.lungcan.2021.03.020";"33839603";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02039674"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02578680"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"3";"Patient-level data used";"No"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02367781"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"4";"Patient-level data used";"No"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02366143"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.lungcan.2021.03.020";"33839603";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"1";"";"Treatment name 1";"pembrolizumab + chemotherapy"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"1";"";"Treatment name 2";"atezolizumab + chemotherapy"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3;4"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"1";"";"Anchored comparison?";"No"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"2";"";"Treatment name 1";"pembrolizumab + chemotherapy"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"2";"";"Treatment name 2";"atezolizumab + bevacizumab + chemotherapy"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3;4"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"2";"";"Anchored comparison?";"No"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1016/j.lungcan.2021.03.020";"33839603";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"451"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"469"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"428"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.8"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.009"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.8"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.012"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"356"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"469"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"389"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"2";"";"Number of covariates adjusted for/matched on";"6"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"2";"";"Primary outcome: unadjusted treatment effect";"0.84"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.04"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.86"
"10.1016/j.lungcan.2021.03.020";"33839603";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.099"
"10.1016/j.msard.2021.102972";"33979770";"general_information";"";"";"Medical Condition of Interest Name";"multiple sclerosis"
"10.1016/j.msard.2021.102972";"33979770";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1016/j.msard.2021.102972";"33979770";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1016/j.msard.2021.102972";"33979770";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1016/j.msard.2021.102972";"33979770";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1016/j.msard.2021.102972";"33979770";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02047734"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02294058"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"3";"Patient-level data used";"No"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02792218"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"4";"Patient-level data used";"No"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02792231"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"5";"Patient-level data used";"No"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00751881"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"6";"Patient-level data used";"No"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"6";"Clinical Trial";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"6";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02425644"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"6";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"6";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"6";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"7";"Patient-level data used";"No"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"7";"Clinical Trial";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"7";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00134563"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"7";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"7";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"7";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"8";"Patient-level data used";"No"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"8";"Clinical Trial";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"8";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00883337"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"8";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"8";"Phase of the clinical trial (clinical trial only)";"3"
"10.1016/j.msard.2021.102972";"33979770";"study_information";"";"8";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1016/j.msard.2021.102972";"33979770";"methodology";"1";"";"Treatment name 1";"ozanimod"
"10.1016/j.msard.2021.102972";"33979770";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1.2"
"10.1016/j.msard.2021.102972";"33979770";"methodology";"1";"";"Treatment name 2";"teriflunomide"
"10.1016/j.msard.2021.102972";"33979770";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3;4;5;6;7;8"
"10.1016/j.msard.2021.102972";"33979770";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1016/j.msard.2021.102972";"33979770";"methodology";"1";"";"Anchored comparison?";"No"
"10.1016/j.msard.2021.102972";"33979770";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1016/j.msard.2021.102972";"33979770";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1016/j.msard.2021.102972";"33979770";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"annualized relapse rate"
"10.1016/j.msard.2021.102972";"33979770";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1016/j.msard.2021.102972";"33979770";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1016/j.msard.2021.102972";"33979770";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1016/j.msard.2021.102972";"33979770";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"2290"
"10.1016/j.msard.2021.102972";"33979770";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"880"
"10.1016/j.msard.2021.102972";"33979770";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"663.53"
"10.1016/j.msard.2021.102972";"33979770";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1016/j.msard.2021.102972";"33979770";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1016/j.msard.2021.102972";"33979770";"results";"1";"";"Number of covariates adjusted for/matched on";"8"
"10.1016/j.msard.2021.102972";"33979770";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.1016/j.msard.2021.102972";"33979770";"results";"1";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1016/j.msard.2021.102972";"33979770";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1016/j.msard.2021.102972";"33979770";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.73"
"10.1016/j.msard.2021.102972";"33979770";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.62;0.84"
"10.1080/03007995.2016.1248380";"27733070";"general_information";"";"";"Medical Condition of Interest Name";"multiple sclerosis"
"10.1080/03007995.2016.1248380";"27733070";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1080/03007995.2016.1248380";"27733070";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1080/03007995.2016.1248380";"27733070";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.1080/03007995.2016.1248380";"27733070";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Not mentioned"
"10.1080/03007995.2016.1248380";"27733070";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/03007995.2016.1248380";"27733070";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/03007995.2016.1248380";"27733070";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00420212"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00451451"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"3";"Patient-level data used";"No"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00289978"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"4";"Patient-level data used";"No"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00355134"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2016.1248380";"27733070";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2016.1248380";"27733070";"methodology";"1";"";"Treatment name 1";"dimethyl fumarate"
"10.1080/03007995.2016.1248380";"27733070";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1080/03007995.2016.1248380";"27733070";"methodology";"1";"";"Treatment name 2";"fingolimod"
"10.1080/03007995.2016.1248380";"27733070";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3;4"
"10.1080/03007995.2016.1248380";"27733070";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2016.1248380";"27733070";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1080/03007995.2016.1248380";"27733070";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1080/03007995.2016.1248380";"27733070";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2016.1248380";"27733070";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"annualized relapse rate"
"10.1080/03007995.2016.1248380";"27733070";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1080/03007995.2016.1248380";"27733070";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/03007995.2016.1248380";"27733070";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/03007995.2016.1248380";"27733070";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/03007995.2016.1248380";"27733070";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2016.1248380";"27733070";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2016.1248380";"27733070";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"783"
"10.1080/03007995.2016.1248380";"27733070";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"773"
"10.1080/03007995.2016.1248380";"27733070";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"769"
"10.1080/03007995.2016.1248380";"27733070";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"771"
"10.1080/03007995.2016.1248380";"27733070";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"587"
"10.1080/03007995.2016.1248380";"27733070";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"599"
"10.1080/03007995.2016.1248380";"27733070";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/03007995.2016.1248380";"27733070";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2016.1248380";"27733070";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.1080/03007995.2016.1248380";"27733070";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1080/03007995.2016.1248380";"27733070";"results";"1";"";"Primary outcome: treatment effect contrast";"RR"
"10.1080/03007995.2016.1248380";"27733070";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2016.1248380";"27733070";"results";"1";"";"Primary outcome: unadjusted treatment effect";"1.07"
"10.1080/03007995.2016.1248380";"27733070";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.5501"
"10.1080/03007995.2016.1248380";"27733070";"results";"1";"";"Primary outcome: adjusted treatment effect";"1.11"
"10.1080/03007995.2016.1248380";"27733070";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.3893"
"10.1080/03007995.2018.1510225";"30086654";"general_information";"";"";"Medical Condition of Interest Name";"chronic phase chronic myeloid leukemia"
"10.1080/03007995.2018.1510225";"30086654";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1080/03007995.2018.1510225";"30086654";"general_information";"";"";"Countries of last author affiliations";"italy"
"10.1080/03007995.2018.1510225";"30086654";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/03007995.2018.1510225";"30086654";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/03007995.2018.1510225";"30086654";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/03007995.2018.1510225";"30086654";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/03007995.2018.1510225";"30086654";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1080/03007995.2018.1510225";"30086654";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/03007995.2018.1510225";"30086654";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/03007995.2018.1510225";"30086654";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01207440"
"10.1080/03007995.2018.1510225";"30086654";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2018.1510225";"30086654";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.1080/03007995.2018.1510225";"30086654";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1080/03007995.2018.1510225";"30086654";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/03007995.2018.1510225";"30086654";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/03007995.2018.1510225";"30086654";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00261846"
"10.1080/03007995.2018.1510225";"30086654";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2018.1510225";"30086654";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.1080/03007995.2018.1510225";"30086654";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1080/03007995.2018.1510225";"30086654";"methodology";"1";"";"Treatment name 1";"ponatinib"
"10.1080/03007995.2018.1510225";"30086654";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2018.1510225";"30086654";"methodology";"1";"";"Treatment name 2";"bosutinib"
"10.1080/03007995.2018.1510225";"30086654";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/03007995.2018.1510225";"30086654";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2018.1510225";"30086654";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/03007995.2018.1510225";"30086654";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2018.1510225";"30086654";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2018.1510225";"30086654";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"cytogenetic response rate"
"10.1080/03007995.2018.1510225";"30086654";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1080/03007995.2018.1510225";"30086654";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/03007995.2018.1510225";"30086654";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/03007995.2018.1510225";"30086654";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/03007995.2018.1510225";"30086654";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2018.1510225";"30086654";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2018.1510225";"30086654";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"119"
"10.1080/03007995.2018.1510225";"30086654";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"97"
"10.1080/03007995.2018.1510225";"30086654";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"70"
"10.1080/03007995.2018.1510225";"30086654";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/03007995.2018.1510225";"30086654";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2018.1510225";"30086654";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.1080/03007995.2018.1510225";"30086654";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1080/03007995.2018.1510225";"30086654";"results";"1";"";"Primary outcome: treatment effect contrast";"No statistics were calculated"
"10.1080/03007995.2018.1520696";"30286627";"general_information";"";"";"Medical Condition of Interest Name";"crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer"
"10.1080/03007995.2018.1520696";"30286627";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1080/03007995.2018.1520696";"30286627";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1080/03007995.2018.1520696";"30286627";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/03007995.2018.1520696";"30286627";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/03007995.2018.1520696";"30286627";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02094573"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01283516"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"1"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"3";"Patient-level data used";"No"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01685060"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"2"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"1"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"4";"Patient-level data used";"No"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01871805"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"5";"Patient-level data used";"No"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01801111"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.1080/03007995.2018.1520696";"30286627";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"1"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"1";"";"Treatment name 1";"brigatinib"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"1";"";"Treatment name 2";"ceritinib"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"2";"";"Treatment name 1";"brigatinib"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"2";"";"Treatment name 2";"ceritinib"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"2";"";"Anchored comparison?";"No"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"3";"";"Treatment name 1";"brigatinib"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"3";"";"Treatment name 2";"alectinib"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"3";"";"Study 'number(s)' for treatment 2";"4"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"3";"";"Anchored comparison?";"No"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"3";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"4";"";"Treatment name 1";"brigatinib"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"4";"";"Treatment name 2";"alectinib"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"4";"";"Study 'number(s)' for treatment 2";"5"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"4";"";"Anchored comparison?";"No"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"4";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"4";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2018.1520696";"30286627";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2018.1520696";"30286627";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"163"
"10.1080/03007995.2018.1520696";"30286627";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"110"
"10.1080/03007995.2018.1520696";"30286627";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"75.8"
"10.1080/03007995.2018.1520696";"30286627";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1080/03007995.2018.1520696";"30286627";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.1080/03007995.2018.1520696";"30286627";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)"
"10.1080/03007995.2018.1520696";"30286627";"results";"1";"";"Primary outcome: treatment effect contrast";"OR"
"10.1080/03007995.2018.1520696";"30286627";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2018.1520696";"30286627";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.96"
"10.1080/03007995.2018.1520696";"30286627";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.29;1.57]"
"10.1080/03007995.2018.1520696";"30286627";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.88"
"10.1080/03007995.2018.1520696";"30286627";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.51;1.53]"
"10.1080/03007995.2018.1520696";"30286627";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"140"
"10.1080/03007995.2018.1520696";"30286627";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"110"
"10.1080/03007995.2018.1520696";"30286627";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"50.8"
"10.1080/03007995.2018.1520696";"30286627";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1080/03007995.2018.1520696";"30286627";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.1080/03007995.2018.1520696";"30286627";"results";"2";"";"Number of covariates adjusted for/matched on";"7"
"10.1080/03007995.2018.1520696";"30286627";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1080/03007995.2018.1520696";"30286627";"results";"2";"";"Primary outcome: treatment effect contrast";"OR"
"10.1080/03007995.2018.1520696";"30286627";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2018.1520696";"30286627";"results";"2";"";"Primary outcome: unadjusted treatment effect";"2.16"
"10.1080/03007995.2018.1520696";"30286627";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[1.30;3.61]"
"10.1080/03007995.2018.1520696";"30286627";"results";"2";"";"Primary outcome: adjusted treatment effect";"2.17"
"10.1080/03007995.2018.1520696";"30286627";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[1.13;4.20]"
"10.1080/03007995.2018.1520696";"30286627";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"87"
"10.1080/03007995.2018.1520696";"30286627";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"110"
"10.1080/03007995.2018.1520696";"30286627";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"77.5"
"10.1080/03007995.2018.1520696";"30286627";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1080/03007995.2018.1520696";"30286627";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"results";"3";"";"Number of covariates adjusted for/matched on";"7"
"10.1080/03007995.2018.1520696";"30286627";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)"
"10.1080/03007995.2018.1520696";"30286627";"results";"3";"";"Primary outcome: treatment effect contrast";"OR"
"10.1080/03007995.2018.1520696";"30286627";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2018.1520696";"30286627";"results";"3";"";"Primary outcome: unadjusted treatment effect";"1.78"
"10.1080/03007995.2018.1520696";"30286627";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[1.01;3.17]"
"10.1080/03007995.2018.1520696";"30286627";"results";"3";"";"Primary outcome: adjusted treatment effect";"1.69"
"10.1080/03007995.2018.1520696";"30286627";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.91;3.15]"
"10.1080/03007995.2018.1520696";"30286627";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"138"
"10.1080/03007995.2018.1520696";"30286627";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"110"
"10.1080/03007995.2018.1520696";"30286627";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"70.7"
"10.1080/03007995.2018.1520696";"30286627";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1080/03007995.2018.1520696";"30286627";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2018.1520696";"30286627";"results";"4";"";"Number of covariates adjusted for/matched on";"8"
"10.1080/03007995.2018.1520696";"30286627";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)"
"10.1080/03007995.2018.1520696";"30286627";"results";"4";"";"Primary outcome: treatment effect contrast";"OR"
"10.1080/03007995.2018.1520696";"30286627";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2018.1520696";"30286627";"results";"4";"";"Primary outcome: unadjusted treatment effect";"1.47"
"10.1080/03007995.2018.1520696";"30286627";"results";"4";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.89;2.44]"
"10.1080/03007995.2018.1520696";"30286627";"results";"4";"";"Primary outcome: adjusted treatment effect";"1.44"
"10.1080/03007995.2018.1520696";"30286627";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.81;2.58]"
"10.1080/03007995.2018.1541443";"30362839";"general_information";"";"";"Medical Condition of Interest Name";"previously untreated advanced anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer"
"10.1080/03007995.2018.1541443";"30362839";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1080/03007995.2018.1541443";"30362839";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1080/03007995.2018.1541443";"30362839";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/03007995.2018.1541443";"30362839";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/03007995.2018.1541443";"30362839";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/03007995.2018.1541443";"30362839";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/03007995.2018.1541443";"30362839";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1080/03007995.2018.1541443";"30362839";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/03007995.2018.1541443";"30362839";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/03007995.2018.1541443";"30362839";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01828099"
"10.1080/03007995.2018.1541443";"30362839";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2018.1541443";"30362839";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2018.1541443";"30362839";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2018.1541443";"30362839";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/03007995.2018.1541443";"30362839";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/03007995.2018.1541443";"30362839";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01154140"
"10.1080/03007995.2018.1541443";"30362839";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2018.1541443";"30362839";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2018.1541443";"30362839";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2018.1541443";"30362839";"methodology";"1";"";"Treatment name 1";"ceritinib"
"10.1080/03007995.2018.1541443";"30362839";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2018.1541443";"30362839";"methodology";"1";"";"Treatment name 2";"crizotinib"
"10.1080/03007995.2018.1541443";"30362839";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/03007995.2018.1541443";"30362839";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2018.1541443";"30362839";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/03007995.2018.1541443";"30362839";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2018.1541443";"30362839";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2018.1541443";"30362839";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression free survival"
"10.1080/03007995.2018.1541443";"30362839";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/03007995.2018.1541443";"30362839";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/03007995.2018.1541443";"30362839";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/03007995.2018.1541443";"30362839";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/03007995.2018.1541443";"30362839";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2018.1541443";"30362839";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2018.1541443";"30362839";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"172"
"10.1080/03007995.2018.1541443";"30362839";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"189"
"10.1080/03007995.2018.1541443";"30362839";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"340"
"10.1080/03007995.2018.1541443";"30362839";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1080/03007995.2018.1541443";"30362839";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2018.1541443";"30362839";"results";"1";"";"Number of covariates adjusted for/matched on";"8"
"10.1080/03007995.2018.1541443";"30362839";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1080/03007995.2018.1541443";"30362839";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/03007995.2018.1541443";"30362839";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2018.1541443";"30362839";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.68"
"10.1080/03007995.2018.1541443";"30362839";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.01"
"10.1080/03007995.2018.1541443";"30362839";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.64"
"10.1080/03007995.2018.1541443";"30362839";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.004"
"10.1080/03007995.2019.1585779";"30786783";"general_information";"";"";"Medical Condition of Interest Name";"active relapsing-remitting multiple sclerosis"
"10.1080/03007995.2019.1585779";"30786783";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.1080/03007995.2019.1585779";"30786783";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1080/03007995.2019.1585779";"30786783";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/03007995.2019.1585779";"30786783";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/03007995.2019.1585779";"30786783";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/03007995.2019.1585779";"30786783";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/03007995.2019.1585779";"30786783";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1080/03007995.2019.1585779";"30786783";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/03007995.2019.1585779";"30786783";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/03007995.2019.1585779";"30786783";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00213135"
"10.1080/03007995.2019.1585779";"30786783";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2019.1585779";"30786783";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2019.1585779";"30786783";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.1080/03007995.2019.1585779";"30786783";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/03007995.2019.1585779";"30786783";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/03007995.2019.1585779";"30786783";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00548405"
"10.1080/03007995.2019.1585779";"30786783";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2019.1585779";"30786783";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2019.1585779";"30786783";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2019.1585779";"30786783";"methodology";"1";"";"Treatment name 1";"cladribine tablets"
"10.1080/03007995.2019.1585779";"30786783";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2019.1585779";"30786783";"methodology";"1";"";"Treatment name 2";"alemtuzumab"
"10.1080/03007995.2019.1585779";"30786783";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/03007995.2019.1585779";"30786783";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2019.1585779";"30786783";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/03007995.2019.1585779";"30786783";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2019.1585779";"30786783";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2019.1585779";"30786783";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"confirmed disability progression"
"10.1080/03007995.2019.1585779";"30786783";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/03007995.2019.1585779";"30786783";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/03007995.2019.1585779";"30786783";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/03007995.2019.1585779";"30786783";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/03007995.2019.1585779";"30786783";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2019.1585779";"30786783";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2019.1585779";"30786783";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"426"
"10.1080/03007995.2019.1585779";"30786783";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"113"
"10.1080/03007995.2019.1585779";"30786783";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"41"
"10.1080/03007995.2019.1585779";"30786783";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1080/03007995.2019.1585779";"30786783";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2019.1585779";"30786783";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.1080/03007995.2019.1585779";"30786783";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1080/03007995.2019.1585779";"30786783";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/03007995.2019.1585779";"30786783";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2019.1585779";"30786783";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.96"
"10.1080/03007995.2019.1585779";"30786783";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.51;1.80]"
"10.1080/03007995.2019.1585779";"30786783";"results";"1";"";"Primary outcome: adjusted treatment effect";"1"
"10.1080/03007995.2019.1585779";"30786783";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.44;2.27]"
"10.1080/03007995.2019.1605239";"30964361";"general_information";"";"";"Medical Condition of Interest Name";"chronic myeloid leukemia"
"10.1080/03007995.2019.1605239";"30964361";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1080/03007995.2019.1605239";"30964361";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1080/03007995.2019.1605239";"30964361";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/03007995.2019.1605239";"30964361";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/03007995.2019.1605239";"30964361";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/03007995.2019.1605239";"30964361";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/03007995.2019.1605239";"30964361";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00261846"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00123474"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"3";"Patient-level data used";"No"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00109707"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.1080/03007995.2019.1605239";"30964361";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"1"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"1";"";"Treatment name 1";"bosutinib"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"1";"";"Treatment name 2";"dasatinib"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"Yes"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"2";"";"Treatment name 1";"bosutinib"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"2";"";"Treatment name 2";"nilotinib"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"2";"";"Anchored comparison?";"No"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2019.1605239";"30964361";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"Yes"
"10.1080/03007995.2019.1605239";"30964361";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"167"
"10.1080/03007995.2019.1605239";"30964361";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"283"
"10.1080/03007995.2019.1605239";"30964361";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"269.7"
"10.1080/03007995.2019.1605239";"30964361";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/03007995.2019.1605239";"30964361";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2019.1605239";"30964361";"results";"1";"";"Number of covariates adjusted for/matched on";"3"
"10.1080/03007995.2019.1605239";"30964361";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1080/03007995.2019.1605239";"30964361";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/03007995.2019.1605239";"30964361";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2019.1605239";"30964361";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.82"
"10.1080/03007995.2019.1605239";"30964361";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.37"
"10.1080/03007995.2019.1605239";"30964361";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"321"
"10.1080/03007995.2019.1605239";"30964361";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"283"
"10.1080/03007995.2019.1605239";"30964361";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"269.9"
"10.1080/03007995.2019.1605239";"30964361";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/03007995.2019.1605239";"30964361";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2019.1605239";"30964361";"results";"2";"";"Number of covariates adjusted for/matched on";"3"
"10.1080/03007995.2019.1605239";"30964361";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1080/03007995.2019.1605239";"30964361";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/03007995.2019.1605239";"30964361";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2019.1605239";"30964361";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.72"
"10.1080/03007995.2019.1605239";"30964361";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.16"
"10.1080/03007995.2020.1747999";"32220214";"general_information";"";"";"Medical Condition of Interest Name";"secondary progressive multiple sclerosis"
"10.1080/03007995.2020.1747999";"32220214";"general_information";"";"";"Countries of first author affiliations";"canada"
"10.1080/03007995.2020.1747999";"32220214";"general_information";"";"";"Countries of last author affiliations";"switzerland"
"10.1080/03007995.2020.1747999";"32220214";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/03007995.2020.1747999";"32220214";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/03007995.2020.1747999";"32220214";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01665144"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01416181"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"3";"Patient-level data used";"No"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"3";"Data source name (only if observational study or clinical trial without NCT)";"nordic spms study"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"4";"Patient-level data used";"No"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"4";"Data source name (only if observational study or clinical trial without NCT)";"panitch et al. (2004) (north american study)"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"5";"Patient-level data used";"No"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"5";"Data source name (only if observational study or clinical trial without NCT)";"cohen et al. (2002) (impact)"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"6";"Patient-level data used";"No"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"6";"Clinical Trial";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"6";"Data source name (only if observational study or clinical trial without NCT)";"spectrims study group (2001) li et al. (2001)"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"6";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"6";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"7";"Patient-level data used";"No"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"7";"Clinical Trial";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"7";"Data source name (only if observational study or clinical trial without NCT)";"european study group (1998) kappos et al. (2001)"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"7";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2020.1747999";"32220214";"study_information";"";"7";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"1";"";"Treatment name 1";"siponimod"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"1";"";"Treatment name 2";"ifnβ-1b 250 μg once every other day (q2d)"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"1";"";"Study 'number(s)' for treatment 2";"4"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"risk of sustained disability at 6 month"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"2";"";"Treatment name 1";"siponimod"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"2";"";"Treatment name 2";"ifnβ-1a 22 μg once weekly (qw)"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"risk of sustained disability at 6 month"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"3";"";"Treatment name 1";"siponimod"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"3";"";"Treatment name 2";"natalizumab"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"3";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"3";"";"Anchored comparison?";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"risk of sustained disability at 6 month"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"3";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"4";"";"Treatment name 1";"siponimod"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"4";"";"Treatment name 2";"sc ifnβ-1a 22 μg three times weekly"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"4";"";"Study 'number(s)' for treatment 2";"6"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"4";"";"Anchored comparison?";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"4";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"risk of sustained disability at 6 month"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"4";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"5";"";"Treatment name 1";"siponimod"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"5";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"5";"";"Treatment name 2";"sc ifnβ-1a 44 μg three times weekly"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"5";"";"Study 'number(s)' for treatment 2";"6"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"5";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"5";"";"Anchored comparison?";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"5";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"5";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"5";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"risk of sustained disability at 6 month"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"5";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"5";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"5";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"5";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"5";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"5";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"6";"";"Treatment name 1";"siponimod"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"6";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"6";"";"Treatment name 2";"ifnβ-1b 8 miu once every other day"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"6";"";"Study 'number(s)' for treatment 2";"7"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"6";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"6";"";"Anchored comparison?";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"6";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"6";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"6";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"risk of sustained disability at 6 month"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"6";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"6";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"6";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"6";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"6";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"6";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"7";"";"Treatment name 1";"siponimod"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"7";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"7";"";"Treatment name 2";"im ifnβ-1a 60 μg once weekly"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"7";"";"Study 'number(s)' for treatment 2";"5"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"7";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"7";"";"Anchored comparison?";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"7";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"7";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"7";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"risk of sustained disability at 6 month"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"7";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"7";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"7";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"7";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"7";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2020.1747999";"32220214";"methodology";"7";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2020.1747999";"32220214";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/03007995.2020.1747999";"32220214";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.1080/03007995.2020.1747999";"32220214";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1080/03007995.2020.1747999";"32220214";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/03007995.2020.1747999";"32220214";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2020.1747999";"32220214";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.55"
"10.1080/03007995.2020.1747999";"32220214";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.33;0.91]"
"10.1080/03007995.2020.1747999";"32220214";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/03007995.2020.1747999";"32220214";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"results";"2";"";"Number of covariates adjusted for/matched on";"5"
"10.1080/03007995.2020.1747999";"32220214";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1080/03007995.2020.1747999";"32220214";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/03007995.2020.1747999";"32220214";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2020.1747999";"32220214";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.43"
"10.1080/03007995.2020.1747999";"32220214";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.20;0.93]"
"10.1080/03007995.2020.1747999";"32220214";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/03007995.2020.1747999";"32220214";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"results";"3";"";"Number of covariates adjusted for/matched on";"10"
"10.1080/03007995.2020.1747999";"32220214";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.1080/03007995.2020.1747999";"32220214";"results";"3";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/03007995.2020.1747999";"32220214";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2020.1747999";"32220214";"results";"3";"";"Primary outcome: adjusted treatment effect";"0.76"
"10.1080/03007995.2020.1747999";"32220214";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.44;1.30]"
"10.1080/03007995.2020.1747999";"32220214";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/03007995.2020.1747999";"32220214";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"results";"4";"";"Number of covariates adjusted for/matched on";"6"
"10.1080/03007995.2020.1747999";"32220214";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1080/03007995.2020.1747999";"32220214";"results";"4";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/03007995.2020.1747999";"32220214";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2020.1747999";"32220214";"results";"4";"";"Primary outcome: adjusted treatment effect";"0.8"
"10.1080/03007995.2020.1747999";"32220214";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.46;1.38]"
"10.1080/03007995.2020.1747999";"32220214";"results";"5";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/03007995.2020.1747999";"32220214";"results";"5";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"results";"5";"";"Number of covariates adjusted for/matched on";"6"
"10.1080/03007995.2020.1747999";"32220214";"results";"5";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1080/03007995.2020.1747999";"32220214";"results";"5";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/03007995.2020.1747999";"32220214";"results";"5";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2020.1747999";"32220214";"results";"5";"";"Primary outcome: adjusted treatment effect";"0.84"
"10.1080/03007995.2020.1747999";"32220214";"results";"5";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.49;1.47]"
"10.1080/03007995.2020.1747999";"32220214";"results";"6";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/03007995.2020.1747999";"32220214";"results";"6";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"results";"6";"";"Number of covariates adjusted for/matched on";"6"
"10.1080/03007995.2020.1747999";"32220214";"results";"6";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1080/03007995.2020.1747999";"32220214";"results";"6";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/03007995.2020.1747999";"32220214";"results";"6";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2020.1747999";"32220214";"results";"6";"";"Primary outcome: adjusted treatment effect";"0.82"
"10.1080/03007995.2020.1747999";"32220214";"results";"6";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.42;1.63]"
"10.1080/03007995.2020.1747999";"32220214";"results";"7";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/03007995.2020.1747999";"32220214";"results";"7";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2020.1747999";"32220214";"results";"7";"";"Number of covariates adjusted for/matched on";"6"
"10.1080/03007995.2020.1747999";"32220214";"results";"7";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1080/03007995.2020.1747999";"32220214";"results";"7";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/03007995.2020.1747999";"32220214";"results";"7";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2020.1747999";"32220214";"results";"7";"";"Primary outcome: adjusted treatment effect";"0.42"
"10.1080/03007995.2020.1747999";"32220214";"results";"7";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.20;0.88]"
"10.1080/03007995.2021.1896489";"33733983";"general_information";"";"";"Medical Condition of Interest Name";"chronic phase chronic myeloid leukemia"
"10.1080/03007995.2021.1896489";"33733983";"general_information";"";"";"Countries of first author affiliations";"netherlands"
"10.1080/03007995.2021.1896489";"33733983";"general_information";"";"";"Countries of last author affiliations";"netherlands"
"10.1080/03007995.2021.1896489";"33733983";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/03007995.2021.1896489";"33733983";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/03007995.2021.1896489";"33733983";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/03007995.2021.1896489";"33733983";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/03007995.2021.1896489";"33733983";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02130557"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00471497"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"3";"Patient-level data used";"No"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00481247"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2021.1896489";"33733983";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"1";"";"Treatment name 1";"bosutinib"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"1";"";"Treatment name 2";"nilotinib"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"major molecular response at 24 months"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"Yes"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"2";"";"Treatment name 1";"bosutinib"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"2";"";"Treatment name 2";"dasatinib"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"2";"";"Anchored comparison?";"No"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"major molecular response by 24 months"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2021.1896489";"33733983";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"Yes"
"10.1080/03007995.2021.1896489";"33733983";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"282"
"10.1080/03007995.2021.1896489";"33733983";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"248"
"10.1080/03007995.2021.1896489";"33733983";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"190"
"10.1080/03007995.2021.1896489";"33733983";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/03007995.2021.1896489";"33733983";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.1080/03007995.2021.1896489";"33733983";"results";"1";"";"Number of covariates adjusted for/matched on";"3"
"10.1080/03007995.2021.1896489";"33733983";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity"
"10.1080/03007995.2021.1896489";"33733983";"results";"1";"";"Primary outcome: treatment effect contrast";"OR"
"10.1080/03007995.2021.1896489";"33733983";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Denominator if ratio, or rightside if difference"
"10.1080/03007995.2021.1896489";"33733983";"results";"1";"";"Primary outcome: adjusted treatment effect";"1.01"
"10.1080/03007995.2021.1896489";"33733983";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.70;1.45]"
"10.1080/03007995.2021.1896489";"33733983";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"259"
"10.1080/03007995.2021.1896489";"33733983";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"244"
"10.1080/03007995.2021.1896489";"33733983";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"118"
"10.1080/03007995.2021.1896489";"33733983";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/03007995.2021.1896489";"33733983";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2021.1896489";"33733983";"results";"2";"";"Number of covariates adjusted for/matched on";"5"
"10.1080/03007995.2021.1896489";"33733983";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1080/03007995.2021.1896489";"33733983";"results";"2";"";"Primary outcome: treatment effect contrast";"OR"
"10.1080/03007995.2021.1896489";"33733983";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Denominator if ratio, or rightside if difference"
"10.1080/03007995.2021.1896489";"33733983";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.81"
"10.1080/03007995.2021.1896489";"33733983";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.51;1.22]"
"10.1080/03007995.2021.1947216";"34236007";"general_information";"";"";"Medical Condition of Interest Name";"spinal muscular atrophy type 1"
"10.1080/03007995.2021.1947216";"34236007";"general_information";"";"";"Countries of first author affiliations";"switzerland"
"10.1080/03007995.2021.1947216";"34236007";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1080/03007995.2021.1947216";"34236007";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/03007995.2021.1947216";"34236007";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/03007995.2021.1947216";"34236007";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/03007995.2021.1947216";"34236007";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/03007995.2021.1947216";"34236007";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02122952"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03306277"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"3";"Patient-level data used";"No"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02594124"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2021.1947216";"34236007";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"1"
"10.1080/03007995.2021.1947216";"34236007";"methodology";"1";"";"Treatment name 1";"onasemnogene abeparvovec"
"10.1080/03007995.2021.1947216";"34236007";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1080/03007995.2021.1947216";"34236007";"methodology";"1";"";"Treatment name 2";"nusinersen"
"10.1080/03007995.2021.1947216";"34236007";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3"
"10.1080/03007995.2021.1947216";"34236007";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2021.1947216";"34236007";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/03007995.2021.1947216";"34236007";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1080/03007995.2021.1947216";"34236007";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2021.1947216";"34236007";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"event-free survival"
"10.1080/03007995.2021.1947216";"34236007";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/03007995.2021.1947216";"34236007";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/03007995.2021.1947216";"34236007";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/03007995.2021.1947216";"34236007";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/03007995.2021.1947216";"34236007";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2021.1947216";"34236007";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2021.1947216";"34236007";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"81"
"10.1080/03007995.2021.1947216";"34236007";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"34"
"10.1080/03007995.2021.1947216";"34236007";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"24.6"
"10.1080/03007995.2021.1947216";"34236007";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/03007995.2021.1947216";"34236007";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2021.1947216";"34236007";"results";"1";"";"Number of covariates adjusted for/matched on";"2"
"10.1080/03007995.2021.1947216";"34236007";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1080/03007995.2021.1947216";"34236007";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/03007995.2021.1947216";"34236007";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2021.1947216";"34236007";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.19"
"10.1080/03007995.2021.1947216";"34236007";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.07;0.54]"
"10.1080/03007995.2021.1953456";"34256668";"general_information";"";"";"Medical Condition of Interest Name";"relapsed or refractory multiple myeloma"
"10.1080/03007995.2021.1953456";"34256668";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1080/03007995.2021.1953456";"34256668";"general_information";"";"";"Countries of last author affiliations";"canada"
"10.1080/03007995.2021.1953456";"34256668";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/03007995.2021.1953456";"34256668";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/03007995.2021.1953456";"34256668";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/03007995.2021.1953456";"34256668";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/03007995.2021.1953456";"34256668";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1080/03007995.2021.1953456";"34256668";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/03007995.2021.1953456";"34256668";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/03007995.2021.1953456";"34256668";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03548207"
"10.1080/03007995.2021.1953456";"34256668";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2021.1953456";"34256668";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.1080/03007995.2021.1953456";"34256668";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1080/03007995.2021.1953456";"34256668";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/03007995.2021.1953456";"34256668";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/03007995.2021.1953456";"34256668";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03361748"
"10.1080/03007995.2021.1953456";"34256668";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2021.1953456";"34256668";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2"
"10.1080/03007995.2021.1953456";"34256668";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1080/03007995.2021.1953456";"34256668";"methodology";"1";"";"Treatment name 1";"ciltacabtagene autoleucel"
"10.1080/03007995.2021.1953456";"34256668";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2021.1953456";"34256668";"methodology";"1";"";"Treatment name 2";"idecabtagene vicleucel"
"10.1080/03007995.2021.1953456";"34256668";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/03007995.2021.1953456";"34256668";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2021.1953456";"34256668";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/03007995.2021.1953456";"34256668";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2021.1953456";"34256668";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2021.1953456";"34256668";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1080/03007995.2021.1953456";"34256668";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1080/03007995.2021.1953456";"34256668";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1080/03007995.2021.1953456";"34256668";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/03007995.2021.1953456";"34256668";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/03007995.2021.1953456";"34256668";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2021.1953456";"34256668";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2021.1953456";"34256668";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"124"
"10.1080/03007995.2021.1953456";"34256668";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"97"
"10.1080/03007995.2021.1953456";"34256668";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"52"
"10.1080/03007995.2021.1953456";"34256668";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1080/03007995.2021.1953456";"34256668";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2021.1953456";"34256668";"results";"1";"";"Number of covariates adjusted for/matched on";"4"
"10.1080/03007995.2021.1953456";"34256668";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1080/03007995.2021.1953456";"34256668";"results";"1";"";"Primary outcome: treatment effect contrast";"OR"
"10.1080/03007995.2021.1953456";"34256668";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2021.1953456";"34256668";"results";"1";"";"Primary outcome: unadjusted treatment effect";"16.52"
"10.1080/03007995.2021.1953456";"34256668";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.0002"
"10.1080/03007995.2021.1953456";"34256668";"results";"1";"";"Primary outcome: adjusted treatment effect";"94.93"
"10.1080/03007995.2021.1953456";"34256668";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.0001"
"10.1080/03007995.2021.1971182";"34445916";"general_information";"";"";"Medical Condition of Interest Name";"paroxysmal nocturnal hemoglobinuria"
"10.1080/03007995.2021.1971182";"34445916";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1080/03007995.2021.1971182";"34445916";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1080/03007995.2021.1971182";"34445916";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/03007995.2021.1971182";"34445916";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/03007995.2021.1971182";"34445916";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/03007995.2021.1971182";"34445916";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/03007995.2021.1971182";"34445916";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1080/03007995.2021.1971182";"34445916";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/03007995.2021.1971182";"34445916";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/03007995.2021.1971182";"34445916";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03500549"
"10.1080/03007995.2021.1971182";"34445916";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2021.1971182";"34445916";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2021.1971182";"34445916";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2021.1971182";"34445916";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/03007995.2021.1971182";"34445916";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/03007995.2021.1971182";"34445916";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03056040"
"10.1080/03007995.2021.1971182";"34445916";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2021.1971182";"34445916";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2021.1971182";"34445916";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2021.1971182";"34445916";"methodology";"1";"";"Treatment name 1";"pegcetacoplan"
"10.1080/03007995.2021.1971182";"34445916";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2021.1971182";"34445916";"methodology";"1";"";"Treatment name 2";"ravulizumab"
"10.1080/03007995.2021.1971182";"34445916";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/03007995.2021.1971182";"34445916";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/03007995.2021.1971182";"34445916";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1080/03007995.2021.1971182";"34445916";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2021.1971182";"34445916";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2021.1971182";"34445916";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"transfusion avoidance"
"10.1080/03007995.2021.1971182";"34445916";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1080/03007995.2021.1971182";"34445916";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/03007995.2021.1971182";"34445916";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1080/03007995.2021.1971182";"34445916";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/03007995.2021.1971182";"34445916";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2021.1971182";"34445916";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2021.1971182";"34445916";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"97"
"10.1080/03007995.2021.1971182";"34445916";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"98"
"10.1080/03007995.2021.1971182";"34445916";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"36"
"10.1080/03007995.2021.1971182";"34445916";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"32"
"10.1080/03007995.2021.1971182";"34445916";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1080/03007995.2021.1971182";"34445916";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2021.1971182";"34445916";"results";"1";"";"Number of covariates adjusted for/matched on";"5"
"10.1080/03007995.2021.1971182";"34445916";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity"
"10.1080/03007995.2021.1971182";"34445916";"results";"1";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1080/03007995.2021.1971182";"34445916";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2021.1971182";"34445916";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.714"
"10.1080/03007995.2021.1971182";"34445916";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.0001"
"10.1080/03007995.2021.1971182";"34445916";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"24"
"10.1080/03007995.2021.1971182";"34445916";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"12"
"10.1080/03007995.2022.2030112";"35042448";"general_information";"";"";"Medical Condition of Interest Name";"uncontrolled hypertension"
"10.1080/03007995.2022.2030112";"35042448";"general_information";"";"";"Countries of first author affiliations";"germany"
"10.1080/03007995.2022.2030112";"35042448";"general_information";"";"";"Countries of last author affiliations";"germany"
"10.1080/03007995.2022.2030112";"35042448";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry"
"10.1080/03007995.2022.2030112";"35042448";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/03007995.2022.2030112";"35042448";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/03007995.2022.2030112";"35042448";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/03007995.2022.2030112";"35042448";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1080/03007995.2022.2030112";"35042448";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/03007995.2022.2030112";"35042448";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/03007995.2022.2030112";"35042448";"study_information";"";"1";"EudraCT (only for clinical trials registered on clinicaltrialsregister.eu";"2019-000751-13"
"10.1080/03007995.2022.2030112";"35042448";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"poland"
"10.1080/03007995.2022.2030112";"35042448";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2022.2030112";"35042448";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2022.2030112";"35042448";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/03007995.2022.2030112";"35042448";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/03007995.2022.2030112";"35042448";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00558428"
"10.1080/03007995.2022.2030112";"35042448";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/03007995.2022.2030112";"35042448";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/03007995.2022.2030112";"35042448";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/03007995.2022.2030112";"35042448";"methodology";"1";"";"Treatment name 1";"amlodipine + bisoprolol"
"10.1080/03007995.2022.2030112";"35042448";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/03007995.2022.2030112";"35042448";"methodology";"1";"";"Treatment name 2";"amlodipine"
"10.1080/03007995.2022.2030112";"35042448";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/03007995.2022.2030112";"35042448";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.1080/03007995.2022.2030112";"35042448";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1080/03007995.2022.2030112";"35042448";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/03007995.2022.2030112";"35042448";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/03007995.2022.2030112";"35042448";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"change in systolic blood pressure at 8 week"
"10.1080/03007995.2022.2030112";"35042448";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1080/03007995.2022.2030112";"35042448";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1080/03007995.2022.2030112";"35042448";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/03007995.2022.2030112";"35042448";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/03007995.2022.2030112";"35042448";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/03007995.2022.2030112";"35042448";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/03007995.2022.2030112";"35042448";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"261"
"10.1080/03007995.2022.2030112";"35042448";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"255"
"10.1080/03007995.2022.2030112";"35042448";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"178"
"10.1080/03007995.2022.2030112";"35042448";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"178"
"10.1080/03007995.2022.2030112";"35042448";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"179"
"10.1080/03007995.2022.2030112";"35042448";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"179"
"10.1080/03007995.2022.2030112";"35042448";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/03007995.2022.2030112";"35042448";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.1080/03007995.2022.2030112";"35042448";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)"
"10.1080/03007995.2022.2030112";"35042448";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1080/03007995.2022.2030112";"35042448";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/03007995.2022.2030112";"35042448";"results";"1";"";"Primary outcome: unadjusted treatment effect";"-0.3"
"10.1080/03007995.2022.2030112";"35042448";"results";"1";"";"Primary outcome: adjusted treatment effect";"-1.6"
"10.1080/03007995.2022.2030112";"35042448";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-5.3;2.2]"
"10.1080/03007995.2022.2030112";"35042448";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/09546634.2020.1747592";"32299269";"general_information";"";"";"Medical Condition of Interest Name";"moderate-to-severe plaque psoriasis"
"10.1080/09546634.2020.1747592";"32299269";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1080/09546634.2020.1747592";"32299269";"general_information";"";"";"Countries of last author affiliations";"germany"
"10.1080/09546634.2020.1747592";"32299269";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.1080/09546634.2020.1747592";"32299269";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/09546634.2020.1747592";"32299269";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01474512"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01597245"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"3";"Patient-level data used";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01646177"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"4";"Patient-level data used";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02561806"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"5";"Patient-level data used";"No"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02207244"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"6";"Patient-level data used";"No"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"6";"Clinical Trial";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"6";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01722331"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"6";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"6";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"7";"Patient-level data used";"No"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"7";"Clinical Trial";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"7";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01729754"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"7";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"7";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"8";"Patient-level data used";"No"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"8";"Clinical Trial";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"8";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02684370"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"8";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"8";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"9";"Patient-level data used";"No"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"9";"Clinical Trial";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"9";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02684357"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"9";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/09546634.2020.1747592";"32299269";"study_information";"";"9";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"1";"";"Treatment name 1";"ixekizumab"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"1";"";"Treatment name 2";"guselkumab"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"1";"";"Study 'number(s)' for treatment 2";"5"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"rate of psoriasis area severity index (pasi) 75% improvement responders"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"2";"";"Treatment name 1";"ixekizumab"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"2";"";"Treatment name 2";"tildrakizumab 100mg"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"2";"";"Study 'number(s)' for treatment 2";"6;7"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"rate of psoriasis area severity index (pasi) 75% improvement responders"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"3";"";"Treatment name 1";"ixekizumab"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"3";"";"Treatment name 2";"tildrakizumab 200mg"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"3";"";"Study 'number(s)' for treatment 2";"6;7"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"3";"";"Anchored comparison?";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"3";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"rate of psoriasis area severity index (pasi) 75% improvement responders"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"3";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"4";"";"Treatment name 1";"ixekizumab"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"4";"";"Treatment name 2";"tildrakizumab 100mg"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"4";"";"Study 'number(s)' for treatment 2";"6;7"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"4";"";"Anchored comparison?";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"4";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"rate of psoriasis area severity index (pasi) 75% improvement responders"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"4";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"5";"";"Treatment name 1";"ixekizumab"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"5";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"5";"";"Treatment name 2";"tildrakizumab 200mg"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"5";"";"Study 'number(s)' for treatment 2";"6;7"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"5";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"5";"";"Anchored comparison?";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"5";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"5";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"5";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"rate of psoriasis area severity index (pasi) 75% improvement responders"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"5";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"5";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"5";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"5";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"5";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"5";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"6";"";"Treatment name 1";"ixekizumab"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"6";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"6";"";"Treatment name 2";"risankizumab"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"6";"";"Study 'number(s)' for treatment 2";"8;9"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"6";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"6";"";"Anchored comparison?";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"6";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"6";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"6";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"rate of psoriasis area severity index (pasi) 75% improvement responders"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"6";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"6";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"6";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"6";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"6";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"6";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"7";"";"Treatment name 1";"ixekizumab"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"7";"";"Study 'number(s)' for treatment 1";"4"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"7";"";"Treatment name 2";"risankizumab"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"7";"";"Study 'number(s)' for treatment 2";"8;9"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"7";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"7";"";"Anchored comparison?";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"7";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"7";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"7";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"rate of psoriasis area severity index (pasi) 75% improvement responders"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"7";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"7";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"7";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"7";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"7";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/09546634.2020.1747592";"32299269";"methodology";"7";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/09546634.2020.1747592";"32299269";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/09546634.2020.1747592";"32299269";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"results";"1";"";"Number of covariates adjusted for/matched on";"8"
"10.1080/09546634.2020.1747592";"32299269";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.1080/09546634.2020.1747592";"32299269";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1080/09546634.2020.1747592";"32299269";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/09546634.2020.1747592";"32299269";"results";"1";"";"Primary outcome: unadjusted treatment effect";"8.3"
"10.1080/09546634.2020.1747592";"32299269";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[2.4;14.2] <0.01"
"10.1080/09546634.2020.1747592";"32299269";"results";"1";"";"Primary outcome: adjusted treatment effect";"8"
"10.1080/09546634.2020.1747592";"32299269";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[2.0;14.1] <0.01"
"10.1080/09546634.2020.1747592";"32299269";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/09546634.2020.1747592";"32299269";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"results";"2";"";"Number of covariates adjusted for/matched on";"5"
"10.1080/09546634.2020.1747592";"32299269";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1080/09546634.2020.1747592";"32299269";"results";"2";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1080/09546634.2020.1747592";"32299269";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/09546634.2020.1747592";"32299269";"results";"2";"";"Primary outcome: unadjusted treatment effect";"27.7"
"10.1080/09546634.2020.1747592";"32299269";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.1080/09546634.2020.1747592";"32299269";"results";"2";"";"Primary outcome: adjusted treatment effect";"27"
"10.1080/09546634.2020.1747592";"32299269";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1080/09546634.2020.1747592";"32299269";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/09546634.2020.1747592";"32299269";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"results";"3";"";"Number of covariates adjusted for/matched on";"5"
"10.1080/09546634.2020.1747592";"32299269";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1080/09546634.2020.1747592";"32299269";"results";"3";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1080/09546634.2020.1747592";"32299269";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/09546634.2020.1747592";"32299269";"results";"3";"";"Primary outcome: unadjusted treatment effect";"26.4"
"10.1080/09546634.2020.1747592";"32299269";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.1080/09546634.2020.1747592";"32299269";"results";"3";"";"Primary outcome: adjusted treatment effect";"25.7"
"10.1080/09546634.2020.1747592";"32299269";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1080/09546634.2020.1747592";"32299269";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/09546634.2020.1747592";"32299269";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"results";"4";"";"Number of covariates adjusted for/matched on";"5"
"10.1080/09546634.2020.1747592";"32299269";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1080/09546634.2020.1747592";"32299269";"results";"4";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1080/09546634.2020.1747592";"32299269";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/09546634.2020.1747592";"32299269";"results";"4";"";"Primary outcome: unadjusted treatment effect";"28.1"
"10.1080/09546634.2020.1747592";"32299269";"results";"4";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.1080/09546634.2020.1747592";"32299269";"results";"4";"";"Primary outcome: adjusted treatment effect";"25.7"
"10.1080/09546634.2020.1747592";"32299269";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1080/09546634.2020.1747592";"32299269";"results";"5";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/09546634.2020.1747592";"32299269";"results";"5";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"results";"5";"";"Number of covariates adjusted for/matched on";"5"
"10.1080/09546634.2020.1747592";"32299269";"results";"5";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1080/09546634.2020.1747592";"32299269";"results";"5";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1080/09546634.2020.1747592";"32299269";"results";"5";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/09546634.2020.1747592";"32299269";"results";"5";"";"Primary outcome: unadjusted treatment effect";"26.4"
"10.1080/09546634.2020.1747592";"32299269";"results";"5";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.1080/09546634.2020.1747592";"32299269";"results";"5";"";"Primary outcome: adjusted treatment effect";"25.7"
"10.1080/09546634.2020.1747592";"32299269";"results";"5";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1080/09546634.2020.1747592";"32299269";"results";"6";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/09546634.2020.1747592";"32299269";"results";"6";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"results";"6";"";"Number of covariates adjusted for/matched on";"8"
"10.1080/09546634.2020.1747592";"32299269";"results";"6";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.1080/09546634.2020.1747592";"32299269";"results";"6";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1080/09546634.2020.1747592";"32299269";"results";"6";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/09546634.2020.1747592";"32299269";"results";"6";"";"Primary outcome: unadjusted treatment effect";"5.5"
"10.1080/09546634.2020.1747592";"32299269";"results";"6";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.5"
"10.1080/09546634.2020.1747592";"32299269";"results";"6";"";"Primary outcome: adjusted treatment effect";"5.5"
"10.1080/09546634.2020.1747592";"32299269";"results";"6";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-0.1;11.0]"
"10.1080/09546634.2020.1747592";"32299269";"results";"7";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/09546634.2020.1747592";"32299269";"results";"7";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/09546634.2020.1747592";"32299269";"results";"7";"";"Number of covariates adjusted for/matched on";"8"
"10.1080/09546634.2020.1747592";"32299269";"results";"7";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.1080/09546634.2020.1747592";"32299269";"results";"7";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1080/09546634.2020.1747592";"32299269";"results";"7";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/09546634.2020.1747592";"32299269";"results";"7";"";"Primary outcome: unadjusted treatment effect";"0.8"
"10.1080/09546634.2020.1747592";"32299269";"results";"7";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-10.9;12.6]"
"10.1080/09546634.2020.1747592";"32299269";"results";"7";"";"Primary outcome: adjusted treatment effect";"7.8"
"10.1080/09546634.2020.1747592";"32299269";"results";"7";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-6.7;22.3]"
"10.1080/10428194.2019.1648806";"31640435";"general_information";"";"";"Medical Condition of Interest Name";"relapsed or refractory multiple myeloma"
"10.1080/10428194.2019.1648806";"31640435";"general_information";"";"";"Countries of first author affiliations";"germany"
"10.1080/10428194.2019.1648806";"31640435";"general_information";"";"";"Countries of last author affiliations";"greece"
"10.1080/10428194.2019.1648806";"31640435";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.1080/10428194.2019.1648806";"31640435";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Not mentioned"
"10.1080/10428194.2019.1648806";"31640435";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/10428194.2019.1648806";"31640435";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/10428194.2019.1648806";"31640435";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1080/10428194.2019.1648806";"31640435";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/10428194.2019.1648806";"31640435";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/10428194.2019.1648806";"31640435";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01568866"
"10.1080/10428194.2019.1648806";"31640435";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/10428194.2019.1648806";"31640435";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/10428194.2019.1648806";"31640435";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/10428194.2019.1648806";"31640435";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/10428194.2019.1648806";"31640435";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/10428194.2019.1648806";"31640435";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02136134"
"10.1080/10428194.2019.1648806";"31640435";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/10428194.2019.1648806";"31640435";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/10428194.2019.1648806";"31640435";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"1";"";"Treatment name 1";"carfilzomib  +  dexamethasone"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"1";"";"Treatment name 2";"bortezomib  +  dexamethasone"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"1";"";"Study 'number(s)' for treatment 2";"1"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression free survival"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"2";"";"Treatment name 1";"bortezomib  +  dexamethasone (vd)"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"2";"";"Treatment name 2";"bortezomib  +  dexamethasone (vd) 8 cycles"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"2";"";"Anchored comparison?";"No"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/10428194.2019.1648806";"31640435";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/10428194.2019.1648806";"31640435";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"247"
"10.1080/10428194.2019.1648806";"31640435";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"465"
"10.1080/10428194.2019.1648806";"31640435";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"378"
"10.1080/10428194.2019.1648806";"31640435";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/10428194.2019.1648806";"31640435";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/10428194.2019.1648806";"31640435";"results";"1";"";"Number of covariates adjusted for/matched on";"9"
"10.1080/10428194.2019.1648806";"31640435";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1080/10428194.2019.1648806";"31640435";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/10428194.2019.1648806";"31640435";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/10428194.2019.1648806";"31640435";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.43"
"10.1080/10428194.2019.1648806";"31640435";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.29;0.65]"
"10.1080/10428194.2019.1648806";"31640435";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.43"
"10.1080/10428194.2019.1648806";"31640435";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.30;0.61]"
"10.1080/10428194.2019.1648806";"31640435";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"247"
"10.1080/10428194.2019.1648806";"31640435";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"465"
"10.1080/10428194.2019.1648806";"31640435";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"378"
"10.1080/10428194.2019.1648806";"31640435";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/10428194.2019.1648806";"31640435";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/10428194.2019.1648806";"31640435";"results";"2";"";"Number of covariates adjusted for/matched on";"15"
"10.1080/10428194.2019.1648806";"31640435";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1080/10428194.2019.1648806";"31640435";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/10428194.2019.1648806";"31640435";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Denominator if ratio, or rightside if difference"
"10.1080/10428194.2019.1648806";"31640435";"results";"2";"";"Primary outcome: adjusted treatment effect";"1.79"
"10.1080/10428194.2019.1648806";"31640435";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[1.36;2.34]"
"10.1080/10428194.2019.1675881";"31686561";"general_information";"";"";"Medical Condition of Interest Name";"transplant ineligible multiple myeloma"
"10.1080/10428194.2019.1675881";"31686561";"general_information";"";"";"Countries of first author affiliations";"spain"
"10.1080/10428194.2019.1675881";"31686561";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1080/10428194.2019.1675881";"31686561";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/10428194.2019.1675881";"31686561";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/10428194.2019.1675881";"31686561";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/10428194.2019.1675881";"31686561";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/10428194.2019.1675881";"31686561";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00111319"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02195479"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"3";"Patient-level data used";"No"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01063179"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"italy"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/10428194.2019.1675881";"31686561";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/10428194.2019.1675881";"31686561";"methodology";"1";"";"Treatment name 1";"bortezomib-melphalan-prednisone"
"10.1080/10428194.2019.1675881";"31686561";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/10428194.2019.1675881";"31686561";"methodology";"1";"";"Treatment name 2";"modified bortezomib-melphalan-prednisone schedules"
"10.1080/10428194.2019.1675881";"31686561";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2;3"
"10.1080/10428194.2019.1675881";"31686561";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/10428194.2019.1675881";"31686561";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/10428194.2019.1675881";"31686561";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1080/10428194.2019.1675881";"31686561";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/10428194.2019.1675881";"31686561";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression free survival"
"10.1080/10428194.2019.1675881";"31686561";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/10428194.2019.1675881";"31686561";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1080/10428194.2019.1675881";"31686561";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/10428194.2019.1675881";"31686561";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/10428194.2019.1675881";"31686561";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/10428194.2019.1675881";"31686561";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/10428194.2019.1675881";"31686561";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"547"
"10.1080/10428194.2019.1675881";"31686561";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"344"
"10.1080/10428194.2019.1675881";"31686561";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"114"
"10.1080/10428194.2019.1675881";"31686561";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/10428194.2019.1675881";"31686561";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/10428194.2019.1675881";"31686561";"results";"1";"";"Number of covariates adjusted for/matched on";"8"
"10.1080/10428194.2019.1675881";"31686561";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1080/10428194.2019.1675881";"31686561";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/10428194.2019.1675881";"31686561";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/10428194.2019.1675881";"31686561";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.911"
"10.1080/10428194.2019.1675881";"31686561";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.326"
"10.1080/10428194.2019.1675881";"31686561";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.991"
"10.1080/10428194.2019.1675881";"31686561";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.935"
"10.1080/10428194.2019.1682571";"31686559";"general_information";"";"";"Medical Condition of Interest Name";"multiple myeloma"
"10.1080/10428194.2019.1682571";"31686559";"general_information";"";"";"Countries of first author affiliations";"greece"
"10.1080/10428194.2019.1682571";"31686559";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1080/10428194.2019.1682571";"31686559";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/10428194.2019.1682571";"31686559";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/10428194.2019.1682571";"31686559";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/10428194.2019.1682571";"31686559";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/10428194.2019.1682571";"31686559";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1080/10428194.2019.1682571";"31686559";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/10428194.2019.1682571";"31686559";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/10428194.2019.1682571";"31686559";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02195479"
"10.1080/10428194.2019.1682571";"31686559";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/10428194.2019.1682571";"31686559";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/10428194.2019.1682571";"31686559";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/10428194.2019.1682571";"31686559";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/10428194.2019.1682571";"31686559";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/10428194.2019.1682571";"31686559";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00689936"
"10.1080/10428194.2019.1682571";"31686559";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/10428194.2019.1682571";"31686559";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/10428194.2019.1682571";"31686559";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"1";"";"Treatment name 1";"daratumumab–bortezomib–melphalan–prednisone"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"1";"";"Treatment name 2";"lenalidomide–dexamethasone continuou"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"2";"";"Treatment name 1";"daratumumab–bortezomib–melphalan–prednisone"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"2";"";"Treatment name 2";"lenalidomide–dexamethasone 18 months (rd18)"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"2";"";"Anchored comparison?";"No"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"3";"";"Treatment name 1";"daratumumab–bortezomib–melphalan–prednisone"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"3";"";"Treatment name 2";"melphalan–prednisone–thalidomide"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"3";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"3";"";"Anchored comparison?";"No"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"3";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/10428194.2019.1682571";"31686559";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/10428194.2019.1682571";"31686559";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"535"
"10.1080/10428194.2019.1682571";"31686559";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"350"
"10.1080/10428194.2019.1682571";"31686559";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"248"
"10.1080/10428194.2019.1682571";"31686559";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/10428194.2019.1682571";"31686559";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/10428194.2019.1682571";"31686559";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.1080/10428194.2019.1682571";"31686559";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1080/10428194.2019.1682571";"31686559";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/10428194.2019.1682571";"31686559";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/10428194.2019.1682571";"31686559";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.88"
"10.1080/10428194.2019.1682571";"31686559";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.51"
"10.1080/10428194.2019.1682571";"31686559";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.68"
"10.1080/10428194.2019.1682571";"31686559";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.086"
"10.1080/10428194.2019.1682571";"31686559";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"541"
"10.1080/10428194.2019.1682571";"31686559";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"350"
"10.1080/10428194.2019.1682571";"31686559";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"246"
"10.1080/10428194.2019.1682571";"31686559";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/10428194.2019.1682571";"31686559";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/10428194.2019.1682571";"31686559";"results";"2";"";"Number of covariates adjusted for/matched on";"7"
"10.1080/10428194.2019.1682571";"31686559";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1080/10428194.2019.1682571";"31686559";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/10428194.2019.1682571";"31686559";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/10428194.2019.1682571";"31686559";"results";"2";"";"Primary outcome: unadjusted treatment effect";"0.78"
"10.1080/10428194.2019.1682571";"31686559";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.16"
"10.1080/10428194.2019.1682571";"31686559";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.6"
"10.1080/10428194.2019.1682571";"31686559";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.02"
"10.1080/10428194.2019.1682571";"31686559";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"547"
"10.1080/10428194.2019.1682571";"31686559";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"535"
"10.1080/10428194.2019.1682571";"31686559";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"248"
"10.1080/10428194.2019.1682571";"31686559";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/10428194.2019.1682571";"31686559";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/10428194.2019.1682571";"31686559";"results";"3";"";"Number of covariates adjusted for/matched on";"7"
"10.1080/10428194.2019.1682571";"31686559";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1080/10428194.2019.1682571";"31686559";"results";"3";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/10428194.2019.1682571";"31686559";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/10428194.2019.1682571";"31686559";"results";"3";"";"Primary outcome: unadjusted treatment effect";"0.68"
"10.1080/10428194.2019.1682571";"31686559";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.024"
"10.1080/10428194.2019.1682571";"31686559";"results";"3";"";"Primary outcome: adjusted treatment effect";"0.53"
"10.1080/10428194.2019.1682571";"31686559";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.003"
"10.1080/10428194.2021.1913143";"33896344";"general_information";"";"";"Medical Condition of Interest Name";"relapsed and refractory multiple myeloma"
"10.1080/10428194.2021.1913143";"33896344";"general_information";"";"";"Countries of first author affiliations";"spain"
"10.1080/10428194.2021.1913143";"33896344";"general_information";"";"";"Countries of last author affiliations";"switzerland"
"10.1080/10428194.2021.1913143";"33896344";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/10428194.2021.1913143";"33896344";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/10428194.2021.1913143";"33896344";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/10428194.2021.1913143";"33896344";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/10428194.2021.1913143";"33896344";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03361748"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02336815"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"3";"Patient-level data used";"No"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03525678"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"2"
"10.1080/10428194.2021.1913143";"33896344";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"1"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"1";"";"Treatment name 1";"idecabtagene vicleucel"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"1";"";"Treatment name 2";"selinexor + dexamethasone"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"2";"";"Treatment name 1";"idecabtagene vicleucel"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"2";"";"Treatment name 2";"belantamab mafodotin"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"2";"";"Anchored comparison?";"No"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/10428194.2021.1913143";"33896344";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/10428194.2021.1913143";"33896344";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"122"
"10.1080/10428194.2021.1913143";"33896344";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"128"
"10.1080/10428194.2021.1913143";"33896344";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"56"
"10.1080/10428194.2021.1913143";"33896344";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/10428194.2021.1913143";"33896344";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/10428194.2021.1913143";"33896344";"results";"1";"";"Number of covariates adjusted for/matched on";"5"
"10.1080/10428194.2021.1913143";"33896344";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1080/10428194.2021.1913143";"33896344";"results";"1";"";"Primary outcome: treatment effect contrast";"OR"
"10.1080/10428194.2021.1913143";"33896344";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/10428194.2021.1913143";"33896344";"results";"1";"";"Primary outcome: unadjusted treatment effect";"7.78"
"10.1080/10428194.2021.1913143";"33896344";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[4.43;13.65]"
"10.1080/10428194.2021.1913143";"33896344";"results";"1";"";"Primary outcome: adjusted treatment effect";"7.74"
"10.1080/10428194.2021.1913143";"33896344";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[3.83;15.62]"
"10.1080/10428194.2021.1913143";"33896344";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"97"
"10.1080/10428194.2021.1913143";"33896344";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"128"
"10.1080/10428194.2021.1913143";"33896344";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"45"
"10.1080/10428194.2021.1913143";"33896344";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/10428194.2021.1913143";"33896344";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/10428194.2021.1913143";"33896344";"results";"2";"";"Number of covariates adjusted for/matched on";"6"
"10.1080/10428194.2021.1913143";"33896344";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.1080/10428194.2021.1913143";"33896344";"results";"2";"";"Primary outcome: treatment effect contrast";"OR"
"10.1080/10428194.2021.1913143";"33896344";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/10428194.2021.1913143";"33896344";"results";"2";"";"Primary outcome: unadjusted treatment effect";"6.17"
"10.1080/10428194.2021.1913143";"33896344";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[3.15;11.05]"
"10.1080/10428194.2021.1913143";"33896344";"results";"2";"";"Primary outcome: adjusted treatment effect";"5.12"
"10.1080/10428194.2021.1913143";"33896344";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[2.35;11.13]"
"10.1080/10428194.2021.1913144";"33955326";"general_information";"";"";"Medical Condition of Interest Name";"chronic lymphocytic leukemia"
"10.1080/10428194.2021.1913144";"33955326";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1080/10428194.2021.1913144";"33955326";"general_information";"";"";"Countries of last author affiliations";"uk"
"10.1080/10428194.2021.1913144";"33955326";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.1080/10428194.2021.1913144";"33955326";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Not mentioned"
"10.1080/10428194.2021.1913144";"33955326";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/10428194.2021.1913144";"33955326";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/10428194.2021.1913144";"33955326";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02475681"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01722487"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"3";"Patient-level data used";"No"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02264574"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"4";"Patient-level data used";"No"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02242942"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/10428194.2021.1913144";"33955326";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"1";"";"Treatment name 1";"acalabrutinib"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"1";"";"Treatment name 2";"ibrutinib"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression free survival"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"2";"";"Treatment name 1";"acalabrutinib"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"2";"";"Treatment name 2";"ibrutinib"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"2";"";"Anchored comparison?";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression free survival"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"3";"";"Treatment name 1";"acalabrutinib + obinutuzumab"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"3";"";"Treatment name 2";"ibrutinib + obinutuzumab"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"3";"";"Study 'number(s)' for treatment 2";"3"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"3";"";"Anchored comparison?";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression free survival"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"3";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"4";"";"Treatment name 1";"acalabrutinib"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"4";"";"Treatment name 2";"obinutuzumab"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"4";"";"Study 'number(s)' for treatment 2";"3"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"4";"";"Anchored comparison?";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"4";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression free survival"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"4";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"5";"";"Treatment name 1";"acalabrutinib + obinutuzumab"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"5";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"5";"";"Treatment name 2";"venetoclax + obinutuzumab"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"5";"";"Study 'number(s)' for treatment 2";"4"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"5";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"5";"";"Anchored comparison?";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"5";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"5";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"5";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression free survival"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"5";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"5";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"5";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"5";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"5";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"5";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"6";"";"Treatment name 1";"acalabrutinib"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"6";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"6";"";"Treatment name 2";"venetoclax + obinutuzumab"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"6";"";"Study 'number(s)' for treatment 2";"4"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"6";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"6";"";"Anchored comparison?";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"6";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"6";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"6";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression free survival"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"6";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"6";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"6";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"6";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"6";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/10428194.2021.1913144";"33955326";"methodology";"6";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/10428194.2021.1913144";"33955326";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"136"
"10.1080/10428194.2021.1913144";"33955326";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"126"
"10.1080/10428194.2021.1913144";"33955326";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"59"
"10.1080/10428194.2021.1913144";"33955326";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1080/10428194.2021.1913144";"33955326";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/10428194.2021.1913144";"33955326";"results";"1";"";"Number of covariates adjusted for/matched on";"12"
"10.1080/10428194.2021.1913144";"33955326";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)"
"10.1080/10428194.2021.1913144";"33955326";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/10428194.2021.1913144";"33955326";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/10428194.2021.1913144";"33955326";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.61"
"10.1080/10428194.2021.1913144";"33955326";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.3"
"10.1080/10428194.2021.1913144";"33955326";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"136"
"10.1080/10428194.2021.1913144";"33955326";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"136"
"10.1080/10428194.2021.1913144";"33955326";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"79"
"10.1080/10428194.2021.1913144";"33955326";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1080/10428194.2021.1913144";"33955326";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/10428194.2021.1913144";"33955326";"results";"2";"";"Number of covariates adjusted for/matched on";"12"
"10.1080/10428194.2021.1913144";"33955326";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)"
"10.1080/10428194.2021.1913144";"33955326";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/10428194.2021.1913144";"33955326";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/10428194.2021.1913144";"33955326";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.92"
"10.1080/10428194.2021.1913144";"33955326";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.83"
"10.1080/10428194.2021.1913144";"33955326";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"97"
"10.1080/10428194.2021.1913144";"33955326";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"113"
"10.1080/10428194.2021.1913144";"33955326";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"97"
"10.1080/10428194.2021.1913144";"33955326";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1080/10428194.2021.1913144";"33955326";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/10428194.2021.1913144";"33955326";"results";"3";"";"Number of covariates adjusted for/matched on";"12"
"10.1080/10428194.2021.1913144";"33955326";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)"
"10.1080/10428194.2021.1913144";"33955326";"results";"3";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/10428194.2021.1913144";"33955326";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/10428194.2021.1913144";"33955326";"results";"3";"";"Primary outcome: adjusted treatment effect";"0.55"
"10.1080/10428194.2021.1913144";"33955326";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.11"
"10.1080/10428194.2021.1913144";"33955326";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"113"
"10.1080/10428194.2021.1913144";"33955326";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"114"
"10.1080/10428194.2021.1913144";"33955326";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"97"
"10.1080/10428194.2021.1913144";"33955326";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1080/10428194.2021.1913144";"33955326";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/10428194.2021.1913144";"33955326";"results";"4";"";"Number of covariates adjusted for/matched on";"12"
"10.1080/10428194.2021.1913144";"33955326";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)"
"10.1080/10428194.2021.1913144";"33955326";"results";"4";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/10428194.2021.1913144";"33955326";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/10428194.2021.1913144";"33955326";"results";"4";"";"Primary outcome: adjusted treatment effect";"0.53"
"10.1080/10428194.2021.1913144";"33955326";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.08"
"10.1080/10428194.2021.1913144";"33955326";"results";"5";"";"Sample size of the population of interest in the non IPD treatment arm";"216"
"10.1080/10428194.2021.1913144";"33955326";"results";"5";"";"Initial sample size of the population of interest in the IPD treatment arm";"83"
"10.1080/10428194.2021.1913144";"33955326";"results";"5";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"43"
"10.1080/10428194.2021.1913144";"33955326";"results";"5";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1080/10428194.2021.1913144";"33955326";"results";"5";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/10428194.2021.1913144";"33955326";"results";"5";"";"Number of covariates adjusted for/matched on";"12"
"10.1080/10428194.2021.1913144";"33955326";"results";"5";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)"
"10.1080/10428194.2021.1913144";"33955326";"results";"5";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/10428194.2021.1913144";"33955326";"results";"5";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/10428194.2021.1913144";"33955326";"results";"5";"";"Primary outcome: adjusted treatment effect";"0.78"
"10.1080/10428194.2021.1913144";"33955326";"results";"5";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.57"
"10.1080/10428194.2021.1913144";"33955326";"results";"6";"";"Sample size of the population of interest in the non IPD treatment arm";"216"
"10.1080/10428194.2021.1913144";"33955326";"results";"6";"";"Initial sample size of the population of interest in the IPD treatment arm";"96"
"10.1080/10428194.2021.1913144";"33955326";"results";"6";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"51"
"10.1080/10428194.2021.1913144";"33955326";"results";"6";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1080/10428194.2021.1913144";"33955326";"results";"6";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/10428194.2021.1913144";"33955326";"results";"6";"";"Number of covariates adjusted for/matched on";"12"
"10.1080/10428194.2021.1913144";"33955326";"results";"6";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)"
"10.1080/10428194.2021.1913144";"33955326";"results";"6";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/10428194.2021.1913144";"33955326";"results";"6";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/10428194.2021.1913144";"33955326";"results";"6";"";"Primary outcome: adjusted treatment effect";"1.24"
"10.1080/10428194.2021.1913144";"33955326";"results";"6";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.59"
"10.1080/10428194.2021.2010069";"34978255";"general_information";"";"";"Medical Condition of Interest Name";"relapsed or refractory large b-cell lymphomas"
"10.1080/10428194.2021.2010069";"34978255";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1080/10428194.2021.2010069";"34978255";"general_information";"";"";"Countries of last author affiliations";"netherlands"
"10.1080/10428194.2021.2010069";"34978255";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/10428194.2021.2010069";"34978255";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/10428194.2021.2010069";"34978255";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/10428194.2021.2010069";"34978255";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/10428194.2021.2010069";"34978255";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1080/10428194.2021.2010069";"34978255";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/10428194.2021.2010069";"34978255";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/10428194.2021.2010069";"34978255";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02445248"
"10.1080/10428194.2021.2010069";"34978255";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/10428194.2021.2010069";"34978255";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.1080/10428194.2021.2010069";"34978255";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1080/10428194.2021.2010069";"34978255";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/10428194.2021.2010069";"34978255";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/10428194.2021.2010069";"34978255";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02631044"
"10.1080/10428194.2021.2010069";"34978255";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1080/10428194.2021.2010069";"34978255";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"1"
"10.1080/10428194.2021.2010069";"34978255";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1080/10428194.2021.2010069";"34978255";"methodology";"1";"";"Treatment name 1";"tisagenlecleucel"
"10.1080/10428194.2021.2010069";"34978255";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/10428194.2021.2010069";"34978255";"methodology";"1";"";"Treatment name 2";"lisocabtagene"
"10.1080/10428194.2021.2010069";"34978255";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/10428194.2021.2010069";"34978255";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/10428194.2021.2010069";"34978255";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/10428194.2021.2010069";"34978255";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/10428194.2021.2010069";"34978255";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/10428194.2021.2010069";"34978255";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1080/10428194.2021.2010069";"34978255";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1080/10428194.2021.2010069";"34978255";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1080/10428194.2021.2010069";"34978255";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/10428194.2021.2010069";"34978255";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/10428194.2021.2010069";"34978255";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/10428194.2021.2010069";"34978255";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/10428194.2021.2010069";"34978255";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"256"
"10.1080/10428194.2021.2010069";"34978255";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"106"
"10.1080/10428194.2021.2010069";"34978255";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"29"
"10.1080/10428194.2021.2010069";"34978255";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/10428194.2021.2010069";"34978255";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/10428194.2021.2010069";"34978255";"results";"1";"";"Number of covariates adjusted for/matched on";"11"
"10.1080/10428194.2021.2010069";"34978255";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1080/10428194.2021.2010069";"34978255";"results";"1";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1080/10428194.2021.2010069";"34978255";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/10428194.2021.2010069";"34978255";"results";"1";"";"Primary outcome: unadjusted treatment effect";"-15.5"
"10.1080/10428194.2021.2010069";"34978255";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.01"
"10.1080/10428194.2021.2010069";"34978255";"results";"1";"";"Primary outcome: adjusted treatment effect";"-9.7"
"10.1080/10428194.2021.2010069";"34978255";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.07"
"10.1080/10428194.2022.2047962";"35289710";"general_information";"";"";"Medical Condition of Interest Name";"10.1080/10428194.2022.2047962"
"10.1080/10428194.2022.2047962";"35289710";"general_information";"";"";"Countries of first author affiliations";"germany"
"10.1080/10428194.2022.2047962";"35289710";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1080/10428194.2022.2047962";"35289710";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.1080/10428194.2022.2047962";"35289710";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/10428194.2022.2047962";"35289710";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/10428194.2022.2047962";"35289710";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/10428194.2022.2047962";"35289710";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1080/10428194.2022.2047962";"35289710";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/10428194.2022.2047962";"35289710";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/10428194.2022.2047962";"35289710";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03158688"
"10.1080/10428194.2022.2047962";"35289710";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/10428194.2022.2047962";"35289710";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/10428194.2022.2047962";"35289710";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/10428194.2022.2047962";"35289710";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/10428194.2022.2047962";"35289710";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/10428194.2022.2047962";"35289710";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02136134"
"10.1080/10428194.2022.2047962";"35289710";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/10428194.2022.2047962";"35289710";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/10428194.2022.2047962";"35289710";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/10428194.2022.2047962";"35289710";"methodology";"1";"";"Treatment name 1";"carfizomib + dexamethasone+daratumumab"
"10.1080/10428194.2022.2047962";"35289710";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/10428194.2022.2047962";"35289710";"methodology";"1";"";"Treatment name 2";"daratumumab + velcade+dexamethasone"
"10.1080/10428194.2022.2047962";"35289710";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/10428194.2022.2047962";"35289710";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/10428194.2022.2047962";"35289710";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/10428194.2022.2047962";"35289710";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/10428194.2022.2047962";"35289710";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1080/10428194.2022.2047962";"35289710";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression free survival"
"10.1080/10428194.2022.2047962";"35289710";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/10428194.2022.2047962";"35289710";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/10428194.2022.2047962";"35289710";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/10428194.2022.2047962";"35289710";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/10428194.2022.2047962";"35289710";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/10428194.2022.2047962";"35289710";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/10428194.2022.2047962";"35289710";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"251"
"10.1080/10428194.2022.2047962";"35289710";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"198"
"10.1080/10428194.2022.2047962";"35289710";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"82"
"10.1080/10428194.2022.2047962";"35289710";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1080/10428194.2022.2047962";"35289710";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/10428194.2022.2047962";"35289710";"results";"1";"";"Number of covariates adjusted for/matched on";"10"
"10.1080/10428194.2022.2047962";"35289710";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)"
"10.1080/10428194.2022.2047962";"35289710";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/10428194.2022.2047962";"35289710";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/10428194.2022.2047962";"35289710";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.54"
"10.1080/10428194.2022.2047962";"35289710";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[.41;0.70]"
"10.1080/10428194.2022.2047962";"35289710";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.64"
"10.1080/10428194.2022.2047962";"35289710";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.46;0.90]"
"10.1080/13696998.2018.1443111";"29458286";"general_information";"";"";"Medical Condition of Interest Name";"metastatic non-small cell lung cancer"
"10.1080/13696998.2018.1443111";"29458286";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1080/13696998.2018.1443111";"29458286";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1080/13696998.2018.1443111";"29458286";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/13696998.2018.1443111";"29458286";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/13696998.2018.1443111";"29458286";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/13696998.2018.1443111";"29458286";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/13696998.2018.1443111";"29458286";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1080/13696998.2018.1443111";"29458286";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/13696998.2018.1443111";"29458286";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/13696998.2018.1443111";"29458286";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01828099"
"10.1080/13696998.2018.1443111";"29458286";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/13696998.2018.1443111";"29458286";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/13696998.2018.1443111";"29458286";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/13696998.2018.1443111";"29458286";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/13696998.2018.1443111";"29458286";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/13696998.2018.1443111";"29458286";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01154140"
"10.1080/13696998.2018.1443111";"29458286";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/13696998.2018.1443111";"29458286";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/13696998.2018.1443111";"29458286";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/13696998.2018.1443111";"29458286";"methodology";"1";"";"Treatment name 1";"ceritinib"
"10.1080/13696998.2018.1443111";"29458286";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/13696998.2018.1443111";"29458286";"methodology";"1";"";"Treatment name 2";"crizotinib"
"10.1080/13696998.2018.1443111";"29458286";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/13696998.2018.1443111";"29458286";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/13696998.2018.1443111";"29458286";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/13696998.2018.1443111";"29458286";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/13696998.2018.1443111";"29458286";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression free survival"
"10.1080/13696998.2018.1443111";"29458286";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/13696998.2018.1443111";"29458286";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/13696998.2018.1443111";"29458286";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/13696998.2018.1443111";"29458286";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/13696998.2018.1443111";"29458286";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/13696998.2018.1443111";"29458286";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/13696998.2018.1443111";"29458286";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/13696998.2018.1443111";"29458286";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/13696998.2018.1443111";"29458286";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.1080/13696998.2018.1443111";"29458286";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/13696998.2018.1443111";"29458286";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.64"
"10.1080/13696998.2018.1443111";"29458286";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.47;0.87]"
"10.1080/13696998.2018.1443111";"29458286";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/13696998.2020.1722139";"31985301";"general_information";"";"";"Medical Condition of Interest Name";"moderate-to-severe psoriasis"
"10.1080/13696998.2020.1722139";"31985301";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1080/13696998.2020.1722139";"31985301";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1080/13696998.2020.1722139";"31985301";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.1080/13696998.2020.1722139";"31985301";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Not mentioned"
"10.1080/13696998.2020.1722139";"31985301";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/13696998.2020.1722139";"31985301";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/13696998.2020.1722139";"31985301";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01866163"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02132936"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"france"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"3";"Patient-level data used";"Yes"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01536886"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"2"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"4";"Patient-level data used";"No"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02462070"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"5";"Patient-level data used";"No"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02462122"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/13696998.2020.1722139";"31985301";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/13696998.2020.1722139";"31985301";"methodology";"1";"";"Treatment name 1";"calcipotriene 0.005%/betamethasone dipropionate 0.064% foam"
"10.1080/13696998.2020.1722139";"31985301";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.1080/13696998.2020.1722139";"31985301";"methodology";"1";"";"Treatment name 2";"halobetasol 0.01%/tazarotene 0.045%"
"10.1080/13696998.2020.1722139";"31985301";"methodology";"1";"";"Study 'number(s)' for treatment 2";"4;5"
"10.1080/13696998.2020.1722139";"31985301";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/13696998.2020.1722139";"31985301";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1080/13696998.2020.1722139";"31985301";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1080/13696998.2020.1722139";"31985301";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1080/13696998.2020.1722139";"31985301";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"physician’s global assessment treatment success"
"10.1080/13696998.2020.1722139";"31985301";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1080/13696998.2020.1722139";"31985301";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/13696998.2020.1722139";"31985301";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1080/13696998.2020.1722139";"31985301";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/13696998.2020.1722139";"31985301";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/13696998.2020.1722139";"31985301";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/13696998.2020.1722139";"31985301";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"249"
"10.1080/13696998.2020.1722139";"31985301";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"142"
"10.1080/13696998.2020.1722139";"31985301";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"649"
"10.1080/13696998.2020.1722139";"31985301";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"199"
"10.1080/13696998.2020.1722139";"31985301";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1080/13696998.2020.1722139";"31985301";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/13696998.2020.1722139";"31985301";"results";"1";"";"Number of covariates adjusted for/matched on";"4"
"10.1080/13696998.2020.1722139";"31985301";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity"
"10.1080/13696998.2020.1722139";"31985301";"results";"1";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1080/13696998.2020.1722139";"31985301";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/13696998.2020.1722139";"31985301";"results";"1";"";"Primary outcome: adjusted treatment effect";"20.7"
"10.1080/13696998.2020.1722139";"31985301";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1080/14656566.2020.1811850";"32892660";"general_information";"";"";"Medical Condition of Interest Name";"hereditary transthyretin-mediated amyloidoisis with polyneuropathy"
"10.1080/14656566.2020.1811850";"32892660";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1080/14656566.2020.1811850";"32892660";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1080/14656566.2020.1811850";"32892660";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/14656566.2020.1811850";"32892660";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/14656566.2020.1811850";"32892660";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/14656566.2020.1811850";"32892660";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/14656566.2020.1811850";"32892660";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1080/14656566.2020.1811850";"32892660";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/14656566.2020.1811850";"32892660";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/14656566.2020.1811850";"32892660";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03997383"
"10.1080/14656566.2020.1811850";"32892660";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/14656566.2020.1811850";"32892660";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/14656566.2020.1811850";"32892660";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/14656566.2020.1811850";"32892660";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/14656566.2020.1811850";"32892660";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/14656566.2020.1811850";"32892660";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01737398"
"10.1080/14656566.2020.1811850";"32892660";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/14656566.2020.1811850";"32892660";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2, 3"
"10.1080/14656566.2020.1811850";"32892660";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/14656566.2020.1811850";"32892660";"methodology";"1";"";"Treatment name 1";"patisiran"
"10.1080/14656566.2020.1811850";"32892660";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/14656566.2020.1811850";"32892660";"methodology";"1";"";"Treatment name 2";"inotersen"
"10.1080/14656566.2020.1811850";"32892660";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/14656566.2020.1811850";"32892660";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/14656566.2020.1811850";"32892660";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1080/14656566.2020.1811850";"32892660";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/14656566.2020.1811850";"32892660";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1080/14656566.2020.1811850";"32892660";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"mean difference 15-month change in neuropathy mnis+7ionis score"
"10.1080/14656566.2020.1811850";"32892660";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1080/14656566.2020.1811850";"32892660";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1080/14656566.2020.1811850";"32892660";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1080/14656566.2020.1811850";"32892660";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/14656566.2020.1811850";"32892660";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/14656566.2020.1811850";"32892660";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/14656566.2020.1811850";"32892660";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"112"
"10.1080/14656566.2020.1811850";"32892660";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"60"
"10.1080/14656566.2020.1811850";"32892660";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"148"
"10.1080/14656566.2020.1811850";"32892660";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"90"
"10.1080/14656566.2020.1811850";"32892660";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"77"
"10.1080/14656566.2020.1811850";"32892660";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"47"
"10.1080/14656566.2020.1811850";"32892660";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1080/14656566.2020.1811850";"32892660";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/14656566.2020.1811850";"32892660";"results";"1";"";"Number of covariates adjusted for/matched on";"9"
"10.1080/14656566.2020.1811850";"32892660";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.1080/14656566.2020.1811850";"32892660";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1080/14656566.2020.1811850";"32892660";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/14656566.2020.1811850";"32892660";"results";"1";"";"Primary outcome: unadjusted treatment effect";"-16.2"
"10.1080/14656566.2020.1811850";"32892660";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.001"
"10.1080/14656566.2020.1811850";"32892660";"results";"1";"";"Primary outcome: adjusted treatment effect";"-12.3"
"10.1080/14656566.2020.1811850";"32892660";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.007"
"10.1080/14760584.2021.1994858";"34672224";"general_information";"";"";"Medical Condition of Interest Name";"pneumococcal disease"
"10.1080/14760584.2021.1994858";"34672224";"general_information";"";"";"Countries of first author affiliations";"switzerland"
"10.1080/14760584.2021.1994858";"34672224";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1080/14760584.2021.1994858";"34672224";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry"
"10.1080/14760584.2021.1994858";"34672224";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/14760584.2021.1994858";"34672224";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/14760584.2021.1994858";"34672224";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/14760584.2021.1994858";"34672224";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03950622"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03480763"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"3";"Patient-level data used";"Yes"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03950856"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"4";"Patient-level data used";"No"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03760146"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.1080/14760584.2021.1994858";"34672224";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1080/14760584.2021.1994858";"34672224";"methodology";"1";"";"Treatment name 1";"15-valent pneumococcal conjugate vaccine"
"10.1080/14760584.2021.1994858";"34672224";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.1080/14760584.2021.1994858";"34672224";"methodology";"1";"";"Treatment name 2";"20-valent pneumococcal conjugate vaccine"
"10.1080/14760584.2021.1994858";"34672224";"methodology";"1";"";"Study 'number(s)' for treatment 2";"4"
"10.1080/14760584.2021.1994858";"34672224";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1080/14760584.2021.1994858";"34672224";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1080/14760584.2021.1994858";"34672224";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1080/14760584.2021.1994858";"34672224";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1080/14760584.2021.1994858";"34672224";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"opsonophagocytic activity (opa) geometric mean titer"
"10.1080/14760584.2021.1994858";"34672224";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1080/14760584.2021.1994858";"34672224";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1080/14760584.2021.1994858";"34672224";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/14760584.2021.1994858";"34672224";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1080/14760584.2021.1994858";"34672224";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1080/14760584.2021.1994858";"34672224";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"Yes"
"10.1080/14760584.2021.1994858";"34672224";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"1507"
"10.1080/14760584.2021.1994858";"34672224";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"1490"
"10.1080/14760584.2021.1994858";"34672224";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"2196"
"10.1080/14760584.2021.1994858";"34672224";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"843"
"10.1080/14760584.2021.1994858";"34672224";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/14760584.2021.1994858";"34672224";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/14760584.2021.1994858";"34672224";"results";"1";"";"Number of covariates adjusted for/matched on";"2"
"10.1080/14760584.2021.1994858";"34672224";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex"
"10.1080/14760584.2021.1994858";"34672224";"results";"1";"";"Primary outcome: treatment effect contrast";"Means Ratio"
"10.1080/14760584.2021.1994858";"34672224";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1080/14760584.2021.1994858";"34672224";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.89"
"10.1080/14760584.2021.1994858";"34672224";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.1080/14760584.2021.1994858";"34672224";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.91"
"10.1080/14760584.2021.1994858";"34672224";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1080/17474086.2018.1475226";"29764245";"general_information";"";"";"Medical Condition of Interest Name";"relapsed and refractory classical hodgkin’s lymphoma"
"10.1080/17474086.2018.1475226";"29764245";"general_information";"";"";"Countries of first author affiliations";"canada"
"10.1080/17474086.2018.1475226";"29764245";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1080/17474086.2018.1475226";"29764245";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1080/17474086.2018.1475226";"29764245";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1080/17474086.2018.1475226";"29764245";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1080/17474086.2018.1475226";"29764245";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1080/17474086.2018.1475226";"29764245";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1080/17474086.2018.1475226";"29764245";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1080/17474086.2018.1475226";"29764245";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1080/17474086.2018.1475226";"29764245";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02453594"
"10.1080/17474086.2018.1475226";"29764245";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.1080/17474086.2018.1475226";"29764245";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1080/17474086.2018.1475226";"29764245";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.1080/17474086.2018.1475226";"29764245";"study_information";"";"2";"Patient-level data used";"No"
"10.1080/17474086.2018.1475226";"29764245";"study_information";"";"2";"Clinical Trial";"No"
"10.1080/17474086.2018.1475226";"29764245";"study_information";"";"2";"Data source name (only if observational study or clinical trial without NCT)";"cheah et al., 2016"
"10.1080/17474086.2018.1475226";"29764245";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1080/17474086.2018.1475226";"29764245";"methodology";"1";"";"Treatment name 1";"pembrolizumab"
"10.1080/17474086.2018.1475226";"29764245";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1080/17474086.2018.1475226";"29764245";"methodology";"1";"";"Treatment name 2";"st + ard of care"
"10.1080/17474086.2018.1475226";"29764245";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1080/17474086.2018.1475226";"29764245";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.1080/17474086.2018.1475226";"29764245";"methodology";"1";"";"Anchored comparison?";"No"
"10.1080/17474086.2018.1475226";"29764245";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1080/17474086.2018.1475226";"29764245";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1080/17474086.2018.1475226";"29764245";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1080/17474086.2018.1475226";"29764245";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1080/17474086.2018.1475226";"29764245";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1080/17474086.2018.1475226";"29764245";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1080/17474086.2018.1475226";"29764245";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1080/17474086.2018.1475226";"29764245";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1080/17474086.2018.1475226";"29764245";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1080/17474086.2018.1475226";"29764245";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"83"
"10.1080/17474086.2018.1475226";"29764245";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"175"
"10.1080/17474086.2018.1475226";"29764245";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1080/17474086.2018.1475226";"29764245";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1080/17474086.2018.1475226";"29764245";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.1080/17474086.2018.1475226";"29764245";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1080/17474086.2018.1475226";"29764245";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1080/17474086.2018.1475226";"29764245";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Denominator if ratio, or rightside if difference"
"10.1080/17474086.2018.1475226";"29764245";"results";"1";"";"Primary outcome: unadjusted treatment effect";"5"
"10.1080/17474086.2018.1475226";"29764245";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[3.56;7.01]"
"10.1080/17474086.2018.1475226";"29764245";"results";"1";"";"Primary outcome: adjusted treatment effect";"6.35"
"10.1080/17474086.2018.1475226";"29764245";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[4.04;9.98]"
"10.1080/17474086.2018.1475226";"29764245";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"175"
"10.1093/europace/euy160";"30052894";"general_information";"";"";"Medical Condition of Interest Name";"non-valvular atrial fibrillation"
"10.1093/europace/euy160";"30052894";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.1093/europace/euy160";"30052894";"general_information";"";"";"Countries of last author affiliations";"canada"
"10.1093/europace/euy160";"30052894";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1093/europace/euy160";"30052894";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1093/europace/euy160";"30052894";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1093/europace/euy160";"30052894";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1093/europace/euy160";"30052894";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1093/europace/euy160";"30052894";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1093/europace/euy160";"30052894";"study_information";"";"1";"Clinical Trial";"No"
"10.1093/europace/euy160";"30052894";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01606995"
"10.1093/europace/euy160";"30052894";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1093/europace/euy160";"30052894";"study_information";"";"2";"Patient-level data used";"No"
"10.1093/europace/euy160";"30052894";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1093/europace/euy160";"30052894";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00403767"
"10.1093/europace/euy160";"30052894";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1093/europace/euy160";"30052894";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1093/europace/euy160";"30052894";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1093/europace/euy160";"30052894";"methodology";"1";"";"Treatment name 1";"rivaroxaban"
"10.1093/europace/euy160";"30052894";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1093/europace/euy160";"30052894";"methodology";"1";"";"Treatment name 2";"rivaroxaban"
"10.1093/europace/euy160";"30052894";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1093/europace/euy160";"30052894";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1093/europace/euy160";"30052894";"methodology";"1";"";"Anchored comparison?";"No"
"10.1093/europace/euy160";"30052894";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1093/europace/euy160";"30052894";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1093/europace/euy160";"30052894";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"treatment-emergent adjudicated major bleeding"
"10.1093/europace/euy160";"30052894";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1093/europace/euy160";"30052894";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1093/europace/euy160";"30052894";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1093/europace/euy160";"30052894";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1093/europace/euy160";"30052894";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1093/europace/euy160";"30052894";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1093/europace/euy160";"30052894";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"7061"
"10.1093/europace/euy160";"30052894";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"4020"
"10.1093/europace/euy160";"30052894";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"2492"
"10.1093/europace/euy160";"30052894";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1093/europace/euy160";"30052894";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1093/europace/euy160";"30052894";"results";"1";"";"Number of covariates adjusted for/matched on";"2"
"10.1093/europace/euy160";"30052894";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex"
"10.1093/europace/euy160";"30052894";"results";"1";"";"Primary outcome: treatment effect contrast";"RR"
"10.1093/europace/euy160";"30052894";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1093/europace/euy160";"30052894";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.86"
"10.1093/europace/euy160";"30052894";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.67;1.12]"
"10.1093/jnci/djab071";"33830214";"general_information";"";"";"Medical Condition of Interest Name";"nonmetastatic castration-resistant prostate cancer"
"10.1093/jnci/djab071";"33830214";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1093/jnci/djab071";"33830214";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1093/jnci/djab071";"33830214";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic"
"10.1093/jnci/djab071";"33830214";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1093/jnci/djab071";"33830214";"general_information";"";"";"Mentioned sources of funding";"Public grants, Pharmaceutical Industry"
"10.1093/jnci/djab071";"33830214";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1093/jnci/djab071";"33830214";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1093/jnci/djab071";"33830214";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1093/jnci/djab071";"33830214";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1093/jnci/djab071";"33830214";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01314118"
"10.1093/jnci/djab071";"33830214";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1093/jnci/djab071";"33830214";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.1093/jnci/djab071";"33830214";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1093/jnci/djab071";"33830214";"study_information";"";"2";"Patient-level data used";"No"
"10.1093/jnci/djab071";"33830214";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1093/jnci/djab071";"33830214";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01946204"
"10.1093/jnci/djab071";"33830214";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1093/jnci/djab071";"33830214";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1093/jnci/djab071";"33830214";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1093/jnci/djab071";"33830214";"methodology";"1";"";"Treatment name 1";"abiraterone acetate"
"10.1093/jnci/djab071";"33830214";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1093/jnci/djab071";"33830214";"methodology";"1";"";"Treatment name 2";"placebo"
"10.1093/jnci/djab071";"33830214";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1093/jnci/djab071";"33830214";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1093/jnci/djab071";"33830214";"methodology";"1";"";"Anchored comparison?";"No"
"10.1093/jnci/djab071";"33830214";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1093/jnci/djab071";"33830214";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1093/jnci/djab071";"33830214";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"metastasis free survival"
"10.1093/jnci/djab071";"33830214";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1093/jnci/djab071";"33830214";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1093/jnci/djab071";"33830214";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1093/jnci/djab071";"33830214";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1093/jnci/djab071";"33830214";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1093/jnci/djab071";"33830214";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1093/jnci/djab071";"33830214";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"806"
"10.1093/jnci/djab071";"33830214";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"131"
"10.1093/jnci/djab071";"33830214";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"81"
"10.1093/jnci/djab071";"33830214";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1093/jnci/djab071";"33830214";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1093/jnci/djab071";"33830214";"results";"1";"";"Number of covariates adjusted for/matched on";"4"
"10.1093/jnci/djab071";"33830214";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1093/jnci/djab071";"33830214";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1093/jnci/djab071";"33830214";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1093/jnci/djab071";"33830214";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.22"
"10.1093/jnci/djab071";"33830214";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.12;0.41]"
"10.1097/brs.0000000000002647";"29570121";"general_information";"";"";"Medical Condition of Interest Name";"symptomatic lumbar disc degeneration"
"10.1097/brs.0000000000002647";"29570121";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1097/brs.0000000000002647";"29570121";"general_information";"";"";"Countries of last author affiliations";"canada"
"10.1097/brs.0000000000002647";"29570121";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Private Data Analysis Company"
"10.1097/brs.0000000000002647";"29570121";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1097/brs.0000000000002647";"29570121";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1097/brs.0000000000002647";"29570121";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1097/brs.0000000000002647";"29570121";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1097/brs.0000000000002647";"29570121";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1097/brs.0000000000002647";"29570121";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1097/brs.0000000000002647";"29570121";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00589797"
"10.1097/brs.0000000000002647";"29570121";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1097/brs.0000000000002647";"29570121";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1097/brs.0000000000002647";"29570121";"study_information";"";"2";"Patient-level data used";"No"
"10.1097/brs.0000000000002647";"29570121";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1097/brs.0000000000002647";"29570121";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00295009"
"10.1097/brs.0000000000002647";"29570121";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1097/brs.0000000000002647";"29570121";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1097/brs.0000000000002647";"29570121";"methodology";"1";"";"Treatment name 1";"total disc replacemen"
"10.1097/brs.0000000000002647";"29570121";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1097/brs.0000000000002647";"29570121";"methodology";"1";"";"Treatment name 2";"fusion"
"10.1097/brs.0000000000002647";"29570121";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1097/brs.0000000000002647";"29570121";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1097/brs.0000000000002647";"29570121";"methodology";"1";"";"Anchored comparison?";"No"
"10.1097/brs.0000000000002647";"29570121";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1097/brs.0000000000002647";"29570121";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1097/brs.0000000000002647";"29570121";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"incidence of progression in radiographic adjacent-level degeneration"
"10.1097/brs.0000000000002647";"29570121";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1097/brs.0000000000002647";"29570121";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1097/brs.0000000000002647";"29570121";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1097/brs.0000000000002647";"29570121";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1097/brs.0000000000002647";"29570121";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1097/brs.0000000000002647";"29570121";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1097/brs.0000000000002647";"29570121";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"43"
"10.1097/brs.0000000000002647";"29570121";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"175"
"10.1097/brs.0000000000002647";"29570121";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"139"
"10.1097/brs.0000000000002647";"29570121";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1097/brs.0000000000002647";"29570121";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1097/brs.0000000000002647";"29570121";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.1097/brs.0000000000002647";"29570121";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1097/brs.0000000000002647";"29570121";"results";"1";"";"Primary outcome: treatment effect contrast";"OR"
"10.1097/brs.0000000000002647";"29570121";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1097/brs.0000000000002647";"29570121";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.28"
"10.1097/brs.0000000000002647";"29570121";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.12;0.63]"
"10.1097/brs.0000000000002647";"29570121";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.35"
"10.1097/brs.0000000000002647";"29570121";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.13;0.76]"
"10.1097/ju.0000000000001767";"33818140";"general_information";"";"";"Medical Condition of Interest Name";"nonmetastatic castration-resistant prostate cancer"
"10.1097/ju.0000000000001767";"33818140";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1097/ju.0000000000001767";"33818140";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1097/ju.0000000000001767";"33818140";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1097/ju.0000000000001767";"33818140";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1097/ju.0000000000001767";"33818140";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1097/ju.0000000000001767";"33818140";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1097/ju.0000000000001767";"33818140";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02200614"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"2";"Patient-level data used";"No"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01946204"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"3";"Patient-level data used";"No"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02003924"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1097/ju.0000000000001767";"33818140";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1097/ju.0000000000001767";"33818140";"methodology";"1";"";"Treatment name 1";"darolutamide"
"10.1097/ju.0000000000001767";"33818140";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1097/ju.0000000000001767";"33818140";"methodology";"1";"";"Treatment name 2";"apalutamide"
"10.1097/ju.0000000000001767";"33818140";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1097/ju.0000000000001767";"33818140";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1097/ju.0000000000001767";"33818140";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1097/ju.0000000000001767";"33818140";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1097/ju.0000000000001767";"33818140";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1097/ju.0000000000001767";"33818140";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"fall risk"
"10.1097/ju.0000000000001767";"33818140";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1097/ju.0000000000001767";"33818140";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1097/ju.0000000000001767";"33818140";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1097/ju.0000000000001767";"33818140";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1097/ju.0000000000001767";"33818140";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1097/ju.0000000000001767";"33818140";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1097/ju.0000000000001767";"33818140";"methodology";"2";"";"Treatment name 1";"darolutamide"
"10.1097/ju.0000000000001767";"33818140";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1097/ju.0000000000001767";"33818140";"methodology";"2";"";"Treatment name 2";"enzalutamide"
"10.1097/ju.0000000000001767";"33818140";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1097/ju.0000000000001767";"33818140";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1097/ju.0000000000001767";"33818140";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.1097/ju.0000000000001767";"33818140";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1097/ju.0000000000001767";"33818140";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1097/ju.0000000000001767";"33818140";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"fall risk"
"10.1097/ju.0000000000001767";"33818140";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1097/ju.0000000000001767";"33818140";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1097/ju.0000000000001767";"33818140";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1097/ju.0000000000001767";"33818140";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1097/ju.0000000000001767";"33818140";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1097/ju.0000000000001767";"33818140";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1097/ju.0000000000001767";"33818140";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"806"
"10.1097/ju.0000000000001767";"33818140";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"401"
"10.1097/ju.0000000000001767";"33818140";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"943"
"10.1097/ju.0000000000001767";"33818140";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"604"
"10.1097/ju.0000000000001767";"33818140";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"553"
"10.1097/ju.0000000000001767";"33818140";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"391"
"10.1097/ju.0000000000001767";"33818140";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1097/ju.0000000000001767";"33818140";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1097/ju.0000000000001767";"33818140";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.1097/ju.0000000000001767";"33818140";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1097/ju.0000000000001767";"33818140";"results";"1";"";"Primary outcome: treatment effect contrast";"Risk difference"
"10.1097/ju.0000000000001767";"33818140";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1097/ju.0000000000001767";"33818140";"results";"1";"";"Primary outcome: adjusted treatment effect";"-6.3"
"10.1097/ju.0000000000001767";"33818140";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.043"
"10.1097/ju.0000000000001767";"33818140";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"933"
"10.1097/ju.0000000000001767";"33818140";"results";"2";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"468"
"10.1097/ju.0000000000001767";"33818140";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"943"
"10.1097/ju.0000000000001767";"33818140";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"580"
"10.1097/ju.0000000000001767";"33818140";"results";"2";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"553"
"10.1097/ju.0000000000001767";"33818140";"results";"2";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"395"
"10.1097/ju.0000000000001767";"33818140";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1097/ju.0000000000001767";"33818140";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1097/ju.0000000000001767";"33818140";"results";"2";"";"Number of covariates adjusted for/matched on";"8"
"10.1097/ju.0000000000001767";"33818140";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)"
"10.1097/ju.0000000000001767";"33818140";"results";"2";"";"Primary outcome: treatment effect contrast";"Risk difference"
"10.1097/ju.0000000000001767";"33818140";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1097/ju.0000000000001767";"33818140";"results";"2";"";"Primary outcome: adjusted treatment effect";"-6.3"
"10.1097/ju.0000000000001767";"33818140";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.004"
"10.1111/bjd.16140";"29171861";"general_information";"";"";"Medical Condition of Interest Name";"moderate-to-severe plaque psoriasis"
"10.1111/bjd.16140";"29171861";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.1111/bjd.16140";"29171861";"general_information";"";"";"Countries of last author affiliations";"germany"
"10.1111/bjd.16140";"29171861";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.1111/bjd.16140";"29171861";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1111/bjd.16140";"29171861";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1111/bjd.16140";"29171861";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1111/bjd.16140";"29171861";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1111/bjd.16140";"29171861";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1111/bjd.16140";"29171861";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1111/bjd.16140";"29171861";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01474512"
"10.1111/bjd.16140";"29171861";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/bjd.16140";"29171861";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/bjd.16140";"29171861";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/bjd.16140";"29171861";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1111/bjd.16140";"29171861";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1111/bjd.16140";"29171861";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01597245"
"10.1111/bjd.16140";"29171861";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/bjd.16140";"29171861";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/bjd.16140";"29171861";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/bjd.16140";"29171861";"study_information";"";"3";"Patient-level data used";"Yes"
"10.1111/bjd.16140";"29171861";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1111/bjd.16140";"29171861";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01646177"
"10.1111/bjd.16140";"29171861";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/bjd.16140";"29171861";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/bjd.16140";"29171861";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/bjd.16140";"29171861";"study_information";"";"4";"Patient-level data used";"Yes"
"10.1111/bjd.16140";"29171861";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1111/bjd.16140";"29171861";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02561806"
"10.1111/bjd.16140";"29171861";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/bjd.16140";"29171861";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/bjd.16140";"29171861";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/bjd.16140";"29171861";"study_information";"";"5";"Patient-level data used";"No"
"10.1111/bjd.16140";"29171861";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1111/bjd.16140";"29171861";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01358578"
"10.1111/bjd.16140";"29171861";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/bjd.16140";"29171861";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/bjd.16140";"29171861";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/bjd.16140";"29171861";"study_information";"";"6";"Patient-level data used";"No"
"10.1111/bjd.16140";"29171861";"study_information";"";"6";"Clinical Trial";"Yes"
"10.1111/bjd.16140";"29171861";"study_information";"";"6";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01365455"
"10.1111/bjd.16140";"29171861";"study_information";"";"6";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/bjd.16140";"29171861";"study_information";"";"6";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/bjd.16140";"29171861";"study_information";"";"6";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/bjd.16140";"29171861";"study_information";"";"7";"Patient-level data used";"No"
"10.1111/bjd.16140";"29171861";"study_information";"";"7";"Clinical Trial";"Yes"
"10.1111/bjd.16140";"29171861";"study_information";"";"7";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01555125"
"10.1111/bjd.16140";"29171861";"study_information";"";"7";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/bjd.16140";"29171861";"study_information";"";"7";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/bjd.16140";"29171861";"study_information";"";"7";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/bjd.16140";"29171861";"study_information";"";"8";"Patient-level data used";"No"
"10.1111/bjd.16140";"29171861";"study_information";"";"8";"Clinical Trial";"Yes"
"10.1111/bjd.16140";"29171861";"study_information";"";"8";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01636687"
"10.1111/bjd.16140";"29171861";"study_information";"";"8";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/bjd.16140";"29171861";"study_information";"";"8";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/bjd.16140";"29171861";"study_information";"";"8";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/bjd.16140";"29171861";"study_information";"";"9";"Patient-level data used";"No"
"10.1111/bjd.16140";"29171861";"study_information";"";"9";"Clinical Trial";"Yes"
"10.1111/bjd.16140";"29171861";"study_information";"";"9";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02074982"
"10.1111/bjd.16140";"29171861";"study_information";"";"9";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/bjd.16140";"29171861";"study_information";"";"9";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/bjd.16140";"29171861";"study_information";"";"9";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/bjd.16140";"29171861";"methodology";"1";"";"Treatment name 1";"ixekizumab"
"10.1111/bjd.16140";"29171861";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.1111/bjd.16140";"29171861";"methodology";"1";"";"Treatment name 2";"secukinumab"
"10.1111/bjd.16140";"29171861";"methodology";"1";"";"Study 'number(s)' for treatment 2";"5;6;7;8"
"10.1111/bjd.16140";"29171861";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/bjd.16140";"29171861";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1111/bjd.16140";"29171861";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1111/bjd.16140";"29171861";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1111/bjd.16140";"29171861";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"pasi 75 at week 12"
"10.1111/bjd.16140";"29171861";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1111/bjd.16140";"29171861";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1111/bjd.16140";"29171861";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1111/bjd.16140";"29171861";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1111/bjd.16140";"29171861";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1111/bjd.16140";"29171861";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/bjd.16140";"29171861";"methodology";"2";"";"Treatment name 1";"ixekizumab"
"10.1111/bjd.16140";"29171861";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.1111/bjd.16140";"29171861";"methodology";"2";"";"Treatment name 2";"secukinumab"
"10.1111/bjd.16140";"29171861";"methodology";"2";"";"Study 'number(s)' for treatment 2";"5;6;7;8"
"10.1111/bjd.16140";"29171861";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/bjd.16140";"29171861";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.1111/bjd.16140";"29171861";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1111/bjd.16140";"29171861";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1111/bjd.16140";"29171861";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"pasi 75 at week 12"
"10.1111/bjd.16140";"29171861";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1111/bjd.16140";"29171861";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1111/bjd.16140";"29171861";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1111/bjd.16140";"29171861";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1111/bjd.16140";"29171861";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1111/bjd.16140";"29171861";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/bjd.16140";"29171861";"methodology";"3";"";"Treatment name 1";"ixekizumab"
"10.1111/bjd.16140";"29171861";"methodology";"3";"";"Study 'number(s)' for treatment 1";"2;3"
"10.1111/bjd.16140";"29171861";"methodology";"3";"";"Treatment name 2";"secukinumab"
"10.1111/bjd.16140";"29171861";"methodology";"3";"";"Study 'number(s)' for treatment 2";"5"
"10.1111/bjd.16140";"29171861";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/bjd.16140";"29171861";"methodology";"3";"";"Anchored comparison?";"Yes"
"10.1111/bjd.16140";"29171861";"methodology";"3";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1111/bjd.16140";"29171861";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1111/bjd.16140";"29171861";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"pasi 75 at week 12"
"10.1111/bjd.16140";"29171861";"methodology";"3";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1111/bjd.16140";"29171861";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1111/bjd.16140";"29171861";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1111/bjd.16140";"29171861";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1111/bjd.16140";"29171861";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1111/bjd.16140";"29171861";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/bjd.16140";"29171861";"methodology";"4";"";"Treatment name 1";"ixekizumab"
"10.1111/bjd.16140";"29171861";"methodology";"4";"";"Study 'number(s)' for treatment 1";"2;3"
"10.1111/bjd.16140";"29171861";"methodology";"4";"";"Treatment name 2";"secukinumab"
"10.1111/bjd.16140";"29171861";"methodology";"4";"";"Study 'number(s)' for treatment 2";"5"
"10.1111/bjd.16140";"29171861";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/bjd.16140";"29171861";"methodology";"4";"";"Anchored comparison?";"Yes"
"10.1111/bjd.16140";"29171861";"methodology";"4";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1111/bjd.16140";"29171861";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1111/bjd.16140";"29171861";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"pasi 75 at week 12"
"10.1111/bjd.16140";"29171861";"methodology";"4";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1111/bjd.16140";"29171861";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1111/bjd.16140";"29171861";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1111/bjd.16140";"29171861";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1111/bjd.16140";"29171861";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1111/bjd.16140";"29171861";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/bjd.16140";"29171861";"methodology";"5";"";"Treatment name 1";"ixekizumab"
"10.1111/bjd.16140";"29171861";"methodology";"5";"";"Study 'number(s)' for treatment 1";"4"
"10.1111/bjd.16140";"29171861";"methodology";"5";"";"Treatment name 2";"secukinumab"
"10.1111/bjd.16140";"29171861";"methodology";"5";"";"Study 'number(s)' for treatment 2";"9"
"10.1111/bjd.16140";"29171861";"methodology";"5";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/bjd.16140";"29171861";"methodology";"5";"";"Anchored comparison?";"Yes"
"10.1111/bjd.16140";"29171861";"methodology";"5";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1111/bjd.16140";"29171861";"methodology";"5";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1111/bjd.16140";"29171861";"methodology";"5";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"pasi 75 at week 12"
"10.1111/bjd.16140";"29171861";"methodology";"5";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1111/bjd.16140";"29171861";"methodology";"5";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1111/bjd.16140";"29171861";"methodology";"5";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1111/bjd.16140";"29171861";"methodology";"5";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1111/bjd.16140";"29171861";"methodology";"5";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1111/bjd.16140";"29171861";"methodology";"5";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/bjd.16140";"29171861";"methodology";"6";"";"Treatment name 1";"ixekizumab"
"10.1111/bjd.16140";"29171861";"methodology";"6";"";"Study 'number(s)' for treatment 1";"4"
"10.1111/bjd.16140";"29171861";"methodology";"6";"";"Treatment name 2";"secukinumab"
"10.1111/bjd.16140";"29171861";"methodology";"6";"";"Study 'number(s)' for treatment 2";"9"
"10.1111/bjd.16140";"29171861";"methodology";"6";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/bjd.16140";"29171861";"methodology";"6";"";"Anchored comparison?";"Yes"
"10.1111/bjd.16140";"29171861";"methodology";"6";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1111/bjd.16140";"29171861";"methodology";"6";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1111/bjd.16140";"29171861";"methodology";"6";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"pasi 75 at week 12"
"10.1111/bjd.16140";"29171861";"methodology";"6";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1111/bjd.16140";"29171861";"methodology";"6";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1111/bjd.16140";"29171861";"methodology";"6";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1111/bjd.16140";"29171861";"methodology";"6";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1111/bjd.16140";"29171861";"methodology";"6";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1111/bjd.16140";"29171861";"methodology";"6";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/bjd.16140";"29171861";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"1956"
"10.1111/bjd.16140";"29171861";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"1666"
"10.1111/bjd.16140";"29171861";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1111/bjd.16140";"29171861";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/bjd.16140";"29171861";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.1111/bjd.16140";"29171861";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.1111/bjd.16140";"29171861";"results";"1";"";"Primary outcome: treatment effect contrast";"Risk difference"
"10.1111/bjd.16140";"29171861";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/bjd.16140";"29171861";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"653"
"10.1111/bjd.16140";"29171861";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.00007"
"10.1111/bjd.16140";"29171861";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.0002"
"10.1111/bjd.16140";"29171861";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1111/bjd.16140";"29171861";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/bjd.16140";"29171861";"results";"2";"";"Number of covariates adjusted for/matched on";"6"
"10.1111/bjd.16140";"29171861";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.1111/bjd.16140";"29171861";"results";"2";"";"Primary outcome: treatment effect contrast";"Risk difference"
"10.1111/bjd.16140";"29171861";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/bjd.16140";"29171861";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"653"
"10.1111/bjd.16140";"29171861";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"1956"
"10.1111/bjd.16140";"29171861";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"1666"
"10.1111/bjd.16140";"29171861";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.00007"
"10.1111/bjd.16140";"29171861";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.0003"
"10.1111/bjd.16140";"29171861";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"1465"
"10.1111/bjd.16140";"29171861";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"989"
"10.1111/bjd.16140";"29171861";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1111/bjd.16140";"29171861";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/bjd.16140";"29171861";"results";"3";"";"Number of covariates adjusted for/matched on";"7"
"10.1111/bjd.16140";"29171861";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.1111/bjd.16140";"29171861";"results";"3";"";"Primary outcome: treatment effect contrast";"Risk difference"
"10.1111/bjd.16140";"29171861";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/bjd.16140";"29171861";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.1"
"10.1111/bjd.16140";"29171861";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.7"
"10.1111/bjd.16140";"29171861";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"653"
"10.1111/bjd.16140";"29171861";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1111/bjd.16140";"29171861";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/bjd.16140";"29171861";"results";"4";"";"Number of covariates adjusted for/matched on";"7"
"10.1111/bjd.16140";"29171861";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.1111/bjd.16140";"29171861";"results";"4";"";"Primary outcome: treatment effect contrast";"Risk difference"
"10.1111/bjd.16140";"29171861";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/bjd.16140";"29171861";"results";"4";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.1"
"10.1111/bjd.16140";"29171861";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.69"
"10.1111/bjd.16140";"29171861";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"653"
"10.1111/bjd.16140";"29171861";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"1465"
"10.1111/bjd.16140";"29171861";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"989"
"10.1111/bjd.16140";"29171861";"results";"5";"";"Initial sample size of the population of interest in the IPD treatment arm";"259"
"10.1111/bjd.16140";"29171861";"results";"5";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"122"
"10.1111/bjd.16140";"29171861";"results";"5";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1111/bjd.16140";"29171861";"results";"5";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/bjd.16140";"29171861";"results";"5";"";"Number of covariates adjusted for/matched on";"8"
"10.1111/bjd.16140";"29171861";"results";"5";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.1111/bjd.16140";"29171861";"results";"5";"";"Primary outcome: treatment effect contrast";"Risk difference"
"10.1111/bjd.16140";"29171861";"results";"5";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/bjd.16140";"29171861";"results";"5";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.21"
"10.1111/bjd.16140";"29171861";"results";"5";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.33"
"10.1111/bjd.16140";"29171861";"results";"5";"";"Sample size of the population of interest in the non IPD treatment arm";"676"
"10.1111/bjd.16140";"29171861";"results";"6";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1111/bjd.16140";"29171861";"results";"6";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/bjd.16140";"29171861";"results";"6";"";"Number of covariates adjusted for/matched on";"8"
"10.1111/bjd.16140";"29171861";"results";"6";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.1111/bjd.16140";"29171861";"results";"6";"";"Primary outcome: treatment effect contrast";"Risk difference"
"10.1111/bjd.16140";"29171861";"results";"6";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/bjd.16140";"29171861";"results";"6";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.21"
"10.1111/bjd.16140";"29171861";"results";"6";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.24"
"10.1111/bjd.16140";"29171861";"results";"6";"";"Sample size of the population of interest in the non IPD treatment arm";"676"
"10.1111/bjd.16140";"29171861";"results";"6";"";"Initial sample size of the population of interest in the IPD treatment arm";"259"
"10.1111/bjd.16140";"29171861";"results";"6";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"122"
"10.1111/cea.13561";"31943429";"general_information";"";"";"Medical Condition of Interest Name";"severe asthma"
"10.1111/cea.13561";"31943429";"general_information";"";"";"Countries of first author affiliations";"france"
"10.1111/cea.13561";"31943429";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1111/cea.13561";"31943429";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1111/cea.13561";"31943429";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1111/cea.13561";"31943429";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1111/cea.13561";"31943429";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1111/cea.13561";"31943429";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1111/cea.13561";"31943429";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1111/cea.13561";"31943429";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1111/cea.13561";"31943429";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02075255"
"10.1111/cea.13561";"31943429";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/cea.13561";"31943429";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/cea.13561";"31943429";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/cea.13561";"31943429";"study_information";"";"2";"Patient-level data used";"No"
"10.1111/cea.13561";"31943429";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1111/cea.13561";"31943429";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01691508"
"10.1111/cea.13561";"31943429";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/cea.13561";"31943429";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/cea.13561";"31943429";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/cea.13561";"31943429";"study_information";"";"3";"Patient-level data used";"No"
"10.1111/cea.13561";"31943429";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1111/cea.13561";"31943429";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02528214"
"10.1111/cea.13561";"31943429";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/cea.13561";"31943429";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/cea.13561";"31943429";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/cea.13561";"31943429";"methodology";"1";"";"Treatment name 1";"benralizumab"
"10.1111/cea.13561";"31943429";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1111/cea.13561";"31943429";"methodology";"1";"";"Treatment name 2";"mepolizumab"
"10.1111/cea.13561";"31943429";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1111/cea.13561";"31943429";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/cea.13561";"31943429";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1111/cea.13561";"31943429";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1111/cea.13561";"31943429";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1111/cea.13561";"31943429";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"mean percentage of oral corticosteroids reduction"
"10.1111/cea.13561";"31943429";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1111/cea.13561";"31943429";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1111/cea.13561";"31943429";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1111/cea.13561";"31943429";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1111/cea.13561";"31943429";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1111/cea.13561";"31943429";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/cea.13561";"31943429";"methodology";"2";"";"Treatment name 1";"benralizumab"
"10.1111/cea.13561";"31943429";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1111/cea.13561";"31943429";"methodology";"2";"";"Treatment name 2";"dupilumab"
"10.1111/cea.13561";"31943429";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1111/cea.13561";"31943429";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/cea.13561";"31943429";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.1111/cea.13561";"31943429";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1111/cea.13561";"31943429";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1111/cea.13561";"31943429";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"mean percentage of oral corticosteroids reduction"
"10.1111/cea.13561";"31943429";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1111/cea.13561";"31943429";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1111/cea.13561";"31943429";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1111/cea.13561";"31943429";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1111/cea.13561";"31943429";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1111/cea.13561";"31943429";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/cea.13561";"31943429";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1111/cea.13561";"31943429";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/cea.13561";"31943429";"results";"1";"";"Number of covariates adjusted for/matched on";"5"
"10.1111/cea.13561";"31943429";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1111/cea.13561";"31943429";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1111/cea.13561";"31943429";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/cea.13561";"31943429";"results";"1";"";"Primary outcome: unadjusted treatment effect";"20.1"
"10.1111/cea.13561";"31943429";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.1584"
"10.1111/cea.13561";"31943429";"results";"1";"";"Primary outcome: adjusted treatment effect";"6.08"
"10.1111/cea.13561";"31943429";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.67"
"10.1111/cea.13561";"31943429";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1111/cea.13561";"31943429";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/cea.13561";"31943429";"results";"2";"";"Number of covariates adjusted for/matched on";"5"
"10.1111/cea.13561";"31943429";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1111/cea.13561";"31943429";"results";"2";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1111/cea.13561";"31943429";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/cea.13561";"31943429";"results";"2";"";"Primary outcome: unadjusted treatment effect";"8.1"
"10.1111/cea.13561";"31943429";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.46"
"10.1111/cea.13561";"31943429";"results";"2";"";"Primary outcome: adjusted treatment effect";"-0.71"
"10.1111/cea.13561";"31943429";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.94"
"10.1111/dom.14497";"34286894";"general_information";"";"";"Medical Condition of Interest Name";"type 2 diabetes"
"10.1111/dom.14497";"34286894";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1111/dom.14497";"34286894";"general_information";"";"";"Countries of last author affiliations";"denmark"
"10.1111/dom.14497";"34286894";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1111/dom.14497";"34286894";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1111/dom.14497";"34286894";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1111/dom.14497";"34286894";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1111/dom.14497";"34286894";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1111/dom.14497";"34286894";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1111/dom.14497";"34286894";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1111/dom.14497";"34286894";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02648204"
"10.1111/dom.14497";"34286894";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/dom.14497";"34286894";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/dom.14497";"34286894";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/dom.14497";"34286894";"study_information";"";"2";"Patient-level data used";"No"
"10.1111/dom.14497";"34286894";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1111/dom.14497";"34286894";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03495102"
"10.1111/dom.14497";"34286894";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/dom.14497";"34286894";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/dom.14497";"34286894";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1111/dom.14497";"34286894";"study_information";"";"3";"Patient-level data used";"No"
"10.1111/dom.14497";"34286894";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1111/dom.14497";"34286894";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03495102"
"10.1111/dom.14497";"34286894";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/dom.14497";"34286894";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/dom.14497";"34286894";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/dom.14497";"34286894";"methodology";"1";"";"Treatment name 1";"semaglutide 1.0mg"
"10.1111/dom.14497";"34286894";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1111/dom.14497";"34286894";"methodology";"1";"";"Treatment name 2";"dulaglutide 3.0mg"
"10.1111/dom.14497";"34286894";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1111/dom.14497";"34286894";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/dom.14497";"34286894";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1111/dom.14497";"34286894";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1111/dom.14497";"34286894";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1111/dom.14497";"34286894";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"change from baseline hba1c"
"10.1111/dom.14497";"34286894";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1111/dom.14497";"34286894";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1111/dom.14497";"34286894";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1111/dom.14497";"34286894";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1111/dom.14497";"34286894";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1111/dom.14497";"34286894";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/dom.14497";"34286894";"methodology";"2";"";"Treatment name 1";"semaglutide 1.0mg"
"10.1111/dom.14497";"34286894";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1111/dom.14497";"34286894";"methodology";"2";"";"Treatment name 2";"dulaglutide 4.5mg"
"10.1111/dom.14497";"34286894";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1111/dom.14497";"34286894";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/dom.14497";"34286894";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.1111/dom.14497";"34286894";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1111/dom.14497";"34286894";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1111/dom.14497";"34286894";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"change from baseline hba1c"
"10.1111/dom.14497";"34286894";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1111/dom.14497";"34286894";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1111/dom.14497";"34286894";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1111/dom.14497";"34286894";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1111/dom.14497";"34286894";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1111/dom.14497";"34286894";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/dom.14497";"34286894";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"616"
"10.1111/dom.14497";"34286894";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"612"
"10.1111/dom.14497";"34286894";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"300"
"10.1111/dom.14497";"34286894";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"299"
"10.1111/dom.14497";"34286894";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1111/dom.14497";"34286894";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/dom.14497";"34286894";"results";"1";"";"Number of covariates adjusted for/matched on";"3"
"10.1111/dom.14497";"34286894";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1111/dom.14497";"34286894";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1111/dom.14497";"34286894";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/dom.14497";"34286894";"results";"1";"";"Primary outcome: unadjusted treatment effect";"-0.24"
"10.1111/dom.14497";"34286894";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.016"
"10.1111/dom.14497";"34286894";"results";"1";"";"Primary outcome: adjusted treatment effect";"-0.26"
"10.1111/dom.14497";"34286894";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.047"
"10.1111/dom.14497";"34286894";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"614"
"10.1111/dom.14497";"34286894";"results";"2";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"612"
"10.1111/dom.14497";"34286894";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"300"
"10.1111/dom.14497";"34286894";"results";"2";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"299"
"10.1111/dom.14497";"34286894";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1111/dom.14497";"34286894";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/dom.14497";"34286894";"results";"2";"";"Number of covariates adjusted for/matched on";"3"
"10.1111/dom.14497";"34286894";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1111/dom.14497";"34286894";"results";"2";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1111/dom.14497";"34286894";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/dom.14497";"34286894";"results";"2";"";"Primary outcome: unadjusted treatment effect";"-0.07"
"10.1111/dom.14497";"34286894";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.484"
"10.1111/dom.14497";"34286894";"results";"2";"";"Primary outcome: adjusted treatment effect";"-0.08"
"10.1111/dom.14497";"34286894";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.523"
"10.1111/head.14128";"34021585";"general_information";"";"";"Medical Condition of Interest Name";"migraine"
"10.1111/head.14128";"34021585";"general_information";"";"";"Countries of first author affiliations";"canada"
"10.1111/head.14128";"34021585";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1111/head.14128";"34021585";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1111/head.14128";"34021585";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1111/head.14128";"34021585";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1111/head.14128";"34021585";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1111/head.14128";"34021585";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1111/head.14128";"34021585";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1111/head.14128";"34021585";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1111/head.14128";"34021585";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03266588"
"10.1111/head.14128";"34021585";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1111/head.14128";"34021585";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2, 3"
"10.1111/head.14128";"34021585";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1111/head.14128";"34021585";"study_information";"";"2";"Patient-level data used";"No"
"10.1111/head.14128";"34021585";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1111/head.14128";"34021585";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02614183"
"10.1111/head.14128";"34021585";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/head.14128";"34021585";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/head.14128";"34021585";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/head.14128";"34021585";"study_information";"";"3";"Patient-level data used";"No"
"10.1111/head.14128";"34021585";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1111/head.14128";"34021585";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02614196"
"10.1111/head.14128";"34021585";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/head.14128";"34021585";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/head.14128";"34021585";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/head.14128";"34021585";"study_information";"";"4";"Patient-level data used";"No"
"10.1111/head.14128";"34021585";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1111/head.14128";"34021585";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02456740"
"10.1111/head.14128";"34021585";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/head.14128";"34021585";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/head.14128";"34021585";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/head.14128";"34021585";"methodology";"1";"";"Treatment name 1";"rimegepant"
"10.1111/head.14128";"34021585";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1111/head.14128";"34021585";"methodology";"1";"";"Treatment name 2";"placebo"
"10.1111/head.14128";"34021585";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2;3"
"10.1111/head.14128";"34021585";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/head.14128";"34021585";"methodology";"1";"";"Anchored comparison?";"No"
"10.1111/head.14128";"34021585";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1111/head.14128";"34021585";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1111/head.14128";"34021585";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"migraine disability assessment test"
"10.1111/head.14128";"34021585";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1111/head.14128";"34021585";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier)"
"10.1111/head.14128";"34021585";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1111/head.14128";"34021585";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1111/head.14128";"34021585";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1111/head.14128";"34021585";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/head.14128";"34021585";"methodology";"2";"";"Treatment name 1";"rimegepant"
"10.1111/head.14128";"34021585";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1111/head.14128";"34021585";"methodology";"2";"";"Treatment name 2";"galcanezumab"
"10.1111/head.14128";"34021585";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2.3"
"10.1111/head.14128";"34021585";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/head.14128";"34021585";"methodology";"2";"";"Anchored comparison?";"No"
"10.1111/head.14128";"34021585";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1111/head.14128";"34021585";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1111/head.14128";"34021585";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"migraine disability assessment test"
"10.1111/head.14128";"34021585";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1111/head.14128";"34021585";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier)"
"10.1111/head.14128";"34021585";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1111/head.14128";"34021585";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1111/head.14128";"34021585";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1111/head.14128";"34021585";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/head.14128";"34021585";"methodology";"3";"";"Treatment name 1";"rimegepant"
"10.1111/head.14128";"34021585";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.1111/head.14128";"34021585";"methodology";"3";"";"Treatment name 2";"placebo"
"10.1111/head.14128";"34021585";"methodology";"3";"";"Study 'number(s)' for treatment 2";"4"
"10.1111/head.14128";"34021585";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/head.14128";"34021585";"methodology";"3";"";"Anchored comparison?";"No"
"10.1111/head.14128";"34021585";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1111/head.14128";"34021585";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1111/head.14128";"34021585";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"migraine disability assessment test"
"10.1111/head.14128";"34021585";"methodology";"3";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1111/head.14128";"34021585";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier)"
"10.1111/head.14128";"34021585";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1111/head.14128";"34021585";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1111/head.14128";"34021585";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1111/head.14128";"34021585";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/head.14128";"34021585";"methodology";"4";"";"Treatment name 1";"rimegepant"
"10.1111/head.14128";"34021585";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1"
"10.1111/head.14128";"34021585";"methodology";"4";"";"Treatment name 2";"erenumab"
"10.1111/head.14128";"34021585";"methodology";"4";"";"Study 'number(s)' for treatment 2";"4"
"10.1111/head.14128";"34021585";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/head.14128";"34021585";"methodology";"4";"";"Anchored comparison?";"No"
"10.1111/head.14128";"34021585";"methodology";"4";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1111/head.14128";"34021585";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1111/head.14128";"34021585";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"migraine disability assessment testmigraine disability assessment test"
"10.1111/head.14128";"34021585";"methodology";"4";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1111/head.14128";"34021585";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier)"
"10.1111/head.14128";"34021585";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1111/head.14128";"34021585";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1111/head.14128";"34021585";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.1111/head.14128";"34021585";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/head.14128";"34021585";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"1773"
"10.1111/head.14128";"34021585";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"257"
"10.1111/head.14128";"34021585";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"169"
"10.1111/head.14128";"34021585";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1111/head.14128";"34021585";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/head.14128";"34021585";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.1111/head.14128";"34021585";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity"
"10.1111/head.14128";"34021585";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1111/head.14128";"34021585";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/head.14128";"34021585";"results";"1";"";"Primary outcome: unadjusted treatment effect";"-3.97"
"10.1111/head.14128";"34021585";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.12"
"10.1111/head.14128";"34021585";"results";"1";"";"Primary outcome: adjusted treatment effect";"-5.54"
"10.1111/head.14128";"34021585";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.026"
"10.1111/head.14128";"34021585";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"257"
"10.1111/head.14128";"34021585";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"169"
"10.1111/head.14128";"34021585";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1111/head.14128";"34021585";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/head.14128";"34021585";"results";"2";"";"Number of covariates adjusted for/matched on";"6"
"10.1111/head.14128";"34021585";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity"
"10.1111/head.14128";"34021585";"results";"2";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1111/head.14128";"34021585";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/head.14128";"34021585";"results";"2";"";"Primary outcome: unadjusted treatment effect";"3.48"
"10.1111/head.14128";"34021585";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.172"
"10.1111/head.14128";"34021585";"results";"2";"";"Primary outcome: adjusted treatment effect";"-5.54"
"10.1111/head.14128";"34021585";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.026"
"10.1111/head.14128";"34021585";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"1773"
"10.1111/head.14128";"34021585";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"257"
"10.1111/head.14128";"34021585";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"214"
"10.1111/head.14128";"34021585";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1111/head.14128";"34021585";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/head.14128";"34021585";"results";"3";"";"Number of covariates adjusted for/matched on";"4"
"10.1111/head.14128";"34021585";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity"
"10.1111/head.14128";"34021585";"results";"3";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1111/head.14128";"34021585";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/head.14128";"34021585";"results";"3";"";"Primary outcome: unadjusted treatment effect";"-5.57"
"10.1111/head.14128";"34021585";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.026"
"10.1111/head.14128";"34021585";"results";"3";"";"Primary outcome: adjusted treatment effect";"-7.37"
"10.1111/head.14128";"34021585";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.009"
"10.1111/head.14128";"34021585";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"955"
"10.1111/head.14128";"34021585";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"257"
"10.1111/head.14128";"34021585";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"214"
"10.1111/head.14128";"34021585";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1111/head.14128";"34021585";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/head.14128";"34021585";"results";"4";"";"Number of covariates adjusted for/matched on";"4"
"10.1111/head.14128";"34021585";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity"
"10.1111/head.14128";"34021585";"results";"4";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1111/head.14128";"34021585";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/head.14128";"34021585";"results";"4";"";"Primary outcome: unadjusted treatment effect";"1.75"
"10.1111/head.14128";"34021585";"results";"4";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.528"
"10.1111/head.14128";"34021585";"results";"4";"";"Primary outcome: adjusted treatment effect";"-0.09"
"10.1111/head.14128";"34021585";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.979"
"10.1111/head.14128";"34021585";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"955"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"general_information";"";"";"Medical Condition of Interest Name";"non-small cell lung cancer"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"general_information";"";"";"Countries of first author affiliations";"taiwan"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"general_information";"";"";"Countries of last author affiliations";"switzerland"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00451906"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"4"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"study_information";"";"2";"Patient-level data used";"No"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"study_information";"";"2";"Data source name (only if observational study or clinical trial without NCT)";"yang et al. (2010)"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"methodology";"1";"";"Treatment name 1";"bevacizumab + cisplatin"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"methodology";"1";"";"Treatment name 2";"pemetrexed + cisplatin"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"Other kind of ""Matching-Adjusted Indirect Comparison"""
"10.1111/j.1743-7563.2011.01400.x";"21585706";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"67"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"72"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"46"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"results";"1";"";"Number of covariates adjusted for/matched on";"2"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Sex, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"results";"1";"";"Primary outcome: treatment effect contrast";"Median difference"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/j.1743-7563.2011.01400.x";"21585706";"results";"1";"";"Primary outcome: adjusted treatment effect";"1"
"10.1111/jdv.15369";"30472749";"general_information";"";"";"Medical Condition of Interest Name";"plaque psoriasis"
"10.1111/jdv.15369";"30472749";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.1111/jdv.15369";"30472749";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1111/jdv.15369";"30472749";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1111/jdv.15369";"30472749";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1111/jdv.15369";"30472749";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1111/jdv.15369";"30472749";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1111/jdv.15369";"30472749";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1111/jdv.15369";"30472749";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1111/jdv.15369";"30472749";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1111/jdv.15369";"30472749";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02132936"
"10.1111/jdv.15369";"30472749";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"france"
"10.1111/jdv.15369";"30472749";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/jdv.15369";"30472749";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/jdv.15369";"30472749";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1111/jdv.15369";"30472749";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1111/jdv.15369";"30472749";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01866163"
"10.1111/jdv.15369";"30472749";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1111/jdv.15369";"30472749";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1111/jdv.15369";"30472749";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/jdv.15369";"30472749";"study_information";"";"3";"Patient-level data used";"Yes"
"10.1111/jdv.15369";"30472749";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1111/jdv.15369";"30472749";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01536886"
"10.1111/jdv.15369";"30472749";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1111/jdv.15369";"30472749";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"2"
"10.1111/jdv.15369";"30472749";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/jdv.15369";"30472749";"study_information";"";"4";"Patient-level data used";"Yes"
"10.1111/jdv.15369";"30472749";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1111/jdv.15369";"30472749";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01536938"
"10.1111/jdv.15369";"30472749";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1111/jdv.15369";"30472749";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"2"
"10.1111/jdv.15369";"30472749";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/jdv.15369";"30472749";"study_information";"";"5";"Patient-level data used";"No"
"10.1111/jdv.15369";"30472749";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1111/jdv.15369";"30472749";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02425826"
"10.1111/jdv.15369";"30472749";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1111/jdv.15369";"30472749";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"4"
"10.1111/jdv.15369";"30472749";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1111/jdv.15369";"30472749";"study_information";"";"6";"Patient-level data used";"No"
"10.1111/jdv.15369";"30472749";"study_information";"";"6";"Clinical Trial";"No"
"10.1111/jdv.15369";"30472749";"study_information";"";"6";"Data source name (only if observational study or clinical trial without NCT)";"zurita et al., (2017)"
"10.1111/jdv.15369";"30472749";"study_information";"";"6";"Country where the clinical trial/observational study was conducted (international if more than one)";"spain"
"10.1111/jdv.15369";"30472749";"study_information";"";"7";"Patient-level data used";"No"
"10.1111/jdv.15369";"30472749";"study_information";"";"7";"Clinical Trial";"No"
"10.1111/jdv.15369";"30472749";"study_information";"";"7";"Data source name (only if observational study or clinical trial without NCT)";"chiricozzi et al. (2016)"
"10.1111/jdv.15369";"30472749";"study_information";"";"7";"Country where the clinical trial/observational study was conducted (international if more than one)";"italy"
"10.1111/jdv.15369";"30472749";"study_information";"";"8";"Patient-level data used";"No"
"10.1111/jdv.15369";"30472749";"study_information";"";"8";"Clinical Trial";"No"
"10.1111/jdv.15369";"30472749";"study_information";"";"8";"Data source name (only if observational study or clinical trial without NCT)";"inzinger et al. (2013)"
"10.1111/jdv.15369";"30472749";"study_information";"";"8";"Country where the clinical trial/observational study was conducted (international if more than one)";"austria"
"10.1111/jdv.15369";"30472749";"methodology";"1";"";"Treatment name 1";"calcipotriol + betamethasone dipropionate aerosol foam"
"10.1111/jdv.15369";"30472749";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2;3;4"
"10.1111/jdv.15369";"30472749";"methodology";"1";"";"Treatment name 2";"apremilast"
"10.1111/jdv.15369";"30472749";"methodology";"1";"";"Study 'number(s)' for treatment 2";"5"
"10.1111/jdv.15369";"30472749";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/jdv.15369";"30472749";"methodology";"1";"";"Anchored comparison?";"No"
"10.1111/jdv.15369";"30472749";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1111/jdv.15369";"30472749";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1111/jdv.15369";"30472749";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"hysician’s global assessment 0/1 response"
"10.1111/jdv.15369";"30472749";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1111/jdv.15369";"30472749";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1111/jdv.15369";"30472749";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1111/jdv.15369";"30472749";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1111/jdv.15369";"30472749";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1111/jdv.15369";"30472749";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/jdv.15369";"30472749";"methodology";"2";"";"Treatment name 1";"calcipotriol + betamethasone dipropionate aerosol foam"
"10.1111/jdv.15369";"30472749";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1;2;3;4"
"10.1111/jdv.15369";"30472749";"methodology";"2";"";"Treatment name 2";"methotrexate"
"10.1111/jdv.15369";"30472749";"methodology";"2";"";"Study 'number(s)' for treatment 2";"6"
"10.1111/jdv.15369";"30472749";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/jdv.15369";"30472749";"methodology";"2";"";"Anchored comparison?";"No"
"10.1111/jdv.15369";"30472749";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1111/jdv.15369";"30472749";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1111/jdv.15369";"30472749";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"pasi 75 locf"
"10.1111/jdv.15369";"30472749";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1111/jdv.15369";"30472749";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1111/jdv.15369";"30472749";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1111/jdv.15369";"30472749";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1111/jdv.15369";"30472749";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1111/jdv.15369";"30472749";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/jdv.15369";"30472749";"methodology";"3";"";"Treatment name 1";"calcipotriol + betamethasone dipropionate aerosol foam"
"10.1111/jdv.15369";"30472749";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1;2;3;4"
"10.1111/jdv.15369";"30472749";"methodology";"3";"";"Treatment name 2";"acitretin"
"10.1111/jdv.15369";"30472749";"methodology";"3";"";"Study 'number(s)' for treatment 2";"7"
"10.1111/jdv.15369";"30472749";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/jdv.15369";"30472749";"methodology";"3";"";"Anchored comparison?";"No"
"10.1111/jdv.15369";"30472749";"methodology";"3";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1111/jdv.15369";"30472749";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1111/jdv.15369";"30472749";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"pasi 75 locf"
"10.1111/jdv.15369";"30472749";"methodology";"3";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1111/jdv.15369";"30472749";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1111/jdv.15369";"30472749";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1111/jdv.15369";"30472749";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1111/jdv.15369";"30472749";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1111/jdv.15369";"30472749";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/jdv.15369";"30472749";"methodology";"4";"";"Treatment name 1";"calcipotriol + betamethasone dipropionate aerosol foam"
"10.1111/jdv.15369";"30472749";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1;2;3;4"
"10.1111/jdv.15369";"30472749";"methodology";"4";"";"Treatment name 2";"fumaric acid esters"
"10.1111/jdv.15369";"30472749";"methodology";"4";"";"Study 'number(s)' for treatment 2";"8"
"10.1111/jdv.15369";"30472749";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1111/jdv.15369";"30472749";"methodology";"4";"";"Anchored comparison?";"No"
"10.1111/jdv.15369";"30472749";"methodology";"4";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1111/jdv.15369";"30472749";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1111/jdv.15369";"30472749";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"pasi 75 locf"
"10.1111/jdv.15369";"30472749";"methodology";"4";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1111/jdv.15369";"30472749";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1111/jdv.15369";"30472749";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1111/jdv.15369";"30472749";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1111/jdv.15369";"30472749";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1111/jdv.15369";"30472749";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1111/jdv.15369";"30472749";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"148"
"10.1111/jdv.15369";"30472749";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"748"
"10.1111/jdv.15369";"30472749";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"640"
"10.1111/jdv.15369";"30472749";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1111/jdv.15369";"30472749";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/jdv.15369";"30472749";"results";"1";"";"Number of covariates adjusted for/matched on";"3"
"10.1111/jdv.15369";"30472749";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.1111/jdv.15369";"30472749";"results";"1";"";"Primary outcome: treatment effect contrast";"Proportions difference"
"10.1111/jdv.15369";"30472749";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/jdv.15369";"30472749";"results";"1";"";"Primary outcome: adjusted treatment effect";"20.3"
"10.1111/jdv.15369";"30472749";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1111/jdv.15369";"30472749";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"218"
"10.1111/jdv.15369";"30472749";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"749"
"10.1111/jdv.15369";"30472749";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"633"
"10.1111/jdv.15369";"30472749";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1111/jdv.15369";"30472749";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/jdv.15369";"30472749";"results";"2";"";"Number of covariates adjusted for/matched on";"2"
"10.1111/jdv.15369";"30472749";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1111/jdv.15369";"30472749";"results";"2";"";"Primary outcome: treatment effect contrast";"Proportions difference"
"10.1111/jdv.15369";"30472749";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/jdv.15369";"30472749";"results";"2";"";"Primary outcome: adjusted treatment effect";"17.3"
"10.1111/jdv.15369";"30472749";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1111/jdv.15369";"30472749";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"41"
"10.1111/jdv.15369";"30472749";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"748"
"10.1111/jdv.15369";"30472749";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"102"
"10.1111/jdv.15369";"30472749";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1111/jdv.15369";"30472749";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/jdv.15369";"30472749";"results";"3";"";"Number of covariates adjusted for/matched on";"4"
"10.1111/jdv.15369";"30472749";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1111/jdv.15369";"30472749";"results";"3";"";"Primary outcome: treatment effect contrast";"Proportions difference"
"10.1111/jdv.15369";"30472749";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/jdv.15369";"30472749";"results";"3";"";"Primary outcome: adjusted treatment effect";"19.2"
"10.1111/jdv.15369";"30472749";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.009"
"10.1111/jdv.15369";"30472749";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"115"
"10.1111/jdv.15369";"30472749";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"749"
"10.1111/jdv.15369";"30472749";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"224"
"10.1111/jdv.15369";"30472749";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1111/jdv.15369";"30472749";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1111/jdv.15369";"30472749";"results";"4";"";"Number of covariates adjusted for/matched on";"2"
"10.1111/jdv.15369";"30472749";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1111/jdv.15369";"30472749";"results";"4";"";"Primary outcome: treatment effect contrast";"Proportions difference"
"10.1111/jdv.15369";"30472749";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1111/jdv.15369";"30472749";"results";"4";"";"Primary outcome: adjusted treatment effect";"-4.4"
"10.1111/jdv.15369";"30472749";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.451"
"10.1136/rmdopen-2019-001131";"32371431";"general_information";"";"";"Medical Condition of Interest Name";"rheumatoid arthritis"
"10.1136/rmdopen-2019-001131";"32371431";"general_information";"";"";"Countries of first author affiliations";"france"
"10.1136/rmdopen-2019-001131";"32371431";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1136/rmdopen-2019-001131";"32371431";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.1136/rmdopen-2019-001131";"32371431";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Not mentioned"
"10.1136/rmdopen-2019-001131";"32371431";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1136/rmdopen-2019-001131";"32371431";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01711359"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"2";"Patient-level data used";"No"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00109408"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"3";"Patient-level data used";"No"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01007435"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"4";"Patient-level data used";"No"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01039688"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"5";"Patient-level data used";"No"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00195663"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"3"
"10.1136/rmdopen-2019-001131";"32371431";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"1";"";"Treatment name 1";"baricitinib"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"1";"";"Treatment name 2";"adalimumab"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"1";"";"Study 'number(s)' for treatment 2";"5"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"change in visual analogue scale for pain"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"2";"";"Treatment name 1";"baricitinib"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"2";"";"Treatment name 2";"tocilizumab"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"change in visual analogue scale for pain"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"3";"";"Treatment name 1";"baricitinib"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"3";"";"Treatment name 2";"tofacitinib"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"3";"";"Study 'number(s)' for treatment 2";"4"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"3";"";"Anchored comparison?";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"change in visual analogue scale for pain"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"3";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1136/rmdopen-2019-001131";"32371431";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1136/rmdopen-2019-001131";"32371431";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"274"
"10.1136/rmdopen-2019-001131";"32371431";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"257"
"10.1136/rmdopen-2019-001131";"32371431";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"159"
"10.1136/rmdopen-2019-001131";"32371431";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"151.5"
"10.1136/rmdopen-2019-001131";"32371431";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"210"
"10.1136/rmdopen-2019-001131";"32371431";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"181.4"
"10.1136/rmdopen-2019-001131";"32371431";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1136/rmdopen-2019-001131";"32371431";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.1136/rmdopen-2019-001131";"32371431";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1136/rmdopen-2019-001131";"32371431";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1136/rmdopen-2019-001131";"32371431";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1136/rmdopen-2019-001131";"32371431";"results";"1";"";"Primary outcome: unadjusted treatment effect";"-12.1"
"10.1136/rmdopen-2019-001131";"32371431";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.1136/rmdopen-2019-001131";"32371431";"results";"1";"";"Primary outcome: adjusted treatment effect";"-12.3"
"10.1136/rmdopen-2019-001131";"32371431";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1136/rmdopen-2019-001131";"32371431";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"159"
"10.1136/rmdopen-2019-001131";"32371431";"results";"2";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"210"
"10.1136/rmdopen-2019-001131";"32371431";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1136/rmdopen-2019-001131";"32371431";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"results";"2";"";"Number of covariates adjusted for/matched on";"7"
"10.1136/rmdopen-2019-001131";"32371431";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1136/rmdopen-2019-001131";"32371431";"results";"2";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1136/rmdopen-2019-001131";"32371431";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1136/rmdopen-2019-001131";"32371431";"results";"2";"";"Primary outcome: unadjusted treatment effect";"-8.7"
"10.1136/rmdopen-2019-001131";"32371431";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.05"
"10.1136/rmdopen-2019-001131";"32371431";"results";"2";"";"Primary outcome: adjusted treatment effect";"-12.1"
"10.1136/rmdopen-2019-001131";"32371431";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.05"
"10.1136/rmdopen-2019-001131";"32371431";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"292"
"10.1136/rmdopen-2019-001131";"32371431";"results";"2";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"287"
"10.1136/rmdopen-2019-001131";"32371431";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"373"
"10.1136/rmdopen-2019-001131";"32371431";"results";"3";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"186"
"10.1136/rmdopen-2019-001131";"32371431";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"159"
"10.1136/rmdopen-2019-001131";"32371431";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"146.5"
"10.1136/rmdopen-2019-001131";"32371431";"results";"3";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"210"
"10.1136/rmdopen-2019-001131";"32371431";"results";"3";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"177.8"
"10.1136/rmdopen-2019-001131";"32371431";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1136/rmdopen-2019-001131";"32371431";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1136/rmdopen-2019-001131";"32371431";"results";"3";"";"Number of covariates adjusted for/matched on";"7"
"10.1136/rmdopen-2019-001131";"32371431";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1136/rmdopen-2019-001131";"32371431";"results";"3";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1136/rmdopen-2019-001131";"32371431";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1136/rmdopen-2019-001131";"32371431";"results";"3";"";"Primary outcome: unadjusted treatment effect";"-7.1"
"10.1136/rmdopen-2019-001131";"32371431";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.05"
"10.1136/rmdopen-2019-001131";"32371431";"results";"3";"";"Primary outcome: adjusted treatment effect";"-5.4"
"10.1136/rmdopen-2019-001131";"32371431";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";">0.05"
"10.1155/2017/6121760";"28607774";"general_information";"";"";"Medical Condition of Interest Name";"basal cell carcinoma"
"10.1155/2017/6121760";"28607774";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1155/2017/6121760";"28607774";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1155/2017/6121760";"28607774";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1155/2017/6121760";"28607774";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1155/2017/6121760";"28607774";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1155/2017/6121760";"28607774";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1155/2017/6121760";"28607774";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1155/2017/6121760";"28607774";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1155/2017/6121760";"28607774";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1155/2017/6121760";"28607774";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01327053"
"10.1155/2017/6121760";"28607774";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1155/2017/6121760";"28607774";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.1155/2017/6121760";"28607774";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1155/2017/6121760";"28607774";"study_information";"";"2";"Patient-level data used";"No"
"10.1155/2017/6121760";"28607774";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1155/2017/6121760";"28607774";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00833417"
"10.1155/2017/6121760";"28607774";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1155/2017/6121760";"28607774";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2"
"10.1155/2017/6121760";"28607774";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1155/2017/6121760";"28607774";"methodology";"1";"";"Treatment name 1";"sonidegib"
"10.1155/2017/6121760";"28607774";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1155/2017/6121760";"28607774";"methodology";"1";"";"Treatment name 2";"vismodegib"
"10.1155/2017/6121760";"28607774";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1155/2017/6121760";"28607774";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1155/2017/6121760";"28607774";"methodology";"1";"";"Anchored comparison?";"No"
"10.1155/2017/6121760";"28607774";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1155/2017/6121760";"28607774";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1155/2017/6121760";"28607774";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1155/2017/6121760";"28607774";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1155/2017/6121760";"28607774";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1155/2017/6121760";"28607774";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1155/2017/6121760";"28607774";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No"
"10.1155/2017/6121760";"28607774";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1155/2017/6121760";"28607774";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1155/2017/6121760";"28607774";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"63"
"10.1155/2017/6121760";"28607774";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"66"
"10.1155/2017/6121760";"28607774";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1155/2017/6121760";"28607774";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1155/2017/6121760";"28607774";"results";"1";"";"Number of covariates adjusted for/matched on";"2"
"10.1155/2017/6121760";"28607774";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Past treatments for the disease of interest"
"10.1155/2017/6121760";"28607774";"results";"1";"";"Primary outcome: treatment effect contrast";"Relative effects (e.g., relative risks and hazard ratios) has not been examined."
"10.1177/1756286420975916";"33488773";"general_information";"";"";"Medical Condition of Interest Name";"relapsing multiple sclerosis"
"10.1177/1756286420975916";"33488773";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1177/1756286420975916";"33488773";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1177/1756286420975916";"33488773";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.1177/1756286420975916";"33488773";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Not mentioned"
"10.1177/1756286420975916";"33488773";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1177/1756286420975916";"33488773";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1177/1756286420975916";"33488773";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1177/1756286420975916";"33488773";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1177/1756286420975916";"33488773";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1177/1756286420975916";"33488773";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00906399"
"10.1177/1756286420975916";"33488773";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1177/1756286420975916";"33488773";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1177/1756286420975916";"33488773";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1177/1756286420975916";"33488773";"study_information";"";"2";"Patient-level data used";"No"
"10.1177/1756286420975916";"33488773";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1177/1756286420975916";"33488773";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01067521"
"10.1177/1756286420975916";"33488773";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1177/1756286420975916";"33488773";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1177/1756286420975916";"33488773";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1177/1756286420975916";"33488773";"methodology";"1";"";"Treatment name 1";"peginterferon beta-1a"
"10.1177/1756286420975916";"33488773";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1177/1756286420975916";"33488773";"methodology";"1";"";"Treatment name 2";"glatiramer acetate"
"10.1177/1756286420975916";"33488773";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1177/1756286420975916";"33488773";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1177/1756286420975916";"33488773";"methodology";"1";"";"Anchored comparison?";"No"
"10.1177/1756286420975916";"33488773";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1177/1756286420975916";"33488773";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1177/1756286420975916";"33488773";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"annualized relapse rate"
"10.1177/1756286420975916";"33488773";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1177/1756286420975916";"33488773";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1177/1756286420975916";"33488773";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1177/1756286420975916";"33488773";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1177/1756286420975916";"33488773";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1177/1756286420975916";"33488773";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1177/1756286420975916";"33488773";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"834"
"10.1177/1756286420975916";"33488773";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"407"
"10.1177/1756286420975916";"33488773";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"276"
"10.1177/1756286420975916";"33488773";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1177/1756286420975916";"33488773";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1177/1756286420975916";"33488773";"results";"1";"";"Number of covariates adjusted for/matched on";"5"
"10.1177/1756286420975916";"33488773";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1177/1756286420975916";"33488773";"results";"1";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1177/1756286420975916";"33488773";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1177/1756286420975916";"33488773";"results";"1";"";"Primary outcome: adjusted treatment effect";"-0.04"
"10.1177/1756286420975916";"33488773";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.278"
"10.1177/17588359211049639";"34616492";"general_information";"";"";"Medical Condition of Interest Name";"advanced ovarian cancer"
"10.1177/17588359211049639";"34616492";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.1177/17588359211049639";"34616492";"general_information";"";"";"Countries of last author affiliations";"uk"
"10.1177/17588359211049639";"34616492";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.1177/17588359211049639";"34616492";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1177/17588359211049639";"34616492";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1177/17588359211049639";"34616492";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1177/17588359211049639";"34616492";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1177/17588359211049639";"34616492";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1177/17588359211049639";"34616492";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1177/17588359211049639";"34616492";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02477644"
"10.1177/17588359211049639";"34616492";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1177/17588359211049639";"34616492";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1177/17588359211049639";"34616492";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1177/17588359211049639";"34616492";"study_information";"";"2";"Patient-level data used";"No"
"10.1177/17588359211049639";"34616492";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1177/17588359211049639";"34616492";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02655016"
"10.1177/17588359211049639";"34616492";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1177/17588359211049639";"34616492";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1177/17588359211049639";"34616492";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1177/17588359211049639";"34616492";"methodology";"1";"";"Treatment name 1";"bevacizumab + olaparib"
"10.1177/17588359211049639";"34616492";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1177/17588359211049639";"34616492";"methodology";"1";"";"Treatment name 2";"niraparib"
"10.1177/17588359211049639";"34616492";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1177/17588359211049639";"34616492";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1177/17588359211049639";"34616492";"methodology";"1";"";"Anchored comparison?";"No"
"10.1177/17588359211049639";"34616492";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1177/17588359211049639";"34616492";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1177/17588359211049639";"34616492";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1177/17588359211049639";"34616492";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1177/17588359211049639";"34616492";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1177/17588359211049639";"34616492";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1177/17588359211049639";"34616492";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1177/17588359211049639";"34616492";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1177/17588359211049639";"34616492";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1177/17588359211049639";"34616492";"methodology";"2";"";"Treatment name 1";"niraparib"
"10.1177/17588359211049639";"34616492";"methodology";"2";"";"Study 'number(s)' for treatment 1";"2"
"10.1177/17588359211049639";"34616492";"methodology";"2";"";"Treatment name 2";"placebo + bevacizumab"
"10.1177/17588359211049639";"34616492";"methodology";"2";"";"Study 'number(s)' for treatment 2";"1"
"10.1177/17588359211049639";"34616492";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1177/17588359211049639";"34616492";"methodology";"2";"";"Anchored comparison?";"No"
"10.1177/17588359211049639";"34616492";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1177/17588359211049639";"34616492";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1177/17588359211049639";"34616492";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1177/17588359211049639";"34616492";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.1177/17588359211049639";"34616492";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1177/17588359211049639";"34616492";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1177/17588359211049639";"34616492";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1177/17588359211049639";"34616492";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1177/17588359211049639";"34616492";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1177/17588359211049639";"34616492";"methodology";"3";"";"Treatment name 1";"bevacizumab + olaparib"
"10.1177/17588359211049639";"34616492";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.1177/17588359211049639";"34616492";"methodology";"3";"";"Treatment name 2";"placebo"
"10.1177/17588359211049639";"34616492";"methodology";"3";"";"Study 'number(s)' for treatment 2";"2"
"10.1177/17588359211049639";"34616492";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1177/17588359211049639";"34616492";"methodology";"3";"";"Anchored comparison?";"No"
"10.1177/17588359211049639";"34616492";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1177/17588359211049639";"34616492";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1177/17588359211049639";"34616492";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1177/17588359211049639";"34616492";"methodology";"3";"";"Primary outcome: variable type";"Time-to-event"
"10.1177/17588359211049639";"34616492";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1177/17588359211049639";"34616492";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1177/17588359211049639";"34616492";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1177/17588359211049639";"34616492";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1177/17588359211049639";"34616492";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1177/17588359211049639";"34616492";"methodology";"4";"";"Treatment name 1";"placebo + bevacizumab"
"10.1177/17588359211049639";"34616492";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1"
"10.1177/17588359211049639";"34616492";"methodology";"4";"";"Treatment name 2";"placebo"
"10.1177/17588359211049639";"34616492";"methodology";"4";"";"Study 'number(s)' for treatment 2";"2"
"10.1177/17588359211049639";"34616492";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1177/17588359211049639";"34616492";"methodology";"4";"";"Anchored comparison?";"No"
"10.1177/17588359211049639";"34616492";"methodology";"4";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1177/17588359211049639";"34616492";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1177/17588359211049639";"34616492";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1177/17588359211049639";"34616492";"methodology";"4";"";"Primary outcome: variable type";"Time-to-event"
"10.1177/17588359211049639";"34616492";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.1177/17588359211049639";"34616492";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1177/17588359211049639";"34616492";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1177/17588359211049639";"34616492";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1177/17588359211049639";"34616492";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1177/17588359211049639";"34616492";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"487"
"10.1177/17588359211049639";"34616492";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"399"
"10.1177/17588359211049639";"34616492";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"358"
"10.1177/17588359211049639";"34616492";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1177/17588359211049639";"34616492";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1177/17588359211049639";"34616492";"results";"1";"";"Number of covariates adjusted for/matched on";"8"
"10.1177/17588359211049639";"34616492";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1177/17588359211049639";"34616492";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1177/17588359211049639";"34616492";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1177/17588359211049639";"34616492";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.57"
"10.1177/17588359211049639";"34616492";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.47;0.69]"
"10.1177/17588359211049639";"34616492";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"487"
"10.1177/17588359211049639";"34616492";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"196"
"10.1177/17588359211049639";"34616492";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"174"
"10.1177/17588359211049639";"34616492";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1177/17588359211049639";"34616492";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1177/17588359211049639";"34616492";"results";"2";"";"Number of covariates adjusted for/matched on";"8"
"10.1177/17588359211049639";"34616492";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1177/17588359211049639";"34616492";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.1177/17588359211049639";"34616492";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Denominator if ratio, or rightside if difference"
"10.1177/17588359211049639";"34616492";"results";"2";"";"Primary outcome: adjusted treatment effect";"1.07"
"10.1177/17588359211049639";"34616492";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.87;1.32]"
"10.1177/17588359211049639";"34616492";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"246"
"10.1177/17588359211049639";"34616492";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"399"
"10.1177/17588359211049639";"34616492";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"358"
"10.1177/17588359211049639";"34616492";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1177/17588359211049639";"34616492";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1177/17588359211049639";"34616492";"results";"3";"";"Number of covariates adjusted for/matched on";"8"
"10.1177/17588359211049639";"34616492";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1177/17588359211049639";"34616492";"results";"3";"";"Primary outcome: treatment effect contrast";"HR"
"10.1177/17588359211049639";"34616492";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1177/17588359211049639";"34616492";"results";"3";"";"Primary outcome: adjusted treatment effect";"0.33"
"10.1177/17588359211049639";"34616492";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.26;0.42]"
"10.1177/17588359211049639";"34616492";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"246"
"10.1177/17588359211049639";"34616492";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"196"
"10.1177/17588359211049639";"34616492";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"174"
"10.1177/17588359211049639";"34616492";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.1177/17588359211049639";"34616492";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1177/17588359211049639";"34616492";"results";"4";"";"Number of covariates adjusted for/matched on";"8"
"10.1177/17588359211049639";"34616492";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1177/17588359211049639";"34616492";"results";"4";"";"Primary outcome: treatment effect contrast";"HR"
"10.1177/17588359211049639";"34616492";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1177/17588359211049639";"34616492";"results";"4";"";"Primary outcome: adjusted treatment effect";"0.55"
"10.1177/17588359211049639";"34616492";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.43;0.70]"
"10.1183/13993003.01393-2018";"30309978";"general_information";"";"";"Medical Condition of Interest Name";"severe uncontrolled asthma"
"10.1183/13993003.01393-2018";"30309978";"general_information";"";"";"Countries of first author affiliations";"france"
"10.1183/13993003.01393-2018";"30309978";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1183/13993003.01393-2018";"30309978";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1183/13993003.01393-2018";"30309978";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1183/13993003.01393-2018";"30309978";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1183/13993003.01393-2018";"30309978";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1183/13993003.01393-2018";"30309978";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01928771"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01914757"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"3";"Patient-level data used";"No"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01691521"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"4";"Patient-level data used";"No"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01000506"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"2"
"10.1183/13993003.01393-2018";"30309978";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1183/13993003.01393-2018";"30309978";"methodology";"1";"";"Treatment name 1";"benralizumab"
"10.1183/13993003.01393-2018";"30309978";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1183/13993003.01393-2018";"30309978";"methodology";"1";"";"Treatment name 2";"mepolizumab"
"10.1183/13993003.01393-2018";"30309978";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3;4"
"10.1183/13993003.01393-2018";"30309978";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1183/13993003.01393-2018";"30309978";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1183/13993003.01393-2018";"30309978";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1183/13993003.01393-2018";"30309978";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1183/13993003.01393-2018";"30309978";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"annual rate of clinically significant exacerbations"
"10.1183/13993003.01393-2018";"30309978";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1183/13993003.01393-2018";"30309978";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1183/13993003.01393-2018";"30309978";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1183/13993003.01393-2018";"30309978";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1183/13993003.01393-2018";"30309978";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1183/13993003.01393-2018";"30309978";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1183/13993003.01393-2018";"30309978";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"538"
"10.1183/13993003.01393-2018";"30309978";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"346"
"10.1183/13993003.01393-2018";"30309978";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1183/13993003.01393-2018";"30309978";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1183/13993003.01393-2018";"30309978";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.1183/13993003.01393-2018";"30309978";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.1183/13993003.01393-2018";"30309978";"results";"1";"";"Primary outcome: treatment effect contrast";"RR"
"10.1183/13993003.01393-2018";"30309978";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1183/13993003.01393-2018";"30309978";"results";"1";"";"Primary outcome: unadjusted treatment effect";"1.06"
"10.1183/13993003.01393-2018";"30309978";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.5533"
"10.1183/13993003.01393-2018";"30309978";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.94"
"10.1183/13993003.01393-2018";"30309978";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.5207"
"10.1185/03007995.2011.576238";"21524239";"general_information";"";"";"Medical Condition of Interest Name";"chronic myeloid leukemia in the chronic phase"
"10.1185/03007995.2011.576238";"21524239";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1185/03007995.2011.576238";"21524239";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1185/03007995.2011.576238";"21524239";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1185/03007995.2011.576238";"21524239";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1185/03007995.2011.576238";"21524239";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1185/03007995.2011.576238";"21524239";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1185/03007995.2011.576238";"21524239";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1185/03007995.2011.576238";"21524239";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1185/03007995.2011.576238";"21524239";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1185/03007995.2011.576238";"21524239";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00471497"
"10.1185/03007995.2011.576238";"21524239";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1185/03007995.2011.576238";"21524239";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1185/03007995.2011.576238";"21524239";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1185/03007995.2011.576238";"21524239";"study_information";"";"2";"Patient-level data used";"No"
"10.1185/03007995.2011.576238";"21524239";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1185/03007995.2011.576238";"21524239";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00481247"
"10.1185/03007995.2011.576238";"21524239";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1185/03007995.2011.576238";"21524239";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1185/03007995.2011.576238";"21524239";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1185/03007995.2011.576238";"21524239";"methodology";"1";"";"Treatment name 1";"nilotinib"
"10.1185/03007995.2011.576238";"21524239";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1185/03007995.2011.576238";"21524239";"methodology";"1";"";"Treatment name 2";"dasatinib"
"10.1185/03007995.2011.576238";"21524239";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1185/03007995.2011.576238";"21524239";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1185/03007995.2011.576238";"21524239";"methodology";"1";"";"Anchored comparison?";"No"
"10.1185/03007995.2011.576238";"21524239";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1185/03007995.2011.576238";"21524239";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1185/03007995.2011.576238";"21524239";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"major molecular response"
"10.1185/03007995.2011.576238";"21524239";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1185/03007995.2011.576238";"21524239";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1185/03007995.2011.576238";"21524239";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1185/03007995.2011.576238";"21524239";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1185/03007995.2011.576238";"21524239";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1185/03007995.2011.576238";"21524239";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1185/03007995.2011.576238";"21524239";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"259"
"10.1185/03007995.2011.576238";"21524239";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"273"
"10.1185/03007995.2011.576238";"21524239";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1185/03007995.2011.576238";"21524239";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1185/03007995.2011.576238";"21524239";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.1185/03007995.2011.576238";"21524239";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1185/03007995.2011.576238";"21524239";"results";"1";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1185/03007995.2011.576238";"21524239";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1185/03007995.2011.576238";"21524239";"results";"1";"";"Primary outcome: unadjusted treatment effect";"9.40%"
"10.1185/03007995.2011.576238";"21524239";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.03"
"10.1185/03007995.2011.576238";"21524239";"results";"1";"";"Primary outcome: adjusted treatment effect";"10.9"
"10.1185/03007995.2011.576238";"21524239";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.014"
"10.1185/03007995.2014.977992";"25356603";"general_information";"";"";"Medical Condition of Interest Name";"chronic myeloid leukemia in chronic phase"
"10.1185/03007995.2014.977992";"25356603";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1185/03007995.2014.977992";"25356603";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1185/03007995.2014.977992";"25356603";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1185/03007995.2014.977992";"25356603";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1185/03007995.2014.977992";"25356603";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1185/03007995.2014.977992";"25356603";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1185/03007995.2014.977992";"25356603";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1185/03007995.2014.977992";"25356603";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1185/03007995.2014.977992";"25356603";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1185/03007995.2014.977992";"25356603";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00471497"
"10.1185/03007995.2014.977992";"25356603";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1185/03007995.2014.977992";"25356603";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1185/03007995.2014.977992";"25356603";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1185/03007995.2014.977992";"25356603";"study_information";"";"2";"Patient-level data used";"No"
"10.1185/03007995.2014.977992";"25356603";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1185/03007995.2014.977992";"25356603";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00481247"
"10.1185/03007995.2014.977992";"25356603";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1185/03007995.2014.977992";"25356603";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1185/03007995.2014.977992";"25356603";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1185/03007995.2014.977992";"25356603";"methodology";"1";"";"Treatment name 1";"nilotinib"
"10.1185/03007995.2014.977992";"25356603";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1185/03007995.2014.977992";"25356603";"methodology";"1";"";"Treatment name 2";"dasatinib"
"10.1185/03007995.2014.977992";"25356603";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1185/03007995.2014.977992";"25356603";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1185/03007995.2014.977992";"25356603";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1185/03007995.2014.977992";"25356603";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1185/03007995.2014.977992";"25356603";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1185/03007995.2014.977992";"25356603";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"molecular response"
"10.1185/03007995.2014.977992";"25356603";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1185/03007995.2014.977992";"25356603";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1185/03007995.2014.977992";"25356603";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1185/03007995.2014.977992";"25356603";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1185/03007995.2014.977992";"25356603";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1185/03007995.2014.977992";"25356603";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1185/03007995.2014.977992";"25356603";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"259"
"10.1185/03007995.2014.977992";"25356603";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"260"
"10.1185/03007995.2014.977992";"25356603";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"278"
"10.1185/03007995.2014.977992";"25356603";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"282"
"10.1185/03007995.2014.977992";"25356603";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1185/03007995.2014.977992";"25356603";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1185/03007995.2014.977992";"25356603";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.1185/03007995.2014.977992";"25356603";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1185/03007995.2014.977992";"25356603";"results";"1";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.1185/03007995.2014.977992";"25356603";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1185/03007995.2014.977992";"25356603";"results";"1";"";"Primary outcome: adjusted treatment effect";"11.7"
"10.1185/03007995.2014.977992";"25356603";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.045"
"10.1185/03007995.2015.1106934";"26455472";"general_information";"";"";"Medical Condition of Interest Name";"genotype 4 hcv"
"10.1185/03007995.2015.1106934";"26455472";"general_information";"";"";"Countries of first author affiliations";"belgium"
"10.1185/03007995.2015.1106934";"26455472";"general_information";"";"";"Countries of last author affiliations";"uk"
"10.1185/03007995.2015.1106934";"26455472";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.1185/03007995.2015.1106934";"26455472";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1185/03007995.2015.1106934";"26455472";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01567735"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"2";"Patient-level data used";"No"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"2";"Data source name (only if observational study or clinical trial without NCT)";"varghese et al. (2009)"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"kuwait"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"3";"Patient-level data used";"No"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"3";"Data source name (only if observational study or clinical trial without NCT)";"rumi et al. (2010)"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"italy"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"4";"Patient-level data used";"No"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"4";"Data source name (only if observational study or clinical trial without NCT)";"el makhzangy et al. (2009)"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"egypt"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"5";"Patient-level data used";"No"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"5";"Clinical Trial";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00421434"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"4"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"6";"Patient-level data used";"No"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"6";"Clinical Trial";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"6";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00502099"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"6";"Country where the clinical trial/observational study was conducted (international if more than one)";"egypt"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"6";"Phase of the clinical trial (clinical trial only)";"2, 3"
"10.1185/03007995.2015.1106934";"26455472";"study_information";"";"6";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"1";"";"Treatment name 1";"simeprevir + peginterferon alfa-2a + ribavirin"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"1";"";"Treatment name 2";"peginterferon alfa-2a + ribavirin"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"1";"";"Anchored comparison?";"No"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained viral response"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"2";"";"Treatment name 1";"simeprevir + peginterferon alfa-2a + ribavirin"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"2";"";"Treatment name 2";"peginterferon alfa-2a + ribavirin"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"2";"";"Anchored comparison?";"No"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained viral response"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"3";"";"Treatment name 1";"simeprevir + peginterferon alfa-2a + ribavirin"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"3";"";"Treatment name 2";"peginterferon alfa-2a + ribavirin"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"3";"";"Study 'number(s)' for treatment 2";"4"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"3";"";"Anchored comparison?";"No"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained viral response"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"3";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"4";"";"Treatment name 1";"simeprevir + peginterferon alfa-2a + ribavirin"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"4";"";"Treatment name 2";"peginterferon alfa-2a + ribavirin"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"4";"";"Study 'number(s)' for treatment 2";"5"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"4";"";"Anchored comparison?";"No"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"4";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained viral response"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"4";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"5";"";"Treatment name 1";"simeprevir + peginterferon alfa-2a + ribavirin"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"5";"";"Study 'number(s)' for treatment 1";"1"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"5";"";"Treatment name 2";"peginterferon alfa-2a + ribavirin"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"5";"";"Study 'number(s)' for treatment 2";"6"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"5";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"5";"";"Anchored comparison?";"No"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"5";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"5";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"5";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained viral response"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"5";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"5";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"5";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"5";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"5";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1185/03007995.2015.1106934";"26455472";"methodology";"5";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1185/03007995.2015.1106934";"26455472";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"30"
"10.1185/03007995.2015.1106934";"26455472";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"30"
"10.1185/03007995.2015.1106934";"26455472";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"29"
"10.1185/03007995.2015.1106934";"26455472";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1185/03007995.2015.1106934";"26455472";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"results";"1";"";"Number of covariates adjusted for/matched on";"5"
"10.1185/03007995.2015.1106934";"26455472";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1185/03007995.2015.1106934";"26455472";"results";"1";"";"Primary outcome: treatment effect contrast";"OR"
"10.1185/03007995.2015.1106934";"26455472";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1185/03007995.2015.1106934";"26455472";"results";"1";"";"Primary outcome: adjusted treatment effect";"3.28"
"10.1185/03007995.2015.1106934";"26455472";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"18"
"10.1185/03007995.2015.1106934";"26455472";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"30"
"10.1185/03007995.2015.1106934";"26455472";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"15"
"10.1185/03007995.2015.1106934";"26455472";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1185/03007995.2015.1106934";"26455472";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"results";"2";"";"Number of covariates adjusted for/matched on";"5"
"10.1185/03007995.2015.1106934";"26455472";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1185/03007995.2015.1106934";"26455472";"results";"2";"";"Primary outcome: treatment effect contrast";"OR"
"10.1185/03007995.2015.1106934";"26455472";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1185/03007995.2015.1106934";"26455472";"results";"2";"";"Primary outcome: adjusted treatment effect";"4.26"
"10.1185/03007995.2015.1106934";"26455472";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"95"
"10.1185/03007995.2015.1106934";"26455472";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"30"
"10.1185/03007995.2015.1106934";"26455472";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"14"
"10.1185/03007995.2015.1106934";"26455472";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1185/03007995.2015.1106934";"26455472";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"results";"3";"";"Number of covariates adjusted for/matched on";"2"
"10.1185/03007995.2015.1106934";"26455472";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1185/03007995.2015.1106934";"26455472";"results";"3";"";"Primary outcome: treatment effect contrast";"OR"
"10.1185/03007995.2015.1106934";"26455472";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1185/03007995.2015.1106934";"26455472";"results";"3";"";"Primary outcome: adjusted treatment effect";"10.02"
"10.1185/03007995.2015.1106934";"26455472";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"40"
"10.1185/03007995.2015.1106934";"26455472";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"30"
"10.1185/03007995.2015.1106934";"26455472";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"26"
"10.1185/03007995.2015.1106934";"26455472";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1185/03007995.2015.1106934";"26455472";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"results";"4";"";"Number of covariates adjusted for/matched on";"2"
"10.1185/03007995.2015.1106934";"26455472";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1185/03007995.2015.1106934";"26455472";"results";"4";"";"Primary outcome: treatment effect contrast";"OR"
"10.1185/03007995.2015.1106934";"26455472";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1185/03007995.2015.1106934";"26455472";"results";"4";"";"Primary outcome: adjusted treatment effect";"6.69"
"10.1185/03007995.2015.1106934";"26455472";"results";"4";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"na"
"10.1185/03007995.2015.1106934";"26455472";"results";"5";"";"Sample size of the population of interest in the non IPD treatment arm";"109"
"10.1185/03007995.2015.1106934";"26455472";"results";"5";"";"Initial sample size of the population of interest in the IPD treatment arm";"30"
"10.1185/03007995.2015.1106934";"26455472";"results";"5";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"17"
"10.1185/03007995.2015.1106934";"26455472";"results";"5";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1185/03007995.2015.1106934";"26455472";"results";"5";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1185/03007995.2015.1106934";"26455472";"results";"5";"";"Number of covariates adjusted for/matched on";"2"
"10.1185/03007995.2015.1106934";"26455472";"results";"5";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1185/03007995.2015.1106934";"26455472";"results";"5";"";"Primary outcome: treatment effect contrast";"OR"
"10.1185/03007995.2015.1106934";"26455472";"results";"5";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1185/03007995.2015.1106934";"26455472";"results";"5";"";"Primary outcome: adjusted treatment effect";"5.43"
"10.1186/2162-3619-2-32";"24314093";"general_information";"";"";"Medical Condition of Interest Name";"advanced pancreatic neuroendocrine tumor"
"10.1186/2162-3619-2-32";"24314093";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1186/2162-3619-2-32";"24314093";"general_information";"";"";"Countries of last author affiliations";"canada"
"10.1186/2162-3619-2-32";"24314093";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1186/2162-3619-2-32";"24314093";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1186/2162-3619-2-32";"24314093";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1186/2162-3619-2-32";"24314093";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1186/2162-3619-2-32";"24314093";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1186/2162-3619-2-32";"24314093";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1186/2162-3619-2-32";"24314093";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1186/2162-3619-2-32";"24314093";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00510068"
"10.1186/2162-3619-2-32";"24314093";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1186/2162-3619-2-32";"24314093";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1186/2162-3619-2-32";"24314093";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1186/2162-3619-2-32";"24314093";"study_information";"";"2";"Patient-level data used";"No"
"10.1186/2162-3619-2-32";"24314093";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1186/2162-3619-2-32";"24314093";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00428597"
"10.1186/2162-3619-2-32";"24314093";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1186/2162-3619-2-32";"24314093";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1186/2162-3619-2-32";"24314093";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1186/2162-3619-2-32";"24314093";"methodology";"1";"";"Treatment name 1";"everolimus"
"10.1186/2162-3619-2-32";"24314093";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1186/2162-3619-2-32";"24314093";"methodology";"1";"";"Treatment name 2";"sunitinb"
"10.1186/2162-3619-2-32";"24314093";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1186/2162-3619-2-32";"24314093";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1186/2162-3619-2-32";"24314093";"methodology";"1";"";"Anchored comparison?";"No"
"10.1186/2162-3619-2-32";"24314093";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1186/2162-3619-2-32";"24314093";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1186/2162-3619-2-32";"24314093";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1186/2162-3619-2-32";"24314093";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1186/2162-3619-2-32";"24314093";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1186/2162-3619-2-32";"24314093";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1186/2162-3619-2-32";"24314093";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1186/2162-3619-2-32";"24314093";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1186/2162-3619-2-32";"24314093";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1186/2162-3619-2-32";"24314093";"methodology";"2";"";"Treatment name 1";"everolimus"
"10.1186/2162-3619-2-32";"24314093";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1186/2162-3619-2-32";"24314093";"methodology";"2";"";"Treatment name 2";"placebo"
"10.1186/2162-3619-2-32";"24314093";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1186/2162-3619-2-32";"24314093";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1186/2162-3619-2-32";"24314093";"methodology";"2";"";"Anchored comparison?";"No"
"10.1186/2162-3619-2-32";"24314093";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1186/2162-3619-2-32";"24314093";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1186/2162-3619-2-32";"24314093";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1186/2162-3619-2-32";"24314093";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.1186/2162-3619-2-32";"24314093";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1186/2162-3619-2-32";"24314093";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1186/2162-3619-2-32";"24314093";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1186/2162-3619-2-32";"24314093";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1186/2162-3619-2-32";"24314093";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1186/2162-3619-2-32";"24314093";"methodology";"3";"";"Treatment name 1";"everolimus"
"10.1186/2162-3619-2-32";"24314093";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.1186/2162-3619-2-32";"24314093";"methodology";"3";"";"Treatment name 2";"sunitinib"
"10.1186/2162-3619-2-32";"24314093";"methodology";"3";"";"Study 'number(s)' for treatment 2";"2"
"10.1186/2162-3619-2-32";"24314093";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1186/2162-3619-2-32";"24314093";"methodology";"3";"";"Anchored comparison?";"Yes"
"10.1186/2162-3619-2-32";"24314093";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1186/2162-3619-2-32";"24314093";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1186/2162-3619-2-32";"24314093";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1186/2162-3619-2-32";"24314093";"methodology";"3";"";"Primary outcome: variable type";"Time-to-event"
"10.1186/2162-3619-2-32";"24314093";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1186/2162-3619-2-32";"24314093";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1186/2162-3619-2-32";"24314093";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1186/2162-3619-2-32";"24314093";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1186/2162-3619-2-32";"24314093";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1186/2162-3619-2-32";"24314093";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"86"
"10.1186/2162-3619-2-32";"24314093";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1186/2162-3619-2-32";"24314093";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1186/2162-3619-2-32";"24314093";"results";"1";"";"Number of covariates adjusted for/matched on";"8"
"10.1186/2162-3619-2-32";"24314093";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1186/2162-3619-2-32";"24314093";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1186/2162-3619-2-32";"24314093";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1186/2162-3619-2-32";"24314093";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.69"
"10.1186/2162-3619-2-32";"24314093";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.087"
"10.1186/2162-3619-2-32";"24314093";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.81"
"10.1186/2162-3619-2-32";"24314093";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.383"
"10.1186/2162-3619-2-32";"24314093";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"207"
"10.1186/2162-3619-2-32";"24314093";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"85"
"10.1186/2162-3619-2-32";"24314093";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"207"
"10.1186/2162-3619-2-32";"24314093";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1186/2162-3619-2-32";"24314093";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1186/2162-3619-2-32";"24314093";"results";"2";"";"Number of covariates adjusted for/matched on";"8"
"10.1186/2162-3619-2-32";"24314093";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1186/2162-3619-2-32";"24314093";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.1186/2162-3619-2-32";"24314093";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1186/2162-3619-2-32";"24314093";"results";"2";"";"Primary outcome: unadjusted treatment effect";"0.53"
"10.1186/2162-3619-2-32";"24314093";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.002"
"10.1186/2162-3619-2-32";"24314093";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.61"
"10.1186/2162-3619-2-32";"24314093";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.042"
"10.1186/2162-3619-2-32";"24314093";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"86"
"10.1186/2162-3619-2-32";"24314093";"results";"3";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"85"
"10.1186/2162-3619-2-32";"24314093";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1186/2162-3619-2-32";"24314093";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1186/2162-3619-2-32";"24314093";"results";"3";"";"Number of covariates adjusted for/matched on";"8"
"10.1186/2162-3619-2-32";"24314093";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.1186/2162-3619-2-32";"24314093";"results";"3";"";"Primary outcome: treatment effect contrast";"HR"
"10.1186/2162-3619-2-32";"24314093";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1186/2162-3619-2-32";"24314093";"results";"3";"";"Primary outcome: unadjusted treatment effect";"0.9"
"10.1186/2162-3619-2-32";"24314093";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.695"
"10.1186/2162-3619-2-32";"24314093";"results";"3";"";"Primary outcome: adjusted treatment effect";"0.84"
"10.1186/2162-3619-2-32";"24314093";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.578"
"10.1186/2162-3619-2-32";"24314093";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"207"
"10.1186/2162-3619-2-32";"24314093";"results";"3";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"203"
"10.1186/s12885-018-5157-0";"30567533";"general_information";"";"";"Medical Condition of Interest Name";"metastatic renal cell carcinoma"
"10.1186/s12885-018-5157-0";"30567533";"general_information";"";"";"Countries of first author affiliations";"canada"
"10.1186/s12885-018-5157-0";"30567533";"general_information";"";"";"Countries of last author affiliations";"uk"
"10.1186/s12885-018-5157-0";"30567533";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1186/s12885-018-5157-0";"30567533";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1186/s12885-018-5157-0";"30567533";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1186/s12885-018-5157-0";"30567533";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1186/s12885-018-5157-0";"30567533";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1186/s12885-018-5157-0";"30567533";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1186/s12885-018-5157-0";"30567533";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1186/s12885-018-5157-0";"30567533";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00678392"
"10.1186/s12885-018-5157-0";"30567533";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1186/s12885-018-5157-0";"30567533";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1186/s12885-018-5157-0";"30567533";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1186/s12885-018-5157-0";"30567533";"study_information";"";"2";"Patient-level data used";"No"
"10.1186/s12885-018-5157-0";"30567533";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1186/s12885-018-5157-0";"30567533";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01865747"
"10.1186/s12885-018-5157-0";"30567533";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1186/s12885-018-5157-0";"30567533";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1186/s12885-018-5157-0";"30567533";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"1";"";"Treatment name 1";"axitinib"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"1";"";"Treatment name 2";"cabozantinib"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"1";"";"Anchored comparison?";"No"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"2";"";"Treatment name 1";"axitinib"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"2";"";"Treatment name 2";"everolimus"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"2";"";"Anchored comparison?";"No"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression free survival"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1186/s12885-018-5157-0";"30567533";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1186/s12885-018-5157-0";"30567533";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"135"
"10.1186/s12885-018-5157-0";"30567533";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"104"
"10.1186/s12885-018-5157-0";"30567533";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1186/s12885-018-5157-0";"30567533";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1186/s12885-018-5157-0";"30567533";"results";"1";"";"Number of covariates adjusted for/matched on";"9"
"10.1186/s12885-018-5157-0";"30567533";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)"
"10.1186/s12885-018-5157-0";"30567533";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1186/s12885-018-5157-0";"30567533";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1186/s12885-018-5157-0";"30567533";"results";"1";"";"Primary outcome: adjusted treatment effect";"1.15"
"10.1186/s12885-018-5157-0";"30567533";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.423"
"10.1186/s12885-018-5157-0";"30567533";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"194"
"10.1186/s12885-018-5157-0";"30567533";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"132"
"10.1186/s12885-018-5157-0";"30567533";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"61"
"10.1186/s12885-018-5157-0";"30567533";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1186/s12885-018-5157-0";"30567533";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1186/s12885-018-5157-0";"30567533";"results";"2";"";"Number of covariates adjusted for/matched on";"9"
"10.1186/s12885-018-5157-0";"30567533";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)"
"10.1186/s12885-018-5157-0";"30567533";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.1186/s12885-018-5157-0";"30567533";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1186/s12885-018-5157-0";"30567533";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.53"
"10.1186/s12885-018-5157-0";"30567533";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.002"
"10.1186/s12885-018-5157-0";"30567533";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"194"
"10.1186/s13045-021-01144-9";"34493319";"general_information";"";"";"Medical Condition of Interest Name";"relapsed or refractory large b cell lymphoma"
"10.1186/s13045-021-01144-9";"34493319";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1186/s13045-021-01144-9";"34493319";"general_information";"";"";"Countries of last author affiliations";"france"
"10.1186/s13045-021-01144-9";"34493319";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1186/s13045-021-01144-9";"34493319";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1186/s13045-021-01144-9";"34493319";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1186/s13045-021-01144-9";"34493319";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1186/s13045-021-01144-9";"34493319";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.1186/s13045-021-01144-9";"34493319";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1186/s13045-021-01144-9";"34493319";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1186/s13045-021-01144-9";"34493319";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02631044"
"10.1186/s13045-021-01144-9";"34493319";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.1186/s13045-021-01144-9";"34493319";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1"
"10.1186/s13045-021-01144-9";"34493319";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1186/s13045-021-01144-9";"34493319";"study_information";"";"2";"Patient-level data used";"No"
"10.1186/s13045-021-01144-9";"34493319";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1186/s13045-021-01144-9";"34493319";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02348216"
"10.1186/s13045-021-01144-9";"34493319";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1186/s13045-021-01144-9";"34493319";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.1186/s13045-021-01144-9";"34493319";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1186/s13045-021-01144-9";"34493319";"methodology";"1";"";"Treatment name 1";"lisocabtagene maraleucel"
"10.1186/s13045-021-01144-9";"34493319";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1186/s13045-021-01144-9";"34493319";"methodology";"1";"";"Treatment name 2";"axicabtagene ciloleucel"
"10.1186/s13045-021-01144-9";"34493319";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1186/s13045-021-01144-9";"34493319";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1186/s13045-021-01144-9";"34493319";"methodology";"1";"";"Anchored comparison?";"No"
"10.1186/s13045-021-01144-9";"34493319";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1186/s13045-021-01144-9";"34493319";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1186/s13045-021-01144-9";"34493319";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.1186/s13045-021-01144-9";"34493319";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1186/s13045-021-01144-9";"34493319";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
"
"10.1186/s13045-021-01144-9";"34493319";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1186/s13045-021-01144-9";"34493319";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1186/s13045-021-01144-9";"34493319";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1186/s13045-021-01144-9";"34493319";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1186/s13045-021-01144-9";"34493319";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"101"
"10.1186/s13045-021-01144-9";"34493319";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"256"
"10.1186/s13045-021-01144-9";"34493319";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"42.1"
"10.1186/s13045-021-01144-9";"34493319";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1186/s13045-021-01144-9";"34493319";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1186/s13045-021-01144-9";"34493319";"results";"1";"";"Number of covariates adjusted for/matched on";"10"
"10.1186/s13045-021-01144-9";"34493319";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)"
"10.1186/s13045-021-01144-9";"34493319";"results";"1";"";"Primary outcome: treatment effect contrast";"OR"
"10.1186/s13045-021-01144-9";"34493319";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1186/s13045-021-01144-9";"34493319";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.92"
"10.1186/s13045-021-01144-9";"34493319";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.753"
"10.1186/s13045-021-01144-9";"34493319";"results";"1";"";"Primary outcome: adjusted treatment effect";"1.4"
"10.1186/s13045-021-01144-9";"34493319";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.476"
"10.1186/s40164-022-00268-z";"35337365";"general_information";"";"";"Medical Condition of Interest Name";"relapsed or refractory aggressive large b-cell lymphomas"
"10.1186/s40164-022-00268-z";"35337365";"general_information";"";"";"Countries of first author affiliations";"france"
"10.1186/s40164-022-00268-z";"35337365";"general_information";"";"";"Countries of last author affiliations";"canada"
"10.1186/s40164-022-00268-z";"35337365";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Private Data Analysis Company, Pharmaceutical Industry"
"10.1186/s40164-022-00268-z";"35337365";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1186/s40164-022-00268-z";"35337365";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1186/s40164-022-00268-z";"35337365";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1186/s40164-022-00268-z";"35337365";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1186/s40164-022-00268-z";"35337365";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1186/s40164-022-00268-z";"35337365";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1186/s40164-022-00268-z";"35337365";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02631044"
"10.1186/s40164-022-00268-z";"35337365";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1"
"10.1186/s40164-022-00268-z";"35337365";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1186/s40164-022-00268-z";"35337365";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"us"
"10.1186/s40164-022-00268-z";"35337365";"study_information";"";"2";"Patient-level data used";"No"
"10.1186/s40164-022-00268-z";"35337365";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1186/s40164-022-00268-z";"35337365";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02445248"
"10.1186/s40164-022-00268-z";"35337365";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2"
"10.1186/s40164-022-00268-z";"35337365";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1186/s40164-022-00268-z";"35337365";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1186/s40164-022-00268-z";"35337365";"methodology";"1";"";"Treatment name 1";"liso-cel"
"10.1186/s40164-022-00268-z";"35337365";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1186/s40164-022-00268-z";"35337365";"methodology";"1";"";"Treatment name 2";"tisagenlecleucel"
"10.1186/s40164-022-00268-z";"35337365";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1186/s40164-022-00268-z";"35337365";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1186/s40164-022-00268-z";"35337365";"methodology";"1";"";"Anchored comparison?";"No"
"10.1186/s40164-022-00268-z";"35337365";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1186/s40164-022-00268-z";"35337365";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1186/s40164-022-00268-z";"35337365";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"objective response rate"
"10.1186/s40164-022-00268-z";"35337365";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1186/s40164-022-00268-z";"35337365";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1186/s40164-022-00268-z";"35337365";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1186/s40164-022-00268-z";"35337365";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1186/s40164-022-00268-z";"35337365";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1186/s40164-022-00268-z";"35337365";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1186/s40164-022-00268-z";"35337365";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"111"
"10.1186/s40164-022-00268-z";"35337365";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"256"
"10.1186/s40164-022-00268-z";"35337365";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"180"
"10.1186/s40164-022-00268-z";"35337365";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, but weights distribution not reported"
"10.1186/s40164-022-00268-z";"35337365";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1186/s40164-022-00268-z";"35337365";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.1186/s40164-022-00268-z";"35337365";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Past treatments for the disease of interest, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.1186/s40164-022-00268-z";"35337365";"results";"1";"";"Primary outcome: treatment effect contrast";"OR"
"10.1186/s40164-022-00268-z";"35337365";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1186/s40164-022-00268-z";"35337365";"results";"1";"";"Primary outcome: unadjusted treatment effect";"2.49"
"10.1186/s40164-022-00268-z";"35337365";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[1.52;4.07]"
"10.1186/s40164-022-00268-z";"35337365";"results";"1";"";"Primary outcome: adjusted treatment effect";"2.78"
"10.1186/s40164-022-00268-z";"35337365";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[1.63;4.74]"
"10.1186/s40734-017-0051-5";"28265459";"general_information";"";"";"Medical Condition of Interest Name";"huntington disease"
"10.1186/s40734-017-0051-5";"28265459";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1186/s40734-017-0051-5";"28265459";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1186/s40734-017-0051-5";"28265459";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1186/s40734-017-0051-5";"28265459";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1186/s40734-017-0051-5";"28265459";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1186/s40734-017-0051-5";"28265459";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1186/s40734-017-0051-5";"28265459";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1186/s40734-017-0051-5";"28265459";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1186/s40734-017-0051-5";"28265459";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1186/s40734-017-0051-5";"28265459";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01795859"
"10.1186/s40734-017-0051-5";"28265459";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1186/s40734-017-0051-5";"28265459";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1186/s40734-017-0051-5";"28265459";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1186/s40734-017-0051-5";"28265459";"study_information";"";"2";"Patient-level data used";"No"
"10.1186/s40734-017-0051-5";"28265459";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1186/s40734-017-0051-5";"28265459";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00219804"
"10.1186/s40734-017-0051-5";"28265459";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.1186/s40734-017-0051-5";"28265459";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1186/s40734-017-0051-5";"28265459";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.1186/s40734-017-0051-5";"28265459";"methodology";"1";"";"Treatment name 1";"deutetrabenazine"
"10.1186/s40734-017-0051-5";"28265459";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1186/s40734-017-0051-5";"28265459";"methodology";"1";"";"Treatment name 2";"tetrabenazine"
"10.1186/s40734-017-0051-5";"28265459";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.1186/s40734-017-0051-5";"28265459";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1186/s40734-017-0051-5";"28265459";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1186/s40734-017-0051-5";"28265459";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.1186/s40734-017-0051-5";"28265459";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1186/s40734-017-0051-5";"28265459";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall adverse events"
"10.1186/s40734-017-0051-5";"28265459";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.1186/s40734-017-0051-5";"28265459";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.1186/s40734-017-0051-5";"28265459";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.1186/s40734-017-0051-5";"28265459";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1186/s40734-017-0051-5";"28265459";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1186/s40734-017-0051-5";"28265459";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1186/s40734-017-0051-5";"28265459";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"54"
"10.1186/s40734-017-0051-5";"28265459";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"30"
"10.1186/s40734-017-0051-5";"28265459";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"45"
"10.1186/s40734-017-0051-5";"28265459";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"45"
"10.1186/s40734-017-0051-5";"28265459";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1186/s40734-017-0051-5";"28265459";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1186/s40734-017-0051-5";"28265459";"results";"1";"";"Number of covariates adjusted for/matched on";"3"
"10.1186/s40734-017-0051-5";"28265459";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.1186/s40734-017-0051-5";"28265459";"results";"1";"";"Primary outcome: treatment effect contrast";"Risk difference"
"10.1186/s40734-017-0051-5";"28265459";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1186/s40734-017-0051-5";"28265459";"results";"1";"";"Primary outcome: unadjusted treatment effect";"-20.7"
"10.1186/s40734-017-0051-5";"28265459";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.1186/s40734-017-0051-5";"28265459";"results";"1";"";"Primary outcome: adjusted treatment effect";"-35.3"
"10.1186/s40734-017-0051-5";"28265459";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.1186/s40734-017-0051-5";"28265459";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"45"
"10.1210/clinem/dgab905";"34922383";"general_information";"";"";"Medical Condition of Interest Name";"type 2 diabetes"
"10.1210/clinem/dgab905";"34922383";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.1210/clinem/dgab905";"34922383";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.1210/clinem/dgab905";"34922383";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.1210/clinem/dgab905";"34922383";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1210/clinem/dgab905";"34922383";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1210/clinem/dgab905";"34922383";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1210/clinem/dgab905";"34922383";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1210/clinem/dgab905";"34922383";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1210/clinem/dgab905";"34922383";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1210/clinem/dgab905";"34922383";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03989232"
"10.1210/clinem/dgab905";"34922383";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1210/clinem/dgab905";"34922383";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.1210/clinem/dgab905";"34922383";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1210/clinem/dgab905";"34922383";"study_information";"";"3";"Patient-level data used";"Yes"
"10.1210/clinem/dgab905";"34922383";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1210/clinem/dgab905";"34922383";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03495102"
"10.1210/clinem/dgab905";"34922383";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1210/clinem/dgab905";"34922383";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1210/clinem/dgab905";"34922383";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1210/clinem/dgab905";"34922383";"methodology";"1";"";"Treatment name 1";"semaglutide 2.0 mg"
"10.1210/clinem/dgab905";"34922383";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.1210/clinem/dgab905";"34922383";"methodology";"1";"";"Treatment name 2";"dulaglutide 3.0"
"10.1210/clinem/dgab905";"34922383";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3"
"10.1210/clinem/dgab905";"34922383";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"Multilevel network meta-regression"
"10.1210/clinem/dgab905";"34922383";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.1210/clinem/dgab905";"34922383";"methodology";"1";"";"Form of the indirect comparison";"Larger network (ie involving more than 2 studies)"
"10.1210/clinem/dgab905";"34922383";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1210/clinem/dgab905";"34922383";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"change in baseline hba1c"
"10.1210/clinem/dgab905";"34922383";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1210/clinem/dgab905";"34922383";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1210/clinem/dgab905";"34922383";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1210/clinem/dgab905";"34922383";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1210/clinem/dgab905";"34922383";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1210/clinem/dgab905";"34922383";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1210/clinem/dgab905";"34922383";"methodology";"2";"";"Treatment name 1";"semaglutide 2.0mg"
"10.1210/clinem/dgab905";"34922383";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.1210/clinem/dgab905";"34922383";"methodology";"2";"";"Treatment name 2";"dulaglutide 4.5 mg"
"10.1210/clinem/dgab905";"34922383";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.1210/clinem/dgab905";"34922383";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"Multilevel network meta-regression"
"10.1210/clinem/dgab905";"34922383";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.1210/clinem/dgab905";"34922383";"methodology";"2";"";"Form of the indirect comparison";"Larger network (ie involving more than 2 studies)"
"10.1210/clinem/dgab905";"34922383";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.1210/clinem/dgab905";"34922383";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"change in baseline hba1c"
"10.1210/clinem/dgab905";"34922383";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.1210/clinem/dgab905";"34922383";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1210/clinem/dgab905";"34922383";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.1210/clinem/dgab905";"34922383";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.1210/clinem/dgab905";"34922383";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1210/clinem/dgab905";"34922383";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1210/clinem/dgab905";"34922383";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"616"
"10.1210/clinem/dgab905";"34922383";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"612"
"10.1210/clinem/dgab905";"34922383";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"480"
"10.1210/clinem/dgab905";"34922383";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"480"
"10.1210/clinem/dgab905";"34922383";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"481"
"10.1210/clinem/dgab905";"34922383";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"481"
"10.1210/clinem/dgab905";"34922383";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1210/clinem/dgab905";"34922383";"results";"1";"";"Number of covariates adjusted for/matched on";"3"
"10.1210/clinem/dgab905";"34922383";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1210/clinem/dgab905";"34922383";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1210/clinem/dgab905";"34922383";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1210/clinem/dgab905";"34922383";"results";"1";"";"Primary outcome: unadjusted treatment effect";"-0.47"
"10.1210/clinem/dgab905";"34922383";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-0.69;-0.23]"
"10.1210/clinem/dgab905";"34922383";"results";"1";"";"Primary outcome: adjusted treatment effect";"-0.44"
"10.1210/clinem/dgab905";"34922383";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-0.68;-0.19]"
"10.1210/clinem/dgab905";"34922383";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"614"
"10.1210/clinem/dgab905";"34922383";"results";"2";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"612"
"10.1210/clinem/dgab905";"34922383";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"480"
"10.1210/clinem/dgab905";"34922383";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"480"
"10.1210/clinem/dgab905";"34922383";"results";"2";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"481"
"10.1210/clinem/dgab905";"34922383";"results";"2";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"481"
"10.1210/clinem/dgab905";"34922383";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1210/clinem/dgab905";"34922383";"results";"2";"";"Number of covariates adjusted for/matched on";"3"
"10.1210/clinem/dgab905";"34922383";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.1210/clinem/dgab905";"34922383";"results";"2";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.1210/clinem/dgab905";"34922383";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1210/clinem/dgab905";"34922383";"results";"2";"";"Primary outcome: unadjusted treatment effect";"-0.31"
"10.1210/clinem/dgab905";"34922383";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-0.53;-0.08]"
"10.1210/clinem/dgab905";"34922383";"results";"2";"";"Primary outcome: adjusted treatment effect";"-0.28"
"10.1210/clinem/dgab905";"34922383";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-0.52;-0.03]"
"10.1634/theoncologist.2017-0103";"29192016";"general_information";"";"";"Medical Condition of Interest Name";"relapsed/refractory multiple myeloma"
"10.1634/theoncologist.2017-0103";"29192016";"general_information";"";"";"Countries of first author affiliations";"belgium"
"10.1634/theoncologist.2017-0103";"29192016";"general_information";"";"";"Countries of last author affiliations";"spain"
"10.1634/theoncologist.2017-0103";"29192016";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.1634/theoncologist.2017-0103";"29192016";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.1634/theoncologist.2017-0103";"29192016";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.1634/theoncologist.2017-0103";"29192016";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.1634/theoncologist.2017-0103";"29192016";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"1";"Patient-level data used";"Yes"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"1";"Clinical Trial";"Yes"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00574288"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"2";"Patient-level data used";"Yes"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"2";"Clinical Trial";"Yes"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01985126"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"3";"Patient-level data used";"No"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"3";"Clinical Trial";"Yes"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01311687"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"4";"Patient-level data used";"No"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"4";"Clinical Trial";"Yes"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01712789"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.1634/theoncologist.2017-0103";"29192016";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"1";"";"Treatment name 1";"nct01712789"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"1";"";"Treatment name 2";"pomalidomide + low-dose dexamethasone"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"1";"";"Anchored comparison?";"No"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"2";"";"Treatment name 1";"daratumumab"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1;2"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"2";"";"Treatment name 2";"pomalidomide + low-dose dexamethasone"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"2";"";"Study 'number(s)' for treatment 2";"4"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"2";"";"Anchored comparison?";"No"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.1634/theoncologist.2017-0103";"29192016";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.1634/theoncologist.2017-0103";"29192016";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"302"
"10.1634/theoncologist.2017-0103";"29192016";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"136"
"10.1634/theoncologist.2017-0103";"29192016";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"55"
"10.1634/theoncologist.2017-0103";"29192016";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1634/theoncologist.2017-0103";"29192016";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1634/theoncologist.2017-0103";"29192016";"results";"1";"";"Number of covariates adjusted for/matched on";"10"
"10.1634/theoncologist.2017-0103";"29192016";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1634/theoncologist.2017-0103";"29192016";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.1634/theoncologist.2017-0103";"29192016";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1634/theoncologist.2017-0103";"29192016";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.61"
"10.1634/theoncologist.2017-0103";"29192016";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.0005"
"10.1634/theoncologist.2017-0103";"29192016";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.56"
"10.1634/theoncologist.2017-0103";"29192016";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.0001"
"10.1634/theoncologist.2017-0103";"29192016";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"682"
"10.1634/theoncologist.2017-0103";"29192016";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"148"
"10.1634/theoncologist.2017-0103";"29192016";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"95"
"10.1634/theoncologist.2017-0103";"29192016";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.1634/theoncologist.2017-0103";"29192016";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.1634/theoncologist.2017-0103";"29192016";"results";"2";"";"Number of covariates adjusted for/matched on";"10"
"10.1634/theoncologist.2017-0103";"29192016";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.1634/theoncologist.2017-0103";"29192016";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.1634/theoncologist.2017-0103";"29192016";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.1634/theoncologist.2017-0103";"29192016";"results";"2";"";"Primary outcome: unadjusted treatment effect";"0.55"
"10.1634/theoncologist.2017-0103";"29192016";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.0001"
"10.1634/theoncologist.2017-0103";"29192016";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.51"
"10.1634/theoncologist.2017-0103";"29192016";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.0001"
"10.2147/ceor.s203482";"31564931";"general_information";"";"";"Medical Condition of Interest Name";"acute myeloid leukemia"
"10.2147/ceor.s203482";"31564931";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2147/ceor.s203482";"31564931";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2147/ceor.s203482";"31564931";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.2147/ceor.s203482";"31564931";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2147/ceor.s203482";"31564931";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2147/ceor.s203482";"31564931";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2147/ceor.s203482";"31564931";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2147/ceor.s203482";"31564931";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2147/ceor.s203482";"31564931";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2147/ceor.s203482";"31564931";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01546038"
"10.2147/ceor.s203482";"31564931";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/ceor.s203482";"31564931";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.2147/ceor.s203482";"31564931";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2147/ceor.s203482";"31564931";"study_information";"";"2";"Patient-level data used";"No"
"10.2147/ceor.s203482";"31564931";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2147/ceor.s203482";"31564931";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01074047"
"10.2147/ceor.s203482";"31564931";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/ceor.s203482";"31564931";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/ceor.s203482";"31564931";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2147/ceor.s203482";"31564931";"study_information";"";"3";"Patient-level data used";"No"
"10.2147/ceor.s203482";"31564931";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2147/ceor.s203482";"31564931";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00260832"
"10.2147/ceor.s203482";"31564931";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/ceor.s203482";"31564931";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/ceor.s203482";"31564931";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2147/ceor.s203482";"31564931";"methodology";"1";"";"Treatment name 1";"glasdegib"
"10.2147/ceor.s203482";"31564931";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2147/ceor.s203482";"31564931";"methodology";"1";"";"Treatment name 2";"azacitidine"
"10.2147/ceor.s203482";"31564931";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2147/ceor.s203482";"31564931";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2147/ceor.s203482";"31564931";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.2147/ceor.s203482";"31564931";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2147/ceor.s203482";"31564931";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2147/ceor.s203482";"31564931";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2147/ceor.s203482";"31564931";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.2147/ceor.s203482";"31564931";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2147/ceor.s203482";"31564931";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2147/ceor.s203482";"31564931";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2147/ceor.s203482";"31564931";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2147/ceor.s203482";"31564931";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/ceor.s203482";"31564931";"methodology";"2";"";"Treatment name 1";"glasdegib"
"10.2147/ceor.s203482";"31564931";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.2147/ceor.s203482";"31564931";"methodology";"2";"";"Treatment name 2";"decitabine"
"10.2147/ceor.s203482";"31564931";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.2147/ceor.s203482";"31564931";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2147/ceor.s203482";"31564931";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.2147/ceor.s203482";"31564931";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2147/ceor.s203482";"31564931";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2147/ceor.s203482";"31564931";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2147/ceor.s203482";"31564931";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.2147/ceor.s203482";"31564931";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2147/ceor.s203482";"31564931";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2147/ceor.s203482";"31564931";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2147/ceor.s203482";"31564931";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2147/ceor.s203482";"31564931";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/ceor.s203482";"31564931";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"241"
"10.2147/ceor.s203482";"31564931";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"158"
"10.2147/ceor.s203482";"31564931";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"78"
"10.2147/ceor.s203482";"31564931";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"78"
"10.2147/ceor.s203482";"31564931";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"38"
"10.2147/ceor.s203482";"31564931";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"38"
"10.2147/ceor.s203482";"31564931";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/ceor.s203482";"31564931";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.2147/ceor.s203482";"31564931";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.2147/ceor.s203482";"31564931";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.2147/ceor.s203482";"31564931";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/ceor.s203482";"31564931";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.514"
"10.2147/ceor.s203482";"31564931";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.310;0.852]"
"10.2147/ceor.s203482";"31564931";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.424"
"10.2147/ceor.s203482";"31564931";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.228;0.789]"
"10.2147/ceor.s203482";"31564931";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"242"
"10.2147/ceor.s203482";"31564931";"results";"2";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"215"
"10.2147/ceor.s203482";"31564931";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"78"
"10.2147/ceor.s203482";"31564931";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"78"
"10.2147/ceor.s203482";"31564931";"results";"2";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"38"
"10.2147/ceor.s203482";"31564931";"results";"2";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"38"
"10.2147/ceor.s203482";"31564931";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/ceor.s203482";"31564931";"results";"2";"";"Number of covariates adjusted for/matched on";"7"
"10.2147/ceor.s203482";"31564931";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.2147/ceor.s203482";"31564931";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.2147/ceor.s203482";"31564931";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/ceor.s203482";"31564931";"results";"2";"";"Primary outcome: unadjusted treatment effect";"0.565"
"10.2147/ceor.s203482";"31564931";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.351;0.909]"
"10.2147/ceor.s203482";"31564931";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.505"
"10.2147/ceor.s203482";"31564931";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.269;0.949]"
"10.2147/ceor.s203482";"31564931";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2147/cmar.s163478";"29861642";"general_information";"";"";"Medical Condition of Interest Name";"hr+, her2− advanced breast cancer"
"10.2147/cmar.s163478";"29861642";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2147/cmar.s163478";"29861642";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2147/cmar.s163478";"29861642";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry"
"10.2147/cmar.s163478";"29861642";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2147/cmar.s163478";"29861642";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2147/cmar.s163478";"29861642";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2147/cmar.s163478";"29861642";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2147/cmar.s163478";"29861642";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2147/cmar.s163478";"29861642";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2147/cmar.s163478";"29861642";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01958021"
"10.2147/cmar.s163478";"29861642";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/cmar.s163478";"29861642";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/cmar.s163478";"29861642";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2147/cmar.s163478";"29861642";"study_information";"";"2";"Patient-level data used";"No"
"10.2147/cmar.s163478";"29861642";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2147/cmar.s163478";"29861642";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01740427"
"10.2147/cmar.s163478";"29861642";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/cmar.s163478";"29861642";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/cmar.s163478";"29861642";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2147/cmar.s163478";"29861642";"methodology";"1";"";"Treatment name 1";"ribociclib + letrozole"
"10.2147/cmar.s163478";"29861642";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2147/cmar.s163478";"29861642";"methodology";"1";"";"Treatment name 2";"palbociclib + letrozole"
"10.2147/cmar.s163478";"29861642";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2147/cmar.s163478";"29861642";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/cmar.s163478";"29861642";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.2147/cmar.s163478";"29861642";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2147/cmar.s163478";"29861642";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2147/cmar.s163478";"29861642";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.2147/cmar.s163478";"29861642";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.2147/cmar.s163478";"29861642";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/cmar.s163478";"29861642";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2147/cmar.s163478";"29861642";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/cmar.s163478";"29861642";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2147/cmar.s163478";"29861642";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/cmar.s163478";"29861642";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"444"
"10.2147/cmar.s163478";"29861642";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"222"
"10.2147/cmar.s163478";"29861642";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2147/cmar.s163478";"29861642";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/cmar.s163478";"29861642";"results";"1";"";"Number of covariates adjusted for/matched on";"9"
"10.2147/cmar.s163478";"29861642";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)"
"10.2147/cmar.s163478";"29861642";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.2147/cmar.s163478";"29861642";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/cmar.s163478";"29861642";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.959"
"10.2147/cmar.s163478";"29861642";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.681;1.350]"
"10.2147/cmar.s163478";"29861642";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.904"
"10.2147/cmar.s163478";"29861642";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.644;1.268]"
"10.2147/cmar.s163478";"29861642";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"227"
"10.2147/cmar.s163478";"29861642";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"220"
"10.2147/cmar.s163478";"29861642";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"244"
"10.2147/cmar.s163478";"29861642";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"237"
"10.2147/cmar.s325043";"34754238";"general_information";"";"";"Medical Condition of Interest Name";"hr+/her2− advanced breast cancer"
"10.2147/cmar.s325043";"34754238";"general_information";"";"";"Countries of first author affiliations";"germany"
"10.2147/cmar.s325043";"34754238";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2147/cmar.s325043";"34754238";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.2147/cmar.s325043";"34754238";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2147/cmar.s325043";"34754238";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2147/cmar.s325043";"34754238";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2147/cmar.s325043";"34754238";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.2147/cmar.s325043";"34754238";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2147/cmar.s325043";"34754238";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2147/cmar.s325043";"34754238";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02422615"
"10.2147/cmar.s325043";"34754238";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/cmar.s325043";"34754238";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/cmar.s325043";"34754238";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2147/cmar.s325043";"34754238";"study_information";"";"2";"Patient-level data used";"No"
"10.2147/cmar.s325043";"34754238";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2147/cmar.s325043";"34754238";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00721409"
"10.2147/cmar.s325043";"34754238";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/cmar.s325043";"34754238";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2"
"10.2147/cmar.s325043";"34754238";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2147/cmar.s325043";"34754238";"methodology";"1";"";"Treatment name 1";"ribociclib + fulvestrant"
"10.2147/cmar.s325043";"34754238";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2147/cmar.s325043";"34754238";"methodology";"1";"";"Treatment name 2";"palbociclib + letrozole"
"10.2147/cmar.s325043";"34754238";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2147/cmar.s325043";"34754238";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/cmar.s325043";"34754238";"methodology";"1";"";"Anchored comparison?";"No"
"10.2147/cmar.s325043";"34754238";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2147/cmar.s325043";"34754238";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2147/cmar.s325043";"34754238";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.2147/cmar.s325043";"34754238";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.2147/cmar.s325043";"34754238";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/cmar.s325043";"34754238";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2147/cmar.s325043";"34754238";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/cmar.s325043";"34754238";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2147/cmar.s325043";"34754238";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/cmar.s325043";"34754238";"methodology";"2";"";"Treatment name 1";"placebo + fulvestrant"
"10.2147/cmar.s325043";"34754238";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.2147/cmar.s325043";"34754238";"methodology";"2";"";"Treatment name 2";"letrozole"
"10.2147/cmar.s325043";"34754238";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.2147/cmar.s325043";"34754238";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/cmar.s325043";"34754238";"methodology";"2";"";"Anchored comparison?";"No"
"10.2147/cmar.s325043";"34754238";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2147/cmar.s325043";"34754238";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2147/cmar.s325043";"34754238";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.2147/cmar.s325043";"34754238";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.2147/cmar.s325043";"34754238";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/cmar.s325043";"34754238";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2147/cmar.s325043";"34754238";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/cmar.s325043";"34754238";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2147/cmar.s325043";"34754238";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/cmar.s325043";"34754238";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"84"
"10.2147/cmar.s325043";"34754238";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"329"
"10.2147/cmar.s325043";"34754238";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"221"
"10.2147/cmar.s325043";"34754238";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.2147/cmar.s325043";"34754238";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/cmar.s325043";"34754238";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.2147/cmar.s325043";"34754238";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2147/cmar.s325043";"34754238";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.2147/cmar.s325043";"34754238";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/cmar.s325043";"34754238";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.83"
"10.2147/cmar.s325043";"34754238";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.2838"
"10.2147/cmar.s325043";"34754238";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.77"
"10.2147/cmar.s325043";"34754238";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.1553"
"10.2147/cmar.s325043";"34754238";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"81"
"10.2147/cmar.s325043";"34754238";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"178"
"10.2147/cmar.s325043";"34754238";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"117"
"10.2147/cmar.s325043";"34754238";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.2147/cmar.s325043";"34754238";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/cmar.s325043";"34754238";"results";"2";"";"Number of covariates adjusted for/matched on";"7"
"10.2147/cmar.s325043";"34754238";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2147/cmar.s325043";"34754238";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.2147/cmar.s325043";"34754238";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/cmar.s325043";"34754238";"results";"2";"";"Primary outcome: unadjusted treatment effect";"0.66"
"10.2147/cmar.s325043";"34754238";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.0094"
"10.2147/cmar.s325043";"34754238";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.58"
"10.2147/cmar.s325043";"34754238";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.0019"
"10.2147/jbm.s104074";"27445511";"general_information";"";"";"Medical Condition of Interest Name";"severe hemophilia a"
"10.2147/jbm.s104074";"27445511";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2147/jbm.s104074";"27445511";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2147/jbm.s104074";"27445511";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.2147/jbm.s104074";"27445511";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2147/jbm.s104074";"27445511";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2147/jbm.s104074";"27445511";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2147/jbm.s104074";"27445511";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2147/jbm.s104074";"27445511";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2147/jbm.s104074";"27445511";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2147/jbm.s104074";"27445511";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01029340"
"10.2147/jbm.s104074";"27445511";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s104074";"27445511";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/jbm.s104074";"27445511";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2147/jbm.s104074";"27445511";"study_information";"";"2";"Patient-level data used";"Yes"
"10.2147/jbm.s104074";"27445511";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2147/jbm.s104074";"27445511";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01233258"
"10.2147/jbm.s104074";"27445511";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s104074";"27445511";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/jbm.s104074";"27445511";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.2147/jbm.s104074";"27445511";"study_information";"";"3";"Patient-level data used";"No"
"10.2147/jbm.s104074";"27445511";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2147/jbm.s104074";"27445511";"study_information";"";"3";"Data source name (only if observational study or clinical trial without NCT)";"tarantino et al. (2004)"
"10.2147/jbm.s104074";"27445511";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s104074";"27445511";"study_information";"";"4";"Patient-level data used";"No"
"10.2147/jbm.s104074";"27445511";"study_information";"";"4";"Clinical Trial";"Yes"
"10.2147/jbm.s104074";"27445511";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00243386"
"10.2147/jbm.s104074";"27445511";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s104074";"27445511";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"4"
"10.2147/jbm.s104074";"27445511";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.2147/jbm.s104074";"27445511";"study_information";"";"5";"Patient-level data used";"No"
"10.2147/jbm.s104074";"27445511";"study_information";"";"5";"Clinical Trial";"Yes"
"10.2147/jbm.s104074";"27445511";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00840086"
"10.2147/jbm.s104074";"27445511";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s104074";"27445511";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/jbm.s104074";"27445511";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"1"
"10.2147/jbm.s104074";"27445511";"methodology";"1";"";"Treatment name 1";"bay 81-8973 (recombinant factor viii)"
"10.2147/jbm.s104074";"27445511";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.2147/jbm.s104074";"27445511";"methodology";"1";"";"Treatment name 2";"rahf-pfm"
"10.2147/jbm.s104074";"27445511";"methodology";"1";"";"Study 'number(s)' for treatment 2";"4"
"10.2147/jbm.s104074";"27445511";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/jbm.s104074";"27445511";"methodology";"1";"";"Anchored comparison?";"No"
"10.2147/jbm.s104074";"27445511";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2147/jbm.s104074";"27445511";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2147/jbm.s104074";"27445511";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"annualized bleed rates for all bleeds (1-year)"
"10.2147/jbm.s104074";"27445511";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2147/jbm.s104074";"27445511";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/jbm.s104074";"27445511";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2147/jbm.s104074";"27445511";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/jbm.s104074";"27445511";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2147/jbm.s104074";"27445511";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/jbm.s104074";"27445511";"methodology";"2";"";"Treatment name 1";"bay 81-8973 (recombinant factor viii)"
"10.2147/jbm.s104074";"27445511";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1;2"
"10.2147/jbm.s104074";"27445511";"methodology";"2";"";"Treatment name 2";"rahf-pfm"
"10.2147/jbm.s104074";"27445511";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.2147/jbm.s104074";"27445511";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/jbm.s104074";"27445511";"methodology";"2";"";"Anchored comparison?";"No"
"10.2147/jbm.s104074";"27445511";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2147/jbm.s104074";"27445511";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2147/jbm.s104074";"27445511";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"annualized bleed rates for all bleeds (1-year)"
"10.2147/jbm.s104074";"27445511";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2147/jbm.s104074";"27445511";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/jbm.s104074";"27445511";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2147/jbm.s104074";"27445511";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/jbm.s104074";"27445511";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2147/jbm.s104074";"27445511";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/jbm.s104074";"27445511";"methodology";"3";"";"Treatment name 1";"bay 81-8973 (recombinant factor viii)"
"10.2147/jbm.s104074";"27445511";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1;2"
"10.2147/jbm.s104074";"27445511";"methodology";"3";"";"Treatment name 2";"turoctocog alfa"
"10.2147/jbm.s104074";"27445511";"methodology";"3";"";"Study 'number(s)' for treatment 2";"5"
"10.2147/jbm.s104074";"27445511";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/jbm.s104074";"27445511";"methodology";"3";"";"Anchored comparison?";"No"
"10.2147/jbm.s104074";"27445511";"methodology";"3";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2147/jbm.s104074";"27445511";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2147/jbm.s104074";"27445511";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"annualized bleed rates for all bleeds (1-year)"
"10.2147/jbm.s104074";"27445511";"methodology";"3";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2147/jbm.s104074";"27445511";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/jbm.s104074";"27445511";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2147/jbm.s104074";"27445511";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/jbm.s104074";"27445511";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2147/jbm.s104074";"27445511";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/jbm.s104074";"27445511";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"107"
"10.2147/jbm.s104074";"27445511";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"121"
"10.2147/jbm.s104074";"27445511";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2147/jbm.s104074";"27445511";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/jbm.s104074";"27445511";"results";"1";"";"Number of covariates adjusted for/matched on";"2"
"10.2147/jbm.s104074";"27445511";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Race/ethnicity"
"10.2147/jbm.s104074";"27445511";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.2147/jbm.s104074";"27445511";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/jbm.s104074";"27445511";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.1"
"10.2147/jbm.s104074";"27445511";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-0.3;0.4]"
"10.2147/jbm.s104074";"27445511";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.1"
"10.2147/jbm.s104074";"27445511";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-0.3;0.4]"
"10.2147/jbm.s104074";"27445511";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"66"
"10.2147/jbm.s104074";"27445511";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"121"
"10.2147/jbm.s104074";"27445511";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2147/jbm.s104074";"27445511";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/jbm.s104074";"27445511";"results";"2";"";"Number of covariates adjusted for/matched on";"2"
"10.2147/jbm.s104074";"27445511";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Race/ethnicity"
"10.2147/jbm.s104074";"27445511";"results";"2";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.2147/jbm.s104074";"27445511";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/jbm.s104074";"27445511";"results";"2";"";"Primary outcome: unadjusted treatment effect";"-1.9"
"10.2147/jbm.s104074";"27445511";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.05"
"10.2147/jbm.s104074";"27445511";"results";"2";"";"Primary outcome: adjusted treatment effect";"-1.5"
"10.2147/jbm.s104074";"27445511";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.18"
"10.2147/jbm.s104074";"27445511";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"150"
"10.2147/jbm.s104074";"27445511";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"121"
"10.2147/jbm.s104074";"27445511";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2147/jbm.s104074";"27445511";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/jbm.s104074";"27445511";"results";"3";"";"Number of covariates adjusted for/matched on";"3"
"10.2147/jbm.s104074";"27445511";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Race/ethnicity, Other(s)"
"10.2147/jbm.s104074";"27445511";"results";"3";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.2147/jbm.s104074";"27445511";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/jbm.s104074";"27445511";"results";"3";"";"Primary outcome: unadjusted treatment effect";"-2.1"
"10.2147/jbm.s104074";"27445511";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.01"
"10.2147/jbm.s104074";"27445511";"results";"3";"";"Primary outcome: adjusted treatment effect";"-2.2"
"10.2147/jbm.s104074";"27445511";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.05"
"10.2147/jbm.s206806";"31417326";"general_information";"";"";"Medical Condition of Interest Name";"severe hemophilia a"
"10.2147/jbm.s206806";"31417326";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2147/jbm.s206806";"31417326";"general_information";"";"";"Countries of last author affiliations";"germany"
"10.2147/jbm.s206806";"31417326";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.2147/jbm.s206806";"31417326";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2147/jbm.s206806";"31417326";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2147/jbm.s206806";"31417326";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2147/jbm.s206806";"31417326";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2147/jbm.s206806";"31417326";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2147/jbm.s206806";"31417326";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2147/jbm.s206806";"31417326";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01580293"
"10.2147/jbm.s206806";"31417326";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s206806";"31417326";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2, 3"
"10.2147/jbm.s206806";"31417326";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.2147/jbm.s206806";"31417326";"study_information";"";"2";"Patient-level data used";"No"
"10.2147/jbm.s206806";"31417326";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2147/jbm.s206806";"31417326";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01181128"
"10.2147/jbm.s206806";"31417326";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s206806";"31417326";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/jbm.s206806";"31417326";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2147/jbm.s206806";"31417326";"study_information";"";"3";"Patient-level data used";"No"
"10.2147/jbm.s206806";"31417326";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2147/jbm.s206806";"31417326";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01736475"
"10.2147/jbm.s206806";"31417326";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s206806";"31417326";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/jbm.s206806";"31417326";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2147/jbm.s206806";"31417326";"study_information";"";"4";"Patient-level data used";"No"
"10.2147/jbm.s206806";"31417326";"study_information";"";"4";"Clinical Trial";"Yes"
"10.2147/jbm.s206806";"31417326";"study_information";"";"4";"Data source name (only if observational study or clinical trial without NCT)";"tarantino et al. (2004)"
"10.2147/jbm.s206806";"31417326";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.2147/jbm.s206806";"31417326";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00157157"
"10.2147/jbm.s206806";"31417326";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s206806";"31417326";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/jbm.s206806";"31417326";"study_information";"";"5";"Patient-level data used";"No"
"10.2147/jbm.s206806";"31417326";"study_information";"";"5";"Clinical Trial";"Yes"
"10.2147/jbm.s206806";"31417326";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00243386"
"10.2147/jbm.s206806";"31417326";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s206806";"31417326";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"4"
"10.2147/jbm.s206806";"31417326";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"1"
"10.2147/jbm.s206806";"31417326";"methodology";"1";"";"Treatment name 1";"bay 94-9027"
"10.2147/jbm.s206806";"31417326";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2147/jbm.s206806";"31417326";"methodology";"1";"";"Treatment name 2";"rfviiifc"
"10.2147/jbm.s206806";"31417326";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2147/jbm.s206806";"31417326";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/jbm.s206806";"31417326";"methodology";"1";"";"Anchored comparison?";"No"
"10.2147/jbm.s206806";"31417326";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2147/jbm.s206806";"31417326";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2147/jbm.s206806";"31417326";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"mean annualized bleeding rate"
"10.2147/jbm.s206806";"31417326";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2147/jbm.s206806";"31417326";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/jbm.s206806";"31417326";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2147/jbm.s206806";"31417326";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/jbm.s206806";"31417326";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2147/jbm.s206806";"31417326";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/jbm.s206806";"31417326";"methodology";"2";"";"Treatment name 1";"bay 94-9027"
"10.2147/jbm.s206806";"31417326";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.2147/jbm.s206806";"31417326";"methodology";"2";"";"Treatment name 2";"bax 855"
"10.2147/jbm.s206806";"31417326";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.2147/jbm.s206806";"31417326";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/jbm.s206806";"31417326";"methodology";"2";"";"Anchored comparison?";"No"
"10.2147/jbm.s206806";"31417326";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2147/jbm.s206806";"31417326";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2147/jbm.s206806";"31417326";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"annualized bleeding rate"
"10.2147/jbm.s206806";"31417326";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2147/jbm.s206806";"31417326";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/jbm.s206806";"31417326";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2147/jbm.s206806";"31417326";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/jbm.s206806";"31417326";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2147/jbm.s206806";"31417326";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/jbm.s206806";"31417326";"methodology";"3";"";"Treatment name 1";"bay 94-9027"
"10.2147/jbm.s206806";"31417326";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.2147/jbm.s206806";"31417326";"methodology";"3";"";"Treatment name 2";"rahf-pfm 2004"
"10.2147/jbm.s206806";"31417326";"methodology";"3";"";"Study 'number(s)' for treatment 2";"4"
"10.2147/jbm.s206806";"31417326";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/jbm.s206806";"31417326";"methodology";"3";"";"Anchored comparison?";"No"
"10.2147/jbm.s206806";"31417326";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2147/jbm.s206806";"31417326";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2147/jbm.s206806";"31417326";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"annualized bleeding rate"
"10.2147/jbm.s206806";"31417326";"methodology";"3";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2147/jbm.s206806";"31417326";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/jbm.s206806";"31417326";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2147/jbm.s206806";"31417326";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/jbm.s206806";"31417326";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2147/jbm.s206806";"31417326";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/jbm.s206806";"31417326";"methodology";"4";"";"Treatment name 1";"bay 94-9027"
"10.2147/jbm.s206806";"31417326";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1"
"10.2147/jbm.s206806";"31417326";"methodology";"4";"";"Treatment name 2";"rahf-pfm 2012"
"10.2147/jbm.s206806";"31417326";"methodology";"4";"";"Study 'number(s)' for treatment 2";"5"
"10.2147/jbm.s206806";"31417326";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/jbm.s206806";"31417326";"methodology";"4";"";"Anchored comparison?";"No"
"10.2147/jbm.s206806";"31417326";"methodology";"4";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2147/jbm.s206806";"31417326";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2147/jbm.s206806";"31417326";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"annualized bleeding rate"
"10.2147/jbm.s206806";"31417326";"methodology";"4";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2147/jbm.s206806";"31417326";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/jbm.s206806";"31417326";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2147/jbm.s206806";"31417326";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/jbm.s206806";"31417326";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2147/jbm.s206806";"31417326";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/jbm.s206806";"31417326";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"140"
"10.2147/jbm.s206806";"31417326";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"103"
"10.2147/jbm.s206806";"31417326";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"44.6"
"10.2147/jbm.s206806";"31417326";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2147/jbm.s206806";"31417326";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/jbm.s206806";"31417326";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.2147/jbm.s206806";"31417326";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/jbm.s206806";"31417326";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.17"
"10.2147/jbm.s206806";"31417326";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-1.35;1.70]"
"10.2147/jbm.s206806";"31417326";"results";"1";"";"Primary outcome: adjusted treatment effect";"-0.12"
"10.2147/jbm.s206806";"31417326";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-1.62;1.37]"
"10.2147/jbm.s206806";"31417326";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.2147/jbm.s206806";"31417326";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.2147/jbm.s206806";"31417326";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"101"
"10.2147/jbm.s206806";"31417326";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"104"
"10.2147/jbm.s206806";"31417326";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"78.3"
"10.2147/jbm.s206806";"31417326";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2147/jbm.s206806";"31417326";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/jbm.s206806";"31417326";"results";"2";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.2147/jbm.s206806";"31417326";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/jbm.s206806";"31417326";"results";"2";"";"Primary outcome: unadjusted treatment effect";"0.35"
"10.2147/jbm.s206806";"31417326";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-1.00;1.70]"
"10.2147/jbm.s206806";"31417326";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.25"
"10.2147/jbm.s206806";"31417326";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-1.19;1.70]"
"10.2147/jbm.s206806";"31417326";"results";"2";"";"Number of covariates adjusted for/matched on";"5"
"10.2147/jbm.s206806";"31417326";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.2147/jbm.s206806";"31417326";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"66"
"10.2147/jbm.s206806";"31417326";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"104"
"10.2147/jbm.s206806";"31417326";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"78.3"
"10.2147/jbm.s206806";"31417326";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2147/jbm.s206806";"31417326";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/jbm.s206806";"31417326";"results";"3";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.2147/jbm.s206806";"31417326";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/jbm.s206806";"31417326";"results";"3";"";"Primary outcome: unadjusted treatment effect";"-2.25"
"10.2147/jbm.s206806";"31417326";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-3.64;-0.85]"
"10.2147/jbm.s206806";"31417326";"results";"3";"";"Primary outcome: adjusted treatment effect";"-2.02"
"10.2147/jbm.s206806";"31417326";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-4.35;0.30]"
"10.2147/jbm.s206806";"31417326";"results";"3";"";"Number of covariates adjusted for/matched on";"3"
"10.2147/jbm.s206806";"31417326";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity"
"10.2147/jbm.s206806";"31417326";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"67"
"10.2147/jbm.s206806";"31417326";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"104"
"10.2147/jbm.s206806";"31417326";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"55.33"
"10.2147/jbm.s206806";"31417326";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2147/jbm.s206806";"31417326";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/jbm.s206806";"31417326";"results";"4";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.2147/jbm.s206806";"31417326";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/jbm.s206806";"31417326";"results";"4";"";"Primary outcome: unadjusted treatment effect";"0.03"
"10.2147/jbm.s206806";"31417326";"results";"4";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-0.32;0.37]"
"10.2147/jbm.s206806";"31417326";"results";"4";"";"Primary outcome: adjusted treatment effect";"0.07"
"10.2147/jbm.s206806";"31417326";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-0.32;0.46]"
"10.2147/jbm.s206806";"31417326";"results";"4";"";"Number of covariates adjusted for/matched on";"3"
"10.2147/jbm.s206806";"31417326";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity"
"10.2147/jbm.s288283";"33664606";"general_information";"";"";"Medical Condition of Interest Name";"hemophilia a without inhibitors"
"10.2147/jbm.s288283";"33664606";"general_information";"";"";"Countries of first author affiliations";"germany"
"10.2147/jbm.s288283";"33664606";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2147/jbm.s288283";"33664606";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.2147/jbm.s288283";"33664606";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2147/jbm.s288283";"33664606";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2147/jbm.s288283";"33664606";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2147/jbm.s288283";"33664606";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.2147/jbm.s288283";"33664606";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2147/jbm.s288283";"33664606";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2147/jbm.s288283";"33664606";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01181128"
"10.2147/jbm.s288283";"33664606";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s288283";"33664606";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/jbm.s288283";"33664606";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.2147/jbm.s288283";"33664606";"study_information";"";"2";"Patient-level data used";"No"
"10.2147/jbm.s288283";"33664606";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2147/jbm.s288283";"33664606";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02622321"
"10.2147/jbm.s288283";"33664606";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s288283";"33664606";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/jbm.s288283";"33664606";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.2147/jbm.s288283";"33664606";"study_information";"";"3";"Patient-level data used";"No"
"10.2147/jbm.s288283";"33664606";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2147/jbm.s288283";"33664606";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03020160"
"10.2147/jbm.s288283";"33664606";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s288283";"33664606";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/jbm.s288283";"33664606";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"1"
"10.2147/jbm.s288283";"33664606";"methodology";"1";"";"Treatment name 1";"rfviiifc"
"10.2147/jbm.s288283";"33664606";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2147/jbm.s288283";"33664606";"methodology";"1";"";"Treatment name 2";"emicizumab every week"
"10.2147/jbm.s288283";"33664606";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2147/jbm.s288283";"33664606";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/jbm.s288283";"33664606";"methodology";"1";"";"Anchored comparison?";"No"
"10.2147/jbm.s288283";"33664606";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2147/jbm.s288283";"33664606";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2147/jbm.s288283";"33664606";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"mean annualized bleeding rate"
"10.2147/jbm.s288283";"33664606";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2147/jbm.s288283";"33664606";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/jbm.s288283";"33664606";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2147/jbm.s288283";"33664606";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/jbm.s288283";"33664606";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.2147/jbm.s288283";"33664606";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/jbm.s288283";"33664606";"methodology";"2";"";"Treatment name 1";"rfviiifc"
"10.2147/jbm.s288283";"33664606";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.2147/jbm.s288283";"33664606";"methodology";"2";"";"Treatment name 2";"emicizumab every 2 weeks"
"10.2147/jbm.s288283";"33664606";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.2147/jbm.s288283";"33664606";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/jbm.s288283";"33664606";"methodology";"2";"";"Anchored comparison?";"No"
"10.2147/jbm.s288283";"33664606";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2147/jbm.s288283";"33664606";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2147/jbm.s288283";"33664606";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"mean annualized bleeding rate"
"10.2147/jbm.s288283";"33664606";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2147/jbm.s288283";"33664606";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/jbm.s288283";"33664606";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2147/jbm.s288283";"33664606";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/jbm.s288283";"33664606";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.2147/jbm.s288283";"33664606";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/jbm.s288283";"33664606";"methodology";"3";"";"Treatment name 1";"rfviiifc"
"10.2147/jbm.s288283";"33664606";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.2147/jbm.s288283";"33664606";"methodology";"3";"";"Treatment name 2";"emicizumab every 4 weeks"
"10.2147/jbm.s288283";"33664606";"methodology";"3";"";"Study 'number(s)' for treatment 2";"2"
"10.2147/jbm.s288283";"33664606";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/jbm.s288283";"33664606";"methodology";"3";"";"Anchored comparison?";"No"
"10.2147/jbm.s288283";"33664606";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2147/jbm.s288283";"33664606";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2147/jbm.s288283";"33664606";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"mean annualized bleeding rate"
"10.2147/jbm.s288283";"33664606";"methodology";"3";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2147/jbm.s288283";"33664606";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/jbm.s288283";"33664606";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2147/jbm.s288283";"33664606";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/jbm.s288283";"33664606";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.2147/jbm.s288283";"33664606";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/jbm.s288283";"33664606";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"99"
"10.2147/jbm.s288283";"33664606";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"117"
"10.2147/jbm.s288283";"33664606";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"94"
"10.2147/jbm.s288283";"33664606";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2147/jbm.s288283";"33664606";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/jbm.s288283";"33664606";"results";"1";"";"Number of covariates adjusted for/matched on";"5"
"10.2147/jbm.s288283";"33664606";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest"
"10.2147/jbm.s288283";"33664606";"results";"1";"";"Primary outcome: treatment effect contrast";"Incidence Rate Ratio"
"10.2147/jbm.s288283";"33664606";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/jbm.s288283";"33664606";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.93"
"10.2147/jbm.s288283";"33664606";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.63;1.39]"
"10.2147/jbm.s288283";"33664606";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"35"
"10.2147/jbm.s288283";"33664606";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"117"
"10.2147/jbm.s288283";"33664606";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"19"
"10.2147/jbm.s288283";"33664606";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2147/jbm.s288283";"33664606";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/jbm.s288283";"33664606";"results";"2";"";"Number of covariates adjusted for/matched on";"5"
"10.2147/jbm.s288283";"33664606";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest"
"10.2147/jbm.s288283";"33664606";"results";"2";"";"Primary outcome: treatment effect contrast";"Incidence Rate Ratio"
"10.2147/jbm.s288283";"33664606";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/jbm.s288283";"33664606";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.57"
"10.2147/jbm.s288283";"33664606";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.28;1.17]"
"10.2147/jbm.s288283";"33664606";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"41"
"10.2147/jbm.s288283";"33664606";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"117"
"10.2147/jbm.s288283";"33664606";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"36"
"10.2147/jbm.s288283";"33664606";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2147/jbm.s288283";"33664606";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/jbm.s288283";"33664606";"results";"3";"";"Number of covariates adjusted for/matched on";"5"
"10.2147/jbm.s288283";"33664606";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest"
"10.2147/jbm.s288283";"33664606";"results";"3";"";"Primary outcome: treatment effect contrast";"Incidence Rate Ratio"
"10.2147/jbm.s288283";"33664606";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/jbm.s288283";"33664606";"results";"3";"";"Primary outcome: adjusted treatment effect";"0.61"
"10.2147/jbm.s288283";"33664606";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.37;1.02]"
"10.2147/jbm.s312885";"34285621";"general_information";"";"";"Medical Condition of Interest Name";"hemophilia b"
"10.2147/jbm.s312885";"34285621";"general_information";"";"";"Countries of first author affiliations";"sweden"
"10.2147/jbm.s312885";"34285621";"general_information";"";"";"Countries of last author affiliations";"germany"
"10.2147/jbm.s312885";"34285621";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.2147/jbm.s312885";"34285621";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2147/jbm.s312885";"34285621";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2147/jbm.s312885";"34285621";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2147/jbm.s312885";"34285621";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.2147/jbm.s312885";"34285621";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2147/jbm.s312885";"34285621";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2147/jbm.s312885";"34285621";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01027364"
"10.2147/jbm.s312885";"34285621";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s312885";"34285621";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/jbm.s312885";"34285621";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.2147/jbm.s312885";"34285621";"study_information";"";"2";"Patient-level data used";"No"
"10.2147/jbm.s312885";"34285621";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2147/jbm.s312885";"34285621";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01496274"
"10.2147/jbm.s312885";"34285621";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s312885";"34285621";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2, 3"
"10.2147/jbm.s312885";"34285621";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.2147/jbm.s312885";"34285621";"methodology";"1";"";"Treatment name 1";"prior prophylaxis rfixfc"
"10.2147/jbm.s312885";"34285621";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2147/jbm.s312885";"34285621";"methodology";"1";"";"Treatment name 2";"prior prophylaxis rix-fp"
"10.2147/jbm.s312885";"34285621";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2147/jbm.s312885";"34285621";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/jbm.s312885";"34285621";"methodology";"1";"";"Anchored comparison?";"No"
"10.2147/jbm.s312885";"34285621";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2147/jbm.s312885";"34285621";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2147/jbm.s312885";"34285621";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"annualized bleeding rate"
"10.2147/jbm.s312885";"34285621";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2147/jbm.s312885";"34285621";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/jbm.s312885";"34285621";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2147/jbm.s312885";"34285621";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/jbm.s312885";"34285621";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.2147/jbm.s312885";"34285621";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/jbm.s312885";"34285621";"methodology";"2";"";"Treatment name 1";"prior episodic treatment rfixfc"
"10.2147/jbm.s312885";"34285621";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.2147/jbm.s312885";"34285621";"methodology";"2";"";"Treatment name 2";"prior episodic treatment rix-fp"
"10.2147/jbm.s312885";"34285621";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.2147/jbm.s312885";"34285621";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/jbm.s312885";"34285621";"methodology";"2";"";"Anchored comparison?";"No"
"10.2147/jbm.s312885";"34285621";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2147/jbm.s312885";"34285621";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2147/jbm.s312885";"34285621";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"annualized bleeding rate"
"10.2147/jbm.s312885";"34285621";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2147/jbm.s312885";"34285621";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/jbm.s312885";"34285621";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2147/jbm.s312885";"34285621";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/jbm.s312885";"34285621";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.2147/jbm.s312885";"34285621";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/jbm.s312885";"34285621";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"40"
"10.2147/jbm.s312885";"34285621";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"45"
"10.2147/jbm.s312885";"34285621";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"26"
"10.2147/jbm.s312885";"34285621";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2147/jbm.s312885";"34285621";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/jbm.s312885";"34285621";"results";"1";"";"Number of covariates adjusted for/matched on";"4"
"10.2147/jbm.s312885";"34285621";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)"
"10.2147/jbm.s312885";"34285621";"results";"1";"";"Primary outcome: treatment effect contrast";"Incidence Rate Ratio"
"10.2147/jbm.s312885";"34285621";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/jbm.s312885";"34285621";"results";"1";"";"Primary outcome: adjusted treatment effect";"1.18"
"10.2147/jbm.s312885";"34285621";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.67;2.10]"
"10.2147/jbm.s312885";"34285621";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"19"
"10.2147/jbm.s312885";"34285621";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"42"
"10.2147/jbm.s312885";"34285621";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"10"
"10.2147/jbm.s312885";"34285621";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2147/jbm.s312885";"34285621";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/jbm.s312885";"34285621";"results";"2";"";"Number of covariates adjusted for/matched on";"4"
"10.2147/jbm.s312885";"34285621";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)"
"10.2147/jbm.s312885";"34285621";"results";"2";"";"Primary outcome: treatment effect contrast";"Incidence Rate Ratio"
"10.2147/jbm.s312885";"34285621";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/jbm.s312885";"34285621";"results";"2";"";"Primary outcome: adjusted treatment effect";"1.01"
"10.2147/jbm.s312885";"34285621";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.40;2.57]"
"10.2147/jbm.s321288";"34754257";"general_information";"";"";"Medical Condition of Interest Name";"severe hemophilia a"
"10.2147/jbm.s321288";"34754257";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2147/jbm.s321288";"34754257";"general_information";"";"";"Countries of last author affiliations";"italy"
"10.2147/jbm.s321288";"34754257";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.2147/jbm.s321288";"34754257";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2147/jbm.s321288";"34754257";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2147/jbm.s321288";"34754257";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2147/jbm.s321288";"34754257";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2147/jbm.s321288";"34754257";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2147/jbm.s321288";"34754257";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2147/jbm.s321288";"34754257";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01580293"
"10.2147/jbm.s321288";"34754257";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s321288";"34754257";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2, 3"
"10.2147/jbm.s321288";"34754257";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.2147/jbm.s321288";"34754257";"study_information";"";"2";"Patient-level data used";"No"
"10.2147/jbm.s321288";"34754257";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2147/jbm.s321288";"34754257";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01480180"
"10.2147/jbm.s321288";"34754257";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/jbm.s321288";"34754257";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/jbm.s321288";"34754257";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.2147/jbm.s321288";"34754257";"methodology";"1";"";"Treatment name 1";"damoctocog alfa pegol (bay 94-9027)"
"10.2147/jbm.s321288";"34754257";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2147/jbm.s321288";"34754257";"methodology";"1";"";"Treatment name 2";"turoctocog alfa pegol (n8-gp)"
"10.2147/jbm.s321288";"34754257";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2147/jbm.s321288";"34754257";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/jbm.s321288";"34754257";"methodology";"1";"";"Anchored comparison?";"No"
"10.2147/jbm.s321288";"34754257";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2147/jbm.s321288";"34754257";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2147/jbm.s321288";"34754257";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"mean annualized bleeding rate"
"10.2147/jbm.s321288";"34754257";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2147/jbm.s321288";"34754257";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/jbm.s321288";"34754257";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2147/jbm.s321288";"34754257";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/jbm.s321288";"34754257";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2147/jbm.s321288";"34754257";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/jbm.s321288";"34754257";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"175"
"10.2147/jbm.s321288";"34754257";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"102"
"10.2147/jbm.s321288";"34754257";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"61.94"
"10.2147/jbm.s321288";"34754257";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2147/jbm.s321288";"34754257";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/jbm.s321288";"34754257";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.2147/jbm.s321288";"34754257";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.2147/jbm.s321288";"34754257";"results";"1";"";"Primary outcome: treatment effect contrast";"Incidence Rate Ratio"
"10.2147/jbm.s321288";"34754257";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/jbm.s321288";"34754257";"results";"1";"";"Primary outcome: unadjusted treatment effect";"1.1"
"10.2147/jbm.s321288";"34754257";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.4492"
"10.2147/jbm.s321288";"34754257";"results";"1";"";"Primary outcome: adjusted treatment effect";"1.11"
"10.2147/jbm.s321288";"34754257";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.449"
"10.2147/ptt.s326121";"34765537";"general_information";"";"";"Medical Condition of Interest Name";"moderate-to-severe plaque psoriasis"
"10.2147/ptt.s326121";"34765537";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.2147/ptt.s326121";"34765537";"general_information";"";"";"Countries of last author affiliations";"germany"
"10.2147/ptt.s326121";"34765537";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.2147/ptt.s326121";"34765537";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2147/ptt.s326121";"34765537";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2147/ptt.s326121";"34765537";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2147/ptt.s326121";"34765537";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.2147/ptt.s326121";"34765537";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2147/ptt.s326121";"34765537";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2147/ptt.s326121";"34765537";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01708603"
"10.2147/ptt.s326121";"34765537";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/ptt.s326121";"34765537";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/ptt.s326121";"34765537";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2147/ptt.s326121";"34765537";"study_information";"";"2";"Patient-level data used";"Yes"
"10.2147/ptt.s326121";"34765537";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2147/ptt.s326121";"34765537";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01708629"
"10.2147/ptt.s326121";"34765537";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/ptt.s326121";"34765537";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/ptt.s326121";"34765537";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2147/ptt.s326121";"34765537";"study_information";"";"3";"Patient-level data used";"No"
"10.2147/ptt.s326121";"34765537";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2147/ptt.s326121";"34765537";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02203032"
"10.2147/ptt.s326121";"34765537";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2147/ptt.s326121";"34765537";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.2147/ptt.s326121";"34765537";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2147/ptt.s326121";"34765537";"methodology";"1";"";"Treatment name 1";"brodalumab"
"10.2147/ptt.s326121";"34765537";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.2147/ptt.s326121";"34765537";"methodology";"1";"";"Treatment name 2";"guselkumab"
"10.2147/ptt.s326121";"34765537";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3"
"10.2147/ptt.s326121";"34765537";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2147/ptt.s326121";"34765537";"methodology";"1";"";"Anchored comparison?";"No"
"10.2147/ptt.s326121";"34765537";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2147/ptt.s326121";"34765537";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2147/ptt.s326121";"34765537";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"psoriasis area and severity index 90 rate"
"10.2147/ptt.s326121";"34765537";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2147/ptt.s326121";"34765537";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2147/ptt.s326121";"34765537";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2147/ptt.s326121";"34765537";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2147/ptt.s326121";"34765537";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2147/ptt.s326121";"34765537";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2147/ptt.s326121";"34765537";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"135"
"10.2147/ptt.s326121";"34765537";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"121"
"10.2147/ptt.s326121";"34765537";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"90"
"10.2147/ptt.s326121";"34765537";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2147/ptt.s326121";"34765537";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2147/ptt.s326121";"34765537";"results";"1";"";"Number of covariates adjusted for/matched on";"11"
"10.2147/ptt.s326121";"34765537";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.2147/ptt.s326121";"34765537";"results";"1";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.2147/ptt.s326121";"34765537";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2147/ptt.s326121";"34765537";"results";"1";"";"Primary outcome: adjusted treatment effect";"14.6"
"10.2147/ptt.s326121";"34765537";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.002"
"10.2165/11592490-000000000-00000";"21819162";"general_information";"";"";"Medical Condition of Interest Name";"type 2 diabetes mellitus"
"10.2165/11592490-000000000-00000";"21819162";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2165/11592490-000000000-00000";"21819162";"general_information";"";"";"Countries of last author affiliations";"switzerland"
"10.2165/11592490-000000000-00000";"21819162";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.2165/11592490-000000000-00000";"21819162";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2165/11592490-000000000-00000";"21819162";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00368134"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"japan"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"2";"Patient-level data used";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00351832"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"japan"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"3";"Patient-level data used";"No"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00411554"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"japan"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"4";"Patient-level data used";"No"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"4";"Clinical Trial";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00127192"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"japan"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"2"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"5";"Patient-level data used";"No"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"5";"Clinical Trial";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"japan"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"2"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2165/11592490-000000000-00000";"21819162";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00371007"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"1";"";"Treatment name 1";"vildagliptin"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"1";"";"Treatment name 2";"sitagliptin 50 mg"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"hba1c change from baseline to week 12"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"2";"";"Treatment name 1";"vildagliptin"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"2";"";"Study 'number(s)' for treatment 1";"2"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"2";"";"Treatment name 2";"sitagliptin 50 mg"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"2";"";"Study 'number(s)' for treatment 2";"4"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"hba1c change from baseline to week 12"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"3";"";"Treatment name 1";"vildagliptin"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"3";"";"Study 'number(s)' for treatment 1";"2"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"3";"";"Treatment name 2";"sitagliptin 100 mg"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"3";"";"Study 'number(s)' for treatment 2";"4.5"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"3";"";"Anchored comparison?";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"3";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"hba1c change from baseline to week 12"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"3";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2165/11592490-000000000-00000";"21819162";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"163"
"10.2165/11592490-000000000-00000";"21819162";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"156"
"10.2165/11592490-000000000-00000";"21819162";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2165/11592490-000000000-00000";"21819162";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.2165/11592490-000000000-00000";"21819162";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.2165/11592490-000000000-00000";"21819162";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.2165/11592490-000000000-00000";"21819162";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2165/11592490-000000000-00000";"21819162";"results";"1";"";"Primary outcome: unadjusted treatment effect";"-0.17"
"10.2165/11592490-000000000-00000";"21819162";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.024"
"10.2165/11592490-000000000-00000";"21819162";"results";"1";"";"Primary outcome: adjusted treatment effect";"-0.2"
"10.2165/11592490-000000000-00000";"21819162";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.009"
"10.2165/11592490-000000000-00000";"21819162";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"188"
"10.2165/11592490-000000000-00000";"21819162";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"192"
"10.2165/11592490-000000000-00000";"21819162";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"72"
"10.2165/11592490-000000000-00000";"21819162";"results";"2";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"73"
"10.2165/11592490-000000000-00000";"21819162";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"76"
"10.2165/11592490-000000000-00000";"21819162";"results";"2";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"72"
"10.2165/11592490-000000000-00000";"21819162";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2165/11592490-000000000-00000";"21819162";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"results";"2";"";"Number of covariates adjusted for/matched on";"6"
"10.2165/11592490-000000000-00000";"21819162";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.2165/11592490-000000000-00000";"21819162";"results";"2";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.2165/11592490-000000000-00000";"21819162";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2165/11592490-000000000-00000";"21819162";"results";"2";"";"Primary outcome: unadjusted treatment effect";"-0.2"
"10.2165/11592490-000000000-00000";"21819162";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.133"
"10.2165/11592490-000000000-00000";"21819162";"results";"2";"";"Primary outcome: adjusted treatment effect";"-0.56"
"10.2165/11592490-000000000-00000";"21819162";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.2165/11592490-000000000-00000";"21819162";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"145"
"10.2165/11592490-000000000-00000";"21819162";"results";"3";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"149"
"10.2165/11592490-000000000-00000";"21819162";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"76"
"10.2165/11592490-000000000-00000";"21819162";"results";"3";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"72"
"10.2165/11592490-000000000-00000";"21819162";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2165/11592490-000000000-00000";"21819162";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2165/11592490-000000000-00000";"21819162";"results";"3";"";"Number of covariates adjusted for/matched on";"6"
"10.2165/11592490-000000000-00000";"21819162";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.2165/11592490-000000000-00000";"21819162";"results";"3";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.2165/11592490-000000000-00000";"21819162";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2165/11592490-000000000-00000";"21819162";"results";"3";"";"Primary outcome: unadjusted treatment effect";"-0.19"
"10.2165/11592490-000000000-00000";"21819162";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.113"
"10.2165/11592490-000000000-00000";"21819162";"results";"3";"";"Primary outcome: adjusted treatment effect";"-0.35"
"10.2165/11592490-000000000-00000";"21819162";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.013"
"10.2217/cer-2016-0085";"28350241";"general_information";"";"";"Medical Condition of Interest Name";"relapsing–remitting multiple sclerosis"
"10.2217/cer-2016-0085";"28350241";"general_information";"";"";"Countries of first author affiliations";"switzerland"
"10.2217/cer-2016-0085";"28350241";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2217/cer-2016-0085";"28350241";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry"
"10.2217/cer-2016-0085";"28350241";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/cer-2016-0085";"28350241";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/cer-2016-0085";"28350241";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/cer-2016-0085";"28350241";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00420212"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"2";"Patient-level data used";"Yes"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00451451"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"3";"Patient-level data used";"No"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00004814"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"4";"Patient-level data used";"No"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"4";"Clinical Trial";"Yes"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"4";"Data source name (only if observational study or clinical trial without NCT)";"eur/can study"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"5";"Patient-level data used";"No"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"5";"Clinical Trial";"Yes"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00099502"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2016-0085";"28350241";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2016-0085";"28350241";"methodology";"1";"";"Treatment name 1";"dimethyl fumarate"
"10.2217/cer-2016-0085";"28350241";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.2217/cer-2016-0085";"28350241";"methodology";"1";"";"Treatment name 2";"glatiramer acetate"
"10.2217/cer-2016-0085";"28350241";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3;4"
"10.2217/cer-2016-0085";"28350241";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2016-0085";"28350241";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.2217/cer-2016-0085";"28350241";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer-2016-0085";"28350241";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2016-0085";"28350241";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"annualized relapse rate"
"10.2217/cer-2016-0085";"28350241";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2217/cer-2016-0085";"28350241";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer-2016-0085";"28350241";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer-2016-0085";"28350241";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer-2016-0085";"28350241";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2016-0085";"28350241";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2016-0085";"28350241";"methodology";"2";"";"Treatment name 1";"dimethyl fumarate"
"10.2217/cer-2016-0085";"28350241";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1;2"
"10.2217/cer-2016-0085";"28350241";"methodology";"2";"";"Treatment name 2";"glatiramer acetate"
"10.2217/cer-2016-0085";"28350241";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3;4"
"10.2217/cer-2016-0085";"28350241";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2016-0085";"28350241";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.2217/cer-2016-0085";"28350241";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer-2016-0085";"28350241";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2016-0085";"28350241";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"annualized relapse rate"
"10.2217/cer-2016-0085";"28350241";"methodology";"2";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2217/cer-2016-0085";"28350241";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer-2016-0085";"28350241";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer-2016-0085";"28350241";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer-2016-0085";"28350241";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2016-0085";"28350241";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2016-0085";"28350241";"methodology";"3";"";"Treatment name 1";"dimethyl fumarate"
"10.2217/cer-2016-0085";"28350241";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1;2"
"10.2217/cer-2016-0085";"28350241";"methodology";"3";"";"Treatment name 2";"glatiramer acetate"
"10.2217/cer-2016-0085";"28350241";"methodology";"3";"";"Study 'number(s)' for treatment 2";"5"
"10.2217/cer-2016-0085";"28350241";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2016-0085";"28350241";"methodology";"3";"";"Anchored comparison?";"No"
"10.2217/cer-2016-0085";"28350241";"methodology";"3";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer-2016-0085";"28350241";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2016-0085";"28350241";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"12-week confirmed disability progression"
"10.2217/cer-2016-0085";"28350241";"methodology";"3";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer-2016-0085";"28350241";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer-2016-0085";"28350241";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer-2016-0085";"28350241";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer-2016-0085";"28350241";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2016-0085";"28350241";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2016-0085";"28350241";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2016-0085";"28350241";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2016-0085";"28350241";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.2217/cer-2016-0085";"28350241";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest"
"10.2217/cer-2016-0085";"28350241";"results";"1";"";"Primary outcome: treatment effect contrast";"RR"
"10.2217/cer-2016-0085";"28350241";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2016-0085";"28350241";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.77"
"10.2217/cer-2016-0085";"28350241";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.027"
"10.2217/cer-2016-0085";"28350241";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.76"
"10.2217/cer-2016-0085";"28350241";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.047"
"10.2217/cer-2016-0085";"28350241";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2016-0085";"28350241";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2016-0085";"28350241";"results";"2";"";"Number of covariates adjusted for/matched on";"5"
"10.2217/cer-2016-0085";"28350241";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.2217/cer-2016-0085";"28350241";"results";"2";"";"Primary outcome: treatment effect contrast";"RR"
"10.2217/cer-2016-0085";"28350241";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2016-0085";"28350241";"results";"2";"";"Primary outcome: unadjusted treatment effect";"0.77"
"10.2217/cer-2016-0085";"28350241";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.027"
"10.2217/cer-2016-0085";"28350241";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.76"
"10.2217/cer-2016-0085";"28350241";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.047"
"10.2217/cer-2016-0085";"28350241";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2016-0085";"28350241";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2016-0085";"28350241";"results";"3";"";"Number of covariates adjusted for/matched on";"7"
"10.2217/cer-2016-0085";"28350241";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest"
"10.2217/cer-2016-0085";"28350241";"results";"3";"";"Primary outcome: treatment effect contrast";"RR"
"10.2217/cer-2016-0085";"28350241";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2016-0085";"28350241";"results";"3";"";"Primary outcome: unadjusted treatment effect";"0.73"
"10.2217/cer-2016-0085";"28350241";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.015"
"10.2217/cer-2016-0085";"28350241";"results";"3";"";"Primary outcome: adjusted treatment effect";"0.51"
"10.2217/cer-2016-0085";"28350241";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.2217/cer-2018-0020";"30168349";"general_information";"";"";"Medical Condition of Interest Name";"advanced pancreatic neuroendocrine tumor"
"10.2217/cer-2018-0020";"30168349";"general_information";"";"";"Countries of first author affiliations";"canada"
"10.2217/cer-2018-0020";"30168349";"general_information";"";"";"Countries of last author affiliations";"uk"
"10.2217/cer-2018-0020";"30168349";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/cer-2018-0020";"30168349";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/cer-2018-0020";"30168349";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/cer-2018-0020";"30168349";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/cer-2018-0020";"30168349";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.2217/cer-2018-0020";"30168349";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/cer-2018-0020";"30168349";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/cer-2018-0020";"30168349";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00428597"
"10.2217/cer-2018-0020";"30168349";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2018-0020";"30168349";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2018-0020";"30168349";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2018-0020";"30168349";"study_information";"";"2";"Patient-level data used";"No"
"10.2217/cer-2018-0020";"30168349";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/cer-2018-0020";"30168349";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00510068"
"10.2217/cer-2018-0020";"30168349";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2018-0020";"30168349";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2018-0020";"30168349";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2018-0020";"30168349";"methodology";"1";"";"Treatment name 1";"sunitinib"
"10.2217/cer-2018-0020";"30168349";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2018-0020";"30168349";"methodology";"1";"";"Treatment name 2";"everolimus"
"10.2217/cer-2018-0020";"30168349";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2217/cer-2018-0020";"30168349";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2018-0020";"30168349";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.2217/cer-2018-0020";"30168349";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2018-0020";"30168349";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer-2018-0020";"30168349";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.2217/cer-2018-0020";"30168349";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2018-0020";"30168349";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer-2018-0020";"30168349";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer-2018-0020";"30168349";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer-2018-0020";"30168349";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2018-0020";"30168349";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2018-0020";"30168349";"methodology";"2";"";"Treatment name 1";"sunitinib"
"10.2217/cer-2018-0020";"30168349";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2018-0020";"30168349";"methodology";"2";"";"Treatment name 2";"everolimus"
"10.2217/cer-2018-0020";"30168349";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.2217/cer-2018-0020";"30168349";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2018-0020";"30168349";"methodology";"2";"";"Anchored comparison?";"No"
"10.2217/cer-2018-0020";"30168349";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2018-0020";"30168349";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer-2018-0020";"30168349";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/cer-2018-0020";"30168349";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2018-0020";"30168349";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer-2018-0020";"30168349";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer-2018-0020";"30168349";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer-2018-0020";"30168349";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2018-0020";"30168349";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2018-0020";"30168349";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"207"
"10.2217/cer-2018-0020";"30168349";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"203"
"10.2217/cer-2018-0020";"30168349";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"86"
"10.2217/cer-2018-0020";"30168349";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"85"
"10.2217/cer-2018-0020";"30168349";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"43"
"10.2217/cer-2018-0020";"30168349";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"31"
"10.2217/cer-2018-0020";"30168349";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2018-0020";"30168349";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2018-0020";"30168349";"results";"1";"";"Number of covariates adjusted for/matched on";"11"
"10.2217/cer-2018-0020";"30168349";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)"
"10.2217/cer-2018-0020";"30168349";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2018-0020";"30168349";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2018-0020";"30168349";"results";"1";"";"Primary outcome: unadjusted treatment effect";"1.2"
"10.2217/cer-2018-0020";"30168349";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.72;2.01]"
"10.2217/cer-2018-0020";"30168349";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.85"
"10.2217/cer-2018-0020";"30168349";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.39;1.89]"
"10.2217/cer-2018-0020";"30168349";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"207"
"10.2217/cer-2018-0020";"30168349";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"86"
"10.2217/cer-2018-0020";"30168349";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2018-0020";"30168349";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2018-0020";"30168349";"results";"2";"";"Number of covariates adjusted for/matched on";"11"
"10.2217/cer-2018-0020";"30168349";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)"
"10.2217/cer-2018-0020";"30168349";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2018-0020";"30168349";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2018-0020";"30168349";"results";"2";"";"Primary outcome: unadjusted treatment effect";"1.03"
"10.2217/cer-2018-0020";"30168349";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.75;1.42]"
"10.2217/cer-2018-0020";"30168349";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.82"
"10.2217/cer-2018-0020";"30168349";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.53;1.27]"
"10.2217/cer-2018-0020";"30168349";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"43"
"10.2217/cer-2018-0141";"30806520";"general_information";"";"";"Medical Condition of Interest Name";"psoriatic arthritis"
"10.2217/cer-2018-0141";"30806520";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2217/cer-2018-0141";"30806520";"general_information";"";"";"Countries of last author affiliations";"uk"
"10.2217/cer-2018-0141";"30806520";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/cer-2018-0141";"30806520";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/cer-2018-0141";"30806520";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/cer-2018-0141";"30806520";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/cer-2018-0141";"30806520";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01752634"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"2";"Patient-level data used";"Yes"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01989468"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"3";"Patient-level data used";"No"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00051623"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2018-0141";"30806520";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.2217/cer-2018-0141";"30806520";"methodology";"1";"";"Treatment name 1";"secukinumab 150mg"
"10.2217/cer-2018-0141";"30806520";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.2217/cer-2018-0141";"30806520";"methodology";"1";"";"Treatment name 2";"infliximab"
"10.2217/cer-2018-0141";"30806520";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3"
"10.2217/cer-2018-0141";"30806520";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2018-0141";"30806520";"methodology";"1";"";"Anchored comparison?";"No"
"10.2217/cer-2018-0141";"30806520";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer-2018-0141";"30806520";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2018-0141";"30806520";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"american college of rheumatology (acr) responses rate at week 24"
"10.2217/cer-2018-0141";"30806520";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer-2018-0141";"30806520";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer-2018-0141";"30806520";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/cer-2018-0141";"30806520";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/cer-2018-0141";"30806520";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2018-0141";"30806520";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2018-0141";"30806520";"methodology";"2";"";"Treatment name 1";"secukinumab 300mg"
"10.2217/cer-2018-0141";"30806520";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1;2"
"10.2217/cer-2018-0141";"30806520";"methodology";"2";"";"Treatment name 2";"infliximab"
"10.2217/cer-2018-0141";"30806520";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.2217/cer-2018-0141";"30806520";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2018-0141";"30806520";"methodology";"2";"";"Anchored comparison?";"No"
"10.2217/cer-2018-0141";"30806520";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer-2018-0141";"30806520";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2018-0141";"30806520";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"american college of rheumatology (acr) responses at week 54"
"10.2217/cer-2018-0141";"30806520";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer-2018-0141";"30806520";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer-2018-0141";"30806520";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/cer-2018-0141";"30806520";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/cer-2018-0141";"30806520";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2018-0141";"30806520";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2018-0141";"30806520";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"100"
"10.2217/cer-2018-0141";"30806520";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"84"
"10.2217/cer-2018-0141";"30806520";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2018-0141";"30806520";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2018-0141";"30806520";"results";"1";"";"Number of covariates adjusted for/matched on";"11"
"10.2217/cer-2018-0141";"30806520";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.2217/cer-2018-0141";"30806520";"results";"1";"";"Primary outcome: treatment effect contrast";"OR"
"10.2217/cer-2018-0141";"30806520";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2018-0141";"30806520";"results";"1";"";"Primary outcome: adjusted treatment effect";"2.31"
"10.2217/cer-2018-0141";"30806520";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.008"
"10.2217/cer-2018-0141";"30806520";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"238"
"10.2217/cer-2018-0141";"30806520";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"100"
"10.2217/cer-2018-0141";"30806520";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"70"
"10.2217/cer-2018-0141";"30806520";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2018-0141";"30806520";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2018-0141";"30806520";"results";"2";"";"Number of covariates adjusted for/matched on";"11"
"10.2217/cer-2018-0141";"30806520";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.2217/cer-2018-0141";"30806520";"results";"2";"";"Primary outcome: treatment effect contrast";"OR"
"10.2217/cer-2018-0141";"30806520";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2018-0141";"30806520";"results";"2";"";"Primary outcome: adjusted treatment effect";"2.72"
"10.2217/cer-2018-0141";"30806520";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.006"
"10.2217/cer-2018-0141";"30806520";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"239"
"10.2217/cer-2019-0145";"31872771";"general_information";"";"";"Medical Condition of Interest Name";"10.2217/cer-2019-0145"
"10.2217/cer-2019-0145";"31872771";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.2217/cer-2019-0145";"31872771";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2217/cer-2019-0145";"31872771";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/cer-2019-0145";"31872771";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/cer-2019-0145";"31872771";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/cer-2019-0145";"31872771";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/cer-2019-0145";"31872771";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.2217/cer-2019-0145";"31872771";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/cer-2019-0145";"31872771";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/cer-2019-0145";"31872771";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01928394"
"10.2217/cer-2019-0145";"31872771";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2019-0145";"31872771";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.2217/cer-2019-0145";"31872771";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer-2019-0145";"31872771";"study_information";"";"2";"Patient-level data used";"No"
"10.2217/cer-2019-0145";"31872771";"study_information";"";"2";"Clinical Trial";"No"
"10.2217/cer-2019-0145";"31872771";"study_information";"";"2";"Data source name (only if observational study or clinical trial without NCT)";"flatiron health’s electronic health record database"
"10.2217/cer-2019-0145";"31872771";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.2217/cer-2019-0145";"31872771";"methodology";"1";"";"Treatment name 1";"nivolumab"
"10.2217/cer-2019-0145";"31872771";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2019-0145";"31872771";"methodology";"1";"";"Treatment name 2";"routine clinical practice"
"10.2217/cer-2019-0145";"31872771";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2217/cer-2019-0145";"31872771";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2217/cer-2019-0145";"31872771";"methodology";"1";"";"Anchored comparison?";"No"
"10.2217/cer-2019-0145";"31872771";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2019-0145";"31872771";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer-2019-0145";"31872771";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"all-cause mortality"
"10.2217/cer-2019-0145";"31872771";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2019-0145";"31872771";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/cer-2019-0145";"31872771";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/cer-2019-0145";"31872771";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/cer-2019-0145";"31872771";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.2217/cer-2019-0145";"31872771";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2019-0145";"31872771";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"34"
"10.2217/cer-2019-0145";"31872771";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"42"
"10.2217/cer-2019-0145";"31872771";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2019-0145";"31872771";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.2217/cer-2019-0145";"31872771";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/cer-2019-0145";"31872771";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2019-0145";"31872771";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2019-0145";"31872771";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.5"
"10.2217/cer-2019-0145";"31872771";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.36;0.68]"
"10.2217/cer-2019-0145";"31872771";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"42"
"10.2217/cer-2019-0145";"31872771";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.46"
"10.2217/cer-2019-0145";"31872771";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.36;0.59]"
"10.2217/cer-2019-0169";"31948278";"general_information";"";"";"Medical Condition of Interest Name";"relapsing multiple sclerosis"
"10.2217/cer-2019-0169";"31948278";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2217/cer-2019-0169";"31948278";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2217/cer-2019-0169";"31948278";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/cer-2019-0169";"31948278";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/cer-2019-0169";"31948278";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/cer-2019-0169";"31948278";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/cer-2019-0169";"31948278";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02047734"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"2";"Patient-level data used";"Yes"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02294058"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"3";"Patient-level data used";"No"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00340834"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"4";"Patient-level data used";"No"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"4";"Clinical Trial";"Yes"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00289978"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"5";"Patient-level data used";"No"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"5";"Clinical Trial";"Yes"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00355134"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2019-0169";"31948278";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2019-0169";"31948278";"methodology";"1";"";"Treatment name 1";"ozanimod"
"10.2217/cer-2019-0169";"31948278";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.2217/cer-2019-0169";"31948278";"methodology";"1";"";"Treatment name 2";"fingolimod"
"10.2217/cer-2019-0169";"31948278";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3;4;5"
"10.2217/cer-2019-0169";"31948278";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2019-0169";"31948278";"methodology";"1";"";"Anchored comparison?";"No"
"10.2217/cer-2019-0169";"31948278";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer-2019-0169";"31948278";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2019-0169";"31948278";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"recorded heart rate < 45bpm"
"10.2217/cer-2019-0169";"31948278";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer-2019-0169";"31948278";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.2217/cer-2019-0169";"31948278";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer-2019-0169";"31948278";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer-2019-0169";"31948278";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.2217/cer-2019-0169";"31948278";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2019-0169";"31948278";"methodology";"2";"";"Treatment name 1";"ozanimod"
"10.2217/cer-2019-0169";"31948278";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2019-0169";"31948278";"methodology";"2";"";"Treatment name 2";"fingolimod"
"10.2217/cer-2019-0169";"31948278";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.2217/cer-2019-0169";"31948278";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2019-0169";"31948278";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.2217/cer-2019-0169";"31948278";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2019-0169";"31948278";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2019-0169";"31948278";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"any adverse event"
"10.2217/cer-2019-0169";"31948278";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer-2019-0169";"31948278";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.2217/cer-2019-0169";"31948278";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer-2019-0169";"31948278";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer-2019-0169";"31948278";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.2217/cer-2019-0169";"31948278";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2019-0169";"31948278";"methodology";"3";"";"Treatment name 1";"ozanimod"
"10.2217/cer-2019-0169";"31948278";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1;2"
"10.2217/cer-2019-0169";"31948278";"methodology";"3";"";"Treatment name 2";"fingolimod"
"10.2217/cer-2019-0169";"31948278";"methodology";"3";"";"Study 'number(s)' for treatment 2";"4;5"
"10.2217/cer-2019-0169";"31948278";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2019-0169";"31948278";"methodology";"3";"";"Anchored comparison?";"No"
"10.2217/cer-2019-0169";"31948278";"methodology";"3";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer-2019-0169";"31948278";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2019-0169";"31948278";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"any adverse event"
"10.2217/cer-2019-0169";"31948278";"methodology";"3";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer-2019-0169";"31948278";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.2217/cer-2019-0169";"31948278";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer-2019-0169";"31948278";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer-2019-0169";"31948278";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.2217/cer-2019-0169";"31948278";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2019-0169";"31948278";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"1212"
"10.2217/cer-2019-0169";"31948278";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"1773"
"10.2217/cer-2019-0169";"31948278";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"597"
"10.2217/cer-2019-0169";"31948278";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2019-0169";"31948278";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2019-0169";"31948278";"results";"1";"";"Number of covariates adjusted for/matched on";"11"
"10.2217/cer-2019-0169";"31948278";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)"
"10.2217/cer-2019-0169";"31948278";"results";"1";"";"Primary outcome: treatment effect contrast";"Risk difference"
"10.2217/cer-2019-0169";"31948278";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2019-0169";"31948278";"results";"1";"";"Primary outcome: adjusted treatment effect";"-1.4"
"10.2217/cer-2019-0169";"31948278";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.2217/cer-2019-0169";"31948278";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"429"
"10.2217/cer-2019-0169";"31948278";"results";"2";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"431"
"10.2217/cer-2019-0169";"31948278";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"882"
"10.2217/cer-2019-0169";"31948278";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"317"
"10.2217/cer-2019-0169";"31948278";"results";"2";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"885"
"10.2217/cer-2019-0169";"31948278";"results";"2";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"317"
"10.2217/cer-2019-0169";"31948278";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2019-0169";"31948278";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2019-0169";"31948278";"results";"2";"";"Number of covariates adjusted for/matched on";"9"
"10.2217/cer-2019-0169";"31948278";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.2217/cer-2019-0169";"31948278";"results";"2";"";"Primary outcome: treatment effect contrast";"Risk difference"
"10.2217/cer-2019-0169";"31948278";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2019-0169";"31948278";"results";"2";"";"Primary outcome: adjusted treatment effect";"-9.9"
"10.2217/cer-2019-0169";"31948278";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.05"
"10.2217/cer-2019-0169";"31948278";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"783"
"10.2217/cer-2019-0169";"31948278";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"434"
"10.2217/cer-2019-0169";"31948278";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"158"
"10.2217/cer-2019-0169";"31948278";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2019-0169";"31948278";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2019-0169";"31948278";"results";"3";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/cer-2019-0169";"31948278";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.2217/cer-2019-0169";"31948278";"results";"3";"";"Primary outcome: treatment effect contrast";"Risk difference"
"10.2217/cer-2019-0169";"31948278";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2019-0169";"31948278";"results";"3";"";"Primary outcome: adjusted treatment effect";"-22.7"
"10.2217/cer-2019-0169";"31948278";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.2217/cer-2020-0063";"32648475";"general_information";"";"";"Medical Condition of Interest Name";"non-small cell lung cancer treatments"
"10.2217/cer-2020-0063";"32648475";"general_information";"";"";"Countries of first author affiliations";"switzerland"
"10.2217/cer-2020-0063";"32648475";"general_information";"";"";"Countries of last author affiliations";"switzerland"
"10.2217/cer-2020-0063";"32648475";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/cer-2020-0063";"32648475";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/cer-2020-0063";"32648475";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/cer-2020-0063";"32648475";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/cer-2020-0063";"32648475";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"1";"EudraCT (only for clinical trials registered on clinicaltrialsregister.eu";"2012-000148-88"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"italy"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"2";"Patient-level data used";"Yes"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02097810"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"1"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"3";"Patient-level data used";"Yes"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02568267"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"4";"Patient-level data used";"No"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"4";"Clinical Trial";"Yes"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00585195"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"1"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"5";"Patient-level data used";"No"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"5";"Clinical Trial";"Yes"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01828099"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"6";"Patient-level data used";"No"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"6";"Clinical Trial";"Yes"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"6";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00932893"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"6";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"6";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2020-0063";"32648475";"study_information";"";"6";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2020-0063";"32648475";"methodology";"1";"";"Treatment name 1";"entrectinib"
"10.2217/cer-2020-0063";"32648475";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.2217/cer-2020-0063";"32648475";"methodology";"1";"";"Treatment name 2";"crizotinib"
"10.2217/cer-2020-0063";"32648475";"methodology";"1";"";"Study 'number(s)' for treatment 2";"4"
"10.2217/cer-2020-0063";"32648475";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2020-0063";"32648475";"methodology";"1";"";"Anchored comparison?";"No"
"10.2217/cer-2020-0063";"32648475";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer-2020-0063";"32648475";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2020-0063";"32648475";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/cer-2020-0063";"32648475";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2020-0063";"32648475";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer-2020-0063";"32648475";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/cer-2020-0063";"32648475";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/cer-2020-0063";"32648475";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2020-0063";"32648475";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2020-0063";"32648475";"methodology";"2";"";"Treatment name 1";"entrectinib"
"10.2217/cer-2020-0063";"32648475";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.2217/cer-2020-0063";"32648475";"methodology";"2";"";"Treatment name 2";"pemetrexed + platinum followed by pemetrexed maintenance"
"10.2217/cer-2020-0063";"32648475";"methodology";"2";"";"Study 'number(s)' for treatment 2";"5"
"10.2217/cer-2020-0063";"32648475";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2020-0063";"32648475";"methodology";"2";"";"Anchored comparison?";"No"
"10.2217/cer-2020-0063";"32648475";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer-2020-0063";"32648475";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2020-0063";"32648475";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/cer-2020-0063";"32648475";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2020-0063";"32648475";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer-2020-0063";"32648475";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/cer-2020-0063";"32648475";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/cer-2020-0063";"32648475";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2020-0063";"32648475";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2020-0063";"32648475";"methodology";"3";"";"Treatment name 1";"entrectinib"
"10.2217/cer-2020-0063";"32648475";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.2217/cer-2020-0063";"32648475";"methodology";"3";"";"Treatment name 2";"pemetrexed/docetaxel"
"10.2217/cer-2020-0063";"32648475";"methodology";"3";"";"Study 'number(s)' for treatment 2";"6"
"10.2217/cer-2020-0063";"32648475";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2020-0063";"32648475";"methodology";"3";"";"Anchored comparison?";"No"
"10.2217/cer-2020-0063";"32648475";"methodology";"3";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer-2020-0063";"32648475";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2020-0063";"32648475";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/cer-2020-0063";"32648475";"methodology";"3";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2020-0063";"32648475";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer-2020-0063";"32648475";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/cer-2020-0063";"32648475";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/cer-2020-0063";"32648475";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2020-0063";"32648475";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2020-0063";"32648475";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"53"
"10.2217/cer-2020-0063";"32648475";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"53"
"10.2217/cer-2020-0063";"32648475";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"34.18"
"10.2217/cer-2020-0063";"32648475";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2020-0063";"32648475";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2020-0063";"32648475";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.2217/cer-2020-0063";"32648475";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.2217/cer-2020-0063";"32648475";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2020-0063";"32648475";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2020-0063";"32648475";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.471"
"10.2217/cer-2020-0063";"32648475";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.112;1.034]"
"10.2217/cer-2020-0063";"32648475";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"187"
"10.2217/cer-2020-0063";"32648475";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"53"
"10.2217/cer-2020-0063";"32648475";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"47.5"
"10.2217/cer-2020-0063";"32648475";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2020-0063";"32648475";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2020-0063";"32648475";"results";"2";"";"Number of covariates adjusted for/matched on";"5"
"10.2217/cer-2020-0063";"32648475";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.2217/cer-2020-0063";"32648475";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2020-0063";"32648475";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2020-0063";"32648475";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.478"
"10.2217/cer-2020-0063";"32648475";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.167;0.918]"
"10.2217/cer-2020-0063";"32648475";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"174"
"10.2217/cer-2020-0063";"32648475";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"53"
"10.2217/cer-2020-0063";"32648475";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"47.5"
"10.2217/cer-2020-0063";"32648475";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2020-0063";"32648475";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2020-0063";"32648475";"results";"3";"";"Number of covariates adjusted for/matched on";"5"
"10.2217/cer-2020-0063";"32648475";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.2217/cer-2020-0063";"32648475";"results";"3";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2020-0063";"32648475";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2020-0063";"32648475";"results";"3";"";"Primary outcome: adjusted treatment effect";"0.434"
"10.2217/cer-2020-0063";"32648475";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.157;0.755]"
"10.2217/cer-2020-0069";"32602756";"general_information";"";"";"Medical Condition of Interest Name";"pediatric acute lymphoblastic leukemia"
"10.2217/cer-2020-0069";"32602756";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2217/cer-2020-0069";"32602756";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2217/cer-2020-0069";"32602756";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/cer-2020-0069";"32602756";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/cer-2020-0069";"32602756";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/cer-2020-0069";"32602756";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/cer-2020-0069";"32602756";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02435849"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"2";"Patient-level data used";"No"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01471782"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"3";"Patient-level data used";"No"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"3";"Data source name (only if observational study or clinical trial without NCT)";"jeha et al. (2006)"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"4";"Patient-level data used";"No"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"4";"Clinical Trial";"Yes"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00315705"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"5";"Patient-level data used";"No"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"5";"Clinical Trial";"Yes"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"5";"Data source name (only if observational study or clinical trial without NCT)";"locatelli et al. (2017)"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"italy"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"6";"Patient-level data used";"No"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"6";"Clinical Trial";"Yes"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"6";"Data source name (only if observational study or clinical trial without NCT)";"miano et al. (2012)"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"6";"Country where the clinical trial/observational study was conducted (international if more than one)";"italy"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"6";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"7";"Patient-level data used";"No"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"7";"Clinical Trial";"Yes"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"7";"Data source name (only if observational study or clinical trial without NCT)";"von stackelbeg et al. (2010)"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"7";"Country where the clinical trial/observational study was conducted (international if more than one)";"germany"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"8";"Patient-level data used";"No"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"8";"Clinical Trial";"Yes"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"8";"Data source name (only if observational study or clinical trial without NCT)";"all-sct-bfm 2003 & all-sct-bfm"
"10.2217/cer-2020-0069";"32602756";"study_information";"";"8";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2020-0069";"32602756";"methodology";"1";"";"Treatment name 1";"tisagenlecleucel"
"10.2217/cer-2020-0069";"32602756";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2020-0069";"32602756";"methodology";"1";"";"Treatment name 2";"blinatumomab"
"10.2217/cer-2020-0069";"32602756";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2217/cer-2020-0069";"32602756";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2020-0069";"32602756";"methodology";"1";"";"Anchored comparison?";"No"
"10.2217/cer-2020-0069";"32602756";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2020-0069";"32602756";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2020-0069";"32602756";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/cer-2020-0069";"32602756";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2020-0069";"32602756";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer-2020-0069";"32602756";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer-2020-0069";"32602756";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer-2020-0069";"32602756";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2020-0069";"32602756";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2020-0069";"32602756";"methodology";"2";"";"Treatment name 1";"tisagenlecleucel"
"10.2217/cer-2020-0069";"32602756";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2020-0069";"32602756";"methodology";"2";"";"Treatment name 2";"clofarabine"
"10.2217/cer-2020-0069";"32602756";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.2217/cer-2020-0069";"32602756";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2020-0069";"32602756";"methodology";"2";"";"Anchored comparison?";"No"
"10.2217/cer-2020-0069";"32602756";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2020-0069";"32602756";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2020-0069";"32602756";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/cer-2020-0069";"32602756";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2020-0069";"32602756";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer-2020-0069";"32602756";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer-2020-0069";"32602756";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer-2020-0069";"32602756";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2020-0069";"32602756";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2020-0069";"32602756";"methodology";"3";"";"Treatment name 1";"tisagenlecleucel"
"10.2217/cer-2020-0069";"32602756";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2020-0069";"32602756";"methodology";"3";"";"Treatment name 2";"clofarabine + etoposide plus cyclophosphamide"
"10.2217/cer-2020-0069";"32602756";"methodology";"3";"";"Study 'number(s)' for treatment 2";"4;5;6"
"10.2217/cer-2020-0069";"32602756";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2020-0069";"32602756";"methodology";"3";"";"Anchored comparison?";"No"
"10.2217/cer-2020-0069";"32602756";"methodology";"3";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer-2020-0069";"32602756";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2020-0069";"32602756";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/cer-2020-0069";"32602756";"methodology";"3";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2020-0069";"32602756";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer-2020-0069";"32602756";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer-2020-0069";"32602756";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer-2020-0069";"32602756";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2020-0069";"32602756";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2020-0069";"32602756";"methodology";"4";"";"Treatment name 1";"tisagenlecleucel"
"10.2217/cer-2020-0069";"32602756";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2020-0069";"32602756";"methodology";"4";"";"Treatment name 2";"salvage chemotherapy/treatment"
"10.2217/cer-2020-0069";"32602756";"methodology";"4";"";"Study 'number(s)' for treatment 2";"7"
"10.2217/cer-2020-0069";"32602756";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2020-0069";"32602756";"methodology";"4";"";"Anchored comparison?";"No"
"10.2217/cer-2020-0069";"32602756";"methodology";"4";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2020-0069";"32602756";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2020-0069";"32602756";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/cer-2020-0069";"32602756";"methodology";"4";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2020-0069";"32602756";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer-2020-0069";"32602756";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer-2020-0069";"32602756";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer-2020-0069";"32602756";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2020-0069";"32602756";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2020-0069";"32602756";"methodology";"5";"";"Treatment name 1";"tisagenlecleucel"
"10.2217/cer-2020-0069";"32602756";"methodology";"5";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2020-0069";"32602756";"methodology";"5";"";"Treatment name 2";"paliative therapy/salvage therapy"
"10.2217/cer-2020-0069";"32602756";"methodology";"5";"";"Study 'number(s)' for treatment 2";"8"
"10.2217/cer-2020-0069";"32602756";"methodology";"5";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2020-0069";"32602756";"methodology";"5";"";"Anchored comparison?";"No"
"10.2217/cer-2020-0069";"32602756";"methodology";"5";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2020-0069";"32602756";"methodology";"5";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2020-0069";"32602756";"methodology";"5";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/cer-2020-0069";"32602756";"methodology";"5";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2020-0069";"32602756";"methodology";"5";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer-2020-0069";"32602756";"methodology";"5";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer-2020-0069";"32602756";"methodology";"5";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer-2020-0069";"32602756";"methodology";"5";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2020-0069";"32602756";"methodology";"5";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2020-0069";"32602756";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"70"
"10.2217/cer-2020-0069";"32602756";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"79"
"10.2217/cer-2020-0069";"32602756";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"28.7"
"10.2217/cer-2020-0069";"32602756";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2020-0069";"32602756";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2020-0069";"32602756";"results";"1";"";"Number of covariates adjusted for/matched on";"9"
"10.2217/cer-2020-0069";"32602756";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.2217/cer-2020-0069";"32602756";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2020-0069";"32602756";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2020-0069";"32602756";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.28"
"10.2217/cer-2020-0069";"32602756";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.0001"
"10.2217/cer-2020-0069";"32602756";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.32"
"10.2217/cer-2020-0069";"32602756";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.0015"
"10.2217/cer-2020-0069";"32602756";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"61"
"10.2217/cer-2020-0069";"32602756";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"79"
"10.2217/cer-2020-0069";"32602756";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"43"
"10.2217/cer-2020-0069";"32602756";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2020-0069";"32602756";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2020-0069";"32602756";"results";"2";"";"Number of covariates adjusted for/matched on";"5"
"10.2217/cer-2020-0069";"32602756";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Race/ethnicity, Past treatments for the disease of interest"
"10.2217/cer-2020-0069";"32602756";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2020-0069";"32602756";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2020-0069";"32602756";"results";"2";"";"Primary outcome: unadjusted treatment effect";"0.17"
"10.2217/cer-2020-0069";"32602756";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.0001"
"10.2217/cer-2020-0069";"32602756";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.24"
"10.2217/cer-2020-0069";"32602756";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.0001"
"10.2217/cer-2020-0069";"32602756";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"74"
"10.2217/cer-2020-0069";"32602756";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"79"
"10.2217/cer-2020-0069";"32602756";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"53.5"
"10.2217/cer-2020-0069";"32602756";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2020-0069";"32602756";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2020-0069";"32602756";"results";"3";"";"Number of covariates adjusted for/matched on";"2"
"10.2217/cer-2020-0069";"32602756";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Sex, Past treatments for the disease of interest"
"10.2217/cer-2020-0069";"32602756";"results";"3";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2020-0069";"32602756";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2020-0069";"32602756";"results";"3";"";"Primary outcome: unadjusted treatment effect";"0.22"
"10.2217/cer-2020-0069";"32602756";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.0001"
"10.2217/cer-2020-0069";"32602756";"results";"3";"";"Primary outcome: adjusted treatment effect";"0.15"
"10.2217/cer-2020-0069";"32602756";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.0001"
"10.2217/cer-2020-0069";"32602756";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"51"
"10.2217/cer-2020-0069";"32602756";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"51"
"10.2217/cer-2020-0069";"32602756";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"75"
"10.2217/cer-2020-0069";"32602756";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2020-0069";"32602756";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2020-0069";"32602756";"results";"4";"";"Number of covariates adjusted for/matched on";"3"
"10.2217/cer-2020-0069";"32602756";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Past treatments for the disease of interest"
"10.2217/cer-2020-0069";"32602756";"results";"4";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2020-0069";"32602756";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2020-0069";"32602756";"results";"4";"";"Primary outcome: unadjusted treatment effect";"0.14"
"10.2217/cer-2020-0069";"32602756";"results";"4";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.0001"
"10.2217/cer-2020-0069";"32602756";"results";"4";"";"Primary outcome: adjusted treatment effect";"0.15"
"10.2217/cer-2020-0069";"32602756";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.0001"
"10.2217/cer-2020-0069";"32602756";"results";"5";"";"Sample size of the population of interest in the non IPD treatment arm";"242"
"10.2217/cer-2020-0069";"32602756";"results";"5";"";"Initial sample size of the population of interest in the IPD treatment arm";"79"
"10.2217/cer-2020-0069";"32602756";"results";"5";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"36.2"
"10.2217/cer-2020-0069";"32602756";"results";"5";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2020-0069";"32602756";"results";"5";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2020-0069";"32602756";"results";"5";"";"Number of covariates adjusted for/matched on";"2"
"10.2217/cer-2020-0069";"32602756";"results";"5";"";"Covariates adjusted for/matched on in the indirect comparison";"Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.2217/cer-2020-0069";"32602756";"results";"5";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2020-0069";"32602756";"results";"5";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2020-0069";"32602756";"results";"5";"";"Primary outcome: unadjusted treatment effect";"0.28"
"10.2217/cer-2020-0069";"32602756";"results";"5";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.0001"
"10.2217/cer-2020-0069";"32602756";"results";"5";"";"Primary outcome: adjusted treatment effect";"0.27"
"10.2217/cer-2020-0069";"32602756";"results";"5";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.0001"
"10.2217/cer-2020-0236";"33442996";"general_information";"";"";"Medical Condition of Interest Name";"advanced hepatocellular carcinoma"
"10.2217/cer-2020-0236";"33442996";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2217/cer-2020-0236";"33442996";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2217/cer-2020-0236";"33442996";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/cer-2020-0236";"33442996";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/cer-2020-0236";"33442996";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/cer-2020-0236";"33442996";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/cer-2020-0236";"33442996";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2217/cer-2020-0236";"33442996";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/cer-2020-0236";"33442996";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/cer-2020-0236";"33442996";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01658878"
"10.2217/cer-2020-0236";"33442996";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2020-0236";"33442996";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.2217/cer-2020-0236";"33442996";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2020-0236";"33442996";"study_information";"";"2";"Patient-level data used";"No"
"10.2217/cer-2020-0236";"33442996";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/cer-2020-0236";"33442996";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01908426"
"10.2217/cer-2020-0236";"33442996";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2020-0236";"33442996";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2020-0236";"33442996";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2020-0236";"33442996";"methodology";"1";"";"Treatment name 1";"nivolumab + ipilimumab"
"10.2217/cer-2020-0236";"33442996";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2020-0236";"33442996";"methodology";"1";"";"Treatment name 2";"placebo"
"10.2217/cer-2020-0236";"33442996";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2217/cer-2020-0236";"33442996";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2020-0236";"33442996";"methodology";"1";"";"Anchored comparison?";"No"
"10.2217/cer-2020-0236";"33442996";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2020-0236";"33442996";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2020-0236";"33442996";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/cer-2020-0236";"33442996";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2020-0236";"33442996";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.2217/cer-2020-0236";"33442996";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/cer-2020-0236";"33442996";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer-2020-0236";"33442996";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2020-0236";"33442996";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2020-0236";"33442996";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"237"
"10.2217/cer-2020-0236";"33442996";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"50"
"10.2217/cer-2020-0236";"33442996";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2020-0236";"33442996";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2020-0236";"33442996";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.2217/cer-2020-0236";"33442996";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/cer-2020-0236";"33442996";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2020-0236";"33442996";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2020-0236";"33442996";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.35"
"10.2217/cer-2020-0236";"33442996";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.21;0.58]"
"10.2217/cer-2020-0272";"33626934";"general_information";"";"";"Medical Condition of Interest Name";"hr+/her2- advanced breast cancer"
"10.2217/cer-2020-0272";"33626934";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2217/cer-2020-0272";"33626934";"general_information";"";"";"Countries of last author affiliations";"canada"
"10.2217/cer-2020-0272";"33626934";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/cer-2020-0272";"33626934";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/cer-2020-0272";"33626934";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/cer-2020-0272";"33626934";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/cer-2020-0272";"33626934";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01942135"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"2";"Patient-level data used";"No"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02107703"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"3";"Patient-level data used";"No"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02422615"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2020-0272";"33626934";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2020-0272";"33626934";"methodology";"1";"";"Treatment name 1";"palbociclib + fulvestran"
"10.2217/cer-2020-0272";"33626934";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2020-0272";"33626934";"methodology";"1";"";"Treatment name 2";"abemaciclib + fulvestrant"
"10.2217/cer-2020-0272";"33626934";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2217/cer-2020-0272";"33626934";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2020-0272";"33626934";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.2217/cer-2020-0272";"33626934";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2020-0272";"33626934";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer-2020-0272";"33626934";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/cer-2020-0272";"33626934";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2020-0272";"33626934";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/cer-2020-0272";"33626934";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.2217/cer-2020-0272";"33626934";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/cer-2020-0272";"33626934";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2020-0272";"33626934";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2020-0272";"33626934";"methodology";"2";"";"Treatment name 1";"palbociclib + fulvestrant"
"10.2217/cer-2020-0272";"33626934";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2020-0272";"33626934";"methodology";"2";"";"Treatment name 2";"ribociclib + fulvestrant"
"10.2217/cer-2020-0272";"33626934";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.2217/cer-2020-0272";"33626934";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2020-0272";"33626934";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.2217/cer-2020-0272";"33626934";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2020-0272";"33626934";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer-2020-0272";"33626934";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/cer-2020-0272";"33626934";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2020-0272";"33626934";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/cer-2020-0272";"33626934";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.2217/cer-2020-0272";"33626934";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/cer-2020-0272";"33626934";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2020-0272";"33626934";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2020-0272";"33626934";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"183"
"10.2217/cer-2020-0272";"33626934";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"97"
"10.2217/cer-2020-0272";"33626934";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2020-0272";"33626934";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2020-0272";"33626934";"results";"1";"";"Number of covariates adjusted for/matched on";"12"
"10.2217/cer-2020-0272";"33626934";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)"
"10.2217/cer-2020-0272";"33626934";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2020-0272";"33626934";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2020-0272";"33626934";"results";"1";"";"Primary outcome: unadjusted treatment effect";"1.09"
"10.2217/cer-2020-0272";"33626934";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.70;1.69]"
"10.2217/cer-2020-0272";"33626934";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.89"
"10.2217/cer-2020-0272";"33626934";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.48;1.63]"
"10.2217/cer-2020-0272";"33626934";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"142"
"10.2217/cer-2020-0272";"33626934";"results";"2";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"75"
"10.2217/cer-2020-0272";"33626934";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2020-0272";"33626934";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2020-0272";"33626934";"results";"2";"";"Number of covariates adjusted for/matched on";"16"
"10.2217/cer-2020-0272";"33626934";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)"
"10.2217/cer-2020-0272";"33626934";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2020-0272";"33626934";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2020-0272";"33626934";"results";"2";"";"Primary outcome: unadjusted treatment effect";"1.09"
"10.2217/cer-2020-0272";"33626934";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.70;1.69]"
"10.2217/cer-2020-0272";"33626934";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.89"
"10.2217/cer-2020-0272";"33626934";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.48;1.63]"
"10.2217/cer-2020-0280";"33733815";"general_information";"";"";"Medical Condition of Interest Name";"acute myeloid leukemia"
"10.2217/cer-2020-0280";"33733815";"general_information";"";"";"Countries of first author affiliations";"canada"
"10.2217/cer-2020-0280";"33733815";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2217/cer-2020-0280";"33733815";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/cer-2020-0280";"33733815";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/cer-2020-0280";"33733815";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/cer-2020-0280";"33733815";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/cer-2020-0280";"33733815";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.2217/cer-2020-0280";"33733815";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/cer-2020-0280";"33733815";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/cer-2020-0280";"33733815";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01546038"
"10.2217/cer-2020-0280";"33733815";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2020-0280";"33733815";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/cer-2020-0280";"33733815";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2020-0280";"33733815";"study_information";"";"2";"Patient-level data used";"No"
"10.2217/cer-2020-0280";"33733815";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/cer-2020-0280";"33733815";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03069352"
"10.2217/cer-2020-0280";"33733815";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2020-0280";"33733815";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2020-0280";"33733815";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2020-0280";"33733815";"methodology";"1";"";"Treatment name 1";"glasdegib + low-dose cytarabine"
"10.2217/cer-2020-0280";"33733815";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2020-0280";"33733815";"methodology";"1";"";"Treatment name 2";"venetoclax + low-dose cytarabine"
"10.2217/cer-2020-0280";"33733815";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2217/cer-2020-0280";"33733815";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2217/cer-2020-0280";"33733815";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.2217/cer-2020-0280";"33733815";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2020-0280";"33733815";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2020-0280";"33733815";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/cer-2020-0280";"33733815";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2020-0280";"33733815";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/cer-2020-0280";"33733815";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/cer-2020-0280";"33733815";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/cer-2020-0280";"33733815";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"Yes"
"10.2217/cer-2020-0280";"33733815";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.2217/cer-2020-0280";"33733815";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"143"
"10.2217/cer-2020-0280";"33733815";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"68"
"10.2217/cer-2020-0280";"33733815";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"78"
"10.2217/cer-2020-0280";"33733815";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"78"
"10.2217/cer-2020-0280";"33733815";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"38"
"10.2217/cer-2020-0280";"33733815";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"38"
"10.2217/cer-2020-0280";"33733815";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2020-0280";"33733815";"results";"1";"";"Number of covariates adjusted for/matched on";"6"
"10.2217/cer-2020-0280";"33733815";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.2217/cer-2020-0280";"33733815";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2020-0280";"33733815";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2020-0280";"33733815";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.66"
"10.2217/cer-2020-0280";"33733815";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.38;1.15]"
"10.2217/cer-2020-0280";"33733815";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.56"
"10.2217/cer-2020-0280";"33733815";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.24;1.32]"
"10.2217/cer-2021-0178";"35068168";"general_information";"";"";"Medical Condition of Interest Name";"parkinson's disease"
"10.2217/cer-2021-0178";"35068168";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2217/cer-2021-0178";"35068168";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2217/cer-2021-0178";"35068168";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/cer-2021-0178";"35068168";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/cer-2021-0178";"35068168";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/cer-2021-0178";"35068168";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/cer-2021-0178";"35068168";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2217/cer-2021-0178";"35068168";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/cer-2021-0178";"35068168";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/cer-2021-0178";"35068168";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02469090"
"10.2217/cer-2021-0178";"35068168";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2021-0178";"35068168";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2021-0178";"35068168";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2021-0178";"35068168";"study_information";"";"2";"Patient-level data used";"No"
"10.2217/cer-2021-0178";"35068168";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/cer-2021-0178";"35068168";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2021-0178";"35068168";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2021-0178";"35068168";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2021-0178";"35068168";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02240030"
"10.2217/cer-2021-0178";"35068168";"methodology";"1";"";"Treatment name 1";"apomorphine sublingual film"
"10.2217/cer-2021-0178";"35068168";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2021-0178";"35068168";"methodology";"1";"";"Treatment name 2";"levodopa inhalation powder"
"10.2217/cer-2021-0178";"35068168";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2217/cer-2021-0178";"35068168";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2021-0178";"35068168";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.2217/cer-2021-0178";"35068168";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2021-0178";"35068168";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2021-0178";"35068168";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"change in updrs part iii score from predose to postdose"
"10.2217/cer-2021-0178";"35068168";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2217/cer-2021-0178";"35068168";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.2217/cer-2021-0178";"35068168";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer-2021-0178";"35068168";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/cer-2021-0178";"35068168";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2021-0178";"35068168";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2021-0178";"35068168";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"114"
"10.2217/cer-2021-0178";"35068168";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"112"
"10.2217/cer-2021-0178";"35068168";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"44"
"10.2217/cer-2021-0178";"35068168";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer-2021-0178";"35068168";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2021-0178";"35068168";"results";"1";"";"Number of covariates adjusted for/matched on";"4"
"10.2217/cer-2021-0178";"35068168";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.2217/cer-2021-0178";"35068168";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.2217/cer-2021-0178";"35068168";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2021-0178";"35068168";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.57"
"10.2217/cer-2021-0178";"35068168";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.818"
"10.2217/cer-2021-0178";"35068168";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.15"
"10.2217/cer-2021-0178";"35068168";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.953"
"10.2217/cer-2021-0178";"35068168";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"37"
"10.2217/cer-2021-0216";"35040693";"general_information";"";"";"Medical Condition of Interest Name";"spinal muscular atrophy"
"10.2217/cer-2021-0216";"35040693";"general_information";"";"";"Countries of first author affiliations";"switzerland"
"10.2217/cer-2021-0216";"35040693";"general_information";"";"";"Countries of last author affiliations";"uk"
"10.2217/cer-2021-0216";"35040693";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/cer-2021-0216";"35040693";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/cer-2021-0216";"35040693";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/cer-2021-0216";"35040693";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/cer-2021-0216";"35040693";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02913482"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2, 3"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"2";"Patient-level data used";"Yes"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02908685"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2, 3"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"3";"Patient-level data used";"No"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02193074"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"4";"Patient-level data used";"No"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"4";"Clinical Trial";"Yes"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02292537"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"5";"Patient-level data used";"No"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"5";"Clinical Trial";"Yes"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03306277"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2021-0216";"35040693";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer-2021-0216";"35040693";"methodology";"1";"";"Treatment name 1";"risdiplam"
"10.2217/cer-2021-0216";"35040693";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2021-0216";"35040693";"methodology";"1";"";"Treatment name 2";"nusinersen"
"10.2217/cer-2021-0216";"35040693";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3"
"10.2217/cer-2021-0216";"35040693";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2021-0216";"35040693";"methodology";"1";"";"Anchored comparison?";"No"
"10.2217/cer-2021-0216";"35040693";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2021-0216";"35040693";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2021-0216";"35040693";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"event-free survival"
"10.2217/cer-2021-0216";"35040693";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2021-0216";"35040693";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/cer-2021-0216";"35040693";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/cer-2021-0216";"35040693";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/cer-2021-0216";"35040693";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2021-0216";"35040693";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2021-0216";"35040693";"methodology";"2";"";"Treatment name 1";"risdiplam"
"10.2217/cer-2021-0216";"35040693";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2021-0216";"35040693";"methodology";"2";"";"Treatment name 2";"onasemnogene abeparvovec"
"10.2217/cer-2021-0216";"35040693";"methodology";"2";"";"Study 'number(s)' for treatment 2";"5"
"10.2217/cer-2021-0216";"35040693";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2217/cer-2021-0216";"35040693";"methodology";"2";"";"Anchored comparison?";"No"
"10.2217/cer-2021-0216";"35040693";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2021-0216";"35040693";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2021-0216";"35040693";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"event-free survival"
"10.2217/cer-2021-0216";"35040693";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/cer-2021-0216";"35040693";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/cer-2021-0216";"35040693";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/cer-2021-0216";"35040693";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No"
"10.2217/cer-2021-0216";"35040693";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2021-0216";"35040693";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2021-0216";"35040693";"methodology";"3";"";"Treatment name 1";"risdiplam"
"10.2217/cer-2021-0216";"35040693";"methodology";"3";"";"Study 'number(s)' for treatment 1";"2"
"10.2217/cer-2021-0216";"35040693";"methodology";"3";"";"Treatment name 2";"nusinersen"
"10.2217/cer-2021-0216";"35040693";"methodology";"3";"";"Study 'number(s)' for treatment 2";"4"
"10.2217/cer-2021-0216";"35040693";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2021-0216";"35040693";"methodology";"3";"";"Anchored comparison?";"Yes"
"10.2217/cer-2021-0216";"35040693";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2021-0216";"35040693";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2021-0216";"35040693";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"rulm change from baseline"
"10.2217/cer-2021-0216";"35040693";"methodology";"3";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2217/cer-2021-0216";"35040693";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/cer-2021-0216";"35040693";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/cer-2021-0216";"35040693";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/cer-2021-0216";"35040693";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2021-0216";"35040693";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2021-0216";"35040693";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"121"
"10.2217/cer-2021-0216";"35040693";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"58"
"10.2217/cer-2021-0216";"35040693";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"36.5"
"10.2217/cer-2021-0216";"35040693";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.2217/cer-2021-0216";"35040693";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2021-0216";"35040693";"results";"1";"";"Number of covariates adjusted for/matched on";"3"
"10.2217/cer-2021-0216";"35040693";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.2217/cer-2021-0216";"35040693";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2021-0216";"35040693";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2021-0216";"35040693";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.24"
"10.2217/cer-2021-0216";"35040693";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.09;0.46]"
"10.2217/cer-2021-0216";"35040693";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.2"
"10.2217/cer-2021-0216";"35040693";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.06;0.42]"
"10.2217/cer-2021-0216";"35040693";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"22"
"10.2217/cer-2021-0216";"35040693";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"58"
"10.2217/cer-2021-0216";"35040693";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"58"
"10.2217/cer-2021-0216";"35040693";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2021-0216";"35040693";"results";"2";"";"Number of covariates adjusted for/matched on";"2"
"10.2217/cer-2021-0216";"35040693";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.2217/cer-2021-0216";"35040693";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/cer-2021-0216";"35040693";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2021-0216";"35040693";"results";"2";"";"Primary outcome: unadjusted treatment effect";"1.532"
"10.2217/cer-2021-0216";"35040693";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.721;2.665]"
"10.2217/cer-2021-0216";"35040693";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.936"
"10.2217/cer-2021-0216";"35040693";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.033;4.064]"
"10.2217/cer-2021-0216";"35040693";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"126"
"10.2217/cer-2021-0216";"35040693";"results";"3";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"126"
"10.2217/cer-2021-0216";"35040693";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"43"
"10.2217/cer-2021-0216";"35040693";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"28.3"
"10.2217/cer-2021-0216";"35040693";"results";"3";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"25"
"10.2217/cer-2021-0216";"35040693";"results";"3";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"8.8"
"10.2217/cer-2021-0216";"35040693";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.2217/cer-2021-0216";"35040693";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2021-0216";"35040693";"results";"3";"";"Number of covariates adjusted for/matched on";"3"
"10.2217/cer-2021-0216";"35040693";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.2217/cer-2021-0216";"35040693";"results";"3";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.2217/cer-2021-0216";"35040693";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2021-0216";"35040693";"results";"3";"";"Primary outcome: unadjusted treatment effect";"-0.6"
"10.2217/cer-2021-0216";"35040693";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[-2.24;1.22]"
"10.2217/cer-2021-0216";"35040693";"results";"3";"";"Primary outcome: adjusted treatment effect";"-0.49"
"10.2217/cer-2021-0216";"35040693";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-3.33;2.53]"
"10.2217/cer-2021-0221";"34751591";"general_information";"";"";"Medical Condition of Interest Name";"hr+/her2- advanced breast cancer"
"10.2217/cer-2021-0221";"34751591";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2217/cer-2021-0221";"34751591";"general_information";"";"";"Countries of last author affiliations";"canada"
"10.2217/cer-2021-0221";"34751591";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/cer-2021-0221";"34751591";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/cer-2021-0221";"34751591";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/cer-2021-0221";"34751591";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/cer-2021-0221";"34751591";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.2217/cer-2021-0221";"34751591";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/cer-2021-0221";"34751591";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/cer-2021-0221";"34751591";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01942135"
"10.2217/cer-2021-0221";"34751591";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2021-0221";"34751591";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2021-0221";"34751591";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2021-0221";"34751591";"study_information";"";"2";"Patient-level data used";"No"
"10.2217/cer-2021-0221";"34751591";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/cer-2021-0221";"34751591";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02107703"
"10.2217/cer-2021-0221";"34751591";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer-2021-0221";"34751591";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer-2021-0221";"34751591";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer-2021-0221";"34751591";"methodology";"1";"";"Treatment name 1";"palbociclib"
"10.2217/cer-2021-0221";"34751591";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer-2021-0221";"34751591";"methodology";"1";"";"Treatment name 2";"abemaciclib"
"10.2217/cer-2021-0221";"34751591";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2217/cer-2021-0221";"34751591";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer-2021-0221";"34751591";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.2217/cer-2021-0221";"34751591";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer-2021-0221";"34751591";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/cer-2021-0221";"34751591";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"eortc qlq-c30 global quality of life"
"10.2217/cer-2021-0221";"34751591";"methodology";"1";"";"Primary outcome: variable type";"Continuous (count, mean, ...)"
"10.2217/cer-2021-0221";"34751591";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/cer-2021-0221";"34751591";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.2217/cer-2021-0221";"34751591";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/cer-2021-0221";"34751591";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer-2021-0221";"34751591";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer-2021-0221";"34751591";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"180"
"10.2217/cer-2021-0221";"34751591";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"90"
"10.2217/cer-2021-0221";"34751591";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials"
"10.2217/cer-2021-0221";"34751591";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer-2021-0221";"34751591";"results";"1";"";"Number of covariates adjusted for/matched on";"11"
"10.2217/cer-2021-0221";"34751591";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)"
"10.2217/cer-2021-0221";"34751591";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.2217/cer-2021-0221";"34751591";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer-2021-0221";"34751591";"results";"1";"";"Primary outcome: unadjusted treatment effect";"4.6"
"10.2217/cer-2021-0221";"34751591";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.016"
"10.2217/cer-2021-0221";"34751591";"results";"1";"";"Primary outcome: adjusted treatment effect";"6.95"
"10.2217/cer-2021-0221";"34751591";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.004"
"10.2217/cer-2021-0221";"34751591";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"180"
"10.2217/cer-2021-0221";"34751591";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"90"
"10.2217/cer.15.33";"26159375";"general_information";"";"";"Medical Condition of Interest Name";"chronic genotype 1b hepatitis c"
"10.2217/cer.15.33";"26159375";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2217/cer.15.33";"26159375";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2217/cer.15.33";"26159375";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/cer.15.33";"26159375";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/cer.15.33";"26159375";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/cer.15.33";"26159375";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/cer.15.33";"26159375";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01497834"
"10.2217/cer.15.33";"26159375";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"japan"
"10.2217/cer.15.33";"26159375";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.33";"26159375";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer.15.33";"26159375";"study_information";"";"10";"Patient-level data used";"No"
"10.2217/cer.15.33";"26159375";"study_information";"";"10";"Clinical Trial";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"10";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01289782"
"10.2217/cer.15.33";"26159375";"study_information";"";"10";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer.15.33";"26159375";"study_information";"";"10";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.33";"26159375";"study_information";"";"10";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer.15.33";"26159375";"study_information";"";"11";"Patient-level data used";"No"
"10.2217/cer.15.33";"26159375";"study_information";"";"11";"Clinical Trial";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"11";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01290679"
"10.2217/cer.15.33";"26159375";"study_information";"";"11";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer.15.33";"26159375";"study_information";"";"11";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.33";"26159375";"study_information";"";"11";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer.15.33";"26159375";"study_information";"";"12";"Patient-level data used";"No"
"10.2217/cer.15.33";"26159375";"study_information";"";"12";"Clinical Trial";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"12";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01281839"
"10.2217/cer.15.33";"26159375";"study_information";"";"12";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer.15.33";"26159375";"study_information";"";"12";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.33";"26159375";"study_information";"";"12";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer.15.33";"26159375";"study_information";"";"13";"Patient-level data used";"No"
"10.2217/cer.15.33";"26159375";"study_information";"";"13";"Clinical Trial";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"13";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01641640"
"10.2217/cer.15.33";"26159375";"study_information";"";"13";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer.15.33";"26159375";"study_information";"";"13";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.33";"26159375";"study_information";"";"13";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer.15.33";"26159375";"study_information";"";"2";"Patient-level data used";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01581203"
"10.2217/cer.15.33";"26159375";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer.15.33";"26159375";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.33";"26159375";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer.15.33";"26159375";"study_information";"";"3";"Patient-level data used";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01718145"
"10.2217/cer.15.33";"26159375";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"japan"
"10.2217/cer.15.33";"26159375";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.33";"26159375";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer.15.33";"26159375";"study_information";"";"4";"Patient-level data used";"No"
"10.2217/cer.15.33";"26159375";"study_information";"";"4";"Clinical Trial";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00627926"
"10.2217/cer.15.33";"26159375";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer.15.33";"26159375";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.33";"26159375";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer.15.33";"26159375";"study_information";"";"5";"Patient-level data used";"No"
"10.2217/cer.15.33";"26159375";"study_information";"";"5";"Clinical Trial";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01241760"
"10.2217/cer.15.33";"26159375";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer.15.33";"26159375";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.33";"26159375";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer.15.33";"26159375";"study_information";"";"6";"Patient-level data used";"No"
"10.2217/cer.15.33";"26159375";"study_information";"";"6";"Clinical Trial";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"6";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00758043"
"10.2217/cer.15.33";"26159375";"study_information";"";"6";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer.15.33";"26159375";"study_information";"";"6";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.33";"26159375";"study_information";"";"6";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer.15.33";"26159375";"study_information";"";"7";"Patient-level data used";"No"
"10.2217/cer.15.33";"26159375";"study_information";"";"7";"Clinical Trial";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"7";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00703118"
"10.2217/cer.15.33";"26159375";"study_information";"";"7";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer.15.33";"26159375";"study_information";"";"7";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.33";"26159375";"study_information";"";"7";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer.15.33";"26159375";"study_information";"";"8";"Patient-level data used";"No"
"10.2217/cer.15.33";"26159375";"study_information";"";"8";"Clinical Trial";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"8";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00705432"
"10.2217/cer.15.33";"26159375";"study_information";"";"8";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.33";"26159375";"study_information";"";"8";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer.15.33";"26159375";"study_information";"";"8";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.2217/cer.15.33";"26159375";"study_information";"";"9";"Patient-level data used";"No"
"10.2217/cer.15.33";"26159375";"study_information";"";"9";"Clinical Trial";"Yes"
"10.2217/cer.15.33";"26159375";"study_information";"";"9";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00708500"
"10.2217/cer.15.33";"26159375";"study_information";"";"9";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.33";"26159375";"study_information";"";"9";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer.15.33";"26159375";"study_information";"";"9";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.2217/cer.15.33";"26159375";"methodology";"1";"";"Treatment name 1";"daclatasvir + asunaprevir"
"10.2217/cer.15.33";"26159375";"methodology";"1";"";"Study 'number(s)' for treatment 1";"2;3"
"10.2217/cer.15.33";"26159375";"methodology";"1";"";"Treatment name 2";"telaprevir + peginterferon-α + ribavirin"
"10.2217/cer.15.33";"26159375";"methodology";"1";"";"Study 'number(s)' for treatment 2";"4;5;6"
"10.2217/cer.15.33";"26159375";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer.15.33";"26159375";"methodology";"1";"";"Anchored comparison?";"No"
"10.2217/cer.15.33";"26159375";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer.15.33";"26159375";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer.15.33";"26159375";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained virologic response"
"10.2217/cer.15.33";"26159375";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer.15.33";"26159375";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer.15.33";"26159375";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"2";"";"Treatment name 1";"daclatasvir + asunaprevir"
"10.2217/cer.15.33";"26159375";"methodology";"2";"";"Study 'number(s)' for treatment 1";"2;3"
"10.2217/cer.15.33";"26159375";"methodology";"2";"";"Treatment name 2";"boceprevir + peginterferon-α + ribavirin"
"10.2217/cer.15.33";"26159375";"methodology";"2";"";"Study 'number(s)' for treatment 2";"8"
"10.2217/cer.15.33";"26159375";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer.15.33";"26159375";"methodology";"2";"";"Anchored comparison?";"No"
"10.2217/cer.15.33";"26159375";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer.15.33";"26159375";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer.15.33";"26159375";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained virologic response"
"10.2217/cer.15.33";"26159375";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer.15.33";"26159375";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer.15.33";"26159375";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"3";"";"Treatment name 1";"daclatasvir + asunaprevir"
"10.2217/cer.15.33";"26159375";"methodology";"3";"";"Study 'number(s)' for treatment 1";"2;3"
"10.2217/cer.15.33";"26159375";"methodology";"3";"";"Treatment name 2";"simeprevir + peginterferon-α + ribavirin"
"10.2217/cer.15.33";"26159375";"methodology";"3";"";"Study 'number(s)' for treatment 2";"10;11"
"10.2217/cer.15.33";"26159375";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer.15.33";"26159375";"methodology";"3";"";"Anchored comparison?";"No"
"10.2217/cer.15.33";"26159375";"methodology";"3";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer.15.33";"26159375";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer.15.33";"26159375";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained virologic response"
"10.2217/cer.15.33";"26159375";"methodology";"3";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer.15.33";"26159375";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer.15.33";"26159375";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"4";"";"Treatment name 1";"daclatasvir + asunaprevir"
"10.2217/cer.15.33";"26159375";"methodology";"4";"";"Study 'number(s)' for treatment 1";"2;3"
"10.2217/cer.15.33";"26159375";"methodology";"4";"";"Treatment name 2";"sofosbuvir + peginterferon-α + ribavirin"
"10.2217/cer.15.33";"26159375";"methodology";"4";"";"Study 'number(s)' for treatment 2";"13"
"10.2217/cer.15.33";"26159375";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer.15.33";"26159375";"methodology";"4";"";"Anchored comparison?";"No"
"10.2217/cer.15.33";"26159375";"methodology";"4";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer.15.33";"26159375";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer.15.33";"26159375";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained virologic response"
"10.2217/cer.15.33";"26159375";"methodology";"4";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer.15.33";"26159375";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer.15.33";"26159375";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"5";"";"Treatment name 1";"daclatasvir + asunaprevir"
"10.2217/cer.15.33";"26159375";"methodology";"5";"";"Study 'number(s)' for treatment 1";"2;3"
"10.2217/cer.15.33";"26159375";"methodology";"5";"";"Treatment name 2";"peginterferon-α + ribavirin"
"10.2217/cer.15.33";"26159375";"methodology";"5";"";"Study 'number(s)' for treatment 2";"4;8;10;11"
"10.2217/cer.15.33";"26159375";"methodology";"5";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer.15.33";"26159375";"methodology";"5";"";"Anchored comparison?";"No"
"10.2217/cer.15.33";"26159375";"methodology";"5";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer.15.33";"26159375";"methodology";"5";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer.15.33";"26159375";"methodology";"5";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained virologic response"
"10.2217/cer.15.33";"26159375";"methodology";"5";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer.15.33";"26159375";"methodology";"5";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer.15.33";"26159375";"methodology";"5";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"5";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"5";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"5";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"6";"";"Treatment name 1";"daclatasvir + asunaprevir"
"10.2217/cer.15.33";"26159375";"methodology";"6";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.2217/cer.15.33";"26159375";"methodology";"6";"";"Treatment name 2";"telaprevir + peginterferon-α + ribavirin"
"10.2217/cer.15.33";"26159375";"methodology";"6";"";"Study 'number(s)' for treatment 2";"7"
"10.2217/cer.15.33";"26159375";"methodology";"6";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer.15.33";"26159375";"methodology";"6";"";"Anchored comparison?";"No"
"10.2217/cer.15.33";"26159375";"methodology";"6";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer.15.33";"26159375";"methodology";"6";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer.15.33";"26159375";"methodology";"6";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained virologic response"
"10.2217/cer.15.33";"26159375";"methodology";"6";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer.15.33";"26159375";"methodology";"6";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer.15.33";"26159375";"methodology";"6";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"6";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"6";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"6";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"7";"";"Treatment name 1";"daclatasvir + asunaprevir"
"10.2217/cer.15.33";"26159375";"methodology";"7";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.2217/cer.15.33";"26159375";"methodology";"7";"";"Treatment name 2";"boceprevir + peginterferon-α + ribavirin"
"10.2217/cer.15.33";"26159375";"methodology";"7";"";"Study 'number(s)' for treatment 2";"9"
"10.2217/cer.15.33";"26159375";"methodology";"7";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer.15.33";"26159375";"methodology";"7";"";"Anchored comparison?";"No"
"10.2217/cer.15.33";"26159375";"methodology";"7";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer.15.33";"26159375";"methodology";"7";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer.15.33";"26159375";"methodology";"7";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained virologic response"
"10.2217/cer.15.33";"26159375";"methodology";"7";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer.15.33";"26159375";"methodology";"7";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer.15.33";"26159375";"methodology";"7";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"7";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"7";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"7";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"8";"";"Treatment name 1";"daclatasvir + asunaprevir"
"10.2217/cer.15.33";"26159375";"methodology";"8";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.2217/cer.15.33";"26159375";"methodology";"8";"";"Treatment name 2";"simeprevir + peginterferon-α + ribavirin"
"10.2217/cer.15.33";"26159375";"methodology";"8";"";"Study 'number(s)' for treatment 2";"12"
"10.2217/cer.15.33";"26159375";"methodology";"8";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer.15.33";"26159375";"methodology";"8";"";"Anchored comparison?";"No"
"10.2217/cer.15.33";"26159375";"methodology";"8";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer.15.33";"26159375";"methodology";"8";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer.15.33";"26159375";"methodology";"8";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained virologic response"
"10.2217/cer.15.33";"26159375";"methodology";"8";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer.15.33";"26159375";"methodology";"8";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer.15.33";"26159375";"methodology";"8";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"8";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"8";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"8";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"9";"";"Treatment name 1";"daclatasvir + asunaprevir"
"10.2217/cer.15.33";"26159375";"methodology";"9";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.2217/cer.15.33";"26159375";"methodology";"9";"";"Treatment name 2";"peginterferon-α + ribavirin"
"10.2217/cer.15.33";"26159375";"methodology";"9";"";"Study 'number(s)' for treatment 2";"9;12"
"10.2217/cer.15.33";"26159375";"methodology";"9";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer.15.33";"26159375";"methodology";"9";"";"Anchored comparison?";"No"
"10.2217/cer.15.33";"26159375";"methodology";"9";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer.15.33";"26159375";"methodology";"9";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer.15.33";"26159375";"methodology";"9";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained virologic response"
"10.2217/cer.15.33";"26159375";"methodology";"9";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer.15.33";"26159375";"methodology";"9";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer.15.33";"26159375";"methodology";"9";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"9";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer.15.33";"26159375";"methodology";"9";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer.15.33";"26159375";"methodology";"9";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer.15.33";"26159375";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"1643"
"10.2217/cer.15.33";"26159375";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer.15.33";"26159375";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.2217/cer.15.33";"26159375";"results";"1";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.2217/cer.15.33";"26159375";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer.15.33";"26159375";"results";"1";"";"Primary outcome: adjusted treatment effect";"8.7"
"10.2217/cer.15.33";"26159375";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.2;17.3]"
"10.2217/cer.15.33";"26159375";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"324"
"10.2217/cer.15.33";"26159375";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"368"
"10.2217/cer.15.33";"26159375";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer.15.33";"26159375";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.2217/cer.15.33";"26159375";"results";"2";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.2217/cer.15.33";"26159375";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer.15.33";"26159375";"results";"2";"";"Primary outcome: adjusted treatment effect";"16.5"
"10.2217/cer.15.33";"26159375";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[2.5;30.5]"
"10.2217/cer.15.33";"26159375";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"324"
"10.2217/cer.15.33";"26159375";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"521"
"10.2217/cer.15.33";"26159375";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer.15.33";"26159375";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.2217/cer.15.33";"26159375";"results";"3";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.2217/cer.15.33";"26159375";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer.15.33";"26159375";"results";"3";"";"Primary outcome: adjusted treatment effect";"0.4"
"10.2217/cer.15.33";"26159375";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-8.9;9.7]"
"10.2217/cer.15.33";"26159375";"results";"3";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"na"
"10.2217/cer.15.33";"26159375";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"324"
"10.2217/cer.15.33";"26159375";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"327"
"10.2217/cer.15.33";"26159375";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer.15.33";"26159375";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.2217/cer.15.33";"26159375";"results";"4";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.2217/cer.15.33";"26159375";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer.15.33";"26159375";"results";"4";"";"Primary outcome: adjusted treatment effect";"3"
"10.2217/cer.15.33";"26159375";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[-21.2;27.1]"
"10.2217/cer.15.33";"26159375";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"324"
"10.2217/cer.15.33";"26159375";"results";"5";"";"Sample size of the population of interest in the non IPD treatment arm";"988"
"10.2217/cer.15.33";"26159375";"results";"5";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer.15.33";"26159375";"results";"5";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.2217/cer.15.33";"26159375";"results";"5";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.2217/cer.15.33";"26159375";"results";"5";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer.15.33";"26159375";"results";"5";"";"Primary outcome: adjusted treatment effect";"39.6"
"10.2217/cer.15.33";"26159375";"results";"5";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[30.3;48.9]"
"10.2217/cer.15.33";"26159375";"results";"5";"";"Initial sample size of the population of interest in the IPD treatment arm";"324"
"10.2217/cer.15.33";"26159375";"results";"6";"";"Sample size of the population of interest in the non IPD treatment arm";"540"
"10.2217/cer.15.33";"26159375";"results";"6";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"AN"
"10.2217/cer.15.33";"26159375";"results";"6";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer.15.33";"26159375";"results";"6";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.2217/cer.15.33";"26159375";"results";"6";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.2217/cer.15.33";"26159375";"results";"6";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer.15.33";"26159375";"results";"6";"";"Primary outcome: adjusted treatment effect";"17"
"10.2217/cer.15.33";"26159375";"results";"6";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[5.3;28.7]"
"10.2217/cer.15.33";"26159375";"results";"6";"";"Initial sample size of the population of interest in the IPD treatment arm";"314"
"10.2217/cer.15.33";"26159375";"results";"7";"";"Sample size of the population of interest in the non IPD treatment arm";"162"
"10.2217/cer.15.33";"26159375";"results";"7";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer.15.33";"26159375";"results";"7";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.2217/cer.15.33";"26159375";"results";"7";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.2217/cer.15.33";"26159375";"results";"7";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer.15.33";"26159375";"results";"7";"";"Primary outcome: adjusted treatment effect";"22.8"
"10.2217/cer.15.33";"26159375";"results";"7";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[6.9;38.7]"
"10.2217/cer.15.33";"26159375";"results";"7";"";"Initial sample size of the population of interest in the IPD treatment arm";"314"
"10.2217/cer.15.33";"26159375";"results";"8";"";"Sample size of the population of interest in the non IPD treatment arm";"260"
"10.2217/cer.15.33";"26159375";"results";"8";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer.15.33";"26159375";"results";"8";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.2217/cer.15.33";"26159375";"results";"8";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.2217/cer.15.33";"26159375";"results";"8";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer.15.33";"26159375";"results";"8";"";"Primary outcome: adjusted treatment effect";"10.3"
"10.2217/cer.15.33";"26159375";"results";"8";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[1.1;19.5]"
"10.2217/cer.15.33";"26159375";"results";"8";"";"Initial sample size of the population of interest in the IPD treatment arm";"314"
"10.2217/cer.15.33";"26159375";"results";"9";"";"Sample size of the population of interest in the non IPD treatment arm";"213"
"10.2217/cer.15.33";"26159375";"results";"9";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer.15.33";"26159375";"results";"9";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.2217/cer.15.33";"26159375";"results";"9";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.2217/cer.15.33";"26159375";"results";"9";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer.15.33";"26159375";"results";"9";"";"Primary outcome: adjusted treatment effect";"57.7"
"10.2217/cer.15.33";"26159375";"results";"9";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[44.0;71.4]"
"10.2217/cer.15.33";"26159375";"results";"9";"";"Initial sample size of the population of interest in the IPD treatment arm";"314"
"10.2217/cer.15.49";"26390233";"general_information";"";"";"Medical Condition of Interest Name";"hepatitis c genotype 3"
"10.2217/cer.15.49";"26390233";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2217/cer.15.49";"26390233";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2217/cer.15.49";"26390233";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/cer.15.49";"26390233";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/cer.15.49";"26390233";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/cer.15.49";"26390233";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/cer.15.49";"26390233";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2217/cer.15.49";"26390233";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/cer.15.49";"26390233";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/cer.15.49";"26390233";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02032901"
"10.2217/cer.15.49";"26390233";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer.15.49";"26390233";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.49";"26390233";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer.15.49";"26390233";"study_information";"";"2";"Patient-level data used";"No"
"10.2217/cer.15.49";"26390233";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/cer.15.49";"26390233";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01682720"
"10.2217/cer.15.49";"26390233";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer.15.49";"26390233";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.49";"26390233";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer.15.49";"26390233";"study_information";"";"3";"Patient-level data used";"No"
"10.2217/cer.15.49";"26390233";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2217/cer.15.49";"26390233";"study_information";"";"3";"Data source name (only if observational study or clinical trial without NCT)";"ferenci et al. (2008)"
"10.2217/cer.15.49";"26390233";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"austria"
"10.2217/cer.15.49";"26390233";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer.15.49";"26390233";"study_information";"";"4";"Patient-level data used";"No"
"10.2217/cer.15.49";"26390233";"study_information";"";"4";"Clinical Trial";"Yes"
"10.2217/cer.15.49";"26390233";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00077636"
"10.2217/cer.15.49";"26390233";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/cer.15.49";"26390233";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"4"
"10.2217/cer.15.49";"26390233";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer.15.49";"26390233";"methodology";"1";"";"Treatment name 1";"daclatasvir + sofosbuvir"
"10.2217/cer.15.49";"26390233";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer.15.49";"26390233";"methodology";"1";"";"Treatment name 2";"sofosbuvir + ribavirin"
"10.2217/cer.15.49";"26390233";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2217/cer.15.49";"26390233";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer.15.49";"26390233";"methodology";"1";"";"Anchored comparison?";"No"
"10.2217/cer.15.49";"26390233";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/cer.15.49";"26390233";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer.15.49";"26390233";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained virologic response"
"10.2217/cer.15.49";"26390233";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer.15.49";"26390233";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer.15.49";"26390233";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer.15.49";"26390233";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer.15.49";"26390233";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.2217/cer.15.49";"26390233";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer.15.49";"26390233";"methodology";"2";"";"Treatment name 1";"daclatasvir + sofosbuvir"
"10.2217/cer.15.49";"26390233";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/cer.15.49";"26390233";"methodology";"2";"";"Treatment name 2";"peginterferon-alfa + ribavirin"
"10.2217/cer.15.49";"26390233";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3;4"
"10.2217/cer.15.49";"26390233";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer.15.49";"26390233";"methodology";"2";"";"Anchored comparison?";"No"
"10.2217/cer.15.49";"26390233";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer.15.49";"26390233";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer.15.49";"26390233";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained virologic response"
"10.2217/cer.15.49";"26390233";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer.15.49";"26390233";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer.15.49";"26390233";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer.15.49";"26390233";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer.15.49";"26390233";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"Yes"
"10.2217/cer.15.49";"26390233";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer.15.49";"26390233";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"250"
"10.2217/cer.15.49";"26390233";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"144"
"10.2217/cer.15.49";"26390233";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer.15.49";"26390233";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer.15.49";"26390233";"results";"1";"";"Number of covariates adjusted for/matched on";"12"
"10.2217/cer.15.49";"26390233";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.2217/cer.15.49";"26390233";"results";"1";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.2217/cer.15.49";"26390233";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer.15.49";"26390233";"results";"1";"";"Primary outcome: unadjusted treatment effect";"4.4"
"10.2217/cer.15.49";"26390233";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.216"
"10.2217/cer.15.49";"26390233";"results";"1";"";"Primary outcome: adjusted treatment effect";"3.6"
"10.2217/cer.15.49";"26390233";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.537"
"10.2217/cer.15.49";"26390233";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"492"
"10.2217/cer.15.49";"26390233";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"74"
"10.2217/cer.15.49";"26390233";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer.15.49";"26390233";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer.15.49";"26390233";"results";"2";"";"Number of covariates adjusted for/matched on";"4"
"10.2217/cer.15.49";"26390233";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.2217/cer.15.49";"26390233";"results";"2";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.2217/cer.15.49";"26390233";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer.15.49";"26390233";"results";"2";"";"Primary outcome: unadjusted treatment effect";"21.3"
"10.2217/cer.15.49";"26390233";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.2217/cer.15.49";"26390233";"results";"2";"";"Primary outcome: adjusted treatment effect";"18.9"
"10.2217/cer.15.49";"26390233";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.2217/cer.15.69";"26793987";"general_information";"";"";"Medical Condition of Interest Name";"hepatitis c virus genotype 1b"
"10.2217/cer.15.69";"26793987";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2217/cer.15.69";"26793987";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2217/cer.15.69";"26793987";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/cer.15.69";"26793987";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/cer.15.69";"26793987";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/cer.15.69";"26793987";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/cer.15.69";"26793987";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2217/cer.15.69";"26793987";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/cer.15.69";"26793987";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/cer.15.69";"26793987";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01497834"
"10.2217/cer.15.69";"26793987";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"japan"
"10.2217/cer.15.69";"26793987";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.69";"26793987";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.2217/cer.15.69";"26793987";"study_information";"";"2";"Patient-level data used";"Yes"
"10.2217/cer.15.69";"26793987";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/cer.15.69";"26793987";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01718145"
"10.2217/cer.15.69";"26793987";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"japan"
"10.2217/cer.15.69";"26793987";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.69";"26793987";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer.15.69";"26793987";"study_information";"";"3";"Patient-level data used";"No"
"10.2217/cer.15.69";"26793987";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2217/cer.15.69";"26793987";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01975675"
"10.2217/cer.15.69";"26793987";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"japan"
"10.2217/cer.15.69";"26793987";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/cer.15.69";"26793987";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/cer.15.69";"26793987";"methodology";"1";"";"Treatment name 1";"daclatasvir + asunaprevir"
"10.2217/cer.15.69";"26793987";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.2217/cer.15.69";"26793987";"methodology";"1";"";"Treatment name 2";"sofosbuvir + ledipasvir"
"10.2217/cer.15.69";"26793987";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3"
"10.2217/cer.15.69";"26793987";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/cer.15.69";"26793987";"methodology";"1";"";"Anchored comparison?";"No"
"10.2217/cer.15.69";"26793987";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/cer.15.69";"26793987";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/cer.15.69";"26793987";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"sustained virologic response at week 12 post-treatment"
"10.2217/cer.15.69";"26793987";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/cer.15.69";"26793987";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.2217/cer.15.69";"26793987";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/cer.15.69";"26793987";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/cer.15.69";"26793987";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/cer.15.69";"26793987";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/cer.15.69";"26793987";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"171"
"10.2217/cer.15.69";"26793987";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"252"
"10.2217/cer.15.69";"26793987";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/cer.15.69";"26793987";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/cer.15.69";"26793987";"results";"1";"";"Number of covariates adjusted for/matched on";"11"
"10.2217/cer.15.69";"26793987";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)"
"10.2217/cer.15.69";"26793987";"results";"1";"";"Primary outcome: treatment effect contrast";"Rate difference"
"10.2217/cer.15.69";"26793987";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/cer.15.69";"26793987";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.004"
"10.2217/cer.15.69";"26793987";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.398"
"10.2217/cer.15.69";"26793987";"results";"1";"";"Primary outcome: unadjusted treatment effect";"-0.048"
"10.2217/cer.15.69";"26793987";"results";"1";"";"Primary outcome: adjusted treatment effect";"-0.007"
"10.2217/fon-2020-0823";"33052055";"general_information";"";"";"Medical Condition of Interest Name";"advanced cutaneous squamous cell carcinoma"
"10.2217/fon-2020-0823";"33052055";"general_information";"";"";"Countries of first author affiliations";"canada"
"10.2217/fon-2020-0823";"33052055";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2217/fon-2020-0823";"33052055";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/fon-2020-0823";"33052055";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/fon-2020-0823";"33052055";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/fon-2020-0823";"33052055";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/fon-2020-0823";"33052055";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02760498"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"10";"Patient-level data used";"No"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"10";"Clinical Trial";"Yes"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"10";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03284424"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"10";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"10";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"10";"Number of treatment arms (clinical trial only)";"1"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"11";"Patient-level data used";"No"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"11";"Clinical Trial";"No"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"11";"Data source name (only if observational study or clinical trial without NCT)";"peyrade et al. (2018)"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"2";"Patient-level data used";"No"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01198028"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"3";"Patient-level data used";"No"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"3";"Clinical Trial";"No"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"3";"Data source name (only if observational study or clinical trial without NCT)";"jarkowski et al. (2016)"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"4";"Patient-level data used";"No"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"4";"Clinical Trial";"Yes"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00240682"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"france"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"5";"Patient-level data used";"No"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"5";"Clinical Trial";"No"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"5";"Data source name (only if observational study or clinical trial without NCT)";"picard et al. (2017)"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"france"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"6";"Patient-level data used";"No"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"6";"Clinical Trial";"Yes"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"6";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00054691"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"6";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"6";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"6";"Number of treatment arms (clinical trial only)";"1"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"7";"Patient-level data used";"No"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"7";"Clinical Trial";"Yes"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"7";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02268747"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"7";"Country where the clinical trial/observational study was conducted (international if more than one)";"italy"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"7";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"7";"Number of treatment arms (clinical trial only)";"1"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"8";"Patient-level data used";"No"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"8";"Clinical Trial";"Yes"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"8";"Data source name (only if observational study or clinical trial without NCT)";"foote et al. (2014)"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"8";"Country where the clinical trial/observational study was conducted (international if more than one)";"australia"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"8";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"8";"Number of treatment arms (clinical trial only)";"1"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"9";"Patient-level data used";"No"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"9";"Clinical Trial";"Yes"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"9";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02883556"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"9";"Country where the clinical trial/observational study was conducted (international if more than one)";"france"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"9";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/fon-2020-0823";"33052055";"study_information";"";"9";"Number of treatment arms (clinical trial only)";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"1";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"1";"";"Treatment name 2";"erlotinib"
"10.2217/fon-2020-0823";"33052055";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2217/fon-2020-0823";"33052055";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/fon-2020-0823";"33052055";"methodology";"1";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"10";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"10";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"10";"";"Treatment name 2";"gefitinib"
"10.2217/fon-2020-0823";"33052055";"methodology";"10";"";"Study 'number(s)' for treatment 2";"6"
"10.2217/fon-2020-0823";"33052055";"methodology";"10";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2217/fon-2020-0823";"33052055";"methodology";"10";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"10";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"10";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"10";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"10";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"10";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"10";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"10";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"10";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"10";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"11";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"11";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"11";"";"Treatment name 2";"dacomitinib"
"10.2217/fon-2020-0823";"33052055";"methodology";"11";"";"Study 'number(s)' for treatment 2";"7"
"10.2217/fon-2020-0823";"33052055";"methodology";"11";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/fon-2020-0823";"33052055";"methodology";"11";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"11";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"11";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"11";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"11";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"11";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"11";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"11";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"11";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"11";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"12";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"12";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"12";"";"Treatment name 2";"dacomitinib"
"10.2217/fon-2020-0823";"33052055";"methodology";"12";"";"Study 'number(s)' for treatment 2";"7"
"10.2217/fon-2020-0823";"33052055";"methodology";"12";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2217/fon-2020-0823";"33052055";"methodology";"12";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"12";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"12";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"12";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"12";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"12";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"12";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"12";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"12";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"12";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"13";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"13";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"13";"";"Treatment name 2";"panitumumab"
"10.2217/fon-2020-0823";"33052055";"methodology";"13";"";"Study 'number(s)' for treatment 2";"8"
"10.2217/fon-2020-0823";"33052055";"methodology";"13";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/fon-2020-0823";"33052055";"methodology";"13";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"13";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"13";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"13";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"13";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"13";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"13";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"13";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"13";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"13";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"14";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"14";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"14";"";"Treatment name 2";"panitumumab"
"10.2217/fon-2020-0823";"33052055";"methodology";"14";"";"Study 'number(s)' for treatment 2";"8"
"10.2217/fon-2020-0823";"33052055";"methodology";"14";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2217/fon-2020-0823";"33052055";"methodology";"14";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"14";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"14";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"14";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"14";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"14";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"14";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"14";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"14";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"14";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"15";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"15";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"15";"";"Treatment name 2";"pembrolizumab"
"10.2217/fon-2020-0823";"33052055";"methodology";"15";"";"Study 'number(s)' for treatment 2";"9"
"10.2217/fon-2020-0823";"33052055";"methodology";"15";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/fon-2020-0823";"33052055";"methodology";"15";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"15";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"15";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"15";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"15";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"15";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"15";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"15";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"15";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"15";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"16";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"16";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"16";"";"Treatment name 2";"pembrolizumab"
"10.2217/fon-2020-0823";"33052055";"methodology";"16";"";"Study 'number(s)' for treatment 2";"9"
"10.2217/fon-2020-0823";"33052055";"methodology";"16";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2217/fon-2020-0823";"33052055";"methodology";"16";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"16";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"16";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"16";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"16";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"16";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"16";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"16";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"16";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"16";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"17";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"17";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"17";"";"Treatment name 2";"pembrolizumab"
"10.2217/fon-2020-0823";"33052055";"methodology";"17";"";"Study 'number(s)' for treatment 2";"10"
"10.2217/fon-2020-0823";"33052055";"methodology";"17";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/fon-2020-0823";"33052055";"methodology";"17";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"17";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"17";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"17";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"17";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"17";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"17";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"17";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"17";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"17";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"18";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"18";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"18";"";"Treatment name 2";"pembrolizumab"
"10.2217/fon-2020-0823";"33052055";"methodology";"18";"";"Study 'number(s)' for treatment 2";"10"
"10.2217/fon-2020-0823";"33052055";"methodology";"18";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2217/fon-2020-0823";"33052055";"methodology";"18";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"18";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"18";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"18";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"18";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"18";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"18";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"18";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"18";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"18";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"19";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"19";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"19";"";"Treatment name 2";"cetuximab"
"10.2217/fon-2020-0823";"33052055";"methodology";"19";"";"Study 'number(s)' for treatment 2";"11"
"10.2217/fon-2020-0823";"33052055";"methodology";"19";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/fon-2020-0823";"33052055";"methodology";"19";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"19";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"19";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"19";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"19";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"19";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"19";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"19";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"19";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"19";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"2";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"2";"";"Treatment name 2";"erlotinib"
"10.2217/fon-2020-0823";"33052055";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.2217/fon-2020-0823";"33052055";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2217/fon-2020-0823";"33052055";"methodology";"2";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"20";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"20";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"20";"";"Treatment name 2";"cetuximab"
"10.2217/fon-2020-0823";"33052055";"methodology";"20";"";"Study 'number(s)' for treatment 2";"11"
"10.2217/fon-2020-0823";"33052055";"methodology";"20";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2217/fon-2020-0823";"33052055";"methodology";"20";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"20";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"20";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"20";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"20";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"20";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"20";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"20";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"20";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"20";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"3";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"3";"";"Treatment name 2";"platinum-based chemotherapy"
"10.2217/fon-2020-0823";"33052055";"methodology";"3";"";"Study 'number(s)' for treatment 2";"3"
"10.2217/fon-2020-0823";"33052055";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/fon-2020-0823";"33052055";"methodology";"3";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"3";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"4";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"4";"";"Treatment name 2";"platinum-based chemotherapy"
"10.2217/fon-2020-0823";"33052055";"methodology";"4";"";"Study 'number(s)' for treatment 2";"3"
"10.2217/fon-2020-0823";"33052055";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2217/fon-2020-0823";"33052055";"methodology";"4";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"4";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"4";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"5";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"5";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"5";"";"Treatment name 2";"cetuximab"
"10.2217/fon-2020-0823";"33052055";"methodology";"5";"";"Study 'number(s)' for treatment 2";"4"
"10.2217/fon-2020-0823";"33052055";"methodology";"5";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/fon-2020-0823";"33052055";"methodology";"5";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"5";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"5";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"5";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"5";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"5";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"5";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"5";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"5";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"5";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"6";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"6";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"6";"";"Treatment name 2";"cetuximab"
"10.2217/fon-2020-0823";"33052055";"methodology";"6";"";"Study 'number(s)' for treatment 2";"4"
"10.2217/fon-2020-0823";"33052055";"methodology";"6";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2217/fon-2020-0823";"33052055";"methodology";"6";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"6";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"6";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"6";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"6";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"6";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"6";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"6";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"6";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"6";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"7";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"7";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"7";"";"Treatment name 2";"cetuximab"
"10.2217/fon-2020-0823";"33052055";"methodology";"7";"";"Study 'number(s)' for treatment 2";"5"
"10.2217/fon-2020-0823";"33052055";"methodology";"7";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/fon-2020-0823";"33052055";"methodology";"7";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"7";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"7";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"7";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"7";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"7";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"7";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"7";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"7";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"7";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"8";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"8";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"8";"";"Treatment name 2";"cetuximab"
"10.2217/fon-2020-0823";"33052055";"methodology";"8";"";"Study 'number(s)' for treatment 2";"5"
"10.2217/fon-2020-0823";"33052055";"methodology";"8";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2217/fon-2020-0823";"33052055";"methodology";"8";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"8";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"8";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"8";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"8";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"8";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"8";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"8";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"8";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"8";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"9";"";"Treatment name 1";"cemiplimab"
"10.2217/fon-2020-0823";"33052055";"methodology";"9";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2020-0823";"33052055";"methodology";"9";"";"Treatment name 2";"gefitinib"
"10.2217/fon-2020-0823";"33052055";"methodology";"9";"";"Study 'number(s)' for treatment 2";"6"
"10.2217/fon-2020-0823";"33052055";"methodology";"9";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/fon-2020-0823";"33052055";"methodology";"9";"";"Anchored comparison?";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"9";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2020-0823";"33052055";"methodology";"9";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2020-0823";"33052055";"methodology";"9";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2020-0823";"33052055";"methodology";"9";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2020-0823";"33052055";"methodology";"9";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2020-0823";"33052055";"methodology";"9";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2020-0823";"33052055";"methodology";"9";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2020-0823";"33052055";"methodology";"9";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2020-0823";"33052055";"methodology";"9";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2020-0823";"33052055";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"39"
"10.2217/fon-2020-0823";"33052055";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/fon-2020-0823";"33052055";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"1";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.28"
"10.2217/fon-2020-0823";"33052055";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.16;0.50]"
"10.2217/fon-2020-0823";"33052055";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.41"
"10.2217/fon-2020-0823";"33052055";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.24;0.70]"
"10.2217/fon-2020-0823";"33052055";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"10";"";"Sample size of the population of interest in the non IPD treatment arm";"40"
"10.2217/fon-2020-0823";"33052055";"results";"10";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"10";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"193"
"10.2217/fon-2020-0823";"33052055";"results";"10";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"10";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"10";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"10";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"10";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"10";"";"Primary outcome: unadjusted treatment effect";"0.27"
"10.2217/fon-2020-0823";"33052055";"results";"10";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.16;0.44]"
"10.2217/fon-2020-0823";"33052055";"results";"10";"";"Primary outcome: adjusted treatment effect";"0.29"
"10.2217/fon-2020-0823";"33052055";"results";"10";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.18;0.45]"
"10.2217/fon-2020-0823";"33052055";"results";"11";"";"Sample size of the population of interest in the non IPD treatment arm";"42"
"10.2217/fon-2020-0823";"33052055";"results";"11";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/fon-2020-0823";"33052055";"results";"11";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"11";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"11";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"11";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"11";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"11";"";"Primary outcome: unadjusted treatment effect";"0.2"
"10.2217/fon-2020-0823";"33052055";"results";"11";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.13;0.33]"
"10.2217/fon-2020-0823";"33052055";"results";"11";"";"Primary outcome: adjusted treatment effect";"0.17"
"10.2217/fon-2020-0823";"33052055";"results";"11";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.10;0.28]"
"10.2217/fon-2020-0823";"33052055";"results";"11";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"12";"";"Sample size of the population of interest in the non IPD treatment arm";"42"
"10.2217/fon-2020-0823";"33052055";"results";"12";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"12";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"193"
"10.2217/fon-2020-0823";"33052055";"results";"12";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"12";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"12";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"12";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"12";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"12";"";"Primary outcome: unadjusted treatment effect";"0.2"
"10.2217/fon-2020-0823";"33052055";"results";"12";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.13;0.33]"
"10.2217/fon-2020-0823";"33052055";"results";"12";"";"Primary outcome: adjusted treatment effect";"0.07"
"10.2217/fon-2020-0823";"33052055";"results";"12";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.04;0.13]"
"10.2217/fon-2020-0823";"33052055";"results";"13";"";"Sample size of the population of interest in the non IPD treatment arm";"16"
"10.2217/fon-2020-0823";"33052055";"results";"13";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/fon-2020-0823";"33052055";"results";"13";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"13";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"13";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"13";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"13";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"13";"";"Primary outcome: unadjusted treatment effect";"0.27"
"10.2217/fon-2020-0823";"33052055";"results";"13";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.13;0.54]"
"10.2217/fon-2020-0823";"33052055";"results";"13";"";"Primary outcome: adjusted treatment effect";"0.52"
"10.2217/fon-2020-0823";"33052055";"results";"13";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.26;1.01]"
"10.2217/fon-2020-0823";"33052055";"results";"13";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"14";"";"Sample size of the population of interest in the non IPD treatment arm";"16"
"10.2217/fon-2020-0823";"33052055";"results";"14";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"14";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"193"
"10.2217/fon-2020-0823";"33052055";"results";"14";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"14";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"14";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"14";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"14";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"14";"";"Primary outcome: unadjusted treatment effect";"0.27"
"10.2217/fon-2020-0823";"33052055";"results";"14";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.13;0.54]"
"10.2217/fon-2020-0823";"33052055";"results";"14";"";"Primary outcome: adjusted treatment effect";"0.36"
"10.2217/fon-2020-0823";"33052055";"results";"14";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.18;0.70]"
"10.2217/fon-2020-0823";"33052055";"results";"15";"";"Sample size of the population of interest in the non IPD treatment arm";"39"
"10.2217/fon-2020-0823";"33052055";"results";"15";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/fon-2020-0823";"33052055";"results";"15";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"15";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"15";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"15";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"15";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"15";"";"Primary outcome: unadjusted treatment effect";"0.41"
"10.2217/fon-2020-0823";"33052055";"results";"15";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.20;0.87]"
"10.2217/fon-2020-0823";"33052055";"results";"15";"";"Primary outcome: adjusted treatment effect";"0.39"
"10.2217/fon-2020-0823";"33052055";"results";"15";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.17;0.86]"
"10.2217/fon-2020-0823";"33052055";"results";"15";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"16";"";"Sample size of the population of interest in the non IPD treatment arm";"39"
"10.2217/fon-2020-0823";"33052055";"results";"16";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"16";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"193"
"10.2217/fon-2020-0823";"33052055";"results";"16";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"16";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"16";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"16";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"16";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"16";"";"Primary outcome: unadjusted treatment effect";"0.41"
"10.2217/fon-2020-0823";"33052055";"results";"16";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.20;0.87]"
"10.2217/fon-2020-0823";"33052055";"results";"16";"";"Primary outcome: adjusted treatment effect";"0.21"
"10.2217/fon-2020-0823";"33052055";"results";"16";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.09;0.48]"
"10.2217/fon-2020-0823";"33052055";"results";"17";"";"Sample size of the population of interest in the non IPD treatment arm";"105"
"10.2217/fon-2020-0823";"33052055";"results";"17";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/fon-2020-0823";"33052055";"results";"17";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"17";"";"Number of covariates adjusted for/matched on";"7"
"10.2217/fon-2020-0823";"33052055";"results";"17";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"17";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"17";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"17";"";"Primary outcome: unadjusted treatment effect";"0.4"
"10.2217/fon-2020-0823";"33052055";"results";"17";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.25;0.63]"
"10.2217/fon-2020-0823";"33052055";"results";"17";"";"Primary outcome: adjusted treatment effect";"0.52"
"10.2217/fon-2020-0823";"33052055";"results";"17";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.34;0.80]"
"10.2217/fon-2020-0823";"33052055";"results";"17";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"18";"";"Sample size of the population of interest in the non IPD treatment arm";"105"
"10.2217/fon-2020-0823";"33052055";"results";"18";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"18";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"193"
"10.2217/fon-2020-0823";"33052055";"results";"18";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"18";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"18";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"18";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"18";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"18";"";"Primary outcome: unadjusted treatment effect";"0.4"
"10.2217/fon-2020-0823";"33052055";"results";"18";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.25;0.63]"
"10.2217/fon-2020-0823";"33052055";"results";"18";"";"Primary outcome: adjusted treatment effect";"0.26"
"10.2217/fon-2020-0823";"33052055";"results";"18";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.16;0.42]"
"10.2217/fon-2020-0823";"33052055";"results";"19";"";"Sample size of the population of interest in the non IPD treatment arm";"58"
"10.2217/fon-2020-0823";"33052055";"results";"19";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/fon-2020-0823";"33052055";"results";"19";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"19";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"19";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"19";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"19";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"19";"";"Primary outcome: unadjusted treatment effect";"0.34"
"10.2217/fon-2020-0823";"33052055";"results";"19";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.21;0.55]"
"10.2217/fon-2020-0823";"33052055";"results";"19";"";"Primary outcome: adjusted treatment effect";"0.29"
"10.2217/fon-2020-0823";"33052055";"results";"19";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.16;0.54]"
"10.2217/fon-2020-0823";"33052055";"results";"19";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"39"
"10.2217/fon-2020-0823";"33052055";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"193"
"10.2217/fon-2020-0823";"33052055";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"2";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"2";"";"Primary outcome: unadjusted treatment effect";"0.28"
"10.2217/fon-2020-0823";"33052055";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.16;0.50]"
"10.2217/fon-2020-0823";"33052055";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.23"
"10.2217/fon-2020-0823";"33052055";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.14;0.39]"
"10.2217/fon-2020-0823";"33052055";"results";"20";"";"Sample size of the population of interest in the non IPD treatment arm";"58"
"10.2217/fon-2020-0823";"33052055";"results";"20";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"20";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"193"
"10.2217/fon-2020-0823";"33052055";"results";"20";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"20";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"20";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"20";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"20";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"20";"";"Primary outcome: unadjusted treatment effect";"0.34"
"10.2217/fon-2020-0823";"33052055";"results";"20";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.21;0.55]"
"10.2217/fon-2020-0823";"33052055";"results";"20";"";"Primary outcome: adjusted treatment effect";"0.19"
"10.2217/fon-2020-0823";"33052055";"results";"20";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.11;0.31]"
"10.2217/fon-2020-0823";"33052055";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"25"
"10.2217/fon-2020-0823";"33052055";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/fon-2020-0823";"33052055";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"3";"";"Number of covariates adjusted for/matched on";"4"
"10.2217/fon-2020-0823";"33052055";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.2217/fon-2020-0823";"33052055";"results";"3";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"3";"";"Primary outcome: unadjusted treatment effect";"0.3"
"10.2217/fon-2020-0823";"33052055";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.16;0.58]"
"10.2217/fon-2020-0823";"33052055";"results";"3";"";"Primary outcome: adjusted treatment effect";"0.19"
"10.2217/fon-2020-0823";"33052055";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.10;0.39]"
"10.2217/fon-2020-0823";"33052055";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"25"
"10.2217/fon-2020-0823";"33052055";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"193"
"10.2217/fon-2020-0823";"33052055";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"4";"";"Number of covariates adjusted for/matched on";"4"
"10.2217/fon-2020-0823";"33052055";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.2217/fon-2020-0823";"33052055";"results";"4";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"4";"";"Primary outcome: unadjusted treatment effect";"0.3"
"10.2217/fon-2020-0823";"33052055";"results";"4";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.16;0.58]"
"10.2217/fon-2020-0823";"33052055";"results";"4";"";"Primary outcome: adjusted treatment effect";"0.17"
"10.2217/fon-2020-0823";"33052055";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.09;0.33]"
"10.2217/fon-2020-0823";"33052055";"results";"5";"";"Sample size of the population of interest in the non IPD treatment arm";"36"
"10.2217/fon-2020-0823";"33052055";"results";"5";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/fon-2020-0823";"33052055";"results";"5";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"5";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"5";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"5";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"5";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"5";"";"Primary outcome: unadjusted treatment effect";"0.25"
"10.2217/fon-2020-0823";"33052055";"results";"5";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.13;0.46]"
"10.2217/fon-2020-0823";"33052055";"results";"5";"";"Primary outcome: adjusted treatment effect";"0.11"
"10.2217/fon-2020-0823";"33052055";"results";"5";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.13;0.49]"
"10.2217/fon-2020-0823";"33052055";"results";"5";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"6";"";"Sample size of the population of interest in the non IPD treatment arm";"25"
"10.2217/fon-2020-0823";"33052055";"results";"6";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"6";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"193"
"10.2217/fon-2020-0823";"33052055";"results";"6";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"6";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"6";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"6";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"6";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"6";"";"Primary outcome: unadjusted treatment effect";"0.25"
"10.2217/fon-2020-0823";"33052055";"results";"6";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.13;0.46]"
"10.2217/fon-2020-0823";"33052055";"results";"6";"";"Primary outcome: adjusted treatment effect";"0.11"
"10.2217/fon-2020-0823";"33052055";"results";"6";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.05;0.22]"
"10.2217/fon-2020-0823";"33052055";"results";"7";"";"Sample size of the population of interest in the non IPD treatment arm";"31"
"10.2217/fon-2020-0823";"33052055";"results";"7";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/fon-2020-0823";"33052055";"results";"7";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"7";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"7";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"7";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"7";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"7";"";"Primary outcome: unadjusted treatment effect";"0.28"
"10.2217/fon-2020-0823";"33052055";"results";"7";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.16;0.50]"
"10.2217/fon-2020-0823";"33052055";"results";"7";"";"Primary outcome: adjusted treatment effect";"0.37"
"10.2217/fon-2020-0823";"33052055";"results";"7";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.20;0.69]"
"10.2217/fon-2020-0823";"33052055";"results";"7";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"8";"";"Sample size of the population of interest in the non IPD treatment arm";"31"
"10.2217/fon-2020-0823";"33052055";"results";"8";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2020-0823";"33052055";"results";"8";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"193"
"10.2217/fon-2020-0823";"33052055";"results";"8";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"8";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"8";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"8";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"8";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"8";"";"Primary outcome: unadjusted treatment effect";"0.28"
"10.2217/fon-2020-0823";"33052055";"results";"8";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.16;0.50]"
"10.2217/fon-2020-0823";"33052055";"results";"8";"";"Primary outcome: adjusted treatment effect";"0.25"
"10.2217/fon-2020-0823";"33052055";"results";"8";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.14;0.44]"
"10.2217/fon-2020-0823";"33052055";"results";"9";"";"Sample size of the population of interest in the non IPD treatment arm";"40"
"10.2217/fon-2020-0823";"33052055";"results";"9";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/fon-2020-0823";"33052055";"results";"9";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2020-0823";"33052055";"results";"9";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/fon-2020-0823";"33052055";"results";"9";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/fon-2020-0823";"33052055";"results";"9";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2020-0823";"33052055";"results";"9";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2020-0823";"33052055";"results";"9";"";"Primary outcome: unadjusted treatment effect";"0.27"
"10.2217/fon-2020-0823";"33052055";"results";"9";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.16;0.44]"
"10.2217/fon-2020-0823";"33052055";"results";"9";"";"Primary outcome: adjusted treatment effect";"0.47"
"10.2217/fon-2020-0823";"33052055";"results";"9";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.29;0.75]"
"10.2217/fon-2020-0823";"33052055";"results";"9";"";"Initial sample size of the population of interest in the IPD treatment arm";"193"
"10.2217/fon-2021-1102";"35232230";"general_information";"";"";"Medical Condition of Interest Name";"ros1-positive non-small-cell lung cancer"
"10.2217/fon-2021-1102";"35232230";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2217/fon-2021-1102";"35232230";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2217/fon-2021-1102";"35232230";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Private Data Analysis Company, Pharmaceutical Industry"
"10.2217/fon-2021-1102";"35232230";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/fon-2021-1102";"35232230";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/fon-2021-1102";"35232230";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/fon-2021-1102";"35232230";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00585195"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"2";"Patient-level data used";"No"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"2";"EudraCT (only for clinical trials registered on clinicaltrialsregister.eu";"2012-000148-88"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"1"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"3";"Patient-level data used";"No"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02097810"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"1"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"4";"Patient-level data used";"No"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"4";"Clinical Trial";"Yes"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02568267"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"5";"Patient-level data used";"No"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"5";"Clinical Trial";"No"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"5";"Data source name (only if observational study or clinical trial without NCT)";"flatiron health"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"6";"Patient-level data used";"No"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"6";"Clinical Trial";"No"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"6";"Data source name (only if observational study or clinical trial without NCT)";"ontada (oncology insights & technology)"
"10.2217/fon-2021-1102";"35232230";"study_information";"";"6";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.2217/fon-2021-1102";"35232230";"methodology";"1";"";"Treatment name 1";"crizotinib"
"10.2217/fon-2021-1102";"35232230";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2021-1102";"35232230";"methodology";"1";"";"Treatment name 2";"entrectinib"
"10.2217/fon-2021-1102";"35232230";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2;3;4"
"10.2217/fon-2021-1102";"35232230";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2217/fon-2021-1102";"35232230";"methodology";"1";"";"Anchored comparison?";"No"
"10.2217/fon-2021-1102";"35232230";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/fon-2021-1102";"35232230";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2021-1102";"35232230";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.2217/fon-2021-1102";"35232230";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.2217/fon-2021-1102";"35232230";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.2217/fon-2021-1102";"35232230";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.2217/fon-2021-1102";"35232230";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2021-1102";"35232230";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2021-1102";"35232230";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2021-1102";"35232230";"methodology";"2";"";"Treatment name 1";"crizotinib"
"10.2217/fon-2021-1102";"35232230";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2021-1102";"35232230";"methodology";"2";"";"Treatment name 2";"crizotinib"
"10.2217/fon-2021-1102";"35232230";"methodology";"2";"";"Study 'number(s)' for treatment 2";"5"
"10.2217/fon-2021-1102";"35232230";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2217/fon-2021-1102";"35232230";"methodology";"2";"";"Anchored comparison?";"No"
"10.2217/fon-2021-1102";"35232230";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2021-1102";"35232230";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2021-1102";"35232230";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression free survival"
"10.2217/fon-2021-1102";"35232230";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2021-1102";"35232230";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2021-1102";"35232230";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2021-1102";"35232230";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/fon-2021-1102";"35232230";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2021-1102";"35232230";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2021-1102";"35232230";"methodology";"3";"";"Treatment name 1";"crizotinib"
"10.2217/fon-2021-1102";"35232230";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/fon-2021-1102";"35232230";"methodology";"3";"";"Treatment name 2";"crizotinib"
"10.2217/fon-2021-1102";"35232230";"methodology";"3";"";"Study 'number(s)' for treatment 2";"6"
"10.2217/fon-2021-1102";"35232230";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.2217/fon-2021-1102";"35232230";"methodology";"3";"";"Anchored comparison?";"No"
"10.2217/fon-2021-1102";"35232230";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2021-1102";"35232230";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.2217/fon-2021-1102";"35232230";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2021-1102";"35232230";"methodology";"3";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2021-1102";"35232230";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/fon-2021-1102";"35232230";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2021-1102";"35232230";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/fon-2021-1102";"35232230";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2021-1102";"35232230";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2021-1102";"35232230";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"161"
"10.2217/fon-2021-1102";"35232230";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"53"
"10.2217/fon-2021-1102";"35232230";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"53"
"10.2217/fon-2021-1102";"35232230";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2021-1102";"35232230";"results";"1";"";"Number of covariates adjusted for/matched on";"4"
"10.2217/fon-2021-1102";"35232230";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.2217/fon-2021-1102";"35232230";"results";"1";"";"Primary outcome: treatment effect contrast";"RR"
"10.2217/fon-2021-1102";"35232230";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2021-1102";"35232230";"results";"1";"";"Primary outcome: unadjusted treatment effect";"1.07"
"10.2217/fon-2021-1102";"35232230";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.88;1.31]"
"10.2217/fon-2021-1102";"35232230";"results";"1";"";"Primary outcome: adjusted treatment effect";"1.04"
"10.2217/fon-2021-1102";"35232230";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.85;1.28]"
"10.2217/fon-2021-1102";"35232230";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"69"
"10.2217/fon-2021-1102";"35232230";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"53"
"10.2217/fon-2021-1102";"35232230";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"53"
"10.2217/fon-2021-1102";"35232230";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2021-1102";"35232230";"results";"2";"";"Number of covariates adjusted for/matched on";"2"
"10.2217/fon-2021-1102";"35232230";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Other(s), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.2217/fon-2021-1102";"35232230";"results";"2";"";"Primary outcome: treatment effect contrast";"Median difference"
"10.2217/fon-2021-1102";"35232230";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2021-1102";"35232230";"results";"2";"";"Primary outcome: unadjusted treatment effect";"10.8"
"10.2217/fon-2021-1102";"35232230";"results";"2";"";"Primary outcome: adjusted treatment effect";"8.3"
"10.2217/fon-2021-1102";"35232230";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.26;16.94"
"10.2217/fon-2021-1102";"35232230";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"38"
"10.2217/fon-2021-1102";"35232230";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"53"
"10.2217/fon-2021-1102";"35232230";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"53"
"10.2217/fon-2021-1102";"35232230";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2021-1102";"35232230";"results";"3";"";"Number of covariates adjusted for/matched on";"4"
"10.2217/fon-2021-1102";"35232230";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Past treatments for the disease of interest, Other(s)"
"10.2217/fon-2021-1102";"35232230";"results";"3";"";"Primary outcome: treatment effect contrast";"Median difference"
"10.2217/fon-2021-1102";"35232230";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2021-1102";"35232230";"results";"3";"";"Primary outcome: unadjusted treatment effect";"15.2"
"10.2217/fon-2021-1102";"35232230";"results";"3";"";"Primary outcome: adjusted treatment effect";"-10.5"
"10.2217/fon-2021-1102";"35232230";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/fon-2021-1509";"35114819";"general_information";"";"";"Medical Condition of Interest Name";"advanced systemic mastocytosis"
"10.2217/fon-2021-1509";"35114819";"general_information";"";"";"Countries of first author affiliations";"uk"
"10.2217/fon-2021-1509";"35114819";"general_information";"";"";"Countries of last author affiliations";"switzerland"
"10.2217/fon-2021-1509";"35114819";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/fon-2021-1509";"35114819";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/fon-2021-1509";"35114819";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/fon-2021-1509";"35114819";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/fon-2021-1509";"35114819";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02561988"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"2";"Patient-level data used";"Yes"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT03580655"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"3";"Patient-level data used";"No"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00782067"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"1"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"4";"Patient-level data used";"No"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"4";"Clinical Trial";"Yes"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00233454"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/fon-2021-1509";"35114819";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"1"
"10.2217/fon-2021-1509";"35114819";"methodology";"1";"";"Treatment name 1";"avapritinib"
"10.2217/fon-2021-1509";"35114819";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.2217/fon-2021-1509";"35114819";"methodology";"1";"";"Treatment name 2";"midostaurin"
"10.2217/fon-2021-1509";"35114819";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3;4"
"10.2217/fon-2021-1509";"35114819";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/fon-2021-1509";"35114819";"methodology";"1";"";"Anchored comparison?";"No"
"10.2217/fon-2021-1509";"35114819";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/fon-2021-1509";"35114819";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/fon-2021-1509";"35114819";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/fon-2021-1509";"35114819";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/fon-2021-1509";"35114819";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset"
"10.2217/fon-2021-1509";"35114819";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/fon-2021-1509";"35114819";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.2217/fon-2021-1509";"35114819";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/fon-2021-1509";"35114819";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/fon-2021-1509";"35114819";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"115"
"10.2217/fon-2021-1509";"35114819";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"85"
"10.2217/fon-2021-1509";"35114819";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/fon-2021-1509";"35114819";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/fon-2021-1509";"35114819";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/fon-2021-1509";"35114819";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/fon-2021-1509";"35114819";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.54"
"10.2217/fon-2021-1509";"35114819";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"[0.32;0.92]"
"10.2217/fon-2021-1509";"35114819";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.44"
"10.2217/fon-2021-1509";"35114819";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.25;0.76]"
"10.2217/fon-2021-1509";"35114819";"results";"1";"";"Number of covariates adjusted for/matched on";"3"
"10.2217/fon-2021-1509";"35114819";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity"
"10.2217/imt-2018-0208";"30852924";"general_information";"";"";"Medical Condition of Interest Name";"braf-mutant advanced melanoma"
"10.2217/imt-2018-0208";"30852924";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2217/imt-2018-0208";"30852924";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2217/imt-2018-0208";"30852924";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/imt-2018-0208";"30852924";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/imt-2018-0208";"30852924";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/imt-2018-0208";"30852924";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/imt-2018-0208";"30852924";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01844505"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"2";"Patient-level data used";"Yes"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01927419"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"3";"Patient-level data used";"No"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01584648"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"4";"Patient-level data used";"No"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"4";"Clinical Trial";"Yes"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01597908"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"5";"Patient-level data used";"No"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"5";"Clinical Trial";"Yes"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"5";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01689519"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"5";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"5";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/imt-2018-0208";"30852924";"study_information";"";"5";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/imt-2018-0208";"30852924";"methodology";"1";"";"Treatment name 1";"nivolumab + ipilimumab"
"10.2217/imt-2018-0208";"30852924";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.2217/imt-2018-0208";"30852924";"methodology";"1";"";"Treatment name 2";"dabrafenib + trametinib"
"10.2217/imt-2018-0208";"30852924";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3;4"
"10.2217/imt-2018-0208";"30852924";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/imt-2018-0208";"30852924";"methodology";"1";"";"Anchored comparison?";"No"
"10.2217/imt-2018-0208";"30852924";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/imt-2018-0208";"30852924";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/imt-2018-0208";"30852924";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/imt-2018-0208";"30852924";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/imt-2018-0208";"30852924";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.2217/imt-2018-0208";"30852924";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/imt-2018-0208";"30852924";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/imt-2018-0208";"30852924";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/imt-2018-0208";"30852924";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/imt-2018-0208";"30852924";"methodology";"2";"";"Treatment name 1";"nivolumab + ipilimumab"
"10.2217/imt-2018-0208";"30852924";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1;2"
"10.2217/imt-2018-0208";"30852924";"methodology";"2";"";"Treatment name 2";"vemurafenib + cobimetinib"
"10.2217/imt-2018-0208";"30852924";"methodology";"2";"";"Study 'number(s)' for treatment 2";"5"
"10.2217/imt-2018-0208";"30852924";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/imt-2018-0208";"30852924";"methodology";"2";"";"Anchored comparison?";"No"
"10.2217/imt-2018-0208";"30852924";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/imt-2018-0208";"30852924";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/imt-2018-0208";"30852924";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/imt-2018-0208";"30852924";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/imt-2018-0208";"30852924";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.2217/imt-2018-0208";"30852924";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/imt-2018-0208";"30852924";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/imt-2018-0208";"30852924";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/imt-2018-0208";"30852924";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/imt-2018-0208";"30852924";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"563"
"10.2217/imt-2018-0208";"30852924";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"124"
"10.2217/imt-2018-0208";"30852924";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"106.3"
"10.2217/imt-2018-0208";"30852924";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/imt-2018-0208";"30852924";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/imt-2018-0208";"30852924";"results";"1";"";"Number of covariates adjusted for/matched on";"7"
"10.2217/imt-2018-0208";"30852924";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest"
"10.2217/imt-2018-0208";"30852924";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/imt-2018-0208";"30852924";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/imt-2018-0208";"30852924";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.58"
"10.2217/imt-2018-0208";"30852924";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.001"
"10.2217/imt-2018-0208";"30852924";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.64"
"10.2217/imt-2018-0208";"30852924";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.009"
"10.2217/imt-2018-0208";"30852924";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"247"
"10.2217/imt-2018-0208";"30852924";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"124"
"10.2217/imt-2018-0208";"30852924";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"59.2"
"10.2217/imt-2018-0208";"30852924";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/imt-2018-0208";"30852924";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/imt-2018-0208";"30852924";"results";"2";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/imt-2018-0208";"30852924";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)"
"10.2217/imt-2018-0208";"30852924";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/imt-2018-0208";"30852924";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/imt-2018-0208";"30852924";"results";"2";"";"Primary outcome: unadjusted treatment effect";"0.53"
"10.2217/imt-2018-0208";"30852924";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.2217/imt-2018-0208";"30852924";"results";"2";"";"Primary outcome: adjusted treatment effect";"0.56"
"10.2217/imt-2018-0208";"30852924";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.014"
"10.2217/imt-2020-0266";"33228440";"general_information";"";"";"Medical Condition of Interest Name";"transplant-eligible newly diagnosed multiple myeloma"
"10.2217/imt-2020-0266";"33228440";"general_information";"";"";"Countries of first author affiliations";"france"
"10.2217/imt-2020-0266";"33228440";"general_information";"";"";"Countries of last author affiliations";"the netherlands"
"10.2217/imt-2020-0266";"33228440";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/imt-2020-0266";"33228440";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/imt-2020-0266";"33228440";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/imt-2020-0266";"33228440";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/imt-2020-0266";"33228440";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02541383"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"france"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"2";"Patient-level data used";"No"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01191060"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"france"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"3";"Patient-level data used";"No"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"3";"EudraCT (only for clinical trials registered on clinicaltrialsregister.eu";"2010-019173-16"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"germany"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"4";"Patient-level data used";"No"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"4";"Clinical Trial";"Yes"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00200681"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"france"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/imt-2020-0266";"33228440";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/imt-2020-0266";"33228440";"methodology";"1";"";"Treatment name 1";"daratumumab, bortezomib, thalidomide  +  dexamethasone"
"10.2217/imt-2020-0266";"33228440";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/imt-2020-0266";"33228440";"methodology";"1";"";"Treatment name 2";"bortezomib, lenalidomide  +  dexamethasone"
"10.2217/imt-2020-0266";"33228440";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.2217/imt-2020-0266";"33228440";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/imt-2020-0266";"33228440";"methodology";"1";"";"Anchored comparison?";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/imt-2020-0266";"33228440";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/imt-2020-0266";"33228440";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.2217/imt-2020-0266";"33228440";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/imt-2020-0266";"33228440";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.2217/imt-2020-0266";"33228440";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/imt-2020-0266";"33228440";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/imt-2020-0266";"33228440";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"2";"";"Treatment name 1";"bortezomib, thalidomide  +  dexamethasone"
"10.2217/imt-2020-0266";"33228440";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/imt-2020-0266";"33228440";"methodology";"2";"";"Treatment name 2";"bortezomib, lenalidomide  +  dexamethasone"
"10.2217/imt-2020-0266";"33228440";"methodology";"2";"";"Study 'number(s)' for treatment 2";"2"
"10.2217/imt-2020-0266";"33228440";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/imt-2020-0266";"33228440";"methodology";"2";"";"Anchored comparison?";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/imt-2020-0266";"33228440";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/imt-2020-0266";"33228440";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.2217/imt-2020-0266";"33228440";"methodology";"2";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/imt-2020-0266";"33228440";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.2217/imt-2020-0266";"33228440";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/imt-2020-0266";"33228440";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/imt-2020-0266";"33228440";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"3";"";"Treatment name 1";"daratumumab, bortezomib, thalidomide  +  dexamethasone"
"10.2217/imt-2020-0266";"33228440";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/imt-2020-0266";"33228440";"methodology";"3";"";"Treatment name 2";"bortezomib, cyclophosphamide  +  dexamethasone"
"10.2217/imt-2020-0266";"33228440";"methodology";"3";"";"Study 'number(s)' for treatment 2";"3"
"10.2217/imt-2020-0266";"33228440";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/imt-2020-0266";"33228440";"methodology";"3";"";"Anchored comparison?";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"3";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/imt-2020-0266";"33228440";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/imt-2020-0266";"33228440";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.2217/imt-2020-0266";"33228440";"methodology";"3";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/imt-2020-0266";"33228440";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.2217/imt-2020-0266";"33228440";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/imt-2020-0266";"33228440";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/imt-2020-0266";"33228440";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"4";"";"Treatment name 1";"bortezomib, thalidomide  +  dexamethasone"
"10.2217/imt-2020-0266";"33228440";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/imt-2020-0266";"33228440";"methodology";"4";"";"Treatment name 2";"bortezomib, cyclophosphamide  +  dexamethasone"
"10.2217/imt-2020-0266";"33228440";"methodology";"4";"";"Study 'number(s)' for treatment 2";"3"
"10.2217/imt-2020-0266";"33228440";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/imt-2020-0266";"33228440";"methodology";"4";"";"Anchored comparison?";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"4";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/imt-2020-0266";"33228440";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/imt-2020-0266";"33228440";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.2217/imt-2020-0266";"33228440";"methodology";"4";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/imt-2020-0266";"33228440";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.2217/imt-2020-0266";"33228440";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/imt-2020-0266";"33228440";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/imt-2020-0266";"33228440";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"5";"";"Treatment name 1";"daratumumab, bortezomib, thalidomide  +  dexamethasone"
"10.2217/imt-2020-0266";"33228440";"methodology";"5";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/imt-2020-0266";"33228440";"methodology";"5";"";"Treatment name 2";"bortezomib  +  dexamethasone"
"10.2217/imt-2020-0266";"33228440";"methodology";"5";"";"Study 'number(s)' for treatment 2";"4"
"10.2217/imt-2020-0266";"33228440";"methodology";"5";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/imt-2020-0266";"33228440";"methodology";"5";"";"Anchored comparison?";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"5";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/imt-2020-0266";"33228440";"methodology";"5";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/imt-2020-0266";"33228440";"methodology";"5";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.2217/imt-2020-0266";"33228440";"methodology";"5";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/imt-2020-0266";"33228440";"methodology";"5";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.2217/imt-2020-0266";"33228440";"methodology";"5";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/imt-2020-0266";"33228440";"methodology";"5";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/imt-2020-0266";"33228440";"methodology";"5";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"5";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"6";"";"Treatment name 1";"bortezomib, thalidomide  +  dexamethasone"
"10.2217/imt-2020-0266";"33228440";"methodology";"6";"";"Study 'number(s)' for treatment 1";"1"
"10.2217/imt-2020-0266";"33228440";"methodology";"6";"";"Treatment name 2";"bortezomib  +  dexamethasone"
"10.2217/imt-2020-0266";"33228440";"methodology";"6";"";"Study 'number(s)' for treatment 2";"4"
"10.2217/imt-2020-0266";"33228440";"methodology";"6";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/imt-2020-0266";"33228440";"methodology";"6";"";"Anchored comparison?";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"6";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.2217/imt-2020-0266";"33228440";"methodology";"6";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/imt-2020-0266";"33228440";"methodology";"6";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"progression-free survival"
"10.2217/imt-2020-0266";"33228440";"methodology";"6";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/imt-2020-0266";"33228440";"methodology";"6";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)"
"10.2217/imt-2020-0266";"33228440";"methodology";"6";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.2217/imt-2020-0266";"33228440";"methodology";"6";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/imt-2020-0266";"33228440";"methodology";"6";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/imt-2020-0266";"33228440";"methodology";"6";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/imt-2020-0266";"33228440";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"543"
"10.2217/imt-2020-0266";"33228440";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"525"
"10.2217/imt-2020-0266";"33228440";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/imt-2020-0266";"33228440";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/imt-2020-0266";"33228440";"results";"1";"";"Number of covariates adjusted for/matched on";"4"
"10.2217/imt-2020-0266";"33228440";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.2217/imt-2020-0266";"33228440";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/imt-2020-0266";"33228440";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/imt-2020-0266";"33228440";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.48"
"10.2217/imt-2020-0266";"33228440";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.2217/imt-2020-0266";"33228440";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.47"
"10.2217/imt-2020-0266";"33228440";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.2217/imt-2020-0266";"33228440";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"350"
"10.2217/imt-2020-0266";"33228440";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"542"
"10.2217/imt-2020-0266";"33228440";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"515"
"10.2217/imt-2020-0266";"33228440";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/imt-2020-0266";"33228440";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/imt-2020-0266";"33228440";"results";"2";"";"Number of covariates adjusted for/matched on";"4"
"10.2217/imt-2020-0266";"33228440";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)"
"10.2217/imt-2020-0266";"33228440";"results";"2";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/imt-2020-0266";"33228440";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/imt-2020-0266";"33228440";"results";"2";"";"Primary outcome: unadjusted treatment effect";"1.07"
"10.2217/imt-2020-0266";"33228440";"results";"2";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.655"
"10.2217/imt-2020-0266";"33228440";"results";"2";"";"Primary outcome: adjusted treatment effect";"1.13"
"10.2217/imt-2020-0266";"33228440";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.419"
"10.2217/imt-2020-0266";"33228440";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"350"
"10.2217/imt-2020-0266";"33228440";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"543"
"10.2217/imt-2020-0266";"33228440";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"206"
"10.2217/imt-2020-0266";"33228440";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/imt-2020-0266";"33228440";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/imt-2020-0266";"33228440";"results";"3";"";"Number of covariates adjusted for/matched on";"12"
"10.2217/imt-2020-0266";"33228440";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)"
"10.2217/imt-2020-0266";"33228440";"results";"3";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/imt-2020-0266";"33228440";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/imt-2020-0266";"33228440";"results";"3";"";"Primary outcome: unadjusted treatment effect";"0.4"
"10.2217/imt-2020-0266";"33228440";"results";"3";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.2217/imt-2020-0266";"33228440";"results";"3";"";"Primary outcome: adjusted treatment effect";"0.35"
"10.2217/imt-2020-0266";"33228440";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.2217/imt-2020-0266";"33228440";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"125"
"10.2217/imt-2020-0266";"33228440";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"542"
"10.2217/imt-2020-0266";"33228440";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"211"
"10.2217/imt-2020-0266";"33228440";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/imt-2020-0266";"33228440";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/imt-2020-0266";"33228440";"results";"4";"";"Number of covariates adjusted for/matched on";"12"
"10.2217/imt-2020-0266";"33228440";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)"
"10.2217/imt-2020-0266";"33228440";"results";"4";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/imt-2020-0266";"33228440";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/imt-2020-0266";"33228440";"results";"4";"";"Primary outcome: unadjusted treatment effect";"0.4"
"10.2217/imt-2020-0266";"33228440";"results";"4";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.2217/imt-2020-0266";"33228440";"results";"4";"";"Primary outcome: adjusted treatment effect";"0.35"
"10.2217/imt-2020-0266";"33228440";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.2217/imt-2020-0266";"33228440";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"126"
"10.2217/imt-2020-0266";"33228440";"results";"5";"";"Initial sample size of the population of interest in the IPD treatment arm";"543"
"10.2217/imt-2020-0266";"33228440";"results";"5";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"416"
"10.2217/imt-2020-0266";"33228440";"results";"5";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/imt-2020-0266";"33228440";"results";"5";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/imt-2020-0266";"33228440";"results";"5";"";"Number of covariates adjusted for/matched on";"7"
"10.2217/imt-2020-0266";"33228440";"results";"5";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.2217/imt-2020-0266";"33228440";"results";"5";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/imt-2020-0266";"33228440";"results";"5";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/imt-2020-0266";"33228440";"results";"5";"";"Primary outcome: unadjusted treatment effect";"0.37"
"10.2217/imt-2020-0266";"33228440";"results";"5";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"<0.001"
"10.2217/imt-2020-0266";"33228440";"results";"5";"";"Primary outcome: adjusted treatment effect";"0.42"
"10.2217/imt-2020-0266";"33228440";"results";"5";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.2217/imt-2020-0266";"33228440";"results";"5";"";"Sample size of the population of interest in the non IPD treatment arm";"240"
"10.2217/imt-2020-0266";"33228440";"results";"6";"";"Initial sample size of the population of interest in the IPD treatment arm";"542"
"10.2217/imt-2020-0266";"33228440";"results";"6";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"393"
"10.2217/imt-2020-0266";"33228440";"results";"6";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/imt-2020-0266";"33228440";"results";"6";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/imt-2020-0266";"33228440";"results";"6";"";"Number of covariates adjusted for/matched on";"7"
"10.2217/imt-2020-0266";"33228440";"results";"6";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)"
"10.2217/imt-2020-0266";"33228440";"results";"6";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/imt-2020-0266";"33228440";"results";"6";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/imt-2020-0266";"33228440";"results";"6";"";"Primary outcome: unadjusted treatment effect";"0.82"
"10.2217/imt-2020-0266";"33228440";"results";"6";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.222"
"10.2217/imt-2020-0266";"33228440";"results";"6";"";"Primary outcome: adjusted treatment effect";"0.94"
"10.2217/imt-2020-0266";"33228440";"results";"6";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.738"
"10.2217/imt-2020-0266";"33228440";"results";"6";"";"Sample size of the population of interest in the non IPD treatment arm";"240"
"10.2217/imt-2021-0273";"35073727";"general_information";"";"";"Medical Condition of Interest Name";"metastatic non-small-cell lung cancer"
"10.2217/imt-2021-0273";"35073727";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.2217/imt-2021-0273";"35073727";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.2217/imt-2021-0273";"35073727";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.2217/imt-2021-0273";"35073727";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.2217/imt-2021-0273";"35073727";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.2217/imt-2021-0273";"35073727";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.2217/imt-2021-0273";"35073727";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"1";"Patient-level data used";"Yes"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"1";"Clinical Trial";"Yes"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02142738"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"2";"Patient-level data used";"Yes"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"2";"Clinical Trial";"Yes"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02220894"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"3";"Patient-level data used";"No"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"3";"Clinical Trial";"Yes"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02477826"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.2217/imt-2021-0273";"35073727";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.2217/imt-2021-0273";"35073727";"methodology";"1";"";"Treatment name 1";"pembrolizumab"
"10.2217/imt-2021-0273";"35073727";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.2217/imt-2021-0273";"35073727";"methodology";"1";"";"Treatment name 2";"nivolumab + ipilimumab"
"10.2217/imt-2021-0273";"35073727";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3"
"10.2217/imt-2021-0273";"35073727";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.2217/imt-2021-0273";"35073727";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.2217/imt-2021-0273";"35073727";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.2217/imt-2021-0273";"35073727";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.2217/imt-2021-0273";"35073727";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.2217/imt-2021-0273";"35073727";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.2217/imt-2021-0273";"35073727";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.2217/imt-2021-0273";"35073727";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.2217/imt-2021-0273";"35073727";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.2217/imt-2021-0273";"35073727";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.2217/imt-2021-0273";"35073727";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.2217/imt-2021-0273";"35073727";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"793"
"10.2217/imt-2021-0273";"35073727";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"1428"
"10.2217/imt-2021-0273";"35073727";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"993"
"10.2217/imt-2021-0273";"35073727";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.2217/imt-2021-0273";"35073727";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.2217/imt-2021-0273";"35073727";"results";"1";"";"Number of covariates adjusted for/matched on";"8"
"10.2217/imt-2021-0273";"35073727";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.2217/imt-2021-0273";"35073727";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.2217/imt-2021-0273";"35073727";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.2217/imt-2021-0273";"35073727";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.98"
"10.2217/imt-2021-0273";"35073727";"results";"1";"";"Primary outcome: adjusted treatment effect";"1.07"
"10.2217/imt-2021-0273";"35073727";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.82;1.39]"
"10.3111/13696998.2013.768530";"23339434";"general_information";"";"";"Medical Condition of Interest Name";"psoriatic arthritis"
"10.3111/13696998.2013.768530";"23339434";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.3111/13696998.2013.768530";"23339434";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.3111/13696998.2013.768530";"23339434";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.3111/13696998.2013.768530";"23339434";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.3111/13696998.2013.768530";"23339434";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.3111/13696998.2013.768530";"23339434";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.3111/13696998.2013.768530";"23339434";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"1";"Patient-level data used";"Yes"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"1";"Clinical Trial";"Yes"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00195689"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"2";"Patient-level data used";"No"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"2";"Clinical Trial";"Yes"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"2";"Data source name (only if observational study or clinical trial without NCT)";"mease et al. (2004)"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"3";"Patient-level data used";"No"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"3";"Clinical Trial";"Yes"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"3";"Data source name (only if observational study or clinical trial without NCT)";"antoni et al. (2005)"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"2"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.3111/13696998.2013.768530";"23339434";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02152254"
"10.3111/13696998.2013.768530";"23339434";"methodology";"1";"";"Treatment name 1";"adalimumab"
"10.3111/13696998.2013.768530";"23339434";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.3111/13696998.2013.768530";"23339434";"methodology";"1";"";"Treatment name 2";"etanercept"
"10.3111/13696998.2013.768530";"23339434";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.3111/13696998.2013.768530";"23339434";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.3111/13696998.2013.768530";"23339434";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.3111/13696998.2013.768530";"23339434";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.3111/13696998.2013.768530";"23339434";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.3111/13696998.2013.768530";"23339434";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"week 12 acr70"
"10.3111/13696998.2013.768530";"23339434";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.3111/13696998.2013.768530";"23339434";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.3111/13696998.2013.768530";"23339434";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.3111/13696998.2013.768530";"23339434";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.3111/13696998.2013.768530";"23339434";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.3111/13696998.2013.768530";"23339434";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.3111/13696998.2013.768530";"23339434";"methodology";"2";"";"Treatment name 1";"adalimumab"
"10.3111/13696998.2013.768530";"23339434";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1"
"10.3111/13696998.2013.768530";"23339434";"methodology";"2";"";"Treatment name 2";"infliximab"
"10.3111/13696998.2013.768530";"23339434";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.3111/13696998.2013.768530";"23339434";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.3111/13696998.2013.768530";"23339434";"methodology";"2";"";"Anchored comparison?";"Yes"
"10.3111/13696998.2013.768530";"23339434";"methodology";"2";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.3111/13696998.2013.768530";"23339434";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.3111/13696998.2013.768530";"23339434";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"week 14 acr70"
"10.3111/13696998.2013.768530";"23339434";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.3111/13696998.2013.768530";"23339434";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.3111/13696998.2013.768530";"23339434";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.3111/13696998.2013.768530";"23339434";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.3111/13696998.2013.768530";"23339434";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.3111/13696998.2013.768530";"23339434";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.3111/13696998.2013.768530";"23339434";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"101"
"10.3111/13696998.2013.768530";"23339434";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"104"
"10.3111/13696998.2013.768530";"23339434";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"142"
"10.3111/13696998.2013.768530";"23339434";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"154"
"10.3111/13696998.2013.768530";"23339434";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.3111/13696998.2013.768530";"23339434";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.3111/13696998.2013.768530";"23339434";"results";"1";"";"Number of covariates adjusted for/matched on";"12"
"10.3111/13696998.2013.768530";"23339434";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest"
"10.3111/13696998.2013.768530";"23339434";"results";"1";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.3111/13696998.2013.768530";"23339434";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.3111/13696998.2013.768530";"23339434";"results";"1";"";"Primary outcome: adjusted treatment effect";"18.9"
"10.3111/13696998.2013.768530";"23339434";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.034"
"10.3111/13696998.2013.768530";"23339434";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"100"
"10.3111/13696998.2013.768530";"23339434";"results";"2";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"100"
"10.3111/13696998.2013.768530";"23339434";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"108"
"10.3111/13696998.2013.768530";"23339434";"results";"2";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"126"
"10.3111/13696998.2013.768530";"23339434";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.3111/13696998.2013.768530";"23339434";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.3111/13696998.2013.768530";"23339434";"results";"2";"";"Number of covariates adjusted for/matched on";"18"
"10.3111/13696998.2013.768530";"23339434";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)"
"10.3111/13696998.2013.768530";"23339434";"results";"2";"";"Primary outcome: treatment effect contrast";"Means difference"
"10.3111/13696998.2013.768530";"23339434";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.3111/13696998.2013.768530";"23339434";"results";"2";"";"Primary outcome: adjusted treatment effect";"18.9"
"10.3111/13696998.2013.768530";"23339434";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.034"
"10.3390/biom11060780";"34067288";"general_information";"";"";"Medical Condition of Interest Name";"metastatic pancreatic cancer"
"10.3390/biom11060780";"34067288";"general_information";"";"";"Countries of first author affiliations";"italy"
"10.3390/biom11060780";"34067288";"general_information";"";"";"Countries of last author affiliations";"italy"
"10.3390/biom11060780";"34067288";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic"
"10.3390/biom11060780";"34067288";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Not mentioned"
"10.3390/biom11060780";"34067288";"general_information";"";"";"Mentioned sources of funding";"None mentioned"
"10.3390/biom11060780";"34067288";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"None"
"10.3390/biom11060780";"34067288";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.3390/biom11060780";"34067288";"study_information";"";"1";"Patient-level data used";"Yes"
"10.3390/biom11060780";"34067288";"study_information";"";"1";"Clinical Trial";"No"
"10.3390/biom11060780";"34067288";"study_information";"";"1";"Data source name (only if observational study or clinical trial without NCT)";"local retrospective cohort from ehr"
"10.3390/biom11060780";"34067288";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"italy"
"10.3390/biom11060780";"34067288";"study_information";"";"2";"Patient-level data used";"No"
"10.3390/biom11060780";"34067288";"study_information";"";"2";"Clinical Trial";"Yes"
"10.3390/biom11060780";"34067288";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01804790"
"10.3390/biom11060780";"34067288";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"france"
"10.3390/biom11060780";"34067288";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.3390/biom11060780";"34067288";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.3390/biom11060780";"34067288";"methodology";"1";"";"Treatment name 1";"folfirinox"
"10.3390/biom11060780";"34067288";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.3390/biom11060780";"34067288";"methodology";"1";"";"Treatment name 2";"gemcitabine + nab-paclitaxel"
"10.3390/biom11060780";"34067288";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.3390/biom11060780";"34067288";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.3390/biom11060780";"34067288";"methodology";"1";"";"Anchored comparison?";"No"
"10.3390/biom11060780";"34067288";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.3390/biom11060780";"34067288";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.3390/biom11060780";"34067288";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.3390/biom11060780";"34067288";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.3390/biom11060780";"34067288";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported
"
"10.3390/biom11060780";"34067288";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.3390/biom11060780";"34067288";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.3390/biom11060780";"34067288";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.3390/biom11060780";"34067288";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.3390/biom11060780";"34067288";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"268"
"10.3390/biom11060780";"34067288";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"171"
"10.3390/biom11060780";"34067288";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.3390/biom11060780";"34067288";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.3390/biom11060780";"34067288";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)"
"10.3390/biom11060780";"34067288";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.3390/biom11060780";"34067288";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Denominator if ratio, or rightside if difference"
"10.3390/biom11060780";"34067288";"results";"1";"";"Primary outcome: adjusted treatment effect";"1.1"
"10.3390/biom11060780";"34067288";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.527"
"10.3390/cancers12123648";"33291810";"general_information";"";"";"Medical Condition of Interest Name";"metastatic non small cell lung cancer"
"10.3390/cancers12123648";"33291810";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.3390/cancers12123648";"33291810";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.3390/cancers12123648";"33291810";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.3390/cancers12123648";"33291810";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.3390/cancers12123648";"33291810";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.3390/cancers12123648";"33291810";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.3390/cancers12123648";"33291810";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.3390/cancers12123648";"33291810";"study_information";"";"1";"Patient-level data used";"Yes"
"10.3390/cancers12123648";"33291810";"study_information";"";"1";"Clinical Trial";"Yes"
"10.3390/cancers12123648";"33291810";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02039674"
"10.3390/cancers12123648";"33291810";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.3390/cancers12123648";"33291810";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"1, 2"
"10.3390/cancers12123648";"33291810";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.3390/cancers12123648";"33291810";"study_information";"";"2";"Patient-level data used";"Yes"
"10.3390/cancers12123648";"33291810";"study_information";"";"2";"Clinical Trial";"Yes"
"10.3390/cancers12123648";"33291810";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02578680"
"10.3390/cancers12123648";"33291810";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.3390/cancers12123648";"33291810";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.3390/cancers12123648";"33291810";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.3390/cancers12123648";"33291810";"study_information";"";"3";"Patient-level data used";"Yes"
"10.3390/cancers12123648";"33291810";"study_information";"";"3";"Clinical Trial";"Yes"
"10.3390/cancers12123648";"33291810";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02775435"
"10.3390/cancers12123648";"33291810";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.3390/cancers12123648";"33291810";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.3390/cancers12123648";"33291810";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.3390/cancers12123648";"33291810";"study_information";"";"4";"Patient-level data used";"No"
"10.3390/cancers12123648";"33291810";"study_information";"";"4";"Clinical Trial";"Yes"
"10.3390/cancers12123648";"33291810";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02477826"
"10.3390/cancers12123648";"33291810";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.3390/cancers12123648";"33291810";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.3390/cancers12123648";"33291810";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.3390/cancers12123648";"33291810";"methodology";"1";"";"Treatment name 1";"pembrolizumab + chemotherapy"
"10.3390/cancers12123648";"33291810";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.3390/cancers12123648";"33291810";"methodology";"1";"";"Treatment name 2";"nivolumab + ipilimumab"
"10.3390/cancers12123648";"33291810";"methodology";"1";"";"Study 'number(s)' for treatment 2";"4"
"10.3390/cancers12123648";"33291810";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.3390/cancers12123648";"33291810";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.3390/cancers12123648";"33291810";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.3390/cancers12123648";"33291810";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.3390/cancers12123648";"33291810";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall survival"
"10.3390/cancers12123648";"33291810";"methodology";"1";"";"Primary outcome: variable type";"Time-to-event"
"10.3390/cancers12123648";"33291810";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported"
"10.3390/cancers12123648";"33291810";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.3390/cancers12123648";"33291810";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.3390/cancers12123648";"33291810";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.3390/cancers12123648";"33291810";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.3390/cancers12123648";"33291810";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.3390/cancers12123648";"33291810";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.3390/cancers12123648";"33291810";"results";"1";"";"Number of covariates adjusted for/matched on";"8"
"10.3390/cancers12123648";"33291810";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)"
"10.3390/cancers12123648";"33291810";"results";"1";"";"Primary outcome: treatment effect contrast";"HR"
"10.3390/cancers12123648";"33291810";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.3390/cancers12123648";"33291810";"results";"1";"";"Primary outcome: unadjusted treatment effect";"0.84"
"10.3390/cancers12123648";"33291810";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.218"
"10.3390/cancers12123648";"33291810";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.8"
"10.3390/cancers12123648";"33291810";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.152"
"10.3390/cancers13102406";"34067521";"general_information";"";"";"Medical Condition of Interest Name";"hepatocellular carcinoma"
"10.3390/cancers13102406";"34067521";"general_information";"";"";"Countries of first author affiliations";"italy"
"10.3390/cancers13102406";"34067521";"general_information";"";"";"Countries of last author affiliations";"italy"
"10.3390/cancers13102406";"34067521";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic"
"10.3390/cancers13102406";"34067521";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Not mentioned"
"10.3390/cancers13102406";"34067521";"general_information";"";"";"Mentioned sources of funding";"None mentioned"
"10.3390/cancers13102406";"34067521";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"None"
"10.3390/cancers13102406";"34067521";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.3390/cancers13102406";"34067521";"study_information";"";"1";"Patient-level data used";"Yes"
"10.3390/cancers13102406";"34067521";"study_information";"";"1";"Clinical Trial";"No"
"10.3390/cancers13102406";"34067521";"study_information";"";"1";"Data source name (only if observational study or clinical trial without NCT)";"retrospective cohort of patients affected by hcc who underwent surgical at the hepatobiliary surgery and liver transplantation unit, university of padua."
"10.3390/cancers13102406";"34067521";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"italy"
"10.3390/cancers13102406";"34067521";"study_information";"";"2";"Patient-level data used";"No"
"10.3390/cancers13102406";"34067521";"study_information";"";"2";"Clinical Trial";"Yes"
"10.3390/cancers13102406";"34067521";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01387503"
"10.3390/cancers13102406";"34067521";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"italy"
"10.3390/cancers13102406";"34067521";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2, 3"
"10.3390/cancers13102406";"34067521";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.3390/cancers13102406";"34067521";"methodology";"1";"";"Treatment name 1";"padua surgical aggressive downstaging"
"10.3390/cancers13102406";"34067521";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.3390/cancers13102406";"34067521";"methodology";"1";"";"Treatment name 2";"xxl protocol downstaging"
"10.3390/cancers13102406";"34067521";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.3390/cancers13102406";"34067521";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.3390/cancers13102406";"34067521";"methodology";"1";"";"Anchored comparison?";"No"
"10.3390/cancers13102406";"34067521";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.3390/cancers13102406";"34067521";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.3390/cancers13102406";"34067521";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"proportion of downstaging failure"
"10.3390/cancers13102406";"34067521";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.3390/cancers13102406";"34067521";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Nothing mentioned, not reported
"
"10.3390/cancers13102406";"34067521";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No discussion (in the main text) of the status of prognostic factors of the variables"
"10.3390/cancers13102406";"34067521";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"No discussion (in the main text) of the status of treatment-effect modifiers of the variables"
"10.3390/cancers13102406";"34067521";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.3390/cancers13102406";"34067521";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.3390/cancers13102406";"34067521";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"74"
"10.3390/cancers13102406";"34067521";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"191"
"10.3390/cancers13102406";"34067521";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.3390/cancers13102406";"34067521";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"No"
"10.3390/cancers13102406";"34067521";"results";"1";"";"Primary outcome: treatment effect contrast";"None"
"10.36469/jheor.2021.19008";"33768123";"general_information";"";"";"Medical Condition of Interest Name";"steroid-refractory acute graft-versus-host disease"
"10.36469/jheor.2021.19008";"33768123";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.36469/jheor.2021.19008";"33768123";"general_information";"";"";"Countries of last author affiliations";"usa"
"10.36469/jheor.2021.19008";"33768123";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Pharmaceutical Industry, Private Data Analysis Company"
"10.36469/jheor.2021.19008";"33768123";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.36469/jheor.2021.19008";"33768123";"general_information";"";"";"Mentioned sources of funding";"None mentioned"
"10.36469/jheor.2021.19008";"33768123";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"No such section presenting competing interest/conflict of interest"
"10.36469/jheor.2021.19008";"33768123";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"No"
"10.36469/jheor.2021.19008";"33768123";"study_information";"";"1";"Patient-level data used";"Yes"
"10.36469/jheor.2021.19008";"33768123";"study_information";"";"1";"Clinical Trial";"Yes"
"10.36469/jheor.2021.19008";"33768123";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02336230"
"10.36469/jheor.2021.19008";"33768123";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.36469/jheor.2021.19008";"33768123";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.36469/jheor.2021.19008";"33768123";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"1"
"10.36469/jheor.2021.19008";"33768123";"study_information";"";"2";"Patient-level data used";"No"
"10.36469/jheor.2021.19008";"33768123";"study_information";"";"2";"Clinical Trial";"Yes"
"10.36469/jheor.2021.19008";"33768123";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02953678"
"10.36469/jheor.2021.19008";"33768123";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"usa"
"10.36469/jheor.2021.19008";"33768123";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"2"
"10.36469/jheor.2021.19008";"33768123";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"1"
"10.36469/jheor.2021.19008";"33768123";"methodology";"1";"";"Treatment name 1";"remestemcel-l-rknd"
"10.36469/jheor.2021.19008";"33768123";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1"
"10.36469/jheor.2021.19008";"33768123";"methodology";"1";"";"Treatment name 2";"ruxolitinib"
"10.36469/jheor.2021.19008";"33768123";"methodology";"1";"";"Study 'number(s)' for treatment 2";"2"
"10.36469/jheor.2021.19008";"33768123";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"STC"
"10.36469/jheor.2021.19008";"33768123";"methodology";"1";"";"Anchored comparison?";"No"
"10.36469/jheor.2021.19008";"33768123";"methodology";"1";"";"Form of the indirect comparison";"Simple (ie treatments effects extracted from two studies)"
"10.36469/jheor.2021.19008";"33768123";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"Yes"
"10.36469/jheor.2021.19008";"33768123";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"overall response rate"
"10.36469/jheor.2021.19008";"33768123";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.36469/jheor.2021.19008";"33768123";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.36469/jheor.2021.19008";"33768123";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.36469/jheor.2021.19008";"33768123";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.36469/jheor.2021.19008";"33768123";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.36469/jheor.2021.19008";"33768123";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.36469/jheor.2021.19008";"33768123";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"49"
"10.36469/jheor.2021.19008";"33768123";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"55"
"10.36469/jheor.2021.19008";"33768123";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"55"
"10.36469/jheor.2021.19008";"33768123";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.36469/jheor.2021.19008";"33768123";"results";"1";"";"Number of covariates adjusted for/matched on";"3"
"10.36469/jheor.2021.19008";"33768123";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity"
"10.36469/jheor.2021.19008";"33768123";"results";"1";"";"Primary outcome: treatment effect contrast";"RR"
"10.36469/jheor.2021.19008";"33768123";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.36469/jheor.2021.19008";"33768123";"results";"1";"";"Primary outcome: unadjusted treatment effect";"1.21"
"10.36469/jheor.2021.19008";"33768123";"results";"1";"";"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])";"0.21"
"10.36469/jheor.2021.19008";"33768123";"results";"1";"";"Primary outcome: adjusted treatment effect";"1.13"
"10.36469/jheor.2021.19008";"33768123";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.45"
"10.5152/eurjrheum.2018.18162";"30388073";"general_information";"";"";"Medical Condition of Interest Name";"ankylosing spondylitis"
"10.5152/eurjrheum.2018.18162";"30388073";"general_information";"";"";"Countries of first author affiliations";"canada"
"10.5152/eurjrheum.2018.18162";"30388073";"general_information";"";"";"Countries of last author affiliations";"switzerland"
"10.5152/eurjrheum.2018.18162";"30388073";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.5152/eurjrheum.2018.18162";"30388073";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.5152/eurjrheum.2018.18162";"30388073";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.5152/eurjrheum.2018.18162";"30388073";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.5152/eurjrheum.2018.18162";"30388073";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"1";"Patient-level data used";"Yes"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"1";"Clinical Trial";"Yes"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01358175"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"2";"Patient-level data used";"Yes"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"2";"Clinical Trial";"Yes"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01649375"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"3";"Patient-level data used";"No"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"3";"Clinical Trial";"Yes"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00085644"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"2"
"10.5152/eurjrheum.2018.18162";"30388073";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"1";"";"Treatment name 1";"secukinumab 150mg"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"1";"";"Treatment name 2";"adalimumab 150mg"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"1";"";"Study 'number(s)' for treatment 2";"3"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"assessment of spondyloarthritis international society at week 8"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"2";"";"Treatment name 1";"secukinumab 150mg"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1;2"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"2";"";"Treatment name 2";"adalimumab 150mg"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"2";"";"Study 'number(s)' for treatment 2";"3"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"2";"";"Anchored comparison?";"No"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"assessment of spondyloarthritis international society at week 16"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"Yes"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.5152/eurjrheum.2018.18162";"30388073";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"208"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"107"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"197"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"120"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"196"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"120"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"1";"";"Number of covariates adjusted for/matched on";"5"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"1";"";"Primary outcome: treatment effect contrast";"OR"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.91"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.795"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"208"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"197"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"120"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"2";"";"Number of covariates adjusted for/matched on";"5"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"2";"";"Primary outcome: treatment effect contrast";"OR"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"2";"";"Primary outcome: adjusted treatment effect";"1.6"
"10.5152/eurjrheum.2018.18162";"30388073";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.047"
"10.5152/eurjrheum.2019.19057";"31364979";"general_information";"";"";"Medical Condition of Interest Name";"psoriatic arthritis"
"10.5152/eurjrheum.2019.19057";"31364979";"general_information";"";"";"Countries of first author affiliations";"usa"
"10.5152/eurjrheum.2019.19057";"31364979";"general_information";"";"";"Countries of last author affiliations";"uk"
"10.5152/eurjrheum.2019.19057";"31364979";"general_information";"";"";"Positions of study investigators (for any authors of the article, any that applies)";"Academic, Pharmaceutical Industry, Private Data Analysis Company"
"10.5152/eurjrheum.2019.19057";"31364979";"general_information";"";"";"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"general_information";"";"";"Mentioned sources of funding";"Pharmaceutical Industry"
"10.5152/eurjrheum.2019.19057";"31364979";"general_information";"";"";"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"general_information";"";"";"Mention of a systematic review to find the studies to compare treatments of interest";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"1";"Patient-level data used";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"1";"Clinical Trial";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"1";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01752634"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"1";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"1";"Phase of the clinical trial (clinical trial only)";"3"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"1";"Number of treatment arms (clinical trial only)";"2 or more"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"2";"Patient-level data used";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"2";"Clinical Trial";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"2";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT01989468"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"2";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"2";"Phase of the clinical trial (clinical trial only)";"3"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"2";"Number of treatment arms (clinical trial only)";"2 or more"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"3";"Patient-level data used";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"3";"Clinical Trial";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"3";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT02404350"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"3";"Country where the clinical trial/observational study was conducted (international if more than one)";"international"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"3";"Phase of the clinical trial (clinical trial only)";"3"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"3";"Number of treatment arms (clinical trial only)";"2 or more"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"4";"Patient-level data used";"No"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"4";"Clinical Trial";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"4";"NCT (only for clinical trial registered on clinicaltrials.gov)";"NCT00317499"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"4";"Phase of the clinical trial (clinical trial only)";"3"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"4";"Number of treatment arms (clinical trial only)";"2 or more"
"10.5152/eurjrheum.2019.19057";"31364979";"study_information";"";"4";"Country where the clinical trial/observational study was conducted (international if more than one)";"unknown"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"1";"";"Treatment name 1";"secukinumab 150 mg"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"1";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"1";"";"Treatment name 2";"etanercept"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"1";"";"Study 'number(s)' for treatment 2";"4"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"1";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"1";"";"Anchored comparison?";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"1";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"1";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"1";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"acr 20 (american college of rheumatology ) response rates at week 12"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"1";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"1";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"1";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"1";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"1";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"1";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"2";"";"Treatment name 1";"secukinumab 150 mg"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"2";"";"Study 'number(s)' for treatment 1";"1.2.3"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"2";"";"Treatment name 2";"etanercept"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"2";"";"Study 'number(s)' for treatment 2";"4"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"2";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"2";"";"Anchored comparison?";"No"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"2";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"2";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"2";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"acr 20 (american college of rheumatology ) response rates at week 24"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"2";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"2";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"2";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"2";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"2";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"2";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"3";"";"Treatment name 1";"secukinumab 300mg"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"3";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"3";"";"Treatment name 2";"etanercept"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"3";"";"Study 'number(s)' for treatment 2";"4"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"3";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"3";"";"Anchored comparison?";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"3";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"3";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"3";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"acr 20 (american college of rheumatology ) response rates at week 12"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"3";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"3";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"3";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"3";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"3";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"3";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"4";"";"Treatment name 1";"secukinumab 300mg"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"4";"";"Study 'number(s)' for treatment 1";"1;2;3"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"4";"";"Treatment name 2";"etanercept"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"4";"";"Study 'number(s)' for treatment 2";"4"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"4";"";"Type of population-adjusted indirect comparisons performed";"MAIC"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"4";"";"Anchored comparison?";"No"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"4";"";"Form of the indirect comparison";"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"4";"";"Definition of a single primary outcome for the indirect comparison";"No primary outcome defined, or multiple primary outcomes without any clear distinction between them"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"4";"";"Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)";"acr 20 (american college of rheumatology ) response rates at week 24"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"4";"";"Primary outcome: variable type";"Binary (eg rates)"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"4";"";"Justification for selecting variables to be included in the adjustment model (in the main text)";"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"4";"";"Inclusion of prognostic factors in the adjustment/matching model";"No"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"4";"";"Inclusion of treatment-effect modifiers in the adjustment/matching model";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"4";"";"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)";"No"
"10.5152/eurjrheum.2019.19057";"31364979";"methodology";"4";"";"Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)";"No"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"1";"";"Sample size of the population of interest in the non IPD treatment arm";"101"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"1";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"104"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"1";"";"Initial sample size of the population of interest in the IPD treatment arm";"458"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"1";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"104"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"1";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"567"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"1";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"159"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"1";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"1";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"1";"";"Number of covariates adjusted for/matched on";"11"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"1";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"1";"";"Primary outcome: treatment effect contrast";"OR"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"1";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"1";"";"Primary outcome: adjusted treatment effect";"0.57"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"1";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.186"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"2";"";"Sample size of the population of interest in the non IPD treatment arm";"101"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"2";"";"Initial sample size of the population of interest in the IPD treatment arm";"458"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"2";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"104"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"2";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"2";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"2";"";"Number of covariates adjusted for/matched on";"11"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"2";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"2";"";"Primary outcome: treatment effect contrast";"OR"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"2";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"2";"";"Primary outcome: adjusted treatment effect";"1.47"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"2";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.173"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"2";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"104"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"2";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"567"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"2";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"159"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"3";"";"Sample size of the population of interest in the non IPD treatment arm";"101"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"3";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"104"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"3";"";"Initial sample size of the population of interest in the IPD treatment arm";"461"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"3";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"75"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"3";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"567"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"3";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"159"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"3";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"3";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"3";"";"Number of covariates adjusted for/matched on";"11"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"3";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"3";"";"Primary outcome: treatment effect contrast";"OR"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"3";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"3";"";"Primary outcome: adjusted treatment effect";"0.86"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"3";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"0.722"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"4";"";"Sample size of the population of interest in the non IPD treatment arm";"101"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"4";"";"Initial sample size of the population of interest in the IPD treatment arm";"461"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"4";"";"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";"75"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"4";"";"Reporting of a weights' distribution evaluation (MAIC)";"Not mentioned"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"4";"";"Reporting of the list of the covariates adjusted for/matched on";"Yes"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"4";"";"Number of covariates adjusted for/matched on";"11"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"4";"";"Covariates adjusted for/matched on in the indirect comparison";"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"4";"";"Primary outcome: treatment effect contrast";"OR"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"4";"";"Direction of the treatment effect contrast: IPD treatment is:";"Numerator if ratio, or left side if difference"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"4";"";"Primary outcome: adjusted treatment effect";"3.28"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"4";"";"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"<0.001"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"4";"";"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm";"104"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"4";"";"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm";"567"
"10.5152/eurjrheum.2019.19057";"31364979";"results";"4";"";"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm";"159"
